WO2009077497A2 - Azolyl methyl oxiranes, the use thereof, and agents containing them - Google Patents

Abstract

The present invention relates to azolyl methyl oxiranes of the formula (I), wherein the variables A, B, and D have the meanings as defined in the description and the claims.

Description

 Azolylmethyloxiranes, their use and agents containing them

description

The present invention of the formula I

worin die Variablen folgende Bedeutungen aufweisen:

wherein the variables have the following meanings:

A or B represents a tri-, tetra-, penta-, hexa-, si-, e-, n- or ten-membered saturated or partially unsaturated heterocycle or five-, six-, seven-, eight-, nine- or ten-membered aromatic heterocycle, wherein the heterocycle each contains one, two, three or four heteroatoms from the group O, N and S;

and the other variable B or A means

one of the above for A or B meanings or Ci-Ce-Al kyl, d-Cs-haloalkyl, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ -haloalkenyl, C ₂ -C ₈ - alkynyl, C C ₂ -C ₈ haloalkynyl, C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ halo genocycloalkyl, phenyl or benzodioxolyl;

wherein A and / or B are independently unsubstituted or substituted with one, two, three or four independently selected substituents L;

L is halogen, cyano, nitro, cyanato (OCN), C ₈ -alkyl, C ₈ - haloalkyl, Ci-Cβ-phenyl-alkyloxy, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ - halo alkenyl, C ₂ -C ₈ -alkyl kinyl, C ₂ -C ₈ haloalkynyl, C4-Cio-alkadienyl, C ₄ - Cio-Halogenalkadienyl, _{Ci-C8-alkoxy, Ci-C8-haloalkoxy,} Ci- C ₈ - alkylcarbonyloxy, Ci-C ₈ alkylsulfonyloxy, C ₂ -C ₈ alkenyloxy, C ₂ -C ₈ -

Haloalkenyloxy, C ₂ -C ₈ alkynyloxy, C ₂ -C ₈ haloalkynyloxy, C ₃ - C ₈ cycloalkyl, C ₃ -C ₈ halocycloalkyl, C ₃ -C ₈ cycloalkenyl, C ₃ -C ₈ - halocycloalkenyl, _{2-C4-alkylene} C ₃ -C ₈ cycloalkoxy, C ₃ -C 6 -cycloalkenyloxy, hydroxyimino-Ci-C ₈ alkyl, Ci-Cβ alkylene, oxy-C, oxy-d- C ₃ alkyleneoxy, Ci- C ₈ -Alkoximino-C ₈ alkyl, C ₂ -C ₈ -Alkenyloximino-

Ci-C ₈ alkyl, C ₂ -C ₈ -Alkinyloximino-Ci-C ₈ alkyl, S (= O) _n A ^1, C (= O) A ^2, C (= S) A ² NA ³ A ⁴ , phenyl, phenyloxy or a five- or six-membered saturated, partially unsaturated or aromatic heteroaryl rocyclus containing one, two, three or four heteroatoms from the group O, N and S; where n, A ¹ , A ² , A ³ , A ⁴ mean:

n is 0, 1 or 2;

A ^{1 is} hydrogen, hydroxy, C 1 -C ₈ -alkyl, C 1 -C -haloalkyl, amino, C 1 -C 6 -alkylamino or C 1 -C ₈ -alkylamino,

A ² A ¹ wherein one of said groups, or C2-C8-alkenyl, C ₂ -C ₈ - oxy -AIk- ₈ haloalkenyl, C ₂ -C ₈ -alkyl kinyl, C ₂ -C ₈ haloalkynyl, CrC, Ci- C ₈ haloalkoxy, C 2 -C ₈ alkenyloxy, C ₂ -C ₈ alkenyloxy-halo, _C2-C8 alkynyloxy, _C2-C8 haloalkynyloxy, Cs-C ₈ - cycloalkyl, _C3-C8 halocycloalkyl, _{C3-C8-cycloalkoxy} or _C3-C8 -Halogencycloalkoxy;

A ^3, A ⁴ are independently hydrogen, Ci-C ₈ alkyl, Ci-Cs-haloalkyl, C ₂ -C ₈ -alkenyl, C 2 -C ₈ haloalkenyl, C ₂ -C ₈ -alkyl kinyl, C ₂ - C ₈ haloalkynyl, _C3-C8 cycloalkyl, C3-C ₈ -Halogencyclo- alkyl, _C3-C8 cycloalkenyl, or _C3-C8 halocycloalkenyl;

where the aliphatic and / or alicyclic and / or aromatic groups of the radical definitions of L can themselves carry one, two, three or four identical or different groups R ^L :

R ^{L is} halogen, cyano, nitro, Ci-C ₈ alkyl, _{Ci-C8-haloalkyl,} CrC ₈ -

Alkoxy, _{Ci-C8-haloalkoxy, C3-C8} cycloalkyl, C3-C ₈ -Halogencyclo- alkyl, _C3-C8 cycloalkenyl, _C3-C8 cycloalkoxy, C3-C ₈ -Halogencyclo- alkoxy, Ci- C ₈ alkylcarbonyl, _{Ci-C8-alkylcarbonyloxy,} CrC ₈ - alkoxycarbonyl, amino, _{Ci-C8-alkylamino,} di-Ci-C ₈ alkylamino;

in which

R is hydrogen, Ci-C ₈ alkyl, Ci-C ₈ haloalkyl, C ₂ -C ₈ alkenyl,

C ₂ -C ₈ -haloalkenyl, C ₂ -C ₈ -alkynyl, C ₂ -C ₈ -haloalkynyl, C (= O) R ³ , C (= S) R ³ , SO ₂ R ⁴ or CN; in which

R ³ represents hydrogen, Ci-C ₈ alkyl, _{Ci-C8-haloalkyl, Ci-C8-haloalkoxy} or NA ³ A ⁴ represents ₈ alkoxy, Ci-C; and

R ⁴ is d-Cs-alkyl, phenyl-Ci-C ₈ -alkyl or phenyl, wherein the

Each phenyl group is unsubstituted or substituted by one, two or three groups independently selected from halogen and C 1 -C 4 alkyl;

wobei A und B wie oben definiert sind;

wherein A and B are as defined above;

wobei # die Verknüpfungsstelle mit dem Triazolylring ist und Q, R¹ und R² bedeuten:- a group of Dil

where # is the point of attachment to the triazolyl ring and Q, R ¹ and R ^{2 are}

Q O or S;

R ¹ , R ² independently of one another are C ¹ -C 6 -alkyl, C ¹ -C -haloalkyl, d-

Cs-alkoxy, Ci-Cs-alkoxy-d-Cs-alkoxy, _{Ci-C8-haloalkoxy,} Ci-C ₈ - alkoxy-Ci-C ₈ alkyl, Ci-C ₈ -alkyl thio, C ₂ -C _8- alkenylthio, C ₂ -C ₈ -alkynylthio, C ₅ -C ₈ -cycloalkyl, C ₃ -C ₈ -cycloalkylthio, phenyl, phenyl-C ₁ -C ₄ -alkyl, phenoxy, phenylthio, phenyl-C ₁ -C 4 -cycloalkyl alkoxy or NR ⁵ R ⁶ , wherein R ^{5 is} H or C 1 -C ⁶ -alkyl and R ^{6 is} C 1 -C ₈ -alkyl, phenyl-C 1 -C ₄ -alkyl or phenyl or R ⁵ and R ⁶ together represent an alkylene chain with four or five carbon atoms or form a radical of the formula -CH ₂ -CH ₂ -O-CH ₂ -CH ₂ - or -CH ₂ -CH ₂ -NR ⁷ -CH ₂ -CH ₂ -, in which R ^{7 is} hydrogen or C 1 -C ₄ -alkyl; wherein the aromatic groups in the aforementioned radicals are each independently unsubstituted or substituted by one, two or three groups selected from halogen and C 1 -C ₄ -alkyl; or a group SM, where M means:

M is an alkali metal cation, one equivalent of an alkaline earth metal cation, one equivalent of a copper, zinc, iron or nickel cation or an ammonium cation of the formula (E) z ²

Z ¹ - NZ ³ (E)

in which

Z ¹ and Z ^{2 are} independently hydrogen or C 1 -C ₈ alkyl; Z ³ and Z ^{4 are} independently hydrogen, C 1 -C ₈ alkyl, benzyl or phenyl; wherein the phenyl groups are each unsubstituted or substituted by one, two or three groups independently selected from halogen and C 1 -C 4 alkyl;

and their agriculturally acceptable salts.

Preference is given to compounds of the formula I in which the variable D denotes: D - S-R, where

R is hydrogen, Ci-Cs-alkyl, Ci-C ₈ haloalkyl, C ₂ -C ₈ alkenyl,

C ₂ -C 8 haloalkenyl, C ₂ -C 8 alkynyl, C ₂ -C 8 haloalkynyl, C (= O) R ³ , C (= S) R ³ , SO ₂ R ⁴ or CN; in which

R ³ is Ci-Cs-alkyl, _{Ci-C8-haloalkyl, Ci-C8-alkoxy,} CrC ₈ - represents halogenoalkoxy or NA ³ A ^4; and

R ⁴ is d-Cs-alkyl, phenyl-Ci-C ₈ -alkyl or phenyl, wherein the

Each phenyl group is unsubstituted or substituted by one, two or three groups independently selected from halogen and C 1 -C ₄ -alkyl;

- a group Dl

wobei A und B wie oben definiert sind;

wherein A and B are as defined above;

wobei # die Verknüpfungsstelle mit dem Triazolylring ist und Q, R¹ und R² bedeuten: Q O oder S;- a group of Dil

where # is the point of attachment to the triazolyl ring and Q, R ¹ and R ^{2 are} QO or S;

R ¹ , R ² independently of one another are C 1 -C 6 -alkyl, C 1 -C 5 -haloalkyl, C 1 -C 5 -alkoxy, C 1 -C 5 -alkoxy-C 1 -C 5 -alkoxy, C 1 -C ₈ -haloalkoxy, C 1 -C ₈ - alkoxy-Ci-C ₈ alkyl, Ci-C ₈ -alkyl thio, C ₂ -C ₈ -alkenylthio, C ₂ -C ₈ -alkyl kinyl- thio, Cs-Cs-cycloalkyl, C ₃ -C ₈ cycloalkylthio , phenyl, phenyl-Ci-C ₄ - alkyl, phenoxy, phenylthio, phenyl-Ci-C4-alkoxy or NR ⁵ R ^6, wherein R ⁵ is H or Ci-C ₈ alkyl and R ⁶ is C ₈ - Al kyl, phenyl-Ci-C ₄ - alkyl or phenyl or R ⁵ and R ⁶ together represent an alkylene chain having four or five carbon atoms or a radical of the formula

-CH ₂ -CH ₂ -O-CH ₂ -CH ₂ - or -CH ₂ -CH ₂ -NR ⁷ -CH ₂ -CH ₂ - form, wherein R ^{7 is} hydrogen or Ci-C ₄ alkyl; wherein the aromatic groups in the aforementioned radicals are each independently unsubstituted or substituted by one, two or three groups selected from halogen and C 1 -C ₄ -alkyl; or a group SM, where M means:

M is an alkali metal cation, one equivalent of an alkaline earth metal cation, one equivalent of a copper, zinc, iron or nickel cation or an ammonium cation of the formula (E) Z ²

Z ¹ - NZ ³ (E)

in which

Z ¹ and Z ^{2 are} independently hydrogen or C 1 -C ₈ -alkyl; Z ³ and Z ^{4 are} independently hydrogen, C 1 -C ₈ alkyl, benzyl or phenyl; wherein the phenyl groups are each unsubstituted or substituted by one, two or three groups independently selected from halogen and C 1 -C ₄ alkyl; and wherein the remaining substituents are as defined above.

The compounds of formula I can in the "thiol" form of the formula Ia or in the "Thiono" form de

!a Ib worin D^* bedeutet:

! a Ib wherein D ^* means:

R, wherein R has the meaning defined above;

wobei # die Verknüpfungsstelle mit dem Schwefelatom in Formel Ia bzw. Azo- lylring in Formel Ib ist und Q, R¹ und R² die oben definierte Bedeutung haben; oder- a group of dil ^*

where # is the point of attachment with the sulfur atom in formula Ia or azolyl ring in formula Ib and Q, R ¹ and R ^{2 have} the meaning defined above; or

- a group M, wherein M has the meaning defined above, and wherein the remaining substituents have the meaning defined above.

For the sake of simplicity, only the "thiol" form is usually listed here in each case.

Furthermore, the invention relates to the preparation of the compounds I, the intermediates for the preparation of the compounds I and their preparation and the use düng of the compounds of the invention for combating phytopathogenic fungi and agents containing them.

Triazolylmethyloxiranes having substituted triazole group e.g. from WO 96/38440, WO 97/41 107, WO 97/42178, WO 97/43269, WO 97/44331, WO 97/443332, WO 99/05149 and WO 99/21853. Furthermore, azolylmethyloxiranes are known from EP 0330132, EP 0421 125, EP 0388871.

The fungicidal action of the compounds known from the prior art, however, leaves something to be desired, in particular at low application rates in some cases. It is an object of the present invention to provide novel compounds which preferably have improved properties, such as a better fungicidal action and / or better toxicological properties. This object has surprisingly been achieved with the compounds of the formula I described herein.

The compounds I are able to form salts or adducts with inorganic or organic acids or with metal ions because of the basic character of the nitrogen atoms contained in them. This also applies to most of the precursors for compounds I described herein, the salts and adducts of which are also subject of the present invention.

Examples of inorganic acids are hydrohalic acids such as hydrogen fluoride, hydrogen chloride, hydrogen bromide and hydrogen iodide, carbonic acid, sulfuric acid, phosphoric acid and nitric acid. Suitable organic acids are, for example, formic acid and alkanoic acids, such as acetic acid, trifluoroacetic acid, trichloroacetic acid and propionic acid, and also glycolic acid, thiocyanic acid, lactic acid, succinic acid, citric acid, benzoic acid and other arylcarboxylic acids, cinnamic acid, oxalic acid, alkylsulfonic acids (sulfonic acids with straight-chain or branched alkyl radicals with 1 to 20 carbon atoms), arylsulfonic acids or disulfonic acids (aromatic radicals such as phenyl and naphthyl which carry one or two sulfonic acid groups), alkylphosphonic acids (phosphonic acids having straight-chain or branched alkyl radicals having 1 to 20 carbon atoms), arylphosphonic acids or diphosphonic acids (aromatic Radicals such as phenyl and naphthyl which carry one or two phosphoric acid radicals), where the alkyl or aryl radicals may carry further substituents, for example p-toluenesulfonic acid, salicylic acid, p-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, etc.

The metal ions are, in particular, the ions of the elements of the second main group, in particular calcium and magnesium, the third and fourth main groups, in particular aluminum, tin and lead, and the first to eighth transition groups, in particular chromium, manganese, iron, cobalt, nickel, Copper, zinc and others into consideration. Particularly preferred are the metal ions of the elements of the subgroups of the fourth period. The metals can be present in the various valences that belong to them.

The compounds of the formula I according to the invention can be prepared in various ways in analogy to prior art processes known per se (see, for example, the cited prior art and Pflanzenschutz-Nachrichten Bayer 57/2004, 2, pages 145-162). For example, the compounds of the invention can be prepared by the syntheses shown in the following Schemes.

The compounds according to the invention can advantageously be prepared starting from compounds of the formula II

worin A und B wie hierin beschrieben definiert sind, durch Umsetzung mit einer starken Base und Schwefelpulver hergestellt werden. Dabei entstehen Verbindungen der Formel I, worin D SH bedeutet (Verbindungen 1-1 ):

wherein A and B are defined as described herein by reaction with a strong base and sulfur powder. Compounds of the formula I are formed in which D is SH (compounds 1-1):

The invention therefore also encompasses a process for the preparation of compounds of the formula I according to the invention in which D is SR with R = hydrogen, C 1 -C ₈ -haloalkyl, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ -haloalkenyl, C ₂ - C ₈ alkynyl or C ₂ -C ₈ haloalkynyl comprising the step

(a5) reacting a compound of formula II wherein A and B are as defined or preferably defined for formula I with a strong base and sulfur powder to obtain a compound 1-1 as defined herein; and in order to obtain compounds I in which D stands for SR, where R d-Cs-haloalkyl, C ₂ - Cs alkenyl, C2-C8 haloalkenyl, C ₂ -C ₈ alkynyl, or C2-C8-haloalkynyl,

(b5) reacting compounds 1-1 with R-X, wherein X is halogen or trifluoro (Ci- C8) alkylsulfonate.

The invention therefore also encompasses a process for the preparation of compounds of the formula I according to the invention in which D is SR where R = hydrogen, C ₁ -C ₈ -alkyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₈ -alkynyl, C ₂ - C ₈ haloalkenyl, C ₂ -C ₈ alkynyl or C ₂ -C ₈ haloalkynyl, comprising the step of (a5) reacting a compound of formula II, wherein A and B are as defined or preferably defined for formula I, with a strong base and sulfur powder to obtain a compound 1-1 as defined herein; and, to obtain compounds I wherein D is SR, wherein R is Ci -Ce-Al kyl, Ci-C ₈ -HaIo- genalkyl, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ haloalkenyl, C C ₂ -C ₈ -alkynyl or C ₂ -C ₈ -haloalkynyl,

(b5) reaction of compounds 1-1 with RX, where X is halogen or trifluoro _(CI-C8) is alkylsulfonate.

Suitable bases are all suitable bases known to those skilled in the art for such reactions. Preferably, strong alkali metal bases such as n-butyl lithium, lithium diisopropylamide, sodium hydride, sodium amide or potassium tert-butoxide are used. It may be preferred to react in the presence of an additive such as e.g. Tetramethylethylenediamine (TMEDA) to perform.

Suitable solvents are all inert organic solvents which are customary for such reactions, preferably ethers, such as tetrahydrofuran, dioxane, Diethyl ether and 1, 2-dimethoxyethane or liquid ammonia or strongly polar solvents such as dimethyl sulfoxide can be used.

Sulfur is preferably used as a powder. Hydrolysis is carried out using water, optionally in the presence of an organic or inorganic acid, e.g. Acetic acid, dilute sulfuric acid or dilute hydrochloric acid.

The reaction temperature is preferably between -70 ⁰ C and + 20 ⁰ C, in particular between -70 ° C and 0 ⁰ C. The reaction is generally carried out under atmospheric pressure.

In general, 1 to 3 equivalents, preferably 1 to 2.5 equivalents, of strong base and then an equivalent amount or an excess of sulfur are used per mole of the compound of the formula II. The reaction may be carried out under a protective gas atmosphere, e.g. under nitrogen or argon. The workup is carried out according to methods generally known to the person skilled in the art. Usually, the reaction mixture is extracted with a suitable organic solvent and the residue is optionally purified by recrystallization and / or chromatography.

It is also possible to prepare compounds I by direct reaction with sulfur, preferably sulfur powder, without the use of a strong base such as butyllithium.

Another possibility, starting from compounds II to prepare compounds I according to the invention, is to prepare compounds II with sulfur in the presence of an aprotic, polar solvent, e.g. an amide (such as dimethylformamide (DMF)) or N-alkylpyrrolidone (such as N-octylpyrrolidone, N-dodecylpyrrolidone or N-methylpyrrolidone (NMP)) implement. See also WO 99/19307, WO 97/06151, WO 97/051 19 and WO 96/41804.

The reaction is usually carried out at temperatures in the range of 140 ° C to 160 ° C. The reaction components are usually employed in amounts such that about 1 to 6 moles of sulfur are used per mole of compound II. Sulfur is usually used in the form of powder. During the reaction, air is passed over the reaction mixture.

The compounds according to the invention can also be prepared advantageously starting from compounds of the formula II by reaction with disulphides or dirhodane:

II-2 wherein A and B are defined as described herein, and R Ci is -Ce-alkyl, Ci-Cs haloalkyl, C2-C8 alkenyl, C2-C8 haloalkenyl, C2-Cs alkynyl, C2-C8 - Haloalkynyl or CN can mean.

Suitable bases are all suitable bases known to those skilled in the art for such reactions. Preferably, strong alkali metal bases such as n-butyl lithium, lithium diisopropylamide, sodium hydride, sodium amide or potassium tert-butoxide are used. It may be preferred to react in the presence of an additive such as e.g. Tetramethylethylenediamine (TMEDA) to perform.

The disulfides are commercially available or synthesized by known manufacturing methods. A special disulfide is the Dirhodan NC-S-S-CN.

Suitable solvents are all inert organic solvents which are customary for such reactions, ethers such as tetrahydrofuran, dioxane, diethyl ether and 1, 2-dimethoxyethane or liquid ammonia or strongly polar solvents such as dimethyl sulfoxide preferably being usable.

The reaction temperature is preferably between -70 ⁰ C and + 20 ⁰ C, in particular between -70 ° C and 0 ⁰ C. The reaction is generally carried out under atmospheric pressure. In general, 1 to 3 equivalents, preferably 1 to 2.5 equivalents, of strong base and then an equivalent amount or an excess of disulfide are used per mole of the compound of the formula II. The reaction can be carried out under a protective gas atmosphere, for example under nitrogen or argon. The workup is carried out according to methods generally known to the person skilled in the art. Usually, the reaction mixture is extracted with a suitable organic solvent and the residue is optionally purified by recrystallization and / or chromatography.

By further reacting compounds 1-1 with RX, wherein R is defined elsewhere herein and X is a leaving group such as halogen, such as Cl, Br or I, or trifluoro-Ci-Cβ-alkyl sulfonate, various Compounds according to the invention of formula I are prepared. For the preparation of compounds with D = SR with R = Ci -Ce-Al alkyl, preferably Ci-C4-alkyl, preferably methyl or ethyl, a compound 1-1 is reacted with the corresponding alkyl halide (see also WO 96/38440). Compounds of the formula I in which D is SC (OO) NA ³ A ⁴ can be synthesized in analogy to the process described in WO 99/21853.

Compounds of the formula I in which D is a group Dil can be synthesized in analogy to the process described in WO 99/05149.

Compounds of the formula I in which D is S-SO ² R ⁴ can be synthesized in analogy to the process described in WO 97/44332.

Compounds of the formula I in which D is S-CN can be synthesized in analogy to the process described in WO 99/44331.

Compounds of the formula I in which D is a group D1 can be synthesized in analogy to the process described in WO 97/43269.

Compounds of the formula I in which D is a group SC (OO) R ³ where R ³ CiC 1 -C -alkyl, C 1 -C 6 -haloalkyl, C 1 -C -alkoxy or C 1 -C -haloalkoxy, can be mentioned in Analogous to the method described in WO 97/42178 be synthesized.

Compounds of the formula I in which D is a group SM can be synthesized in analogy to the process described in WO 97/41 107.

The synthesis of the compounds of the formula II can be carried out on the basis of the cited prior art. Compounds of formula II and their preparation are also described in part in international patent applications PCT / EP2007 / 055932, PCT / EP2007 / 055870, PCT / EP2007 / 056124, PCT / EP2007 / 056403, PCT / EP2007 / 056306, PCT / EP2007 / 057404 and PCT / EP2007 / 057353.

Some of the compounds of the formula II are novel and these and their agriculturally acceptable salts and adducts are likewise provided by the present invention. The present invention therefore also relates to compounds of the formula II in which A and B are

A or B represents a tri-, tetra-, penta-, hexa-, si-, e-, n- or ten-membered saturated or partially unsaturated heterocycle or five-, six-, seven-, eight-, nine- or ten-membered aromatic heterocycle, wherein the heterocycle each contains one, two, three or four heteroatoms from the group O, N and S and wherein the saturated and partially unsaturated heterocycle is unsubstituted or independently substituted by one, two, three or four L, and wherein the aromatic Heterocycle contains one, two, three or four identical or different groups L; the other variable B or A: three-, four-, five-, six-, seven-, eight-, nine- or ten-membered saturated or partially unsaturated heterocycle, five, six, seven, eight, nine or a ten-membered aromatic heterocycle, the heterocycle containing in each case one, two, three or four heteroatoms from the group consisting of O, N and S, C 1 -C 6 -alkyl, C 1 -C 12 -haloalkyl, C 2 -C 8 -alkenyl, C 2 -C 8 haloalkenyl, C 2 -C 8 alkynyl, C 2 -C 8 haloalkynyl, C 3 -C 8 cycloalkyl or C 5 -C 8 halocycloalkyl, where this other variable B or A is unsubstituted or denoted by one, two, three or four groups L is substituted;

wherein compounds of formula II wherein A or B is selected from 2-chloropyridin-4-yl, 3-chloropyridin-4-yl, 2,6-dichloropyridin-4-yl, 3,5-dichloropyridin-4-yl, 3 , 6-dichloropyridin-4-yl, 2-fluoropyridin-4-yl, 3-fluoropyridin-4-yl, 2-chloropyridin-3-yl, 4-chloropyridin-3-yl, 5-chloropyridin-3-yl , 6-Chloropyridin-3-yl, 2,4-dichloropyridin-3-yl, 2,5-dichloropyridin-3-yl, 2,6-dichloropyridin-3-yl, 2-fluoropyridin-3-yl, 4-fluoropyridine 3-yl, 5-fluoropyridin-3-yl, 6-fluoropyridin-3-yl, 3-chloropyridin-2-yl, 4-chloropyridin-2-yl, 5-chloropyridin-2-yl, 6-chloropyridine -2-yl, 3-fluoropyridin-2-yl, 4-fluoropyridin-2-yl, 5-fluoropyridin-2-yl, 6-fluoropyridin-2-yl, 2-methylpyridin-4-yl, 3-methylpyridine-4 -yl, 2-methylpyridin-3-yl, 4-methylpyridin-3-yl, 5-methylpyridin-3-yl, 6-methylpyridin-3-yl, 3-methylpyridin-2-yl, 4-methylpyridin-2-yl , 5-Methylpyridin-2-yl, 6-methylpyridin-2-yl, 2-methoxypyridin-4-yl, 3-methoxypyridin-4-yl, 2-methoxypyridin-3-yl, 4-methoxypyridin-3-yl, 5 -Methoxypyridin-3-yl, 6-methoxypyridine 3-yl, 3-methoxypyridin-2-yl, 4-methoxypyridin-2-yl, 5-methoxypyridin-2-yl, 6-methoxypyridin-2-yl, 6-chloropyrimidin-3-yl, 6-methylpyrimidine 3-yl, 6-methoxypyrimidin-3-yl, 2,4-dichloropyrimidin-3-yl, 2,6-dichloropyrimidin-3-yl, 2,4-difluoropyrimidin-3-yl, 2,6-difluoropyrimidine 3-yl, 2-chlorothien-3-yl, 4-chlorothien-3-yl, 5-chlorothien-3-yl, 2,5-dichlorothien-3-yl, 2,4,5-trichlorothien-3-yl, 2-bromothien-3-yl, 4-bromothien-3-yl, 5-bromothien-3-yl, 2,5-dibromothien-3-yl, 2,4,5-tribromothien-3-yl, 3-bromo- fur-2-yl, 4-bromo-fur-2-yl, 5-bromo-fur-2-yl, 4,5-dibromo-fur-2-yl, 4-chlorofur-2-yl, 5-chlorofur-2-yl, 3 4-Dichlorofur-2-yl, 2-chlorothiazol-5-yl, 4-chlorothiazol-5-yl, 2,4-dichlorothiazol-5-yl, 2-bromothiazol-5-yl, 2-chlorothiazole; yl, 2-bromothiazol-4-yl, 1-methylpyrazol-4-yl, 1, 3-dimethylpyrazol-4-yl, 1, 5-dimethylpyrazol-4-yl, 1, 3,5-trimethylpyrazole-4 yl, 1-methylpyrazol-3-yl, 1-methylimidazol-4-yl, 1, 5-dimethylimidazol-4-yl, 1-methylpyrazol-5-yl, 1, 2-dimethylimidazol-5-yl and 1, 4 Dimethylimi dazol-5-yl, and the other variable B or A is unsubstituted 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 4-pyridinyl, 2-thienyl, 3-thienyl, thiazol-4-yl, thiazole-5 yl, oxazol-4-yl, oxazol-5-yl or 2-furyl are excluded.

A and B in formula II preferably have the meanings as described in more detail below for compounds of the formula I, provided that they are included in the definition of the variables for the compounds II. In particular, it may be preferred that A and B have the following meanings: A or B is a five- or six-membered aromatic heterocycle, wherein the heterocycle contains in each case one, two, three or four heteroatoms from the group O, N and S and is substituted by one, two, three or four independently selected L; and

the other variable B or A: five- or six-membered saturated or aromatic heterocycle, wherein the heterocycle contains one, two, three or four heteroatoms from the group O, N and S and substituted by one, two, three or four groups L. is C 1 -C 6 -alkyl, C 1 -C 12 -haloalkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -haloalkenyl, C 2 -C -alkynyl, C 2 -C 8 -haloalkynyl, C 1 -C -cycloalkyl or C 3 -C 5 -substituted Halocycloalkyl, which are each unsubstituted or substituted by one, two, three or four groups L.

A and B preferably have the following meanings:

A or B is a tri-, tetra-, penta-, hexa-, seven-, eight-, nine- or ten-membered saturated or partially unsaturated heterocycle or five-, six-, seven-, eight-, nine- or ten-membered aromatic Heterocycle, wherein the heterocycle each contains one, two, three or four heteroatoms from the group O, N and S and wherein the saturated and partially unsaturated heterocycle (1) is substituted by either an L selected from fluoro, chloro, methyl or methoxy, and additionally substituted by one, two or three independently selected substituents L other than the first substituent L;

(2) or is substituted by two, three or four identical L's other than chlorine, bromine and fluorine;

(3) or substituted by an L other than fluoro, chloro, methyl or methoxy;

the other variable B or A: three-, four-, five-, six-, seven-, eight-, nine- or ten-membered saturated or partially unsaturated heterocycle, five, six, seven, eight, nine or a ten-membered aromatic heterocycle, the heterocycle containing in each case one, two, three or four heteroatoms from the group consisting of O, N and S, C 1 -C 6 -alkyl, C 1 -C 5 -haloalkyl, C 2 -C 5 -alkenyl, C 2 -C 8 -synyl Haloalkenyl, C2-Cs-alkynyl, C2-Cs-haloalkynyl, C3-Cs-cycloalkyl or Cs-Cs-halocycloalkyl, wherein this other variable B or A is unsubstituted or substituted by one, two, three or four groups L.

L has the meanings described herein or preferred meanings for L. Compounds II also possess fungicidal activity and the present invention therefore also relates to the use of the compounds II and / or the salts and adducts thereof as fungicides.

Compounds of the formula III

worin Z für eine Abgangsgruppe X (Verbindungen III.1 , siehe unten) oder OH (Verbindungen III.2, siehe unten) steht und A und B wie unten definiert sind, stellen wichtige Ausgangsverbindungen dar, um letztlich zu den erfindungsgemäßen Verbindungen zu gelangen.

wherein Z is a leaving group X (Compounds III.1, see below) or OH (Compounds III.2, see below) and A and B are as defined below, are important starting compounds to ultimately arrive at the compounds of the invention.

Thus, compounds II, for example, starting from compounds III.1

hergestellt werden, wobei X für eine Abgangsgruppe steht, wie beispielsweise Halogen (z.B. Cl oder Br) oder OSO₂R, worin R für Ci -C₆-Al kyl, d-Ce-Haloalkyl, Aryl oder substituiertes Aryl steht, insbesondere steht OSO₂R für eine Mesylat-, Triflat-, Phenyl- oder Toluolsulfonatgruppe. Um Verbindungen der Formel Il zu erhalten, werden Verbindungen der Formel III.1 mit 1 ,2,4-Triazol und einer Base wie beispielsweise Natriumhydrid in z.B. DMF umgesetzt. Siehe auch z.B. EP O 421 125 A2.

where X is a leaving group such as, for example, halogen (eg Cl or Br) or OSO ₂ R, where R is C ₁ -C ₆ -alkyl, d-Ce-haloalkyl, aryl or substituted aryl, in particular OSO ₂ R for a mesylate, triflate, phenyl or toluenesulfonate group. In order to obtain compounds of the formula II, compounds of the formula III.1 are reacted with 1, 2,4-triazole and a base such as, for example, sodium hydride in, for example, DMF. See also, for example, EP 0 421 125 A2.

Compounds of the formula III.1 are partly new and these are likewise the subject of the present invention. The present invention therefore also relates to compounds of the formula III.1, in which X, A and B are

A or B is a five-, six-, seven-, eight-, nine- or ten-membered partially unsaturated heterocycle or five- or six-membered aromatic heterocycle, wherein the heterocycle each contains one, two, three or four heteroatoms from the group consisting of O, N and S. and wherein the partially unsaturated heterocycle is unsubstituted or substituted by one, two, three or four L, and wherein the aromatic heterocycle contains one, two, three or four identical or different groups L;

and the other variable B or A: five-, six-, seven-, eight-, nine- or ten-membered partially unsaturated or aromatic heterocycle, wherein the heterocycle each having one, two, three or four heteroatoms from the group O, N and includes S, Ci-C ₈ -alkyl, C ₈ haloalkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ - haloalkenyl, C ₂ -C ₈ -alkyl kinyl, C ₂ -C ₈ haloalkynyl , C ₃ -C ₈ -cycloalkyl, C ₃ -C ₈ - Halocycloalkyl or phenyl; wherein this other variable B or A is each unsubstituted or substituted by one, two, three or four L groups;

or

A is phenyl substituted with two F; and

B is unsubstituted pyridyl, thienyl, thiazolyl, oxazolyl or furyl;

or

A is phenyl substituted with three F; and

B is unsubstituted pyridyl, thienyl, thiazolyl, oxazolyl or furyl;

or

A is phenyl which is substituted by one F and one further substituent selected from Cl, C 1 -C ₄ -alkyl, C 1 -C ₄ -haloalkyl and C 1 -C ₄ -alkoxy; and B is unsubstituted pyridyl, thienyl, thiazolyl, oxazolyl or furyl;

or

A or B is phenyl which is substituted by one CN and optionally additionally one, two or three substituents independently selected from halogen, NO 2, amino, C 1 -C ₄ -alkyl, C 1 -C ₄ -alkoxy, C 1 -C ₄ -haloalkyl, Ci-C ₄ haloalkoxy, _{Ci-C4-alkylamino,} C1-C4-

Dialkylamino, thio and C 1 -C ₄ -alkylthio;

and the other variable B or A is unsubstituted 5-membered or 6-membered heteroaryl containing one, two, three or four heteroatoms from the group O, N and S;

or

A or B is benzodioxolyl which is unsubstituted or independently selected from one, two, three, four or five substituents selected from halogen, CN, NO ₂ , amino, C 1 -C ₄ -alkyl, C 1 -C ₄ -alkoxy, C ₄ haloalkyl, _{Ci-C4-haloalkoxy,} Ci-C ₄ alkylamino, Ci-C ₄ dialkylamino, thio, and Ci-C ₄ alkylthio, substituted,

and the other substituent B or A 5-membered or 6-membered heteroaryl containing one, two, three or four heteroatoms from the group O, N and S, wherein the heteroaryl is in each case unsubstituted or by one, two or three substituents independently selected from halogen, CN, NO _2, amino, Ci _-C4 -alkyl, Ci-C ₄ alkoxy, Ci-C ₄ - haloalkyl, _{Ci-C4-haloalkoxy,} Ci- C ₄ alkylamino, Ci-C ₄ - dialkylamino, thio and CrC ₄ -AI kyl thio, is substituted;

and X is a leaving group as defined above;

wherein the compounds [(2RS, 3SR) -3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) oxiran-2-yl] methyl methanesulfonate and [(2SR, 3RS) -3- (2, 5-dichlorothiophene-3-yl) -2- (4-fluorophenyl) oxiran-2-yl] methyl methanesulfonate are excluded.

A and B in formula III.1 preferably have the meanings as described in more detail below for compounds of the formula I, if they are included in the definition of the variables for the compounds III.1. L has the meanings described herein or preferred meanings for L.

It may be preferred according to one embodiment of the invention if A and B in the compounds III.1 have the following meanings:

A or B is a five- or six-membered aromatic heterocycle containing one, two, three or four heteroatoms from the group O, N and S and containing one, two, three or four identical or different groups L;

and the other variable B or A: five- or six-membered aromatic heterocycle containing one, two, three or four heteroatoms from the group O, N and S, or phenyl; wherein said other variable B or A is substituted by one, two, three or four independently selected groups L;

wherein the compounds [(2RS, 3SR) -3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) oxiran-2-yl] methyl methanesulfonate and [(2SR, 3RS) -3- (2, 5-dichlorothiophene-3-yl) -2- (4-fluorophenyl) oxiran-2-yl] methyl methanesulfonate are excluded.

According to a further embodiment, A and B in the compounds III.1 have the following meanings:

A or B is a five- or six-membered aromatic heterocycle containing one, two, three or four heteroatoms from the group O, N and S, preferably the aromatic heterocycle is selected from thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, Pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl, in particular selected from thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, pyridinyl, pyrimidinyl and pyrazinyl, where the aromatic heterocycle contains one, two, three or four independently selected groups L; and the other variable B or A: a five- or six-membered aromatic heterocycle containing one, two, three or four heteroatoms from the group O, N and S and substituted by one, two, three or four independently selected groups L. or phenyl substituted by two, three or four independently selected L groups.

In this embodiment, particular preference is given to the meanings in which the compounds III.1 are not [(2RS, 3SR) -3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) oxiran-2-yl] methyl methanesulfonate or [(2SR, 3RS) -3- (2,5-dichlorothiophen-3-yl) -2- (4-fluorophenyl) oxiran-2-yl] methyl methanesulfonate.

According to yet another embodiment, A and B in the compounds III.1 have the following meanings:

A is phenyl substituted with two F; Phenyl substituted with three F; or phenyl substituted with one F and another substituent selected from Cl, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl and C 1 -C 4 alkoxy; and B is unsubstituted pyridyl, thienyl, thiazolyl, oxazolyl or furyl.

durch Einführen der Abgangsgruppe X mittels dem Fachmann bekannter Methoden erhalten werden. Dementsprechend wird eine Verbindung der Formel III.2 beispiels- weise mit R-SO2Y, wobei R wie für Formel III.1 definiert ist und Y für Halogen steht, wobei R-SO2Y bspw. Mesylchlorid bedeutet, in Gegenwart einer Base (z.B. NEt.3) umgesetzt (siehe auch EP386557). Um Verbindungen III.1 zu erhalten, worin X für Halogen steht, kann die entsprechende Verbindung III.2 mit C(HaI)₄ (HaI = Br oder Cl) mit PPhi3 in bspw. CH2CI2 zu einer Verbindung III.1 umgesetzt werden. Alternativ kann eine Verbindung III.2 mit SOCb/Pyridin umgesetzt werden (siehe auch WO 2005/056548).In turn, compounds of the formula III.1 can be prepared from compounds of the formula III.2,

by introducing the leaving group X by methods known to those skilled in the art. Accordingly, a compound of the formula III.2 is obtained, for example, with R-SO 2 Y, where R is as defined for formula III.1 and Y is halogen, where R-SO 2 Y is, for example, mesyl chloride, in the presence of a base (for example NEt. 3) reacted (see also EP386557). In order to obtain compounds III.1 in which X is halogen, the corresponding compound III.2 can be reacted with C (Hal) ₄ (Hal = Br or Cl) with PPhi 3 in, for example, CH 2 Cl 2 to give a compound III.1. Alternatively, a compound III.2 can be reacted with SOCb / pyridine (see also WO 2005/056548).

Compounds of the formula III.2 are partly new and these are likewise the subject of the present invention. The present invention therefore also relates to compounds of formula III.2, wherein A and B are as defined or preferred for formula III.1 above, wherein the compounds {(2RS, 3SR) - [3- (2-chloropyridine 3-yl) -2- (4-fluorophenyl) oxiran-2-yl] methanol and [(2SR, 3RS) -3- (2,5-dichlorothiophen-3-yl) -2- (4-fluorophenyl) oxirane -2-yl) methanol are excluded.

Furthermore, A and B in formula III.2 preferably have the meanings as described in more detail for compounds of formula I, provided that they are defined by the definition of the formula Variables for the compounds III.2 are included. L has the meanings described herein or preferred meanings for L.

Compounds of the formula III.2 can be prepared from α, β-disubstituted acroleins of the formula V

erhalten werden, indem zunächst epoxidiert wird beispielsweise mit H2O2 in Gegenwart einer Base wie z.B. NaOH oder durch Umsetzung mit einer Persäure (z.B. MCPBA=m- Chlorperoxybenzoesäure) oder tert-Butylhydroperoxid). Dabei entstehen Verbindungen der Formel Va

are obtained by first epoxidizing example with H2O2 in the presence of a base such as NaOH or by reaction with a peracid (eg MCPBA = m-chloroperoxybenzoic acid) or tert-butyl hydroperoxide). This gives rise to compounds of the formula Va

By reduction of the aldehyde group in compounds Va, for example with NaBH ₄ (see also EP 0 386 557 A1), compounds III.2 are formed. Methods for epoxidizing and reducing the aldehyde group are well known to those skilled in the art.

In Formula V, the double bond may be in both (E) and (Z) configurations. This is represented by the jagged bond between B and the double bond. Compounds of the formula V are partly new and these are also the subject of the present invention. The present invention therefore also relates to compounds of the formula V in which A and B are

A or B represents a tri-, tetra-, penta-, hexa-, si-, e-, n- or ten-membered saturated or partially unsaturated heterocycle or five-, six-, seven-, eight-, nine- or ten-membered aromatic heterocycle, where the heteroaromatic, if it is five- or six-membered, is selected from thienyl,

Furyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl and isothiazolyl or pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl, wherein the heterocycle each contains one, two, three or four heteroatoms from the group O, N and S and wherein the partially unsaturated heterocycle unsubstituted or independently substituted by one, two, three or four L, and wherein the saturated and aromatic heterocycle each contains one, two, three or four identical or different groups L; and

the other variable B or A: three-, four-, five-, six-, seven-, eight-, nine- or ten-membered saturated or partially unsaturated heterocycle, five, six, seven, eight, nine or a ten-membered aromatic heterocycle, where the heterocycle each contains one, two, three or four heteroatoms from the group O, N and S and unsubstituted or substituted by one, two, three or four L groups, C ₁ -C ₈ -alkyl, C ₁ -C ₈ -haloalkyl, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ -haloalkenyl, C ₂ -C ₈ Alkynyl, C ₂ -C ₈ haloalkynyl, Cs-Cs-cycloalkyl, Cs-Cs-halocycloalkyl or phenyl substituted by one, two, three or four L;

or

A is phenyl substituted with two F; and B is unsubstituted pyridyl, thienyl, thiazolyl, oxazolyl or furyl;

or

A is phenyl substituted with three F; and B is unsubstituted pyridyl, thienyl, thiazolyl, oxazolyl or furyl,

or

A is phenyl substituted with one F and another substituent selected from Cl, C 1 -C ₄ alkyl, C 1 -C ₄ haloalkyl and C 1 -C ₄ alkoxy; and B is unsubstituted pyridyl, thienyl, thiazolyl, oxazolyl or furyl,

or

A or B is phenyl which is substituted with a CN and, optionally, one, two or three substituents independently selected from halogen, NO _2, amino, Ci-C ₄ -alkyl, -C ₄ -alkoxy, C 1 -C 4 haloalkyl, C -C 4 haloalkoxy, C 1 -C 4 alkylamino, C 1 -C 4 dialkylamino, thio and C 1 -C 4 alkylthio;

and the other substituent B or A is unsubstituted or substituted by one, two, three or four identical or different groups L 5- or θ-membered heteroaryl heteroaryl, the one, two, three or four heteroatoms from the group O, N and S contains

or

A or B represents benzodioxolyl which is unsubstituted or independently selected from one, two, three, four or five substituents selected from halogen, CN, NO ₂ , amino, C 1 -C ₄ alkyl, C 1 -C ₄ alkoxy, C 1 -C _{4 4} -haloalkyl, Ci-C4-haloalkoxy, Ci-C4-alkylamino, Ci-C4-dialkylamino, thio and Ci-C4-alkylthio, is substituted; and the other substituent B or A is 5-membered or 6-membered heteroaryl which contains one, two, three or four heteroatoms from the group O, N and S, where the heteroaryl is in each case unsubstituted or by one, two or three substituents independently selected from halogen, CN, NO 2, amino, C 1 -C ₄ -alkyl, C 1 -C ₄ -alkyl,

Alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, C 1 -C 4 alkylamino, C 1 -C 4 dialkylamino, thio and C 1 -C 4 alkylthio;

with the exception of the compounds (E) -3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) acrylaldehyde and E) -3- (2,5-dichlorothiophene-3-yl) -2- (4-fluorophenyl) acrylaldehyde.

A and B in formula V preferably have the meanings as described in more detail below for compounds of the formula I, provided that they are included in the definition of the variables for the compounds V. In particular, it may be preferred if A and B mean:

A or B aromatic heterocycle selected from thienyl, furyl, Pyrazo- IyI, imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl, in particular selected from thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl , Pyridinyl, pyrimidinyl and pyrazinyl, wherein the

Heterocycle contains one, two, three or four identical or different groups L; and

the other variable B or A: five- or six-membered aromatic heterocycle containing one, two, three or four heteroatoms from the group O, N and S and unsubstituted or by one, two, three or four independently selected groups L is substituted Ci-C ₈ alkyl, Ci-C ₈ haloalkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ - haloalkenyl, C ₂ -C ₈ kinyl -alkyl, C ₂ -C ₈ haloalkynyl, C ₃ -C ₈ -cycloalkyl, C ₃ -C ₈ -HiIo- gencycloalkyl or substituted by one, two, three or four L-substituted phenyl; excluding the compounds mentioned above.

According to a further embodiment, A and B in the compounds V have the following meanings:

A or B aromatic heterocycle selected from thienyl, furyl, Pyrazo- IyI, imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl, in particular selected from thienyl, furyl, pyrazolyl, imidazolyl, oxazolyl, pyridinyl , Pyrimidinyl and pyrazinyl, wherein the heterocycle contains one, two, three or four identical or different groups L; and and the respective other variable B or A: a five- or six-membered aromatic heterocycle which contains one, two, three or four heteroatoms from the group consisting of O, N and S and is substituted by one, two, three or four independently selected groups L, or phenyl substituted by two, three or four independently selected groups L.

In a particular embodiment, the compounds are (E) -3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) acrylaldehyde and E) -3- (2,5-dichlorothiophen-3-yl) -2 - (4-fluorophenyl) acrylaldehyde excepted.

According to yet another embodiment, A and B in the compounds V have the following meanings:

A is phenyl substituted with two F; Phenyl substituted with three F; or phenyl substituted with one F and another substituent selected from Cl, C 1 -C ₄ alkyl, C 1 -C ₄ haloalkyl and C 1 -C ₄ alkoxy; and

B unsubstituted pyridyl, thienyl, thiazolyl, oxazolyl or furyl.

L has the meanings or preferred meanings described herein.

Compounds Va wherein A and B are so defined or preferably defined as described herein for compounds of formula I are also an object of the present invention. Preferred are the compounds Va wherein A and B are so defined or preferably defined as described herein for compounds of formula V.

The synthesis of compounds V can e.g. based on the procedure described in DE3601927, namely by reaction of compounds of the type of formula VI

mit entsprechenden Phosphorverbindungen vom Wittig oder Horner-Emmons-Typ mit anschliessender saurer Spaltung des Acetals. R^y steht dabei jeweils unabhängig für Ci-C₄-Alkyl.

with corresponding phosphorus compounds of the Wittig or Horner-Emmons type with subsequent acid cleavage of the acetal. Each R ^y is independently C 1 -C ₄ -alkyl.

An alternative to prepare compounds V is to prepare compounds of formula VII

HO \ _ / _{V | |} to oxidize. Suitable oxidizing agents and conditions are known to those skilled in the art. For example, a reaction according to Swern (Australian Journal of Chemistry, 57 (6), 537-548, 2004), reactions with hypervalent iodine compounds (Organic Letters, 5 (17), 2989-2992, 2003), with chromium compounds such as, for example, pyridinium di chromate (cf. Tetrahedron, 45 (1), 239-58, 1989) or with manganese oxides such as MnC2 (Journal of the American Chemical Society, 107 (13), 3963-71, 1985). Martin oxidation can be carried out in a solvent such as CH2Cl2.

In formula VII, the double bond can be in both (E) and (Z) configurations. This is represented by the jagged bond between B and the double bond. Compounds of formula VII are partially new and these are also the subject of the present invention. The present invention therefore also relates to compounds of the formula VII in which A and B are as defined or preferably defined for formula V, the compounds being (E) -3- (2-chloropyridin-3-yl) -2- ( 4-fluorophenyl) prop-2-en-1-ol and (E) -3- (2,5-dichlorothiophen-3-yl) -2- (4-fluorophenyl) prop-2-en-1-ol ,

Starting from compounds VII, compounds III.2 can also be prepared directly by epoxidation in the presence of a transition metal alkoxylate such as, for example, V (O) (OR) ₃ or Ti (OR) ₄ (R = C ₁ -C ₆ -alkyl) and an oxidizing agent such as, for example tBuOOH in analogy to US Pat. No. 5,399,708.

Compounds of the formula VII can be prepared from α, β-unsaturated acrylic esters of the formula VIII:

For this purpose, esters of the formula VIII are reduced to the alcohol VII. Suitable reduction methods are well known to those skilled in the art.

In Formula VIII, the double bond may be in both (E) and (Z) configurations. This is represented by the jagged bond between B and the double bond. Some of the compounds of formula VIII are novel and these are also the subject of the present invention. The present invention therefore also relates to compounds of the formula VIII in which A and B are as defined or preferably defined for formula V, the compounds being ethyl 3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl ) acrylate and ethyl 3- (2,5-dichlorothiophen-3-yl) -2- (4-fluorophenyl) acrylate are excluded.

Compounds of the formula VIII can also be reduced in one stage to the acrolein of the formula V, for example with metal hydrides such as diisobutylaluminum hydride at low Temperatures. In particular, aluminum hydrides, preferably lithium alanate (European Journal of Medicinal Chemistry, 40 (6), 529-541, 2005) or dialkylaluminum hydrides such as DIBAL-H (Synlett, (18), 3182-3184, 2006) can be used here.

The acrylic esters of formula VIII are available from glyoxylic esters of formula IX by reaction with phosphorus compounds, e.g. Horner-Emmons type or Wittig connections.

Such reactions are described, inter alia. in Tetrahedron, 46 (13-14), 4951-94; 1990, Tetrahedron Letters, 47 (16), 2675-2678; 2006, Synthesis, (12), 1797-1802; 2003, WO9929645 or Synthetic Communications, 20 (12), 1781-91; 1990th

The synthesis of glyoxylic acid esters is described, inter alia, in Journal of Organic Chemistry, 52 (22), 5026-30; 1987 by reaction of Grignard compounds (starting from commercially available halogen compounds and magnesium) X ¹ MgA with oxalic acid esters of the formula

Suitable phosphorus compounds (Horner-Emmons type and Wittig type) can be prepared by known standard methods, for example from a compound of the following type:

B is as defined above, X ¹ represents a leaving group such as a halide, preferably chlorine or bromine. The reaction of such halides to the desired Horner-Emmons or Wittig reagents can be carried out as described, for example, in Chemistry of Materials, 13 (9), 3009-3017; 2001, European Journal of Organic Chemistry, (7), 1247-1257; 2005 or WO1992 / 05145.

The alkyl halides are either commercially available or can be prepared by standard methods, e.g. by halogenation of the corresponding methyl compound. Suitable halogenating agents for this reaction are N-bromosuccinimide (Chemistry-A European Journal, 12 (21), 5632-5641, 2006) and N-chlorosuccinimide (Tetrahedron Letters, 47 (37), 6607-6609, 2006).

In an alternative, compounds of formula V may also be prepared via aldol synthesis according to the following scheme:

Another possibility of preparing compounds of the formula II is to prepare a compound of the formula IVb

zu epoxidieren. Geeignete Epoxidierungsverfahren sind dem Fachmann bekannt, siehe auch Herstellung der Verbindungen III.2 ausgehend von Verbindungen V.

to epoxidize. Suitable epoxidation processes are known to the person skilled in the art, see also preparation of compounds III.2 starting from compounds V.

In formula IVb, the double bond may exist in both (E) and (Z) configurations. This is represented by the jagged bond between B and the double bond. Another object of the present invention are compounds of formula IVb, wherein A and B are as defined or preferably defined for formula I.

Compounds of formula IVb can be obtained by reacting a compound of formula IVa

worin X für eine Abgangsgruppe steht, wie oben definiert, insbesondere steht X für Halogenid, mit 1 ,2,4-Triazol und einer Base umgesetzt wird. Die Reaktionsbedingungen können so gewählt werden, wie es oben bei der Herstellung von Verbindungen Il ausgehend von Verbindungen III.1 beschreiben ist. Die Verbindungen IVa haben dabei die Bedeutungen, wie sie für Formel III oben beschrieben sind.

wherein X is a leaving group as defined above, in particular X is halide, is reacted with 1, 2,4-triazole and a base. The reaction conditions can be selected as described above in the preparation of compounds II starting from compounds III.1. The compounds IVa have the meanings as described for formula III above.

A further possibility for preparing compounds of the formula I consists, starting with compounds of the formula III (see above), first with hydrazine to give compounds of the formula IIIa

An object of the present invention are also compounds of the formula IIIa, wherein A and B are as defined or preferably defined for formula I.

Subsequently, compounds of the formula IIIa can be reacted with a thiocyanate YSCN in which Y is an alkali metal or ammonium, preferably sodium, potassium or ammonium. monium, are reacted, with particular preference NH ₄ SCN is used. Thiosemicarbazide compounds IHb are obtained

By reaction with formic acid, the triazolyl ring can be formed to give the thione form of the corresponding compound of formula I (D = SH) according to the invention, which can optionally be reacted further (see above). See also DE19744400 (WO99 / 18088).

The invention therefore also encompasses a process for the preparation of compounds of the formula I according to the invention in which D is SR with R = hydrogen, C 1 -C ₈ -haloalkyl, C 2 -C ₈ -alkenyl, C 2 -C ₈ -haloalkenyl, C 2 -C ₈ alkynyl or C ₂ -C ₈ -

Haloalkynyl comprising the step

(a1) reacting a compound INb, wherein A and B are as defined or preferably defined for formula I, with formic acid to compounds 1-1

zu erhalten; und, um Verbindungen I zu erhalten, worin D für SR steht, wobei R Ci-C₈- Halogenalkyl, C2-C8-Alkenyl, C2-C8-Halogenalkenyl, C2-C₈-Alkinyl oder C₂-C₈- Halogenalkinyl bedeutet: (b1 ) Umsetzen von Verbindungen 1-1 mit R-X, wobei X für Halogen oder Trifluor(Ci- C8)alkylsulfonat steht.

to obtain; and, to obtain compounds I wherein D is SR, wherein R is Ci-C ₈ - haloalkyl, C2-C8-alkenyl, C2-C8-haloalkenyl, C2-C ₈ alkynyl, or C ₂ -C ₈ - haloalkynyl means (b1) reacting compounds 1-1 with RX, wherein X is halogen or trifluoro (Ci- C8) alkylsulfonate.

zu erhalten; und, um Verbindungen I zu erhalten, worin D für SR steht, wobei R Ci-C₈- Alkyl, C-i-Cs-Halogenalkyl, C₂-C₈-Alkenyl, C₂-C₈-Halogenalkenyl, C₂-C₈-Alkinyl oder C₂- Cs-Halogenalkinyl bedeutet: (b1 ) Umsetzen von Verbindungen 1-1 mit R-X, wobei X für Halogen oder Trifluor(Ci- C8)alkylsulfonat steht.The invention also encompasses a process for preparing compounds of the formula I according to the invention in which D is SR with R = hydrogen, C ₁ -C ₈ -alkyl, C ₁ -C ₅ -haloalkyl, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ haloalkenyl, C ₂ -C ₈ alkynyl, or C ₂ -C ₈ - haloalkynyl, comprising the step of (a1) reacting a compound IIIb, wherein a and B are as defined for formula I or preferably as defined, with formic acid to give compounds 1 -1 (D = SH)

to obtain; and, to obtain compounds I wherein D is SR, wherein R is Ci-C ₈ - alkyl, Ci-Cs-haloalkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ haloalkenyl, C ₂ -C ₈ Alkynyl or C ₂ - Cs -haloalkynyl means: (b1) reacting compounds 1-1 with RX, wherein X is halogen or trifluoro (C 1 -C 8) alkylsulfonate.

An object of the present invention are also compounds of the formula INb, wherein A and B are as defined or preferably defined for formula I.

In another alternative, compounds IIIa may be reacted with formaldehyde ((CH ₂ O) _n ) and a thiocyanate (YSCN, supra) to give

Compounds of formula INc receives

Durch Oxidation mit z.B. Eisen(lll)chlorid in wässriger HCl (siehe auch DE19961603 bzw. WO 00/146158) oder durch Sauerstoff in Gegenwart von KOH und Schwefel (siehe auch WO 99/18087) wird dann der Triazolylring und somit die entsprechende Verbindung der Formel I gebildet.

By oxidation with, for example, iron (III) chloride in aqueous HCl (see also DE19961603 or WO 00/146158) or by oxygen in the presence of KOH and sulfur (see also WO 99/18087), the triazolyl ring and thus the corresponding compound of Formula I formed.

The invention therefore also comprises a process for the preparation of compounds of the formula I wherein D is SR where R is hydrogen, Ci-C ₈ -HaIo- genalkyl, C ₂ -C 8 alkenyl, C ₂ -C 8 haloalkenyl, C C ₂ -C ₈ alkynyl or C ₂ -C ₈ haloalkynyl, comprising the step of (a3) oxidizing a compound of formula INc, wherein A and B are as defined for formula I or preferably defined to obtain a compound 1-1 ; and to obtain compounds I in which D is SR, where R is C ₁ -haloalkyl, C ₂ -C ₈ -alkynyl, C ₂ -C ₈ -haloalkenyl, C ₂ -C ₈ -alkynyl or C ₂ - C ₈ - haloalkynyl means: (b3) reacting compounds 1-1 with RX, wherein X is halogen or trifluoro (C 1 -C ₈ ) alkylsulfonate.

The invention therefore also encompasses a process for preparing compounds of the formula I according to the invention in which D is SR with R = hydrogen, C 1 -C ₈ -alkyl, Ci-Cβ-haloalkyl, C ₂ -C ₈ -alkenyl -alkyl, C ₂ -C ₈ haloalkenyl, C ₂ -C ₈ alkynyl, or C ₂ -C ₈ - haloalkynyl, comprising the step (a3) oxidizing a compound of formula INc, wherein A and B are as defined for formula I or preferably defined to obtain a compound fertil 1-1; and to obtain compounds I in which D is SR, wherein R is C ₁ -C ₆ -alkyl, C ₁ -C ₆ -haloalkyl, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ -haloalkenyl, C ₂ -C ₈ - Alkynyl or C ₂ -C ₈ haloalkynyl means:

(b3) reacting compounds 1-1 with RX, wherein X is halogen or trifluoro (Ci- C ₈ ) alkylsulfonate.

An object of the present invention are also compounds of the formula INc, wherein A and B are as defined or preferably defined for formula I.

Yet another possibility for synthesis is a compound IIIa with a carbonyl compound (R ^x1 R ^x2 ) C = O (R ^x1 = C 1 -C ₄ -alkyl or phenyl, R ^x2 = hydrogen or C 1 -C ₄ -alkyl or R ^x1 and R ^x2 together form a - (CH _{2) 5} chain), for example with acetone ((CH) ₂ CO), and a thiocyanate YSCN, wherein Y stands for sodium, potassium or ammonium, to

und die so gebildete Verbindung dann mit Ameisensäure, gegebenenfalls in Gegenwart eines Katalysators (z.B. HCl, H₂SO₄, p-Toluolsulfonsäure, Metalloxide wie z.B. amorphes TiO₂) zu der entsprechenden Triazolverbindung I umzuwandeln. R^x1 und R^x2 bedeuten dabei vorzugsweise beide Methyl (Verbindungen llld-1 ). Siehe auch DE19744401 und WO 99/18086.

and then converting the compound so formed with formic acid, optionally in the presence of a catalyst (eg, HCl, H ₂ SO ₄ , p-toluenesulfonic acid, metal oxides such as amorphous TiO ₂ ) to the corresponding triazole compound I. R ^x1 and R ^{x2 are} preferably both methyl (compounds IIId-1). See also DE19744401 and WO99 / 18086.

The invention therefore also comprises a process for the preparation of compounds of the formula I wherein D is SR with R = hydrogen, Ci-C ₈ -HaIo- genalkyl, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ - haloalkenyl, C ₂ -C ₈ alkynyl, or C ₂ -C ₈ - haloalkynyl, comprising the step of:

(a4) Reaction of a compound INd where R ^x1 = C 1 -C ₄ -alkyl or phenyl, R ^x2 = hydrogen or C 1 -C ₄ -alkyl, or R ^x1 and R ^x2 together form a - (CH ₂ ) ₅ -chain form and A and B are as defined for formula I or preferably defined with formic acid to obtain compounds 1-1 as herein defined or preferably defined; and to obtain compounds I wherein D is SR, where R is C -C ₈ -alkyl, C ₈ haloalkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ - haloalkenyl, C2-C ₈ alkynyl, or means _C2-C8 haloalkynyl :

(b4) reacting compounds 1-1 with RX, wherein X is halogen or trifluoro (Ci- C ₈ ) alkylsulfonate.

The invention therefore also comprises a process for the preparation of compounds of the formula I wherein D is SR with R = hydrogen, Ci-C ₈ alkyl, Ci-Cβ-haloalkyl, C ₂ -C ₈ -alkenyl -alkyl, C ₂ C ₈ haloalkenyl, C ₂ -C ₈ alkynyl or C ₂ -C ₈ haloalkynyl, comprising the step:

(a4) Reaction of a compound INd where R ^x1 = C 1 -C ₄ -alkyl or phenyl, R ^x2 = hydrogen or C 1 -C ₄ -alkyl, or R ^x1 and R ^x2 together form a - (CH ₂ ) ₅ -chain form and A and B are as defined for formula I or preferably defined with formic acid to obtain compounds 1-1 as herein defined or preferably defined; and, to obtain compounds I wherein D is SR, wherein R is Ci-C ₈ -alkyl, C ₈ haloalkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ - haloalkenyl, C ₂ - C ₈ alkynyl or C ₂ -C ₈ haloalkynyl means:

(b4) reacting compounds 1-1 with RX, wherein X is halogen or trifluoro (Ci- C ₈ ) alkylsulfonate.

An object of the present invention are furthermore compounds of the formula INd, wherein A and B are as defined or preferably defined for formula I.

In the definitions of the symbols in the formulas given herein, partial collective terms are used which are generally representative of the following substituents:

Halogen: fluorine, chlorine, bromine and iodine;

Alkyl and the alkyl moieties of compound groups such as alkylamino: saturated, straight-chain or branched hydrocarbon radicals having 1 to 4, 6, 8 or 12 carbon atoms, for example Ci-C ₆ alkyl such as methyl, ethyl, propyl, 1-methylethyl, butyl , 1-methylpropyl, 2-methylpropyl, 1, 1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1, 1 -Dimethylpropyl, 1, 2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1, 1-dimethylbutyl, 1, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2,2-dimethylbutyl, 2 , 3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1, 1, 2-trimethylpropyl, 1, 2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl -2-methylpropyl; Haloalkyl: alkyl as mentioned above, wherein in these groups partially or completely the hydrogen atoms are replaced by halogen atoms as mentioned above; in particular C 1 -C 2 -haloalkyl, such as chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl , 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl or 1, 1 , 1-trifluoroprop-2-yl;

Alkenyl and the alkenyl moieties in a compound group, such as alkenyloxy: unsaturated, straight-chain or branched hydrocarbon radicals having 2 to 4, 2 to 6 or 2 to 8 carbon atoms and a double bond in any position. In the present invention, it may be preferable to use small alkenyl groups such as (C 2 -C 4) alkenyl, but on the other hand, it may also be preferable to use larger alkenyl groups such as (C 5 -C 8) alkenyl. Examples of alkenyl groups are e.g. C2-C6 alkenyl such as ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1 Methyl 2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl 1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3- butenyl, 1, 1-dimethyl-2-propenyl, 1, 2-dimethyl-1-propenyl, 1, 2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl , 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1 Methyl 2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3 pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1, 1-dimethyl-2 Butenyl, 1, 1-dimethyl-3-butenyl, 1, 2-dimethyl-1-butene yl, 1, 2-dimethyl-2-butenyl, 1, 2-dimethyl-3-butenyl, 1, 3-dimethyl-1-butenyl, 1, 3-dimethyl-2-butenyl, 1, 3-dimethyl-3 butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-1 butenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2- butenyl, 2-ethyl-3-butenyl, 1, 1, 2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl-1-propenyl and 1-ethyl-2 -methyl-2-propenyl;

Haloalkenyl: alkenyl as defined above, wherein in these groups the hydrogen atoms are partially or completely replaced by halogen atoms as described above under haloalkyl, in particular fluorine, chlorine or bromine;

Alkadienyl: unsaturated, straight-chain or branched hydrocarbon radicals having 4 to 6 or 4 to 8 carbon atoms and two double bonds in any position;

Alkynyl and the alkynyl moieties in compound groups: straight-chain or branched hydrocarbon groups having 2 to 4, 2 to 6 or 2 to 8 carbon atoms and one or two triple bonds in any position, for example C 2 -C 6 -alkynyl, such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-pentynyl , 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 3-methyl-1-butynyl, 1, 1-dimethyl 2-propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1 Methyl 4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-1-pentynyl, 3-methyl-4-pentynyl, 4-methyl-1-pentynyl, 4-methyl 2-pentynyl, 1, 1-dimethyl-2-butynyl, 1, 1-dimethyl-3-butynyl, 1, 2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 3,3-dimethyl 1-butynyl, 1-ethyl-2-butynyl, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl and 1-ethyl-1-methyl-2-propynyl;

Haloalkynyl: alkynyl, as defined above, wherein in these groups the hydrogen atoms are partially or completely replaced by halogen atoms, as described above under haloalkyl, in particular fluorine, chlorine or bromine;

Cycloalkyl and the cycloalkyl moieties in assembled groups: mono- or bicyclic, saturated hydrocarbon groups having 3 to 8, in particular 3 to 6, carbon ring members, e.g. C3-C6 cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl;

Halogencycloalkyl: cycloalkyl as defined above, wherein in these groups the hydrogen atoms are partially or completely replaced by halogen atoms as described above under haloalkyl, in particular fluorine, chlorine or bromine;

Cycloalkenyl: monocyclic, monounsaturated hydrocarbon groups having preferably 3 to 8 or 4 to 6, in particular 5 to 6 carbon ring members, such as cyclopenten-1-yl, cyclopenten-3-yl, cyclohexen-1-yl, cyclohexen-3-yl, Cyclohexene-4-yl and the like;

Halocycloalkenyl: cycloalkenyl as defined above, wherein in these groups the hydrogen atoms are partially or completely replaced by halogen atoms as described above under haloalkyl, in particular fluorine, chlorine or bromine;

Alkoxy: for an oxygen-bonded alkyl group as defined above, preferably with 1 to 8, more preferably 2 to 6 carbon atoms. Examples are: methoxy, ethoxy, n-propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1, 1-dimethylethoxy; and also, for example, pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1, 1-dimethylpropoxy, 1, 2-dimethylpropoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexoxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, 1, 1-dimethylbutoxy, 1, 2-dimethylbutoxy, 1, 3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2- Ethyl butoxy, 1, 1, 2 Trimethylpropoxy, 1, 2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy or 1-ethyl-2-methylpropoxy;

Haloalkoxy: Alkoxy, as defined above, wherein in these groups, the hydrogen atoms are partially or completely replaced by halogen atoms, as described above under haloalkyl, in particular fluorine, chlorine or bromine. Examples of these are OCH ₂ F, OCHF ₂ , OCF ₃ , OCH ₂ Cl, OCHCl ₂ , OCCl ₃ , chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 2-iodoethoxy, 2,2 Difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy, OC ₂ F ₅ , 2-fluoropropoxy, 3-fluoropropoxy, 2,2-difluoropropoxy, 2,3-difluoropropoxy, 2-chloropropoxy, 3-chloropropoxy, 2,3-dichloropropoxy, 2-bromopropoxy, 3-bromopropoxy, 3,3,3- Trifluoropropoxy, 3,3,3-trichloropropoxy, OCH ₂ -C ₂ F ₅ , OCF ₂ -C ₂ F ₅ , 1- (CH ₂ F) -2-fluoroethoxy, 1- (CH ₂ Cl) -2-chloroethoxy, 1- (CH ₂ Br) -2-bromoethoxy, 4-fluorobutoxy, 4-chlorobutoxy, 4-bromobutoxy or nonafluorobutoxy; and 5-fluoropentoxy, 5-chloropentoxy, 5-

Bromopentoxy, 5-iodopentoxy, undecafluoropentoxy, 6-fluorohexoxy, 6-chlorohexoxy, 6-bromohexoxy, 6-iodohexoxy or dodecafluorohexoxy.

Alkylene: divalent linear chains of CH ₂ groups. Preference is given to (C ₁ -C 6) -alkylene, more preferably (C ₂ -C 4) -alkylene, and furthermore it may be preferable to use (C ₁ -C ₃ ) -alkylene groups. Examples of preferred alkylene radicals are CH ₂ , CH ₂ CH ₂ , CH ₂ CH ₂ CH ₂ , CH ₂ (CH ₂ ) ₂ CH ₂ , CH ₂ (CH ₂ ) ₃ CH ₂ and CH ₂ (CH ₂ ) ₄ CH ₂ ;

3-, 4-, 5-, 6-, 7-, 8-, 9- or 10-membered saturated or partially unsaturated heterocycle containing 1, 2, 3 or 4 heteroatoms from the group O, N and S, wherein the respective heterocycle may be attached via a carbon atom or via a nitrogen atom, if present. It may be preferred according to the invention that the respective heterocycle is bonded via carbon, on the other hand it may also be preferred that the heterocycle is bonded via nitrogen. In particular: - three- or four-membered saturated heterocycle (hereinafter also Heterocyc IyI), containing one or two heteroatoms from the group O, N and S as ring members; A five- or six-membered saturated or partially unsaturated heterocycle containing one, two, three or four heteroatoms from the group O, N and S as ring members: e.g. monocyclic saturated or partially unsaturated heterocycles containing, in addition to carbon ring members, one, two or three nitrogen atoms and / or one oxygen or sulfur atom or one or two oxygen and / or sulfur atoms, e.g. 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl, 4-isoxazolidinyl, 5-isoxazolidinyl, 3-isothiazolidinyl, 4-

Isothiazolidinyl, 5-isothiazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5-oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5- Thiazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 1, 2,4-oxadiazolidin-3-yl, 1, 2,4-oxadiazolidin-5-yl, 1, 2,4-thiadiazolidin-3-yl, 1, 2, 4-thiadiazolidin-5-yl, 1, 2,4-triazolidin-3-yl, 1, 3,4-oxadiazolidin-2-yl, 1, 3,4-thiadiazolidin-2-yl, 1, 3,4- Triazolidin-2-yl, 2,3-dihydrofur-2-yl, 2,3-dihydrofur-3-yl, 2,4-dihydrofur-2-yl, 2,4-dihydrofur-3-yl, 2,3- Dihydrothien-2-yl, 2,3-dihydro-thien-3-yl,

2,4-dihydro-thien-2-yl, 2,4-dihydro-thien-3-yl, 2-pyrrolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrroline-3 yl, 2-isoxazolin-3-yl, 3-isoxazolin-3-yl, 4-isoxazolin-3-yl, 2-isoxazolin-4-yl, 3-isoxazolin-4-yl, 4-isoxazolin-4-yl, 2-isoxazolin-5-yl, 3-isoxazolin-5-yl, 4-isoxazolin-5-yl, 2-isothiazolin-3-yl, 3-isothiazolin-3-yl, 4-isothiazolin-3-yl, 2 isothiazolin-4-yl, 3-isothiazolin-4-yl, 4-isothiazolin-4-yl, 2-isothiazolin-5-yl, 3-isothiazolin-5-yl, 4-isothiazolin-5-yl, 2,3- Dihydropyrazol-1-yl, 2,3-dihydropyrazol-2-yl, 2,3-dihydropyrazol-3-yl, 2,3-dihydropyrazol-4-yl, 2,3-dihydropyrazol-5-yl, 3,4- Dihydropyrazol-1-yl, 3,4-dihydropyrazol-3-yl, 3,4-dihydropyrazol-4-yl, 3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-1-yl, 4, 5-dihydropyrazol-3-yl, 4,5-dihydropyrazol-4-yl, 4,5-dihydropyrazol-5-yl, 2,3-dihydrooxazole

2-yl, 2,3-dihydrooxazol-3-yl, 2,3-dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazole 3-yl, 3,4-dihydrooxazol-4-yl, 3,4-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4- Dihydrooxazol-4-yl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1, 3-dioxan-5-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydrothienyl, 3-hexahydropyridazinyl, 4-hexa hydropyridazinyl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydro-pyrimidinyl, 2-piperazinyl, 1, 3,5-hexahydro-triazin-2-yl and 1,2,4-hexahydro-triazin-3-yl, and the like -ylidene residues; Seven-membered saturated or partially unsaturated heterocycle containing one, two, three or four heteroatoms from the group O, N and S as ring members: e.g. mono- and bicyclic heterocycles having 7 ring members, containing, in addition to carbon ring members, one, two or three nitrogen atoms and / or one oxygen or sulfur atom or one or two oxygen and / or sulfur atoms, for example tetra- and hexahydroazepinyl, such as 2,3,4,5 Tetrahydro [1 H] azepine-1, -2, -3, -4, 5, 6 or 7-yl, 3,4,5,6-tetrahydro [2H] azepine-2-, -3-, -A-, -5-, -6- or -7-yl, 2,3,4,7-tetrahydro [1 H] azepine-1, -2, -3 -, -A-, -5-, -6- or -7-yl, 2,3,6,7-tetrahydro [1 H] azepine-1, -2, -3, -A-, - 5-, 6- or -7-yl, hexahydroazepine-1, -2-, -3- or -4-yl, tetra-. and hexahydrooxepinyl, such as 2,3,4,5-tetrahydro [1H] oxepin-2, -3, -4, -5, -6 or -7-yl, 2, 3, 4, 7-tetrahydro [1 H] oxepin-2-, -3-, -4-, -5-, -6- or -7-yl, 2,3,6,7-tetrahydro [1 H] oxepin

2-, -3-, -A-, -5-, -6- or -7-yl, hexahydroazepine-1, -2-, -3- or -4-yl, tetra- and hexahydro-1, 3 diazepinyl, tetra- and hexahydro-1,4-diazepinyl, tetra- and hexahydro-1,3-oxazepinyl, tetra- and hexahydro-1,4-oxazepinyl, tetra- and hexa-hydro-1,3-dioxepinyl Tetra- and hexahydro-1,4-dioxepinyl and the corresponding ylidene radicals; 5-, 6-, 7-, 8-, 9- or 10-membered aromatic heterocycle containing 1, 2, 3 or 4 heteroatoms from the group O, N and S: in particular five- or six-membered aromatic mono- or Bicyclic heterocycle containing one, two, three or four heteroatoms from the group O, N and S: The respective heterocycle may be attached via a carbon atom or via a nitrogen atom, if present. It may be preferred according to the invention that the respective heterocycle is bonded via carbon, on the other hand it may also be preferred that the heterocycle is bonded via nitrogen. The heterocycle means in particular:

5-membered heteroaryl containing one, two, three or four nitrogen atoms or one, two or three nitrogen atoms and / or a sulfur or oxygen atom, which heteroaryl may be attached via C or N, if present: 5- ring heteroaryl groups which may contain, in addition to carbon atoms, one to four nitrogen atoms or one, two or three nitrogen atoms and / or one sulfur or oxygen atom as ring members, eg Furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl (1,2,3-; 1,2,4-triazolyl), tetrazolyl, oxazolyl, isoxazolyl, 1, 3,4-oxadiazolyl, thiazolyl, isothiazolyl and thiadiazolyl, in particular 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 3 Pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-imidazolyl, 4-imidazolyl, 1, 2,4-oxadiazole -3-yl, 1, 2,4-

Oxadiazol-5-yl, 1, 2,4-thiadiazol-3-yl, 1, 2,4-thiadiazol-5-yl, 1, 2,4-triazol-3-yl, 1, 3,4-oxadiazole 2-yl, 1, 3,4-thiadiazol-2-yl and 1, 3,4-triazol-2-yl;

-6-membered heteroaryl containing one, two, three or four, preferably one, two or three nitrogen atoms, wherein the heteroaryl can be attached via C or N, if present: 6-ring heteroaryl groups which contain, in addition to carbon atoms, one to four or . One, two or three nitrogen atoms may contain as ring members, eg Pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, 1, 2,3-triazinyl, 1, 2,4-triazinyl, 1, 3,5-triazinyl, especially 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyridazinyl, 4 Pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl,

2-pyrazinyl, 1, 3,5-triazin-2-yl and 1, 2,4-triazin-3-yl.

The novel compounds of this invention contain chiral centers and are generally obtained in the form of racemates or as diastereomeric mixtures of erythro and threo forms. The erythro and threo diastereomers can be separated in the compounds of the invention, for example, due to their different solubility or by column chromatography and isolated in pure form. From such uniform pairs of diastereomers can be obtained by known methods uniform enantiomers. As antimicrobial agents it is possible to use both the uniform diastereomers or enantiomers and also their mixtures obtained in the synthesis. The same applies to the fungicides. The invention therefore relates both to the pure enantiomers or diastereomers and to mixtures thereof. This applies to the compounds of the formula I according to the invention and, if appropriate, correspondingly to their precursors. In particular, the scope of the present invention includes the (R) and (S) isomers and the racemates of the compounds of the invention, in particular of the formula I or II, which have chiral centers. Suitable compounds according to the invention, in particular of the formula I or II, also include all possible stereoisomers (cis / trans isomers) and mixtures thereof.

The compounds according to the invention, in particular of the formula I or II, can be present in various crystal modifications whose biological activity can be different. These are included in the scope of the present invention.

In the compounds I according to the invention, the following meanings of the substituents, in each case alone or in combination, are particularly preferred.

According to one embodiment of the invention, a variable of A and B is a five- or six-membered heteroaromatic unsubstituted or substituted by one, two or three identical or different substituents L. In another embodiment, the respective other substituent of A and B is an optionally substituted five-membered heteroaromatic, as defined herein and preferably defined. In yet another embodiment, the other substituent of A and B is an optionally substituted six-membered heteroaromatic, as defined herein and preferably defined.

According to another embodiment of the invention, one variable of A and B is an optionally substituted five-membered heteroaromatic and the other variable is optionally substituted phenyl. According to another embodiment of the invention, a variable of A and B is an optionally substituted six-membered heteroaromatic and the other variable is optionally substituted phenyl. In these embodiments, the phenyl group preferably carries one, two or three groups L, preferably independently selected from halogen, NO _2, amino, Ci _-C4 -alkyl, Ci-C ₄ alkoxy, _{Ci-C4-haloalkyl,} Ci- C ₄ - haloalkoxy, C 1 -C ₄ -alkylamino, C 1 -C ₄ -dialkylamino, thiol and C 1 -C ₄ -alkylthio, in particular selected from halogen, C 1 -C ₄ -alkyl, C 1 -C ₄ -alkoxy, C i C ₄ haloalkyl and C 1 -C ₄ haloalkoxy. According to a specific embodiment, L is in each case independently selected from halogen, C 1 -C ₄ -alkyl and C 1 -C ₄ -alkoxy, in particular selected from F, Cl, methyl and methoxy, in particular independently selected from F and Cl.

In yet another embodiment, a variable of A and B is an optionally substituted five-membered heteroaromatic, and according to yet another In the embodiment, one variable of A and B is an optionally substituted six-membered heteroaromatic, and the other variable of A and B in these embodiments represents saturated or partially unsaturated heterocyclyl, C 1 -C 6 -alkyl, C 2 -C 8 -alkenyl, C 2 -C 8 -cycloalkyl. Alkynyl or Cs-Cs-cycloalkyl, which are each optionally substituted.

In another embodiment, the substituent A is a cyclic system, preferably a heteroaromatic or phenyl, as defined herein, containing a substituent para to the point of attachment to the oxirane ring. The para substituent is preferably selected from halogen, Ci-C ₄ -alkyl, -C ₄ -alkoxy, d- C ₄ haloalkyl and _{Ci-C4-haloalkoxy,} in particular selected from halogen, methyl, difluoromethyl, trifluoromethyl, methoxy and trifluoromethoxy , According to a specific embodiment, L is in each case independently selected from halogen, C 1 -C ₄ -alkyl and C 1 -C ₄ -alkoxy, in particular selected from F, Cl, methyl and methoxy, independently selected in the spectrum from F and Cl. In this case, the cyclic system may optionally contain further independently selected substituents L, in which case preferably one or two further L are present.

In another embodiment, the substituent A is a cyclic system, preferably a heteroaromatic or phenyl, as defined herein, containing a substituent ortho to the point of attachment to the oxirane ring. In this case, the cyclic system may optionally contain further independently selected substituents L, in which case preferably one or two further L are present.

According to a further embodiment, the substituent B is a cyclic system, preferably a heteroaromatic or phenyl, which contains a substituent in the para position to the point of attachment. In this case, the cyclic system may optionally contain further independently selected substituents L, in which case preferably one or two further L are present.

In another embodiment, the substituent B is a cyclic system, preferably a heteroaromatic or phenyl, which contains a substituent ortho to the point of attachment. The ortho substituent is preferably selected from halogen, _Ci-C4-alkyl, Ci-C ₄ alkoxy, _{Ci-C4-haloalkyl} and _{Ci-C4-haloalkoxy,} in particular selected from halogen, methyl, difluoromethyl, trifluoromethyl, methoxy and trifluoromethoxy. According to a specific embodiment, L is in each case independently selected from halogen, C 1 -C ₄ -alkyl and C 1 -C ₄ -alkoxy, in particular selected from F, Cl, methyl and methoxy, in particular independently selected from F and Cl. In this case, the cyclic system may optionally contain further independently selected substituents L, in which case preferably one or two further L are present. According to another embodiment of the invention, when A and / or B is a heteroaromatic, each independently selected from thiophene, pyrrole, pyrazole, imidazole, isoxazole, isothiazole, oxazole, thiazole, thiadiazole, oxadiazole, triazole and tetrazole , preferably selected from thiophene, pyrazole, isoxazole and thiazole, which are each optionally substituted. According to a further embodiment, the heteroaromatic is in each case independently selected from pyridine, pyrimidine, pyrazinyl, pyridazinyl and triazine, in particular selected from pyridine and pyrimidine, which are each optionally substituted. Of / heteroaromatics According to one aspect of this embodiment carries / carry one, two or three independently selected group L, preferably independently selected from halogen, -C ₄ - alkyl, Ci-C ₄ -alkoxy, Ci-C4-haloalkyl and d-C4- haloalkoxy. According to a specific embodiment, L is in each case independently selected from halogen, C 1 -C ₄ -alkyl and C 1 -C ₄ -alkoxy, in particular selected from F, Cl, methyl and methoxy, independently selected in the spectrum from F and Cl.

In one embodiment, when A or B is phenyl, it is unsubstituted phenyl, and in another embodiment, it is phenyl represented by one, two, or three L groups, independently selected from halogen, NO 2, amino, C 1 -C ₄ -alkyl, -C ₄ alkoxy, -C ₄ haloalkyl, -C ₄ -haloalkoxy, -C ₄ alkylamino, -C ₄ dialkylamino, thiol, and -C ₄ -alkylthio, in particular selected from halogen, -C ₄ alkyl, -C ₄ alkoxy, CrC ₄ - Haloalkyl and CrC ₄ haloalkoxy substituted. According to a specific embodiment, each L is independently selected from halogen, C 1 -C ₄ -alkyl and C 1 -C ₄ -alkoxy, especially selected from F, Cl, methyl and methoxy, in particular independently selected from F and Cl.

According to a preferred embodiment (I-A1) of the invention, A and B independently of one another each represent a saturated heterocycle which is independently unsubstituted or substituted by one, two or three identical or different groups L and one, two or three heteroatoms selected from N, O and S included. In one embodiment, B represents a tri-, four-, five-, six- or seven-membered saturated heterocycle. In particular, the heterocycle is five- or six-membered and contains at least one nitrogen atom as heteroatoms. According to a preferred embodiment, the heterocycle is bonded via C to the oxirane unit. In one embodiment, B is unsubstituted or substituted morpholine. In another embodiment, B is unsubstituted or substituted piperidine. In another embodiment, B is unsubstituted or substituted tetrahydrofuran. In another embodiment, B is unsubstituted or substituted tetrahydropyran.

According to a further preferred embodiment (I-A2) of the invention, A is a saturated heterocycle and B is an unsubstituted or with a, two or three identical or different groups L substituted partially unsaturated heterocycle containing one, two or three heteroatoms selected from N, O and S. B is preferably a four-, five-, six- or seven-membered heterocycle, wherein the heterocycle in particular five - or six-membered. According to a preferred embodiment, the heterocycle is bonded via C to the oxirane moiety.

According to another preferred embodiment (I-A3) of the invention, A is a saturated heterocycle, and B is an unsubstituted or substituted by one, two or three identical or different groups L heteroaromatic containing one, two or three heteroatoms selected from N , O and S. According to one embodiment of the invention, B contains at least one nitrogen atom. According to another embodiment, the heteroaromatic is bonded via C to the oxirane moiety.

In one embodiment, B in the embodiment I-A3 is an unsubstituted or substituted by one, two or three groups L five-membered heteroaromatic. In another embodiment, B is substituted or unsubstituted thienyl. According to another embodiment, B is substituted or unsubstituted pyrazolyl. In yet another embodiment, B is substituted or unsubstituted furyl. According to yet another embodiment, B represents substituted or unsubstituted pyrrolyl. In yet another embodiment, B represents substituted or unsubstituted imidazolyl. In yet another embodiment, B represents substituted or unsubstituted oxazolyl. According to yet another embodiment, B represents substituted or unsubstituted thiazolyl. According to yet another embodiment, B represents substituted or unsubstituted isoxazolyl. According to yet another embodiment, B represents substituted or unsubstituted isothiazolyl. According to yet another embodiment, B represents substituted or unsubstituted thiadiazolyl. In yet another embodiment, B represents substituted or unsubstituted oxadiazolyl. According to yet another embodiment, B represents substituted or unsubstituted triazolyl. According to one embodiment of the five-membered heteroaromatic it comprises one, two or three groups independently selected from halogen, NO2, amino, Ci-C ₄ -alkyl, C ₄ -alkoxy, Ci-C ₄ haloalkyl, _Ci-4 haloalkoxy C d , Ci-C ₄ alkylamino, Ci-C ₄ - dialkylamino, thiol, and Ci-C ₄ alkylthio, preferably halogen, _Ci-C4-alkyl, Ci-C ₄ alkoxy, Ci-C ₄ haloalkyl or C C ₄ haloalkoxy, more preferably halogen, C 1 -C ₄ -alkyl or C 1 -C ₄ -alkoxy, in particular F, Cl, methyl and methoxy, in particular F and Cl.

In another embodiment, B in the embodiment I-A3 is a six-membered heteroaromatic which is unsubstituted or substituted by one, two or three L. In one embodiment, B is pyridyl which is unsubstituted or substituted. According to another embodiment, B is pyrimidinyl, which is unsubstituted or substituted. In yet another embodiment, B is pyrazinyl which is unsubstituted or substituted. In yet another embodiment, B is pyridazinyl which is unsubstituted or substituted. In yet another embodiment, B is triazinyl which is unsubstituted or substituted. L is defined as in the embodiment according to which B is a five-membered heteroaromatic.

According to a further preferred embodiment (I-A4) of the invention, A is a saturated heterocycle, and B is phenyl which is unsubstituted or substituted by one, two or three identical or different substituents L. According to one embodiment, phenyl is unsubstituted, according to another embodiment includes phenyl, one, two or three independently selected L. Vorzusgweise L is in each case independently selected from halogen, NO2, amino, Ci-C ₄ -alkyl, C ₄ -alkoxy, Ci-C _d-4 haloalkyl, Ci-C ₄ haloalkoxy, Ci-C ₄ alkylamino, Ci-C ₄ - dialkylamino, thiol, and Ci-C ₄ alkylthio. According to another embodiment, B is phenyl substituted by one, two or three L, independently selected from halogen, d- _C4-alkyl, Ci-C ₄ alkoxy, _{Ci-C4-haloalkyl} and _Ci-4 haloalkoxy C , is substituted. According to one embodiment, B is halophenyl, in particular phenyl, which is substituted by one, two or three identical or different halogen atoms. In another embodiment, B is phenyl substituted by one, two or three L independently selected from F, Cl, methyl and methoxy. In yet another embodiment, B is phenyl substituted by one, two or three Ls selected from F and Cl. In another embodiment, B contains at least one substituent L ortho to the point of attachment to the oxirane moiety. It is possible for B to carry one or two further identical or different Ls.

In the embodiments I-A1 to I-A4, A is in particular a tri-, four-, five-, six- or seven-membered saturated heterocycle having one, two or three heteroatoms selected from N, O and S. In particular, the heterocycle is five - or six-membered, preferably the heterocycle contains at least one nitrogen atom. According to a preferred embodiment, the heterocycle is bonded via C to the oxirane moiety. The saturated heterocycle is in each case unsubstituted or contains one, two or three groups L as defined herein. In one embodiment, A is unsubstituted or substituted morpholine. In another embodiment, B is unsubstituted or substituted piperidine. In another embodiment, B is unsubstituted or substituted tetrahydrofuran. In another embodiment, B is unsubstituted or substituted tetrahydropyran. According to a further preferred embodiment (I-A5) of the invention, A is a partially unsaturated heterocycle, and B is a saturated heterocycle as described for A in the embodiments I-A1 to I-A4.

According to a further preferred embodiment (I-A6) of the invention, A and B independently of one another each represent a partially unsaturated heterocycle which are independently unsubstituted or substituted by one, two or three identical or different groups L and one, two or three heteroatoms selected from N, O and S included. Inventive embodiments for B are as described in the embodiment I-A2.

According to a further preferred embodiment (I-A7) of the invention, A is a partially unsaturated heterocycle, and B is an unsubstituted or substituted with one, two or three identical or different groups L heteroaromatic, containing one, two or three heteroatoms selected from N, O and S as described for B in the embodiment I-A3.

According to a further preferred embodiment (I-A8) of the invention, A is a partially unsaturated heterocycle, and B is phenyl which is unsubstituted or substituted by one, two or three identical or different L groups, as described for B in the embodiment I-A4 ,

In the embodiments I-A5 to I-A8, A is in particular an unsubstituted or substituted by one, two or three identical or different groups L partially unsaturated heterocycle containing one, two or three heteroatoms selected from N, O and S. A is preferably a four-, five-, six- or seven-membered heterocycle, wherein the heterocycle is in particular five- or six-membered. According to a preferred embodiment, the heterocycle is bonded via C to the oxirane unit.

According to a further preferred embodiment (I-A9) of the invention, A is an aromatic heterocycle, and B is a saturated heterocycle, as described for A in the embodiments I-A1 to I-A4.

According to a further preferred embodiment (I-A10) of the invention, A is an aromatic heterocycle, and B is a partially unsaturated heterocycle, as described for A in the embodiments I-A5 to I-A8.

According to a further preferred embodiment (I-A11) of the invention, A and B are each independently an aromatic heterocycle which are independently unsubstituted or substituted by one, two or three identical or different groups L, and one, two or three heteroatoms selected from N, O and S included. Inventive embodiments for B are as described in the embodiment I-A3.

According to a further preferred embodiment (I-A12) of the invention, A is an aromatic heterocycle, and B is C 1 -C 6 -alkyl which may carry one, two or three independently selected groups L. According to one embodiment, B is C-i-Cs-haloalkyl.

According to a further preferred embodiment (I-A13) of the invention, A is an aromatic heterocycle, and B is Cs-Cs-cycloalkyl which may carry one, two or three independently selected groups L. In one embodiment, B is Cs-Cs-halocycloalkyl.

According to a further preferred embodiment (I-A18) of the invention, A is an aromatic heterocycle, and B is phenyl which is unsubstituted or substituted by one, two or three identical or different L groups, as described for B in the embodiment I-A4.

In the embodiments I-A9 to I-A14, A is an unsubstituted or substituted by one, two or three identical or different groups L heteroaromatic, containing one, two or three heteroatoms selected from N, O and S. According to one embodiment A of the invention contains at least one nitrogen atom. According to another embodiment, the heteroaromatic is bonded via C to the oxirane unit.

According to one embodiment, A in embodiments I-A9 to I-A14 is a five-membered heteroaromatic unsubstituted or substituted by one, two or three groups L. In one embodiment, A is substituted or unsubstituted thienyl. According to a further embodiment, A is substituted or unsubstituted pyrazolyl. According to yet another embodiment, A is substituted or unsubstituted furyl. According to yet another embodiment, A is substituted or unsubstituted pyrrolyl. According to yet another embodiment, A is substituted or unsubstituted imidazolyl. According to yet another embodiment, A is substituted or unsubstituted oxazolyl. According to yet another embodiment, A is substituted or unsubstituted thiazolyl. According to yet another embodiment, A is substituted or unsubstituted isoxazolyl. According to yet another embodiment, A is substituted or unsubstituted isothiazolyl. According to yet another embodiment, A is substituted or unsubstituted thiadiazolyl. In yet another embodiment, A is substituted or unsubstituted oxadiazolyl. According to yet another embodiment, A is substituted or unsubstituted triazolyl. In one embodiment, the five-membered heteroaromatic contains one, two or three groups L independently selected from halogen, NO 2, amino, C 1 -C ₄ -alkyl, C 1 -C ₄ -alkoxy, C 1 -C ₄ -haloalkyl, C 1 -C ₄ -haloalkoxy, C 1 -C ₄ -alkylamino, C 1 -C ₄ -dialkylamino, Thiol and C 1 -C 4 -alkylthio, preferably halogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -haloalkyl or C 1 -C 4 -haloalkoxy, more preferably halogen, C 1 -C 4 -alkyl or C 1 -C 4 -alkoxy , in particular F, Cl, methyl and methoxy, in particular F and Cl.

According to a further embodiment, A in the embodiments I-A9 to I-A14 is a six-membered heteroaromatic which is unsubstituted or substituted by one, two or three L. In one embodiment, A is pyridyl which is unsubstituted or substituted. In another embodiment, A is pyrimidinyl which is unsubstituted or substituted. In yet another embodiment, A is pyrazinyl which is unsubstituted or substituted. In yet another embodiment, A is pyridazinyl which is unsubstituted or substituted. According to yet another embodiment, A is triazinyl which is unsubstituted or substituted. L is defined as in the embodiment according to which A is a five-membered heteroaromatic.

According to a further preferred embodiment (I-A15) of the invention, A is C 1 -C 8 -alkyl which is unsubstituted or substituted by one, two or three identical or different groups L, and B is an aromatic heterocycle, such as A in Embodiments I-A9 to I-A14 described. According to one embodiment, A is d-Cs-haloalkyl.

According to a further preferred embodiment (I-A16) of the invention A is unsubstituted or substituted by one, two or three identical or different groups L Cs-Cs-cycloalkyl, preferably Cs-Cβ-cycloalkyl, and B is an aromatic heterocycle, as described in embodiments I-A9 to I-A14 for A. According to one embodiment, A is Cs-Cs-halocycloalkyl.

According to a further preferred embodiment (I-A17) of the invention, A is phenyl, and B is a saturated heterocycle, as described for A in the embodiments I-A1 to I-A4.

According to a further preferred embodiment (I-A18) of the invention, A is phenyl, and B is a partially unsaturated heterocycle, as described for A in the embodiments I-A5 to I-A8.

According to a further preferred embodiment (I-A19) of the invention, A is phenyl, and B is an aromatic heterocycle, as described for A in the embodiments I-A9 to I-A14. In the embodiments I-A17 to I-A19, A is phenyl which is unsubstituted or substituted by one, two or three identical or different L groups. In one embodiment, phenyl is unsubstituted, according to a further embodiment, phenyl, one, two, or three L, independently selected from halogen, NO2, amino, Ci-C ₄ -alkyl, -C ₄ -alkoxy, Ci-C ₄ haloalkyl, Ci- C ₄ haloalkoxy, -C ₄ - alkylamino, Ci-C ₄ dialkylamino, thiol, and Ci-C ₄ alkylthio. According to a further embodiment, A is phenyl substituted by one, two or three L is independently selected from halogen, _Ci-C4-alkyl, Ci-C ₄ alkoxy, _{Ci-C4-haloalkyl} and _Ci-C4-halo- alkoxy is substituted. According to one embodiment, A is halophenyl, in particular phenyl, which is substituted by one, two or three identical or different halogen atoms. In another embodiment, A is phenyl substituted by one, two or three L independently selected from F, Cl, methyl and methoxy. In yet another embodiment, A is phenyl substituted by one, two or three Ls selected from F and Cl.

If it is not otherwise indicated herein, each L is preferably independently selected from halogen, cyano, nitro, _{Ci-C4-alkyl, Ci-C4-haloalkyl,} phenyl-Ci-C ₄ - alkyloxy, C2-C6-alkenyl, C2-C6 haloalkenyl, C2-C6-alkynyl, C2-C6-haloalkynyl, C d- ₄ alkoxy, _{Ci-C4-haloalkoxy,} Cs-Cβ cycloalkyl, Cs-Cβ-halocycloalkyl, amino, Ci-C ₄ Alkylamino, di-C 1 -C ₄ -alkylamino, phenyl, halophenyl, phenyloxy and halo genophenyloxy. According to one embodiment of the invention, L is preferably in each case independently selected from halogen, C 1 -C 6 -alkyl, C 1 -C 5 -haloalkyl, C 2 -C 8 -alkenyl, C 1 -C 6 -alkoxy and C 1 -C 8 -haloalkoxy. According to a further embodiment, L is independently selected from halogen, _{Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy, Ci-C4-haloalkoxy,} Cs-Cβ cycloalkyl, Cs-Cβ-halocycloalkyl , phenyl and halophenyl, especially selected from halogen, such as fluorine and chlorine, _{Ci-C4-alkyl, Ci-C4-haloalkyl} and _{Ci-C4-alkoxy.} It may be particularly preferred that the substituents L are independently selected from C 1 -C ₄ -alkyl, fluorine and chlorine.

The above-described meanings of the variables A, B and L for compounds I apply mutatis mutandis to the precursors of the compounds of the invention, if included in the scope of the definitions (as described above).

According to one embodiment of the invention, D is a group SR, where R is hydrogen or C 1 -C ₄ -alkyl. According to a specific embodiment, D stands for SH.

According to another embodiment of the invention, D is a group SR, where RC (= O) R ³ and R ^{3 is} NA ³ A ⁴ , where A ³ and A ⁴ independently of one another are hydrogen or C ¹ -C 8 -alkyl , According to a further embodiment of the invention, D is a group SR, where R is C (= O) R, and R ^{3 3} _Ci-C4 alkyl, _{Ci-C4-haloalkyl,} Ci-C ₄ alkoxy or C C ₄ haloalkoxy means. In particular, R ³ in this embodiment is C 1 -C ₄ -alkyl.

According to another embodiment of the invention, D is a group SR, where R is CN.

According to a further embodiment of the invention, D is a group SR, where R is SO ₂ R ⁴ and R ^{4 is} C 1 -C ₄ -alkyl, phenyl-C 1 -C ₄ -alkyl or phenyl, where the phenyl groups are each unsubstituted or are substituted by one, two or three groups independently selected from halogen and C 1 -C ₄ -alkyl.

According to another embodiment of the invention, D is a group SM, wherein M is an alkali metal cation, one equivalent of an alkaline earth metal cation, one equivalent of a copper, zinc, iron or nickel cation or an ammonium cation of the formula (E )

Z ²

Z ¹ - NZ ³ (E), wherein

Z ¹ and Z ^{2 are} independently hydrogen or C 1 -C ₄ -alkyl; and Z ³ and Z ^{4 are} independently hydrogen, C 1 -C ₄ alkyl, benzyl or phenyl.

In one embodiment, M represents Na, 1/2 Cu, 1/3 Fe, HN (C ₂ H ₅ ) S, N (CHs) ₄

According to a further embodiment of the invention, D is a group D 1 (compounds I-2), where A and B are independently defined or preferably defined herein:

Dl I-2

Preferably both A and B have the same meaning in compounds I-2. According to another embodiment of the invention, D is a group Dil, where # is the point of attachment to the triazolyl ring and Q, R ¹ and R ^{2 are} as defined herein or preferably defined:

I-2

In particular, with regard to their use, the compounds I according to the invention which are compiled in the following Tables 1a to 308a and Tables 1aa to 308aa are preferred. The groups mentioned in the tables for a substituent are also considered individually, regardless of the combination in which they are mentioned, a particularly preferred embodiment of the substituent in question.

Table 1 a

Compounds 1-1, wherein A is pyridin-2-yl and B in each case corresponds to one group of one row of Table A (Compounds 1-1.1 aA-1 to l-1.1aA-425) Table 2a Compounds 1-1, wherein A is pyridin-3-yl and B is each a group of one

Row of Table A corresponds (Compounds 1-1.2aA-1 to 1-1.2aA-425) Table 3a

Compounds 1-1, wherein A is pyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.3aA-1 to 1-1.3aA-425) Table 4a

Compounds 1-1, wherein A is 3-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.4aA-1 to 1-1.4aA-425) Table 5a

Compounds 1-1, wherein A is 4-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.5aA-1 to 1-1.5aA-425)

Table 6a

Compounds 1-1, wherein A is 5-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.6aA-1 to 1-1.6aA-425) Table 7a Compounds 1-1, where A is 6-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.7aA-1 to 1-1.7aA-425) Table 8a

Compounds 1-1, wherein A is 2-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.8aA-1 to 1-1.8aA-425) Table 9a

Compounds 1-1, wherein A is 4-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.9aA-1 to 1-1.9aA-425)

Table 10a Compounds 1-1, wherein A is 5-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.10aA-1 to I-1.10aA-425)

Table 1 1a

Compounds 1-1, wherein A is 6-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.11 aA-1 to 1-1.11 aA-425) Table 12a

Compounds 1-1, wherein A is 2-chloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.12aA-1 to 1-1.12aA-425)

Table 13a

Compounds 1-1, wherein A is 3-chloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.13aA-1 to I-1.13aA-425)

Table 14a

Compounds 1-1, wherein A is 4-chloropyridin-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.14aA-1 to 1-1.14aA-425)

Table 15a Compounds 1-1, wherein A is 3-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.15aA-1 to 1.15aA-425)

Table 16a

Compounds 1-1, wherein A is 4-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.16aA-1 to I-1.16aA-425) Table 17a

Compounds 1-1, wherein A is 5-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds I-1.17aA-1 to I-1.17aA-425)

Table 18a

Compounds 1-1, wherein A is 6-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.18aA-1 to 1.18aA-425)

Table 19a

Compounds 1-1, wherein A is 2-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.19aA-1 to I-1.19aA-425)

Table 20a Compounds 1-1, wherein A is 4-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.2OaA-I to 1-1.20aA-425)

Table 21a

Compounds 1-1, wherein A is 5-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.21 aA-1 to 1-1.21 aA-425) Table 22a

Compounds 1-1, wherein A is 6-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.22aA-1 to 1-1.22aA-425) Table 23a

Compounds 1-1, wherein A is 2-fluoropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.23aA-1 to 1-1.23aA-425)

Table 24a Compounds 1-1, wherein A is 3-fluoropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.24aA-1 to 1-1.24aA-425)

Table 25a

Compounds 1-1, wherein A is 3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.25aA-1 to 1-1.25aA-425) Table 26a

Compounds 1-1, wherein A is 4-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.26aA-1 to 1-1.26aA-425)

Table 27a

Compounds 1-1, wherein A is 5-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.27aA-1 to 1-1.27aA-425)

Table 28a

Compounds 1-1, wherein A is 6-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.28aA-1 to 1-1.28aA-425)

Table 29a Compounds 1-1, wherein A is 2-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.29aA-1 to 1-1.29aA-425)

Table 30a

Compounds 1-1, wherein A is 4-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.3OaA-I to 1-1.30aA-425) Table 31a

Compounds 1-1, wherein A is 5-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.31 aA-1 to 1-1.31 aA-425)

Table 32a

Compounds 1-1, wherein A is 6-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.32aA-1 to 1-1.32aA-425)

Table 33a

Compounds 1-1, wherein A is 2-methylpyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.33aA-1 to 1-1.33aA-425)

Table 34a Compounds 1-1, wherein A is 3-methylpyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.34aA-1 to 1-1.34aA-425)

Table 35a

Compounds 1-1, wherein A is 4-methylpyridin-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.35aA-1 to 1-1.35aA-425) Table 36a

Compounds 1-1, wherein A is 3-methoxypyridin-2-yl and B are each one Group of a row corresponds to Table A (compounds 1-1.36aA-1 to 1-1.36aA-

425) Table 37a

Compounds 1-1, wherein A is 4-methoxypyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.37aA-1 to 1-1.37aA-

425) Table 38a

Compounds 1-1, wherein A is 5-methoxypyridin-2-yl and B are each one

Group of a row corresponds to Table A (compounds 1-1.38aA-1 to 1-1.38aA-425)

Table 39a

Compounds 1-1, wherein A is 6-methoxypyridin-2-yl and B are each one

Group of a row corresponds to Table A (compounds 1-1.39aA-1 to 1-1.39aA-

425) Table 40a

Compounds 1-1, wherein A is 2-methoxypyridin-3-yl and B are each one

Group of a row corresponds to Table A (compounds 1-1.4OaA-I to 1-1.4OaA-

425)

Table 41a Compounds 1-1, wherein A is 4-methoxypyridin-3-yl and B are each one

Group of a row corresponds to Table A (Compounds 1-1.41 aA-1 to 1-1.41 aA-

425) Table 42a

Compounds 1-1, wherein A is 5-methoxypyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.42aA-1 to 1-1.42aA-

425) Table 43a

Compounds 1-1, wherein A is 6-methoxypyridin-3-yl and B are each one

Group of a row corresponds to Table A (Compounds 1-1.43aA-1 to 1-1.43aA-425)

Table 44a

Compounds 1-1, wherein A is 2-methoxypyridin-4-yl and B are each one

Group of a row corresponds to Table A (compounds 1-1.44aA-1 to 1-1.44aA-

425) Table 45a

Compounds 1-1, wherein A is 3-methoxypyridin-4-yl and B are each one

Group of a row corresponds to Table A (compounds 1-1.45aA-1 to 1-1.45aA-

425)

Table 46a Compounds 1-1, wherein A is 3,5-dichloropyridin-2-yl and B are each one

Group of a row corresponds to Table A (compounds 1-1.46aA-1 to 1-1.46aA-

425) Table 47a

Compounds 1-1, wherein A is 2,4-dichloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.47aA-1 to 1-1.47aA-425) Table 48a

Compounds 1-1, wherein A is 2,5-dichloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.48aA-1 to 1-1.48aA-425)

Table 49a compounds 1-1, wherein A is 2,6-dichloropyridin-3-yl and B are each one

Group of one row corresponds to Table A (Compounds 1-1.49aA-1 to 1-1.49aA-425)

Table 50a

Compounds 1-1, wherein A is 2,6-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.5OaA-I to 1-1.5OaA-

425)

Table 51a

Compounds 1-1, wherein A is 3,5-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.51 aA-1 to 1-1.51 aA-425)

Table 52a

Compounds 1-1, wherein A is 3,6-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.52aA-1 to 1-1.52aA-425) Table 53a

Compounds 1-1, wherein A is 2,5-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.53aA-1 to 1-1.53aA-425)

Table 54a Compounds 1-1 wherein A is 2,3-dichloropyridin-4-yl and B are each one

Group of a row corresponds to Table A (Compounds 1-1.54aA-1 to 1-1.54aA-425)

Table 55a

Compounds 1-1, wherein A is 2,4-dichloropyridin-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.55aA-1 to 1-1.55aA-

425)

Table 56a

Compounds 1-1, wherein A is 3,5-difluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.56aA-1 to 1-1.56aA-425) Table 57a

Compounds 1-1, wherein A is 3,5-difluoropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.57aA-1 to 1-1.57aA-425) Table 58a

Compounds 1-1, wherein A is 2,3-difluoropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.58aA-1 to 1-1.58aA-425)

Table 59a Compounds 1-1, wherein A is 3,5-dimethylpyridin-2-yl and B are each one

Group of a row corresponds to Table A (Compounds 1-1.59aA-1 to 1-1.59aA-425)

Table 60a

Compounds 1-1, wherein A is 3,4-dimethylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.6OaA-I to 1-1.6OaA-

425)

Table 61a

Compounds 1-1, wherein A is 4,6-dimethylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.61 aA-1 to 1-1.61 aA-425)

Table 62a

Compounds 1-1, wherein A is 2,4-dimethylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.62aA-1 to 1-1.62aA-425) Table 63a

Compounds 1-1, wherein A is 3,5-dimethylpyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.63aA-1 to 1-1.63aA-425)

Table 64a compounds 1-1, wherein A is 2-chloro-3-fluoropyridin-4-yl and B are each one

Group of one row corresponds to Table A (Compounds 1-1.64aA-1 to 1-1.64aA-425)

Table 65a

Compounds 1-1, wherein A is 4-chloro-3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.65aA-1 to 1-1.65aA-

425)

Table 66a

Compounds 1-1, wherein A is 5-chloro-3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.66aA-1 to 1-1.66aA-425)

Table 67a

Compounds 1-1, wherein A is 5-fluoro-3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.67aA-1 to 1-1.67aA-425) Table 68a

Compounds 1-1, wherein A is 3-chloro-5-trifluoromethylpyridin-2-yl and B is each because one group corresponds to one row of Table A (Compounds 1-1.68aA-1 to 1-1.68aA-425)

Table 69a

Compounds 1-1, wherein A is 2-chloro-6-trifluoromethylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.69aA-1 to 1-1.69aA-425)

Table 70a

Compounds 1-1, wherein A is 2,4-dichloro-6-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.7OaA-I to I-1.70aA-425)

Table 71a

Compounds 1-1, wherein A is 3,4,5-trichloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.71 aA-1 to 1-1.71 aA-425) Table 72a

Compounds 1-1, wherein A is 2,4,6-trichloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.72aA-1 to 1-1.72aA-425)

Table 73a Compounds 1-1, wherein A is pyrimidin-2-yl and B are each a group of one

Row of Table A corresponds (Compounds 1-1.73aA-1 to 1-1.73aA-425)

Table 74a

Compounds 1-1, wherein A is pyrimidin-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.74aA-1 to 1-1.74aA-425) Table 75a

Compounds 1-1, wherein A is 6-chloropyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.75aA-1 to 1-1.75aA-425)

Table 76a

Compounds 1-1, wherein A is 6-methylpyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.76aA-1 to 1-1.76aA-

425)

Table 77a

Compounds 1-1, wherein A is 6-methoxypyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.77aA-1 to 1-1.77aA-425)

Table 78a

Compounds 1-1, wherein A is 2,4-dichloropyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.78aA-1 to 1-1.78aA-425) Table 79a

Compounds 1-1, wherein A is 2,6-dichloropyrimidin-3-yl and B are each one Group of a row corresponds to Table A (Compounds 1-1.79aA-1 to 1-1.79aA-425)

Table 80a

Compounds 1-1, wherein A is 2,4-difluoropyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.8OaA-I to 1-1.8OaA-

425)

Table 81a

Compounds 1-1, wherein A is 2,6-difluoropyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.81 aA-1 to 1-1.81 aA-425)

Table 82a

Compounds 1-1, wherein A is 1, 3,5-triazin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.82aA-1 to 1-1.82aA-425)

Table 83a Compounds 1-1, wherein A is thien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.83aA-1 to 1-1.83aA-425)

Table 84a

Compounds 1-1, wherein A is thien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.84aA-1 to 1-1.84aA-425) Table 85a

Compounds 1-1, wherein A is 5-chlorothien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.85aA-1 to 1-1.85aA-425)

Table 86a

Compounds 1-1, wherein A is 2-chlorothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.86aA-1 to 1-1.86aA-425)

Table 87a

Compounds 1-1, wherein A is 4-chlorothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.87aA-1 to 1-1.87aA-425)

Table 88a Compounds 1-1, wherein A is 5-chlorothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.88aA-1 to 1-1.88aA-425)

Table 89a

Compounds 1-1, wherein A is 2-bromothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.89aA-1 to 1-1.89aA-425) Table 90a

Compounds 1-1, wherein A is 4-bromothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.9OaA-I to 1-1.90aA-425)

Table 91a

Compounds 1-1, wherein A is 5-bromothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.91 aA-1 to 1-1.91 aA-425) Table 92a

Compounds 1-1, wherein A is 5-methylthien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.92aA-1 to 1-1.92aA-425)

Table 93a Compounds 1-1, wherein A is 2-methylthien-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.93aA-1 to 1-1.93aA-425)

Table 94a

Compounds 1-1, wherein A is 4,5-dichlorothien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.94aA-1 to 1-1.94aA-425) Table 95a

Compounds 1-1, wherein A is 2,5-dichlorothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.95aA-1 to 1-1.95aA-425)

Table 96a

Compounds 1-1, wherein A is 2,3-dichlorothien-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.96aA-1 to 1-1.96aA-425)

Table 97a

Compounds 1-1, wherein A is 2,5-dibromothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.97aA-1 to 1-1.97aA-425)

Table 98a compounds 1-1, wherein A is 4,5-dimethylthien-2-yl and B are each one

Group of a row corresponds to Table A (Compounds 1-1.98aA-1 to 1-1.98aA-425)

Table 99a

Compounds 1-1, wherein A is 2,5-dimethylthien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.99aA-1 to 1-1.99aA-

425)

Table 100a

Compounds 1-1, wherein A is 2,3-dimethylthien-4-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.100aA-1 to I-1.100aA-425)

Table 101 a

Compounds 1-1, wherein A is 3,4,5-trichlorothien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.101 aA-1 to I-1.101aA-425) Table 102a

Compounds 1-1, wherein A is 2,4,5-trichlorothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.102aA-1 to I-1.102aA-425)

Table 103a compounds 1-1, wherein A is 2,4,5-tribromothien-3-yl and B are each one

Group of one row corresponds to Table A (Compounds I-1.103aA-1 to I-1.103aA-425) Table 104a

Compounds 1-1, wherein A is 3,4,5-trimethylthien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.104aA-1 to I-1.104aA-425) Table 105a

Compounds 1-1, wherein A is 4-chlorofur-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.105aA-1 to 1.105aA-425)

Table 106a

Compounds 1-1, wherein A is 5-chlorofur-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.106aA-1 to 1.106aA-425)

Table 107a

Compounds 1-1, wherein A is 3-bromo-fur-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.107aA-1 to 1.107aA-425)

Table 108a Compounds 1-1 wherein A is 4-bromo-fur-2-yl and B each represents a group of one

Row of Table A corresponds (Compounds I-1.108aA-1 to I-1.108aA-425)

Table 109a

Compounds 1-1, wherein A is 5-bromo-fur-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.109aA-1 to 1.109aA-425) Table 1 10a

Compounds 1-1, wherein A is 3,4-dichloropur-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.1 10aA-1 to 1-1.1 10aA-425)

Table 1 11 a

Compounds 1-1, wherein A is 4,5-dichloropur-2-yl and B in each case corresponds to one group of one row of Table A (Compounds 1-1.1 11 aA-1 to 1-1.1 11 aA-425)

Table 1 12a

Compounds 1-1, wherein A is thiazol-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.1 12aA-1 to 1-1.1 12aA-425)

Table 1 13a Compounds 1-1, wherein A is thiazol-4-yl and B are each a group of one

Row of Table A corresponds (Compounds 1-1.1 13aA-1 to 1-1.1 13aA-425)

Table 1 14a

Compounds 1-1, wherein A is thiazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.1 14aA-1 to 1-1.1 14aA-425). Table 1 15a

Compounds 1-1, wherein A is isothiazol-3-yl and B in each case corresponds to one group of one row of Table A (Compounds 1-1.1 15aA-1 to 1-1.1 15aA-425)

Table 1 16a

Compounds 1-1, wherein A is isothiazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.1 16aA-1 to 1-1.1 16aA-425) Table 1 17a

Compounds 1-1 wherein A is isothiazol-5-yl and B is each a group of one

Line of Table A corresponds (Compounds 1-1.1 17aA-1 to 1-1.1 17aA-425) Table 1 18a Compounds 1-1, wherein A is 2-chlorothiazol-4-yl and B is in each case one group of a row of Table A. corresponds (compounds 1-1.1 18aA-1 to 1-1.1 18aA-425) Table 1 19a

Compounds 1-1, wherein A is 2-chlorothiazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.1 19aA-1 to 1-1.1 19aA-425) Table 120a

Compounds 1-1, wherein A is 4-chlorothiazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.12OaA-I to l-1,120aA-425). Table 121a

Compounds 1-1, wherein A is 2-bromothiazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.121 aA-1 to 1-1.121 aA-425)

Table 122a

Compounds 1-1, wherein A is 2-bromothiazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.122aA-1 to 1.122aA-425) Table 123a Compounds 1-1, wherein A is 2,4-dichlorothiazol-5-yl and B are each one

Group of a row corresponds to Table A (Compounds I-1.123aA-1 to I-

1.123aA-425) Table 124a

Compounds 1-1, wherein A is 3-chloroisothiazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds I-1.124aA-1 to I-1.124aA-

425) Table 125a

Compounds 1-1, wherein A is 5-methylisothiazol-3-yl and B are each one

Group of a row corresponds to Table A (compounds I-1.125aA-1 to I-1.125aA-425)

Table 126a

Compounds 1-1, wherein A is 3-methylisothiazol-4-yl and B are each one

Group of a row corresponds to Table A (compounds I-1.126aA-1 to I-

1.126aA-425) Table 127a

Compounds 1-1, wherein A is 3-methylisothiazol-5-yl and B are each one

Group of a row corresponds to Table A (compounds I-1.127aA-1 to I-

1.127aA-425) Table 128a Compounds 1-1 wherein A is 4,5-dichloroisothiazol-3-yl and B is each one

Group of a row corresponds to Table A (compounds I-1.128aA-1 to I-

1.128aA-425) Table 129a

Compounds 1-1, wherein A is 4,5-dimethylisothiazol-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.129aA-1 to I-1.129aA-425) Table 130a

Compounds 1-1, wherein A is 3,5-dimethylisothiazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.130aA-1 to I-1.130aA-425)

Table 131a Compounds 1-1, wherein A is 3,4-dichloroisothiazol-5-yl and B are each one

Group of a row corresponds to Table A (compounds 1-1.131 aA-1 to I-1.131aA-425)

Table 132a

Compounds 1-1, wherein A is oxazol-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.132aA-1 to 1.132aA-425)

Table 133a

Compounds 1-1, wherein A is oxazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds I-1.133aA-1 to 1.133aA-425)

Table 134a compounds 1-1, wherein A is oxazol-5-yl and B each represents a group of one

Line of Table A corresponds (compounds I-1.134aA-1 to I-1.134aA-425)

Table 135a

Compounds 1-1, wherein A is isoxazol-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.135aA-1 to I-1.135aA-425) Table 136a

Compounds 1-1, wherein A is isoxazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.136aA-1 to 1.136aA-425)

Table 137a

Compounds 1-1, wherein A is isoxazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.137aA-1 to 1.137aA-425)

Table 138a

Compounds 1-1, wherein A is 3-chloroisoxazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.138aA-1 to l-1.138aA-425)

Table 139a Compounds 1-1, wherein A is 5-methylisoxazol-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.139aA-1 to l-1.139aA-425)

Table 140a

Compounds 1-1, wherein A is 5-methylisoxazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.14OaA-I to 1-1.14OaA-

425) Table 141 a

Compounds 1-1, wherein A is 3-methylisoxazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1,141 aA-1 to 1-1,141 aA-425) Table 142a

Compounds 1-1, wherein A is 3,5-dimethylisoxazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds I-1.142aA-1 to I-1.142aA-425)

Table 143a Compounds 1-1, wherein A is 3-chloro-5-methylisoxazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.143aA-1 to I-1.143aA-425)

Table 144a

Compounds 1-1, wherein A is 3-methyl-4-chloroisoxazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds I-1.144aA-1 to I-1)

1.144aA-425)

Table 145a

Compounds 1-1, wherein A is 1-methylpyrazol-3-yl and B corresponds in each case to one group of one row of Table A (compounds I-1.145aA-1 to I-1.145aA-425)

Table 146a

Compounds 1-1, wherein A is 1-methylpyrazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds I-1.146aA-1 to 1.146aA-425) Table 147a

Compounds 1-1, wherein A is 1-methylpyrazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds I-1.147aA-1 to 1.147aA-425)

Table 148a compounds 1-1, wherein A is 1, 3-dimethylpyrazol-4-yl and B are each one

Group of a row corresponds to Table A (compounds I-1.148aA-1 to I-1.148aA-425)

Table 149a

Compounds 1-1, wherein A is 1,5-dimethylpyrazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds I-1.149aA-1 to I-1)

1.149aA-425)

Table 150a

Compounds 1-1, wherein A is 1, 3,5-trimethylpyrazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.150aA-1 to I-1.150aA-425)

Table 151 a

Compounds 1-1, wherein A is 1-methylimidazol-4-yl and B is in each case a group pe corresponds to one row of Table A (compounds 1-1.151 aA-1 to 1-1.151 aA-

425) Table 152a

Compounds 1-1, wherein A is 1,5-dimethylimidazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-1.152aA-1 to I-

1.152aA-425) Table 153a

Compounds 1-1 wherein A is 1,2-dimethylimidazol-5-yl and B is each one

Group of one row corresponds to Table A (Compounds I-1.153aA-1 to I-1.153aA-425)

Table 154a

Compounds 1-1 wherein A is 1,4-dimethylimidazol-5-yl and B is one each

Group of a row corresponds to Table A (compounds I-1.154aA-1 to I-

1.154aA-425) Table 155a

Compounds 1-1, wherein B is pyridin-2-yl and A is each a group of one

Row of Table A corresponds (Compounds 1-1.155aA-1 to 1-1155aA-425) Table 156a

Compounds 1-1, wherein B is pyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.156aA-1 to 1.156aA-425)

Table 157a

Compounds 1-1 wherein B is pyridin-4-yl and A is each a group of one

Line of Table A corresponds (Compounds 1-1157aA-1 to 1-1157aA-425) Table 158a Compounds 1-1, wherein B is 3-chloropyridin-2-yl and A corresponds in each case to one group of one line of Table A. (Compounds I-1.158aA-1 to I-1.158aA-425) Table 159a

Compounds 1-1, wherein B is 4-chloropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.159aA-1 to 1.159aA-425) Table 160a

Compounds 1-1, wherein B is 5-chloropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.160aA-1 to 1-160aA-425) Table 161a

Compounds 1-1, wherein B is 6-chloropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.161 aA-1 to 1-1.161 aA-425)

Table 162a

Compounds 1-1, wherein B is 2-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.162aA-1 to 1.162aA-425) Table 163a Compounds 1-1, in which B is 4-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds I-1.163aA-1 to 1.163aA-425) Table 164a

Compounds 1-1, wherein B is 5-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.164aA-1 to l-1.164aA-425)

Table 165a Compounds 1-1, wherein B is 6-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.165aA-1 to l-1.165aA-425)

Table 166a

Compounds 1-1, wherein B is 2-chloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.166aA-1 to 1.166aA-425) Table 167a

Compounds 1-1, wherein B is 3-chloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.167aA-1 to 1.167aA-425)

Table 168a

Compounds 1-1, wherein B is 4-chloropyridin-5-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.168aA-1 to 1.168aA-425)

Table 169a

Compounds 1-1, wherein B is 3-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.169aA-1 to l-1.169aA-425)

Table 170a Compounds 1-1, wherein B is 4-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.170aA-1 to 1-170aA-425)

Table 171 a

Compounds 1-1, wherein B is 5-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.171 aA-1 to 1-1.171 aA-425) Table 172a

Compounds 1-1, wherein B is 6-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.172aA-1 to 1.172aA-425)

Table 173a

Compounds 1-1, wherein B is 2-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.173aA-1 to 1.173aA-425)

Table 174a

Compounds 1-1, wherein B is 4-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.174aA-1 to 1.174aA-425)

Table 175a Compounds 1-1, wherein B is 5-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.175aA-1 to 1.175aA-425)

Table 176a

Compounds 1-1, wherein B is 6-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.176aA-1 to l-1.176aA-425) Table 177a

Compounds 1-1, wherein B is 2-fluoropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.177aA-1 to 1.177aA-425) Table 178a

Compounds 1-1, wherein B is 3-fluoropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.178aA-1 to 1.178aA-425)

Table 179a Compounds 1-1, wherein B is 3-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.179aA-1 to 1.179aA-425)

Table 180a

Compounds 1-1, wherein B is 4-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1,180aA-1 to 1,180aA-425)

Table 181 a

Compounds 1-1, wherein B is 5-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.181 aA-1 to 1-1.181 aA-425)

Table 182a Compounds 1-1, wherein B is 6-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.182aA-1 to 1.182aA-425)

Table 183a

Compounds 1-1, wherein B is 2-methylpyridin-3-yl and A corresponds in each case to one group of a row of Table A (Compounds 1-1.183aA-1 to l-1.183aA-425) Table 184a

Compounds 1-1, wherein B is 4-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.184aA-1 to 1.184aA-425)

Table 185a

Compounds 1-1, wherein B is 5-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.185aA-1 to 1.185aA-425)

Table 186a

Compounds 1-1, wherein B is 6-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.186aA-1 to 1.186aA-425)

Table 187a Compounds 1-1, wherein B is 2-methylpyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.187aA-1 to 1.187aA-425)

Table 188a

Compounds 1-1, wherein B is 3-methylpyridin-4-yl and A corresponds in each case to one group of a row of Table A (Compounds 1-1.188aA-1 to l-1.188aA-425) Table 189a

Compounds 1-1, wherein B is 4-methylpyridin-5-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.189aA-1 to 1.189aA-425)

Table 190a

Compounds 1-1, wherein B is 3-methoxypyridin-2-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1.190aA-1 to I-

1.190aA-425) Table 191 a

Compounds 1-1 wherein B is 4-methoxypyridin-2-yl and A is each one

Group of one row of Table A (compounds 1-1.191 aA-1 to I-

1.191aA-425) Table 192a

Compounds 1-1 wherein B is 5-methoxypyridin-2-yl and A is each one

Group of a row corresponds to Table A (compounds 1-1.192aA-1 to I-

1.192aA-425) Table 193a Compounds 1-1 wherein B is 6-methoxypyridin-2-yl and A is each one

Group of a row corresponds to Table A (compounds I-1.193aA-1 to I-

1.193aA-425) Table 194a

Compounds 1-1, wherein B is 2-methoxypyridin-3-yl and A in each case corresponds to one group of one row of Table A (Compounds I-1.194aA-1 to I-

1.194aA-425) Table 195a

Compounds 1-1 wherein B is 4-methoxypyridin-3-yl and A is each one

Group of one row corresponds to Table A (Compounds 1-1.195aA-1 to I-1.195aA-425)

Table 196a

Compounds 1-1 wherein B is 5-methoxypyridin-3-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-1.196aA-1 to I-

1.196aA-425) Table 197a

Compounds 1-1, wherein B is 6-methoxypyridin-3-yl and A is each one

Group of a row corresponds to Table A (compounds I-1.197aA-1 to I-

1.197aA-425) Table 198a Compounds 1-1 wherein B is 2-methoxypyridin-4-yl and A is each one

Group of a row corresponds to Table A (compounds 1-1.198aA-1 to I-

1.198aA-425) Table 199a

Compounds 1-1, in which B is 3-methoxypyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.199aA-1 to I-

1.199aA-425) Table 200a

Compounds 1-1 wherein B is 3,5-dichloropyridin-2-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-1.20OaA-I to I-1.200aA-425)

Table 201 a

Compounds 1-1 wherein B is 2,4-dichloropyridin-3-yl and A is each one Group of a row corresponds to Table A (Compounds 1-1.201 aA-1 to I-1.201aA-425)

Table 202a

Compounds 1-1, wherein B is 2,5-dichloropyridin-3-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1,202aA-1 to I-

1.202aA-425)

Table 203a

Compounds 1-1, wherein B is 2,6-dichloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.203aA-1 to I-1.203aA-425)

Table 204a

Compounds 1-1, wherein B is 2,6-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.204aA-1 to I-1.204aA-425) Table 205a

Compounds 1-1, wherein B is 3,5-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.205aA-1 to I-1.205aA-425)

Table 206a compounds 1-1 wherein B is 3,6-dichloropyridin-4-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-1.206aA-1 to I-1.206aA-425)

Table 207a

Compounds 1-1, wherein B is 2,5-dichloropyridin-4-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1,207aA-1 to I-

1.207aA-425)

Table 208a

Compounds 1-1, wherein B is 2,3-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.208aA-1 to I-1.208aA-425)

Table 209a

Compounds 1-1, wherein B is 2,4-dichloropyridin-5-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1.209aA-1 to I-1.209aA-425) Table 210a

Compounds 1-1, wherein B is 3,5-difluoropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.21 OaA-I to 1-1.21 OaA-425)

Table 211a Compounds 1-1, wherein B is 3,5-difluoropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.211 aA-1 to 1-1.211 aA-425) Table 212a

Compounds 1-1, wherein B is 2,3-difluoropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.212aA-1 to 1-1.212aA-

425) Table 213a

Compounds 1-1 wherein B is 3,5-dimethylpyridin-2-yl and A is each one

Group of one row of Table A (Compounds 1-1.213aA-1 to I-

1.213aA-425) Table 214a compounds 1-1 wherein B is 3,4-dimethylpyridin-2-yl and A is each one

Group of one row of Table A (compounds 1-1.214aA-1 to I-

1.214aA-425) Table 215a

Compounds 1-1, in which B is 4,6-dimethylpyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds I-1.215aA-1 to I-

1.215aA-425) Table 216a

Compounds 1-1, wherein B is 2,4-dimethylpyridin-3-yl and A is one each

Group of one row corresponds to Table A (Compounds 1-1.216aA-1 to I-1.216aA-425)

Table 217a

Compounds 1-1 wherein B is 3,5-dimethylpyridin-4-yl and A is each one

Group of a row corresponds to Table A (Compounds I-1.217aA-1 to I-

1.217aA-425) Table 218a

Compounds 1-1 wherein B is 2-chloro-3-fluoropyridin-4-yl and A is each one

Group of a row corresponds to Table A (compounds I-1.218aA-1 to I-

1.218aA-425). Table 219a Compounds 1-1 wherein B is 4-chloro-3-methylpyridin-2-yl and A is each one

Group of a row corresponds to Table A (compounds I-1.219aA-1 to I-

1.219aA-425) Table 220a

Compounds 1-1, wherein B is 5-chloro-3-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.22 OaA-I to I-

1.220aA-425) Table 221 a

Compounds 1-1 wherein B is 5-fluoro-3-methylpyridin-2-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-1.221 aA-1 to I-1.221aA-425)

Table 222a

Compounds 1-1, wherein B is 3-chloro-5-trifluoromethylpyridin-2-yl and A is each because one group corresponds to one row of Table A (Compounds 1-1.222aA-1 to 1-1.222aA-425) Table 223a

Compounds 1-1, wherein B is 2-chloro-6-trifluoromethylpyridin-3-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1.223aA-1 to l-1.223aA-425) 224a

Compounds 1-1, wherein B is 2,4-dichloro-6-methylpyridin-3-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1.224aA-1 to I-1.224aA-425)

Table 225a

Compounds 1-1 wherein B is 3,4,5-trichloropyridin-2-yl and A is each one

Group of a row corresponds to Table A (compounds 1-1.225aA-1 to I-

1.225aA-425) Table 226a

Compounds 1-1 wherein B is 2,4,6-trichloropyridin-3-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-1.226aA-1 to I-

1.226aA-425). Table 227a Compounds 1-1 wherein B is pyrimidin-2-yl and A is each a group of one

Row of Table A corresponds (Compounds 1-1.227aA-1 to 1-1.227aA-425) Table 228a

Compounds 1-1 wherein B is pyrimidin-5-yl and A is a group of each

Row of Table A corresponds (Compounds 1-1.228aA-1 to 1-1.228aA-425) Table 229a

Compounds 1-1, wherein B is 6-chloropyrimidin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.229aA-1 to 1-1.229aA-

425)

Table 230a Compounds 1-1 wherein B is 6-methylpyrimidin-3-yl and A is each one

Group of a row corresponds to Table A (compounds 1-1.23OaA-I to I-

1.230aA-425) Table 231 a

Compounds 1-1, wherein B is 6-methoxypyrimidin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.231 aA-1 to I-

1.231aA-425) Table 232a

Compounds 1-1 wherein B is 2,4-dichloropyrimidin-3-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-1.232aA-1 to I-1.232aA-425)

Table 233a

Compounds 1-1 wherein B is 2,6-dichloropyrimidin-3-yl and A is each one Group of a row corresponds to Table A (Compounds 1-1.233aA-1 to I-1.233aA-425)

Table 234a

Compounds 1-1, wherein B is 2,4-difluoropyrimidin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.234aA-1 to I-

1.234aA-425)

Table 235a

Compounds 1-1, wherein B is 2,6-difluoropyrimidin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.235aA-1 to I-1.235aA-425)

Table 236a

Compounds 1-1, wherein B is 1, 3,5-triazin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.236aA-1 to 1-1.236aA-425)

Table 237a Compounds 1-1, wherein B is thien-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.237aA-1 to 1-1.237aA-425)

Table 238a

Compounds 1-1, wherein B is thien-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.238aA-1 to 1-1.238aA-425) Table 239a

Compounds 1-1, wherein B is 5-chlorothien-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.239aA-1 to 1-1.239aA-425)

Table 240a

Compounds 1-1, wherein B is 2-chlorothien-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.24OaA-I to 1-1.240aA-425)

Table 241 a

Compounds 1-1, wherein B is 4-chlorothien-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.241 aA-1 to 1-1.241 aA-425)

Table 242a Compounds 1-1, wherein B is 5-chlorothien-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.242aA-1 to 1-1.242aA-425)

Table 243a

Compounds 1-1, wherein B is 2-bromothien-3-yl and A corresponds in each case to one group of a row of Table A (Compounds 1-1.243aA-1 to 1-1.243aA-425) Table 244a

Compounds 1-1, wherein B is 4-bromothien-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.244aA-1 to 1-1.244aA-425)

Table 245a

Compounds 1-1, wherein B is 5-bromothien-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.245aA-1 to 1-1.245aA-425) Table 246a

Compounds 1-1, wherein B is 5-methylthien-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.246aA-1 to 1-1.246aA-425)

Table 247a Compounds 1-1, wherein B is 2-methylthien-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.247aA-1 to 1-1.247aA-425)

Table 248a

Compounds 1-1, wherein B is 4,5-dichlorothien-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.248aA-1 to 1-1.248aA-425) Table 249a

Compounds 1-1, wherein B is 2,5-dichlorothien-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.249aA-1 to 1-1.249aA-425)

Table 250a

Compounds 1-1, wherein B is 2,3-dichlorothien-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.25OaA-I to 1-1.250aA-425)

Table 251 a

Compounds 1-1, wherein B is 2,5-dibromothien-3-yl and A in each case corresponds to one group of a row of Table A (Compounds 1-1.251 aA-1 to 1-1.251 aA-425) Table 252a

Compounds 1-1, wherein B is 4,5-dimethylthien-2-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1.252aA-1 to I-1.252aA-425)

Table 253a Compounds 1-1 wherein B is 2,5-dimethylthien-3-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-1.253aA-1 to I-1.253aA-425)

Table 254a

Compounds 1-1, wherein B is 2,3-dimethylthien-4-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1.254aA-1 to I-

1.254aA-425)

Table 255a

Compounds 1-1, wherein B is 3,4,5-trichlorothien-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.255aA-1 to I-1.255aA-425)

Table 256a

Compounds 1-1, wherein B is 2,4,5-trichlorothien-3-yl and A corresponds in each case to one group of a row of Table A (Compounds 1-1.256aA-1 to I-1.256aA-425) Table 257a

Compounds 1-1 wherein B is 2,4,5-tribromothien-3-yl and A is each one Group of one row corresponds to Table A (Compounds 1-1.257aA-1 to I-1.257aA-425)

Table 258a

Compounds 1-1, wherein B is 3,4,5-trimethylthien-2-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1.258aA-1 to I-

1.258aA-425)

Table 259a

Compounds 1-1, wherein B is 4-chlorofur-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.259aA-1 to 1-1.259aA-425) Table 260a

Compounds 1-1, wherein B is 5-chlorofur-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.26OaA-I to 1-1.260aA-425)

Table 261 a

Compounds 1-1, wherein B is 3-bromo-fur-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.261 aA-1 to 1-1.261 aA-425)

Table 262a

Compounds 1-1, wherein B is 4-bromo-fur-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.262aA-1 to 1-1.262aA-425)

Table 263a Compounds 1-1 wherein B is 5-bromo-fur-2-yl and A is each a group of one

Row of Table A corresponds (Compounds 1-1.263aA-1 to 1-1.263aA-425)

Table 264a

Compounds 1-1, wherein B is 3,4-dichloropur-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.264aA-1 to 1-1.264aA-425) Table 265a

Compounds 1-1, wherein B is 4,5-dichloropur-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.265aA-1 to 1-1.265aA-425)

Table 266a

Compounds 1-1, wherein B is thiazol-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.266aA-1 to 1-1.266aA-425)

Table 267a

Compounds 1-1, wherein B is thiazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.267aA-1 to 1-1.267aA-425)

Table 268a Compounds 1-1 wherein B is thiazol-5-yl and A is each a group of one

Row of Table A corresponds (Compounds 1-1.268aA-1 to 1-1.268aA-425)

Table 269a

Compounds 1-1, wherein B is isothiazol-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.269aA-1 to 1-1.269aA-425) Table 270a

Compounds 1-1, wherein B is isothiazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.27OaA-I to 1-1.270aA-425) Table 271 a

Compounds 1-1 wherein B is isothiazol-5-yl and A is each a group of one

Table 272a Compounds 1-1, wherein B is 2-chlorothiazol-4-yl and A corresponds in each case to one group of one row of Table A. Table 272a Compounds 1-1, where B is 2-chlorothiazol-4-yl and A corresponds in each case to one group of one row of Table A. Table 272a Compounds 1-1.271 aA-1 to 1-1.271 aA-425 (Compounds 1-1.272aA-1 to 1-1.272aA-425) Table 273a

Compounds 1-1, wherein B is 2-chlorothiazol-5-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.273aA-1 to 1-1.273aA-425) Table 274a

Compounds 1-1, wherein B is 4-chlorothiazol-5-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.274aA-1 to 1-1.274aA-425) Table 275a

Compounds 1-1, wherein B is 2-bromothiazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.275aA-1 to 1-1.275aA-425)

Table 276a

Compounds 1-1, wherein B is 2-bromothiazol-5-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1.276aA-1 to 1-1.276aA-425) Table 277a Compounds 1-1, wherein B is 2,4-dichlorothiazol-5-yl and A is each one

Group of one row of Table A (Compounds 1-1.277aA-1 to I-

1.277aA-425) Table 278a

Compounds 1-1, wherein B is 3-chloroisothiazol-4-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1.278aA-1 to 1-1.278aA-

425) Table 279a

Compounds 1-1 wherein B is 5-methylisothiazol-3-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-1.279aA-1 to I-1.279aA-425)

Table 280a

Compounds 1-1 wherein B is 3-methylisothiazol-4-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-1.28OaA-I to I-

1.280aA-425) Table 281 a

Compounds 1-1 wherein B is 3-methylisothiazol-5-yl and A is each one

Group of a row corresponds to Table A (compounds 1-1.281 aA-1 to I-

1.281aA-425). Table 282a Compounds 1-1 wherein B is 4,5-dichloroisothiazol-3-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-1.282aA-1 to I-

1.282aA-425) Table 283a

Compounds 1-1, wherein B is 4,5-dimethylisothiazol-3-yl and A corresponds in each case to one group of one row of Table A (compounds 1-1.283aA-1 to I-1.283aA-425) Table 284a

Compounds 1-1, wherein B is 3,5-dimethylisothiazol-4-yl and A in each case corresponds to one group of one row of Table A (compounds 1-1.284aA-1 to I-1.284aA-425)

Table 285a Compounds 1-1 wherein B is 3,4-dichloroisothiazol-5-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-1.285aA-1 to I-1.285aA-425)

Table 286a

Compounds 1-1, wherein B is oxazol-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.286aA-1 to 1-1.286aA-425)

Table 287a

Compounds 1-1, wherein B is oxazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.287aA-1 to 1-1.287aA-425)

Table 288a compounds 1-1 wherein B is oxazol-5-yl and A is each a group of one

Row of Table A corresponds (Compounds 1-1.288aA-1 to 1-1.288aA-425)

Table 289a

Compounds 1-1, wherein B is isoxazol-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.289aA-1 to 1-1.289aA-425) Table 290a

Compounds 1-1, wherein B is isoxazol-4-yl and A corresponds in each case to one group of one line of Table A (Compounds 1-1.29OaA-I to 1-1.290aA-425)

Table 291 a

Compounds 1-1, wherein B is isoxazol-5-yl and A corresponds in each case to one group of one row of Table A (compounds I-1.291 aA-1 to I-1.291aA-425)

Table 292a

Compounds 1-1, wherein B is 3-chloroisoxazol-5-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.292aA-1 to 1-1.292aA-425)

Table 293a Compounds 1-1, wherein B is 5-methylisoxazol-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.293aA-1 to 1-1.293aA-425)

Table 294a

Compounds 1-1, in which B is 5-methylisoxazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.294aA-1 to 1-1.294aA-

425) Table 295a

Compounds 1-1, wherein B is 3-methylisoxazol-5-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.295aA-1 to 1-1.295aA-425) Table 296a

Compounds 1-1, wherein B is 3,5-dimethylisoxazol-4-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1.296aA-1 to I-1.296aA-425)

Table 297a Compounds 1-1, wherein B is 3-chloro-5-methylisoxazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.297aA-1 to I-1.297aA-425)

Table 298a

Compounds 1-1 in which B is 3-methyl-4-chloroisoxazol-5-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1.298aA-1 to I-

1.298aA-425)

Table 299a

Compounds 1-1, wherein B is 1-methylpyrazol-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.299aA-1 to 1-1.299aA-425)

Table 300a

Compounds 1-1, wherein B is 1-methylpyrazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.30OaA-I to 1-1.30OaA-425) Table 301a

Compounds 1-1, wherein B is 1-methylpyrazol-5-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.301 aA-1 to 1-1.301 aA-425)

Table 302a compounds 1-1, wherein B is 1, 3-dimethylpyrazol-4-yl and A is one each

Group of one row corresponds to Table A (Compounds 1-1.302aA-1 to I-1.302aA-425)

Table 303a

Compounds 1-1 in which B is 1,5-dimethylpyrazol-4-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-1.303aA-1 to I-

1.303aA-425)

Table 304a

Compounds 1-1, wherein B is 1, 3,5-trimethylpyrazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.304aA-1 to I-1.304aA-425)

Table 305a

Compounds 1-1, wherein B is 1-methylimidazol-4-yl and A is in each case a group pe corresponds to one line of Table A (compounds 1-1.305aA-1 to 1-1.305aA-

425) Table 306a

Compounds 1-1, wherein B is 1,5-dimethylimidazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-1.306aA-1 to I-

1.306aA-425) Table 307a

Compounds 1-1, wherein B is 1, 2-dimethylimidazol-5-yl and A is one each

Group of one row corresponds to Table A (Compounds 1-1.307aA-1 to I-1.307aA-425)

Table 308a

Compounds 1-1 wherein B is 1,4-dimethylimidazol-5-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-1.308aA-1 to I-

1.308aA-425)

Table 1 aa

Compounds I-2, wherein A is pyridin-2-yl and B in each case corresponds to one group of one row of Table A (Compounds 1-2.1 aaA-1 to 1-2.1 aaA-425) Table 2aa

Compounds I-2, wherein A is pyridin-3-yl and B in each case corresponds to one group of one row of Table A (Compounds I-2.2aaA-1 to l-2.2aaA-425) Table 3aa

Compounds I-2 in which A is pyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.3aaA-1 to I-2.3aaA-425)

Table 4aa

Compounds I-2, wherein A is 3-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.4aaA-1 to L-2.4aaA-425) Table 5aa Compounds I-2, in which A is 4-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.5aaA-1 to I-2.5aaA-425) Table 6aa

Compounds I-2, wherein A is 5-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.6aaA-1 to L-2.6aaA-425). TABLE 7aa

Compounds I-2, wherein A is 6-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.7aaA-1 to I-2.7aaA-425) Table 8aa

Compounds I-2 in which A is 2-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.8aaA-1 to l-2.8aaA-425) Table 9aa

Compounds I-2 in which A is 4-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.9aaA-1 to I-2.9aaA-425)

Table 10aa compounds I-2, wherein A is 5-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.1 OaaA-1 to 1-2.1 OaaA-425)

Table 1 1aa

Compounds I-2, wherein A is 6-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.1 1aaA-1 to 1-2.1 1aaA-425) Table 12aa

Compounds I-2, wherein A is 2-chloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.12aaA-1 to 1-2.12aaA-425)

Table 13aa

Compounds I-2, wherein A is 3-chloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.13aaA-1 to 1-2.13aaA-425)

Table 14aa

Compounds I-2, wherein A is 4-chloropyridin-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.14aaA-1 to 1-2.14aaA-425)

Table 15aa compounds I-2, wherein A is 3-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.15aaA-1 to 1-2.15aaA-425)

Table 16aa

Compounds I-2, wherein A is 4-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.16aaA-1 to 1-2.16aaA-425) Table 17aa

Compounds I-2, wherein A is 5-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.17aaA-1 to 1-2.17aaA-425)

Table 18aa

Compounds I-2, wherein A is 6-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.18aaA-1 to 1-2.18aaA-425)

Table 19aa

Compounds I-2, wherein A is 2-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.19aaA-1 to 1-2.19aaA-425)

Table 20aa Compounds I-2, wherein A is 4-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.20aaA-1 to I-2.20aaA-425)

Table 21aa

Compounds I-2, wherein A is 5-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.21 aaA-1 to 1-2.21 aaA-425) Table 22aa

Compounds I-2, wherein A is 6-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.22aaA-1 to I-2.22aaA-425) Table 23aa

Compounds 1-2, wherein A is 2-fluoropyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.23aaA-1 to l-2.23aaA-425)

Table 24aa compounds I-2, wherein A is 3-fluoropyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.24aaA-1 to l-2.24aaA-425)

Table 25aa

Compounds I-2 in which A is 3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.25aaA-1 to I-2.25aaA-425)

Table 26aa

Compounds I-2 in which A is 4-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.26aaA-1 to I-2.26aaA-425)

Table 27aa compounds I-2, wherein A is 5-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.27aaA-1 to I-2.27aaA-425)

Table 28aa

Compounds I-2, wherein A is 6-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.28aaA-1 to I-2.28aaA-425) Table 29aa

Compounds I-2, wherein A is 2-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.29aaA-1 to I-2.29aaA-425)

Table 30aa

Compounds I-2 in which A is 4-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.30aaA-1 to I-2.30aaA-425)

Table 31aa

Compounds I-2, wherein A is 5-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.31 aaA-1 to 1-2.31 aaA-425)

Table 32aa compounds I-2, wherein A is 6-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.32aaA-1 to l-2.32aaA-425)

Table 33aa

Compounds I-2 in which A is 2-methylpyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.33aaA-1 to I-2.33aaA-425) Table 34aa

Compounds I-2 in which A is 3-methylpyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.34aaA-1 to I-2.34aaA-425)

Table 35aa

Compounds I-2 in which A is 4-methylpyridin-5-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.35aaA-1 to I-2.35aaA-425)

Table 36aa

Compounds I-2 wherein A is 3-methoxypyridin-2-yl and B are each one Group of a row corresponds to Table A (compounds I-2.36aaA-1 to I-

2.36aaA-425) Table 37aa

Compounds I-2, in which A is 4-methoxypyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.37aaA-1 to I-

2.37aaA-425) Table 38aa

Compounds I-2 wherein A is 5-methoxypyridin-2-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.38aaA-1 to I-2.38aaA-425)

Table 39aa

Compounds I-2 wherein A is 6-methoxypyridin-2-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.39aaA-1 to I-

2.39aaA-425) Table 40aa

Compounds I-2 wherein A is 2-methoxypyridin-3-yl and B are each one

Group of a row corresponds to Table A (Compounds I-2.40aaA-1 to I-

2.40aaA-425) Table 41aa compounds I-2 wherein A is 4-methoxypyridin-3-yl and B is one each

Group of a row corresponds to Table A (Compounds 1-2.41 aaA-1 to I-

2.41 aaA-425) Table 42aa

Compounds I-2, in which A is 5-methoxypyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.42aaA-1 to I-

2.42aaA-425) Table 43aa

Compounds I-2 wherein A is 6-methoxypyridin-3-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.43aaA-1 to I-2.43aaA-425)

Table 44aa

Compounds I-2 wherein A is 2-methoxypyridin-4-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.44aaA-1 to I-

2.44aaA-425) Table 45aa

Compounds I-2 wherein A is 3-methoxypyridin-4-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.45aaA-1 to I-

2.45aaA-425) Table 46aa compounds I-2 wherein A is 3,5-dichloropyridin-2-yl and B is one each

Group of a row corresponds to Table A (compounds I-2.46aaA-1 to I-

2.46aaA-425) Table 47aa

Compounds 1-2 wherein A is 2,4-dichloropyridin-3-yl and B are each one

Group of a row corresponds to Table A (Compounds I-2.47aaA-1 to I-

2.47aaA-425) Table 48aa

Compounds I-2 wherein A is 2,5-dichloropyridin-3-yl and B are each one

Group of one row of Table A (Compounds I-2.48aaA-1 to I-

2.48aaA-425) Table 49aa compounds I-2 wherein A is 2,6-dichloropyridin-3-yl and B is one each

Group of one row of Table A (Compounds I-2.49aaA-1 to I-

2.49aaA-425) Table 50aa

Compounds I-2, in which A is 2,6-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.50aaA-1 to I-

2.50aaA-425) Table 51 aa

Compounds I-2 wherein A is 3,5-dichloropyridin-4-yl and B are each one

Group of a row corresponds to Table A (Compounds 1-2.51 aaA-1 to I-2.51 aaA-425)

Table 52aa

Compounds I-2 wherein A is 3,6-dichloropyridin-4-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.52aaA-1 to I-

2.52aaA-425) Table 53aa

Compounds I-2 wherein A is 2,5-dichloropyridin-4-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.53aaA-1 to I-

2.53aaA-425) Table 54aa compounds I-2 wherein A is 2,3-dichloropyridin-4-yl and B is one each

Group of a row corresponds to Table A (compounds I-2.54aaA-1 to I-

2.54aaA-425) Table 55aa

Compounds I-2, in which A is 2,4-dichloropyridin-5-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.55aaA-1 to I-

2.55aaA-425) Table 56aa

Compounds I-2 in which A is 3,5-difluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.56aaA-1 to I-2.56aaA-425)

Table 57aa

Compounds I-2, wherein A is 3,5-difluoropyridin-4-yl and B is in each case a group pe corresponds to one line of Table A (compounds I-2.57aaA-1 to I-2.57aaA-

425) Table 58aa

Compounds I-2, in which A is 2,3-difluoropyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.58aaA-1 to I-2.58aaA-

425) Table 59aa

Compounds I-2 wherein A is 3,5-dimethylpyridin-2-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.59aaA-1 to I-2.59aaA-425)

Table 60aa

Compounds I-2 wherein A is 3,4-dimethylpyridin-2-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.60aaA-1 to I-

2.60aaA-425) Table 61 aa

Compounds I-2 wherein A is 4,6-dimethylpyridin-3-yl and B are each one

Group of a row corresponds to Table A (Compounds 1-2.61 aaA-1 to I-

2.61 aaA-425) Table 62aa Compounds I-2, wherein A is 2,4-dimethylpyridin-3-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.62aaA-1 to I-

2.62aaA-425) Table 63aa

Compounds I-2, in which A is 3,5-dimethylpyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.63aaA-1 to I-

2.63aaA-425) Table 64aa

Compounds I-2 wherein A is 2-chloro-3-fluoropyridin-4-yl and B is one each

Group of a row corresponds to Table A (compounds I-2.64aaA-1 to I-2.64aaA-425)

Table 65aa

Compounds I-2 wherein A is 4-chloro-3-methylpyridin-2-yl and B is one each

Group of a row corresponds to Table A (compounds I-2.65aaA-1 to I-

2.65aaA-425) Table 66aa

Compounds I-2 wherein A is 5-chloro-3-methylpyridin-2-yl and B is one each

Group of a row corresponds to Table A (Compounds I-2.66aaA-1 to I-

2.66aaA-425) Table 67a Compounds I-2 wherein A is 5-fluoro-3-methylpyridin-2-yl and B is one each

Group of a row corresponds to Table A (Compounds I-2.67aaA-1 to I-

2.67aaA-425) Table 68aa

Compounds 1-2, wherein A is 3-chloro-5-trifluoromethylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.68aaA-1 to I-2.68aaA-425) Table 69aa

Compounds I-2 in which A is 2-chloro-6-trifluoromethylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.69aaA-1 to I-2.69aaA-425)

Table 70aa Compounds I-2, wherein A is 2,4-dichloro-6-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.70aaA-1 to I-2.70aaA-425 )

Table 71 aa

Compounds I-2, in which A is 3,4,5-trichloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.71 aaA-1 to I-

2.71 aaA-425)

Table 72aa

Compounds I-2, in which A is 2,4,6-trichloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.72aaA-1 to I-2.72aaA-425)

Table 73aa

Compounds I-2, in which A is pyrimidin-2-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.73aaA-1 to I-2.73aaA-425)

Table 74aa Compounds I-2 wherein A is pyrimidin-5-yl and B is each a group of one

Line of Table A corresponds (compounds I-2.74aaA-1 to I-2.74aaA-425)

Table 75aa

Compounds I-2 in which A is 6-chloropyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.75aaA-1 to I-2.75aaA-425)

Table 76aa

Compounds I-2, wherein A is 6-methylpyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.76aaA-1 to I-2.76aaA-425) Table 77aa

Compounds I-2 in which A is 6-methoxypyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.77aaA-1 to I-2.77aaA-425)

Table 78aa Compounds I-2 wherein A is 2,4-dichloropyrimidin-3-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.78aaA-1 to I-2.78aaA-425) Table 79aa

Compounds 1-2, wherein A is 2,6-dichloropyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.79aaA-1 to I-2.79aaA-425) Table 80aa

Compounds I-2 in which A is 2,4-difluoropyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.80aaA-1 to I-2.80aaA-425)

Table 81 aa Compounds I-2, wherein A is 2,6-difluoropyrimidin-3-yl and B are each one

Group of a row corresponds to Table A (Compounds 1-2.81 aaA-1 to I-2.81 aaA-425)

Table 82aa

Compounds I-2 in which A is 1, 3,5-triazin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.82aaA-1 to I-2.82aaA-425)

Table 83aa

Compounds I-2, in which A is thien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.83aaA-1 to I-2.83aaA-425)

Table 84aa compounds I-2, in which A is thien-3-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.84aaA-1 to I-2.84aaA-425)

Table 85aa

Compounds I-2 in which A is 5-chlorothien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.85aaA-1 to I-2.85aaA-425) Table 86aa

Compounds I-2, wherein A is 2-chlorothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.86aaA-1 to I-2.86aaA-425)

Table 87aa

Compounds I-2 in which A is 4-chlorothien-3-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.87aaA-1 to I-2.87aaA-425)

Table 88aa

Compounds I-2, wherein A is 5-chlorothien-3-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.88aaA-1 to l-2.88aaA-425)

Table 89aa Compounds I-2, wherein A is 2-bromothien-3-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.89aaA-1 to I-2.89aaA-425)

Table 90aa

Compounds I-2 in which A is 4-bromothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.90aaA-1 to I-2.90aaA-425) Table 91aa

Compounds I-2, wherein A is 5-bromothien-3-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.91 aaA-1 to 1-2.91 aaA-425) Table 92aa

Compounds 1-2, wherein A is 5-methylthien-2-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.92aaA-1 to I-2.92aaA-425)

Table 93aa compounds I-2 in which A is 2-methylthien-4-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.93aaA-1 to I-2.93aaA-425)

Table 94aa

Compounds I-2, wherein A is 4,5-dichlorothien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.94aaA-1 to I-2.94aaA-425) Table 95aa

Compounds I-2, wherein A is 2,5-dichlorothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.95aaA-1 to I-2.95aaA-425)

Table 96aa

Compounds I-2, wherein A is 2,3-dichlorothien-4-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.96aaA-1 to I-2.96aaA-425)

Table 97aa

Compounds I-2, wherein A is 2,5-dibromothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.97aaA-1 to I-2.97aaA-425). Table 98aa

Compounds I-2, wherein A is 4,5-dimethylthien-2-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.98aaA-1 to I-2.98aaA-425)

Table 99aa Compounds I-2 wherein A is 2,5-dimethylthien-3-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.99aaA-1 to I-2.99aaA-425)

Table 100aa

Compounds I-2, in which A is 2,3-dimethylthien-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.100aaA-1 to I-

2.100aaA-425)

Table 101 aa

Compounds I-2 in which A is 3,4,5-trichlorothien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.101aaA-1 to I-2.101 aaA-425)

Table 102aa

Compounds I-2, wherein A is 2,4,5-trichlorothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.102aaA-1 to I-2.102aaA-425) Table 103aa

Compounds I-2 wherein A is 2,4,5-tribromothien-3-yl and B are each one Group of a row corresponds to Table A (compounds I-2.103aaA-1 to I-

2.103aaA-425) Table 104aa

Compounds I-2, in which A is 3,4,5-trimethylthien-2-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.104aaA-1 to I-

2.104aaA-425) Table 105aa

Compounds I-2 wherein A is 4-chlorofur-2-yl and B are each a group of one

Row of Table A corresponds (Compounds 1-2.105aaA-1 to 1-2.105aaA-425) Table 106aa

Compounds I-2 wherein A is 5-chlorofur-2-yl and B are each a group of one

Row of Table A corresponds (Compounds 1-2.106aaA-1 to 1-2.106aaA-425) Table 107aa

Compounds I-2, wherein A is 3-bromo-fur-2-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.107aaA-1 to 1-2.107aaA-425)

Table 108aa

Compounds I-2 wherein A is 4-bromo-fur-2-yl and B are each a group of one

Line of Table A corresponds (compounds I-2.108aaA-1 to 1-2.108aaA-425). Table 109aa compounds I-2 wherein A is 5-bromo-fur-2-yl and B is each a group of one

Row of Table A corresponds (Compounds 1-2.109aaA-1 to 1-2.109aaA-425). Table 1 10aa

Compounds I-2, wherein A is 3,4-dichloropur-2-yl and B corresponds in each case to one group of one line of Table A (compounds 1-2.110aaA-1 to 1-2.110aaA-425)

Table 1 11 aa

Compounds I-2, wherein A is 4,5-dichloropur-2-yl and B in each case corresponds to one group of one row of Table A (Compounds 1-2.11 1 aaA-1 to 1-2.11 1 aaA-

425) Table 1 12aa

Compounds I-2 wherein A is thiazol-2-yl and B are each a group of one

Row of Table A corresponds (Compounds 1-2.1 12aaA-1 to 1-2.1 12aaA-425) Table 1 13aa

Compounds I-2, wherein A is thiazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.1 13aaA-1 to 1-2.1 13aaA-425)

Table 1 14aa

Compounds I-2 wherein A is thiazol-5-yl and B are each a group of one

Line of Table A corresponds (compounds 1-2.1 14aaA-1 to 1-2.1 14aaA-425). Table 1 15aa Compounds I-2 wherein A is isothiazol-3-yl and B is each a group of one

Row of Table A corresponds (Compounds 1-2.1 15aaA-1 to 1-2.1 15aaA-425) Table 1 16aa

Compounds I-2, wherein A is isothiazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.1 16aaA-1 to 1-2.1 16aaA-425)

17aa compounds I-2 wherein A is isothiazol-5-yl and B is each a group of one

Line of Table A corresponds (compounds 1-2.1 17aaA-1 to 1-2.1 17aaA-425)

Table 1 18aa

Compounds I-2, wherein A is 2-chlorothiazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.118aaA-1 to 1-2.118aaA-425)

Table 1 19aa

Compounds I-2, wherein A is 2-chlorothiazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.119aaA-1 to 1-2.119aaA-425) Table 120aa

Compounds I-2 in which A is 4-chlorothiazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.120aaA-1 to 1-2.120aaA-425)

Table 121a Compounds I-2, wherein A is 2-bromothiazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds I-2.121aaA-1 to l-2.121aaA-425)

Table 122aa

Compounds I-2, wherein A is 2-bromothiazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.122aaA-1 to 1-2.122aaA-

425)

Table 123aa

Compounds I-2, wherein A is 2,4-dichlorothiazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.123aaA-1 to I-2.123aaA-425)

Table 124aa

Compounds I-2, wherein A is 3-chloroisothiazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.124aaA-1 to 1-2.124aaA-425) Table 125aa

Compounds I-2, wherein A is 5-methylisothiazol-3-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.125aaA-1 to I-2.125aaA-425)

Table 126aa Compounds I-2 wherein A is 3-methylisothiazol-4-yl and B are each one

Group of a row corresponds to Table A (compounds 1-2.126aaA-1 to I-2.126aaA-425) Table 127aa

Compounds I-2 wherein A is 3-methylisothiazol-5-yl and B are each one

Group of a row corresponds to Table A (compounds 1-2.127aaA-1 to I-

2.127aaA-425) Table 128aa

Compounds I-2 wherein A is 4,5-dichloroisothiazol-3-yl and B are each one

Group of a row corresponds to Table A (Compounds 1-2.128aaA-1 to I-

2.128aaA-425). Table 129aa compounds I-2 wherein A is 4,5-dimethylisothiazol-3-yl and B is each one

Group of a row corresponds to Table A (compounds 1-2.129aaA-1 to I-

2.129aaA-425) Table 130aa

Compounds I-2, in which A is 3,5-dimethylisothiazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.130aaA-1 to I-

2.130aaA-425) Table 131aa

Compounds I-2 wherein A is 3,4-dichloroisothiazol-5-yl and B are each one

Group of a row corresponds to Table A (compounds I-2.131aaA-1 to I-2.131 aaA-425)

Table 132aa

Compounds I-2 wherein A is oxazol-2-yl and B each represents a group of one

Line of Table A corresponds (Compounds 1-2.132aaA-1 to 1-2.132aaA-425) Table 133aa Compounds I-2 wherein A is oxazol-4-yl and B is each a group of one

Row of Table A corresponds (Compounds 1-2.133aaA-1 to 1-2.133aaA-425) Table 134aa

Compounds I-2, wherein A is oxazol-5-yl and B each represents a group of one

Row of Table A corresponds (Compounds I-2.134aaA-1 to 1-2.134aaA-425) Table 135aa

Compounds I-2 wherein A is isoxazol-3-yl and B are each a group of one

Row of Table A corresponds (Compounds 1-2.135aaA-1 to 1-2.135aaA-425) Table 136aa

Compounds I-2, wherein A is isoxazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.136aaA-1 to 1-2.136aaA-425)

Table 137aa

Compounds I-2 wherein A is isoxazol-5-yl and B are each a group of one

Row of Table A corresponds (Compounds 1-2.137aaA-1 to 1-2.137aaA-425) Table 138aa Compounds I-2 wherein A is 3-chloroisoxazol-5-yl and B corresponds in each case to one group of one row of Table A. (Compounds 1-2.138aaA-1 to 1-2.138aaA-

425) Table 139aa

Compounds I-2, wherein A is 5-methylisoxazol-3-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.139aaA-1 to 1-2.139aaA-425) Table 140aa

Compounds I-2, wherein A is 5-methylisoxazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.140aaA-1 to 1-2.140aaA-425)

Table 141a Compounds I-2, wherein A is 3-methylisoxazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds I-2.141aaA-1 to l-2.141aaA-425)

Table 142aa

Compounds I-2, in which A is 3,5-dimethylisoxazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.142aaA-1 to I-2)

2.142aaA-425)

Table 143aa

Compounds I-2, wherein A is 3-chloro-5-methylisoxazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.143aaA-1 to I-2.143aaA-425)

Table 144aa

Compounds I-2, wherein A is 3-methyl-4-chloroisoxazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.144aaA-1 to I-2.144aaA-425) Table 145aa

Compounds I-2 in which A is 1-methylpyrazol-3-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.145aaA-1 to 1-2.145aaA-425)

Table 146aa compounds I-2, wherein A is 1-methylpyrazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.146aaA-1 to 1-2.146aaA-425)

Table 147aa

Compounds I-2, wherein A is 1-methylpyrazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.147aaA-1 to 1-2.147aaA-

425)

Table 148aa

Compounds I-2, wherein A is 1, 3-dimethylpyrazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.148aaA-1 to I-2.148aaA-425)

Table 149aa

Compounds I-2, wherein A is 1, 5-dimethylpyrazol-4-yl and B are each one Group of a row corresponds to Table A (compounds I-2.149aaA-1 to I-2.149aaA-425)

Table 150aa

Compounds I-2, in which A is 1, 3,5-trimethylpyrazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.150aaA-1 to I-

2.150aaA-425)

Table 151 aa

Compounds I-2, wherein A is 1-methylimidazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.151 aaA-1 to 1-2.151 aaA-425)

Table 152aa

Compounds I-2, wherein A is 1, 5-dimethylimidazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds 1-2.152aaA-1 to I-2.152aaA-425) Table 153aa

Compounds I-2 in which A is 1,2-dimethylimidazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds 1-2.153aaA-1 to I-2.153aaA-425)

Table 154aa Compounds I-2 wherein A is 1,4-dimethylimidazol-5-yl and B is each one

Group of a row corresponds to Table A (compounds 1-2.154aaA-1 to I-2.154aaA-425)

Table 155aa

Compounds I-2, wherein B is pyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.155aaA-1 to 1-2.155aaA-425)

Table 156aa

Compounds I-2, wherein B is pyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.156aaA-1 to 1-2.156aaA-425)

Table 157aa compounds I-2 wherein B is pyridin-4-yl and A is each a group of one

Row of Table A corresponds (Compounds 1-2.157aaA-1 to 1-2.157aaA-425)

Table 158aa

Compounds I-2, wherein B is 3-chloropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.158aaA-1 to 1-2.158aaA-425)

Table 159aa

Compounds I-2, wherein B is 4-chloropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.159aaA-1 to 1-2.159aaA-425) Table 160aa

Compounds I-2 wherein B is 5-chloropyridin-2-yl and A are each a group corresponds to one line of Table A (compounds I-2.160aaA-1 to 1-2.160aaA-

425) Table 161 aa

Compounds I-2, wherein B is 6-chloropyridin-2-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-2.161 aaA-1 to 1-2.161 aaA-

425) Table 162aa

Compounds I-2, wherein B is 2-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.162aaA-1 to 1-2.162aaA-425)

Table 163aa

Compounds I-2, wherein B is 4-chloropyridin-3-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-2.163aaA-1 to 1-2.163aaA-

425) Table 164aa

Compounds I-2, wherein B is 5-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.164aaA-1 to 1-2.164aaA-

425)

Table 165aa compounds I-2, wherein B is 6-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.165aaA-1 to 1-2.165aaA-

425) Table 166aa

Compounds I-2, wherein B is 2-chloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.166aaA-1 to 1-2.166aaA-

425) Table 167aa

Compounds I-2, wherein B is 3-chloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.167aaA-1 to 1-2.167aaA-425)

Table 168aa

Compounds I-2, wherein B is 4-chloropyridin-5-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.168aaA-1 to 1-2.168aaA-

425) Table 169aa

Compounds I-2, wherein B is 3-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.169aaA-1 to 1-2.169aaA-

425)

Table 170aa Compounds I-2, wherein B is 4-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.170aaA-1 to 1-2.170aaA-

425) Table 171 aa

Compounds I-2, wherein B is 5-fluoropyridin-2-yl and A in each case corresponds to one group of one row of Table A (compounds 1-2.171 aaA-1 to 1-2.171 aaA-

425) Table 172aa

Compounds I-2, wherein B is 6-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.172aaA-1 to 1-2.172aaA-

425)

Table 173aa Compounds I-2, wherein B is 2-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.173aaA-1 to 1-2.173aaA-

425) Table 174aa

Compounds I-2, wherein B is 4-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.174aaA-1 to 1-2.174aaA-

425) Table 175aa

Compounds I-2, wherein B is 5-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.175aaA-1 to 1-2.175aaA-425)

Table 176aa

Compounds I-2, wherein B is 6-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.176aaA-1 to 1-2.176aaA-

425) Table 177aa

Compounds I-2, wherein B is 2-fluoropyridin-4-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.177aaA-1 to 1-2.177aaA-

425)

Table 178aa Compounds I-2, wherein B is 3-fluoropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.178aaA-1 to 1-2.178aaA-

425) Table 179aa

Compounds I-2 in which B is 3-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.179aaA-1 to 1-2.179aaA-

425) Table 180aa

Compounds I-2, wherein B is 4-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.180aaA-1 to 1-2.180aaA-425)

Table 181 aa

Compounds I-2 wherein B is 5-methylpyridin-2-yl and A is each a group corresponds to one line of Table A (compounds 1-2.181 aaA-1 to 1-2.181 aaA-

425) Table 182aa

Compounds I-2 in which B is 6-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.182aaA-1 to 1-2.182aaA-

425) Table 183aa

Compounds I-2, wherein B is 2-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.183aaA-1 to 1-2.183aaA-425)

Table 184aa

Compounds I-2, wherein B is 4-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.184aaA-1 to 1-2.184aaA-

425) Table 185aa

Compounds I-2, wherein B is 5-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.185aaA-1 to 1-2.185aaA-

425)

Table 186aa compounds I-2, wherein B is 6-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.186aaA-1 to 1-2.186aaA-

425) Table 187aa

Compounds I-2, wherein B is 2-methylpyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.187aaA-1 to 1-2.187aaA-

425) Table 188aa

Compounds I-2, wherein B is 3-methylpyridin-4-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.188aaA-1 to 1-2.188aaA-425)

Table 189aa

Compounds I-2, wherein B is 4-methylpyridin-5-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.189aaA-1 to 1-2.189aaA-

425) Table 190aa

Compounds I-2 wherein B is 3-methoxypyridin-2-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-2.190aaA-1 to I-

2.190aaA-425). Table 191aa Compounds I-2 wherein B is 4-methoxypyridin-2-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.191aaA-1 to I-

2.191 aaA-425) Table 192aa

Compounds I-2 wherein B is 5-methoxypyridin-2-yl and A is each one

Group of a row corresponds to Table A (compounds 1-2.192aaA-1 to I-

2.192aaA-425) Table 193aa

Compounds I-2 wherein B is 6-methoxypyridin-2-yl and A is each one

Group of a row corresponds to Table A (compounds 1-2.193aaA-1 to I-

2.193aaA-425) Table 194aa compounds I-2 wherein B is 2-methoxypyridin-3-yl and A is each one

Group of a row corresponds to Table A (compounds 1-2.194aaA-1 to I-

2.194aaA-425) Table 195aa

Compounds I-2, wherein B is 4-methoxypyridin-3-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-2.195aaA-1 to I-

2.195aaA-425) Table 196aa

Compounds I-2 wherein B is 5-methoxypyridin-3-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-2.196aaA-1 to I-2.196aaA-425)

Table 197aa

Compounds I-2 wherein B is 6-methoxypyridin-3-yl and A is each one

Group of a row corresponds to Table A (compounds 1-2.197aaA-1 to I-

2.197aaA-425) Table 198aa

Compounds I-2 wherein B is 2-methoxypyridin-4-yl and A is each one

Group of a row corresponds to Table A (compounds 1-2.198aaA-1 to I-

2.198aaA-425) Table 199aa compounds I-2 wherein B is 3-methoxypyridin-4-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-2.199aaA-1 to I-

2.199aaA-425) Table 200aa

Compounds I-2, in which B is 3,5-dichloropyridin-2-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.200aaA-1 to I-2)

2.200aaA-425) Table 201 aa

Compounds I-2 wherein B is 2,4-dichloropyridin-3-yl and A is each one

Group of a row corresponds to Table A (compounds 1-2.201 aaA-1 to I-2.201 aaA-425)

Table 202aa

Compounds I-2 wherein B is 2,5-dichloropyridin-3-yl and A is one each Group of a row corresponds to Table A (compounds I-2.202aaA-1 to I-2.202aaA-425)

Table 203aa

Compounds I-2, in which B is 2,6-dichloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2.203aaA-1 to I-

2.203aaA-425)

Table 204aa

Compounds I-2 in which B is 2,6-dichloropyridin-4-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.204aaA-1 to I-2.204aaA-425)

Table 205aa

Compounds I-2, wherein B is 3,5-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.205aaA-1 to I-2.205aaA-425) Table 206aa

Compounds I-2 in which B is 3,6-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2.206aaA-1 to I-2.206aaA-425)

Table 207aa Compounds I-2 wherein B is 2,5-dichloropyridin-4-yl and A is each one

Group of one row corresponds to Table A (compounds I-2.207aaA-1 to I-2.207aaA-425)

Table 208aa

Compounds I-2, in which B is 2,3-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2.208aaA-1 to I-

2.208aaA-425)

Table 209aa

Compounds I-2 in which B is 2,4-dichloropyridin-5-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2.209aaA-1 to I-2.209aaA-425)

Table 21aa

Compounds I-2, wherein B is 3,5-difluoropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.210aaA-1 to 1-2.21 OaaA-425) Table 211aa

Compounds I-2, wherein B is 3,5-difluoropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.21 1aaA-1 to 1-2.21 1aaA-425)

Table 212aa Compounds I-2, wherein B is 2,3-difluoropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.212aaA-1 to 1-2.212aaA-425) Table 213aa

Compounds I-2 wherein B is 3,5-dimethylpyridin-2-yl and A is one each

Group of a row corresponds to Table A (compounds 1-2.213aaA-1 to I-

2.213aaA-425) Table 214aa

Compounds I-2 wherein B is 3,4-dimethylpyridin-2-yl and A is each one

Group of a row corresponds to Table A (compounds 1-2.214aaA-1 to I-

2.214aaA-425) Table 215aa Compounds I-2 wherein B is 4,6-dimethylpyridin-3-yl and A is each one

Group of a row corresponds to Table A (compounds 1-2.215aaA-1 to I-

2.215aaA-425) Table 216aa

Compounds I-2 in which B is 2,4-dimethylpyridin-3-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-2.216aaA-1 to I-

2.216aaA-425) Table 217aa

Compounds I-2 wherein B is 3,5-dimethylpyridin-4-yl and A is each one

Group of a row corresponds to Table A (compounds 1-2.217aaA-1 to I-2.217aaA-425)

Table 218aa

Compounds I-2 wherein B is 2-chloro-3-fluoropyridin-4-yl and A is each one

Group of a row corresponds to Table A (compounds 1-2.218aaA-1 to I-

2.218aaA-425) Table 219aa

Compounds I-2 wherein B is 4-chloro-3-methylpyridin-2-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-2.219aaA-1 to I-

2.219aaA-425) Table 220aa compounds I-2 wherein B is 5-chloro-3-methylpyridin-2-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.220aaA-1 to I-

2.220aaA-425) Table 221 aa

Compounds I-2 in which B is 5-fluoro-3-methylpyridin-2-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-2.221 aaA-1 to I-

2.221 aaA-425) Table 222aa

Compounds I-2 in which B is 3-chloro-5-trifluoromethylpyridin-2-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.222aaA-1 to I-2.222aaA-425)

Table 223aa

Compounds I-2, wherein B is 2-chloro-6-trifluoromethylpyridin-3-yl and A is each because one group corresponds to one row of Table A (compounds I-2.223aaA-

1 to l-2.223aaA-425) Table 224aa

Compounds I-2 in which B is 2,4-dichloro-6-methylpyridin-3-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.224aaA-1 to I-

2.224aaA-425) Table 225aa

Compounds I-2 wherein B is 3,4,5-trichloropyridin-2-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.225aaA-1 to I-2.225aaA-425)

Table 226aa

Compounds I-2 wherein B is 2,4,6-trichloropyridin-3-yl and A is each one

Group of one row of Table A (Compounds I-2.226aaA-1 to I-

2.226aaA-425) Table 227aa

Compounds I-2 wherein B is pyrimidin-2-yl and A is each a group of one

Row of Table A corresponds (Compounds l-2.227aaA-1 to l-2.227aaA-425) Table 228aa

Compounds I-2 in which B is pyrimidin-5-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.228aaA-1 to I-2.228aaA-425)

Table 229aa

Compounds I-2 in which B is 6-chloropyrimidin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2.229aaA-1 to I-2.229aaA-

425) Table 230aa

Compounds I-2 wherein B is 6-methylpyrimidin-3-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.230aaA-1 to I-

2.230aaA-425) Table 231aa compounds I-2 wherein B is 6-methoxypyrimidin-3-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-2.231 aaA-1 to I-

2.231 aaA-425) Table 232aa

Compounds I-2, wherein B is 2,4-dichloropyrimidin-3-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.232aaA-1 to I-

2.232aaA-425) Table 233aa

Compounds I-2 wherein B is 2,6-dichloropyrimidin-3-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.233aaA-1 to I-2.233aaA-425)

Table 234aa

Compounds I-2 wherein B is 2,4-difluoropyrimidin-3-yl and A is each one Group of a row corresponds to Table A (compounds I-2.234aaA-1 to I-2.234aaA-425)

Table 235aa

Compounds I-2 in which B is 2,6-difluoropyrimidin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2.235aaA-1 to I-

2.235aaA-425)

Table 236aa

Compounds I-2, wherein B is 1, 3,5-triazin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-.226aaA-1 to l-2,236aaA-425)

Table 237aa

Compounds I-2, wherein B is thien-2-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2237aaA-1 to l-2.237aaA-425)

Table 238aa Compounds I-2, wherein B is thien-3-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.238aaA-1 to I-2.238aaA-425)

Table 239aa

Compounds I-2 in which B is 5-chlorothien-2-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.239aaA-1 to I-2.239aaA-425)

Table 240aa

Compounds I-2, wherein B is 2-chlorothien-3-yl and A in each case corresponds to one group of one row of Table A (Compounds l-2.240aaA-1 to l-2.240aa-425) Table 241aa

Compounds I-2, wherein B is 4-chlorothien-3-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.241 aaA-1 to 1-2.241 aaA-425)

Table 242aa Compounds I-2, wherein B is 5-chlorothien-3-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.242aaA-1 to l-2.242aaA-425)

Table 243aa

Compounds I-2 in which B is 2-bromothien-3-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.243aaA-1 to I-2.243aaA-

425)

Table 244aa

Compounds I-2, wherein B is 4-bromothien-3-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2244aaA-1 to l-2.244aaA-425)

Table 245aa

Compounds I-2 wherein B is 5-bromothien-3-yl and A is each a group corresponds to one line of Table A (compounds l-2.245aaA-1 to l-2.245aaA-

425) Table 246aa

Compounds I-2 in which B is 5-methylthien-2-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.246aaA-1 to I-2.246aaA-

425) Table 247aa

Compounds I-2 in which B is 2-methylthien-4-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.247aaA-1 to I-2.247aaA-425)

Table 248aa

Compounds I-2, in which B is 4,5-dichlorothien-2-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.248aaA-1 to I-2.248aaA-

425) Table 249aa

Compounds I-2, in which B is 2,5-dichlorothien-3-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2.249aaA-1 to I-2.249aaA-

425)

Table 250aa Compounds I-2, wherein B is 2,3-dichlorothien-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2,250aaA-1 to l-2,250aaA-

425) Table 251 aa

Compounds I-2, where B is 2,5-dibromothien-3-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.251 aaA-1 to 1-2.251 aaA-

425) Table 252aa

Compounds I-2 wherein B is 4,5-dimethylthien-2-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.252aaA-1 to I-2.252aaA-425)

Table 253aa

Compounds I-2 wherein B is 2,5-dimethylthien-3-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.253aaA-1 to I-

2.253aaA-425) Table 254aa

Compounds I-2 wherein B is 2,3-dimethylthien-4-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.254aaA-1 to I-

2.254aaA-425) Table 255aa compounds I-2 wherein B is 3,4,5-trichlorothien-2-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.255aaA-1 to I-

2.255aaA-425) Table 256aa

Compounds 1-2 wherein B is 2,4,5-trichlorothien-3-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.256aaA-1 to I-

2.256aaA-425) Table 257aa

Compounds I-2 wherein B is 2,4,5-tribromothien-3-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.257aaA-1 to I-

2.257aaA-425) Table 258aa compounds I-2 wherein B is 3,4,5-trimethylthien-2-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.258aaA-1 to I-

2.258aaA-425) Table 259aa

Compounds I-2 in which B is 4-chlorofur-2-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2.259aaA-1 to 1.2559aaA-425)

Table 260aa

Compounds I-2 wherein B is 5-chlorofur-2-yl and A is each a group of one

Line of Table A corresponds (Compounds l-2.260aaA-1 to l-2.260aaA-425) Table 261aa Compounds I-2 wherein B is 3-bromo-fur-2-yl and A is each a group of one

Row of Table A corresponds (Compounds 1-2.261 aaA-1 to 1-2.261 aaA-425) Table 262aa

Compounds I-2 wherein B is 4-bromo-fur-2-yl and A is each a group of one

Line of Table A corresponds (compounds I-2.262aaA-1 to I-2.262aaA-425) Table 263aa

Compounds I-2 wherein B is 5-bromo-fur-2-yl and A is each a group of one

Line of Table A corresponds (compounds I-2.263aaA-1 to I-2.263aaA-425) Table 264aa

Compounds I-2 in which B is 3,4-dichloropur-2-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.264aaA-1 to I-2.264aaA-

425) Table 265aa

Compounds I-2, wherein B is 4,5-dichloropur-2-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.265aaA-1 to l-2.265aaA-425)

Table 266aa

Compounds I-2 wherein B is thiazol-2-yl and A is a group of each

Table 267aa Compounds I-2 where B is thiazol-4-yl and A is each a group of one of the following: Compounds 1-2266aaA-1 to l-2.266aaA-425

Line of Table A corresponds (compounds I-2.267aaA-1 to I-2.267aaA-425) Table 268aa

Compounds 1-2, wherein B is thiazol-5-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-2,628aaA-1 to l-2,268aaA-425)

Table 269aa compounds I-2 wherein B is isothiazol-3-yl and A is each a group of one

Line of Table A corresponds (Compounds l-2.269aaA-1 to l-2.269aaA-425)

Table 270aa

Compounds I-2, wherein B is isothiazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2,270aaA-1 to I-2,270aaA-425) Table 271aa

Compounds I-2, wherein B is isothiazol-5-yl and A corresponds in each case to one group of one row of Table A (compounds 1-2.271 aaA-1 to 1-2.271 aaA-425)

Table 272aa

Compounds I-2, in which B is 2-chlorothiazol-4-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.272aaA-1 to I-2.272aaA-

425)

Table 273aa

Compounds I-2, wherein B is 2-chlorothiazol-5-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2273aaA-1 to l-2.273aaA-425)

Table 274aa

Compounds I-2, wherein B is 4-chlorothiazol-5-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2274aaA-1 to l-2.274aaA-425) Table 275aa

Compounds I-2 in which B is 2-bromothiazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2,275aaA-1 to I-2,275aaA-425)

Table 276aa Compounds I-2, wherein B is 2-bromothiazol-5-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.276aaA-1 to l-2.276aaA-425)

Table 277aa

Compounds I-2 in which B is 2,4-dichlorothiazol-5-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.277aaA-1 to I-2)

2.277aaA-425)

Table 278aa

Compounds I-2 in which B is 3-chloroisothiazol-4-yl and A in each case corresponds to one group of one row of Table A (compounds I-2.278aaA-1 to I-2.278aaA-425)

Table 279aa

Compounds I-2 wherein B is 5-methylisothiazol-3-yl and A is each one Group of a row corresponds to Table A (compounds I-2.279aaA-1 to I-

2.279aaA-425) Table 280aa

Compounds I-2 in which B is 3-methylisothiazol-4-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.280aaA-1 to I-2)

2.280aaA-425) Table 281 aa

Compounds I-2 wherein B is 3-methylisothiazol-5-yl and A is each one

Group of a row corresponds to Table A (Compounds 1-2.281 aaA-1 to I-2.281 aaA-425)

Table 282aa

Compounds I-2 wherein B is 4,5-dichloroisothiazol-3-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.282aaA-1 to I-

2.282aaA-425) Table 283aa

Compounds I-2 wherein B is 4,5-dimethylisothiazol-3-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.283aaA-1 to I-

2.283aaA-425) Table 284aa compounds I-2 wherein B is 3,5-dimethylisothiazol-4-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.284aaA-1 to I-

2.284aaA-425) Table 285aa

Compounds I-2, in which B is 3,4-dichloroisothiazol-5-yl and A in each case corresponds to one group of one row of Table A (compounds I-2.285aaA-1 to I-2)

2.285aaA-425) Table 286aa

Compounds I-2 wherein B is oxazol-2-yl and A is a group of each

Row of Table A corresponds (Compounds l-2.286aaA-1 to l-2.286aaA-425) Table 287aa

Compounds I-2 wherein B is oxazol-4-yl and A is a group of each

Row of Table A corresponds (Compounds l-2.287aaA-1 to l-2.287aaA-425) Table 288aa

Compounds I-2 in which B is oxazol-5-yl and A in each case corresponds to one group of one row of Table A (Compounds 1-2288aaA-1 to l-2.288aaA-425)

Table 289aa

Compounds I-2 wherein B is isoxazol-3-yl and A is each a group of one

Table 290aa Compounds I-2 wherein B is isoxazol-4-yl and A is each a group of one

Row of Table A corresponds (Compounds l-2.290aaA-1 to l-2.290aaA-425) Table 291 aa

Compounds I-2, wherein B is isoxazol-5-yl and A corresponds in each case to one group of one row of Table A (Compounds 1-2.291 aaA-1 to 1-2.291 aaA-425)

Table 292aa Compounds I-2, wherein B is 3-chloroisoxazol-5-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.292aaA-1 to l-2.292aaA-425)

Table 293aa

Compounds I-2 in which B is 5-methylisoxazol-3-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.293aaA-1 to I-2.293aaA-

425)

Table 294aa

Compounds I-2 in which B is 5-methylisoxazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2.294aaA-1 to 1.2994aa-425)

Table 295aa

Compounds I-2, wherein B is 3-methylisoxazol-5-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.295aaA-1 to I-2.295aaA-425) Table 296aa

Compounds I-2 in which B is 3,5-dimethylisoxazol-4-yl and A in each case corresponds to one group of one row of Table A (compounds I-2.296aaA-1 to I-2.296aaA-425)

Table 297aa compounds I-2, wherein B is 3-chloro-5-methylisoxazol-4-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.297aaA-1 to I-2.297aaA-425)

Table 298aa

Compounds I-2 in which B is 3-methyl-4-chloroisoxazol-5-yl and A in each case corresponds to one group of one row of Table A (compounds I-2.298aaA-1 to I-

2.298aaA-425)

Table 299aa

Compounds I-2, wherein B is 1-methylpyrazol-3-yl and A corresponds in each case to one group of one row of Table A (compounds I-2.299aaA-1 to I-2.299aaA-425)

Table 300aa

Compounds I-2, wherein B is 1-methylpyrazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2,300aaA-1 to l-2,300aaA-425) Table 301 aa

Compounds I-2, wherein B is 1-methylpyrazol-5-yl and A is in each case a group pe corresponds to one line of Table A (compounds 1-2.301 aaA-1 to 1-2.301 aaA-425)

Table 302aa

Compounds I-2, wherein B is 1, 3-dimethylpyrazol-4-yl and A in each case corresponds to one group of one row of Table A (compounds I-2.302aaA-1 to I-

2.302aaA-425)

Table 303aa

Compounds I-2, wherein B is 1, 5-dimethylpyrazol-4-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.303aaA-1 to I-2.303aaA-425)

Table 304aa

Compounds I-2, wherein B is 1, 3,5-trimethylpyrazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2.304aaA-1 to I-2.304aaA-425) Table 305aa

Compounds I-2 in which B is 1-methylimidazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds I-2.305aaA-1 to 1.305aaA-425)

Table 306aa compounds I-2 wherein B is 1,5-dimethylimidazol-4-yl and A is each one

Group of a row corresponds to Table A (compounds I-2.306aaA-1 to I-2.306aaA-425)

Table 307aa

Compounds I-2, wherein B is 1, 2-dimethylimidazol-5-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.307aaA-1 to I-

2.307aaA-425)

Table 308aa

Compounds I-2 in which B is 1,4-dimethylimidazol-5-yl and A in each case corresponds to one group of one row of Table A (Compounds I-2.308aaA-1 to I-2.308aaA-425)

Table A

Likewise preferred are the compounds of the formula I-3, in particular the compounds I-3.1aA1 to I-3.308-A-425, which are different from the corresponding compounds I-1.1aA-1 to I-1.308aA-425, which are shown in Table 1a to Table 308a, differ in that

Likewise preferred are the compounds of formula I-4, in particular the compounds 1-4.1 aA1 to I-4.308-A-425, which are different from the corresponding compounds I-1.1aA-1 to l-1.308aA-425, which are shown in Table 1 a to Table 308a, differ in that D is S-CO-CH 3:

Likewise preferred are the compounds of the formula I-5, in particular the compounds 1-5.1 aA1 to I-5.308-A-425, which are different from the corresponding compounds I-5. 1.1aA-1 to l-1.308aA-425, which are listed in Table 1 a to Table 308a, differing in that D is S-CO-OCH 3:

Also preferred are the compounds of formula I-6, in particular the compounds 1-6.1 aA1 to I-6.308-A-425, which are different from the corresponding compounds I-1.1aA-1 to l-1.308aA-425, which are listed in Table 1 a to Table 308a, differ in that D is S-CN:

In particular, with regard to their use, the compounds II according to the invention which are combined in the following Tables 1 b to 324 b are preferred.

Die in den Tabellen für einen Substituenten genannten Gruppen stellen außerdem für sich betrachtet, unabhängig von der Kombination, in der sie genannt sind, eine besonders bevorzugte Ausgestaltung des betreffenden Substituenten dar.

The groups mentioned in the tables for a substituent are also considered individually, regardless of the combination in which they are mentioned, a particularly preferred embodiment of the substituent in question.

Table 1 b Compounds II, wherein A is pyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds II.1 bB-1 to ll.1 bB-134)

Compounds II, wherein A is pyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.2bB-1 to N.2bB-134). Table 3b

Compounds II, wherein A is pyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.3bB-1 to N.3bB-134) Table 4b

Compounds II, wherein A is 3-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.4bB-1 to M.4bB-134)

Table 5b Compounds II, wherein A is 4-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.5bB-1 to M.5bB-134)

Table 6b

Compounds II, wherein A is 5-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds II.6bB-1 to N.6bB-134) Table 7b

Compounds II in which A is 6-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.7bB-1 to N.7bB-134)

Table 8b

Compounds II in which A is 2-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds II.8bB-1 to II.8bB-134)

Table 9b

Compounds II in which A is 4-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.9bB-1 to M.9bB-134)

Table 10b Compounds II, wherein A is 5-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds IM ObB-1 to II.10bB-134)

Table 1 1 b

Compounds II, wherein A is 6-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.1 1 bB-1 to 11.1 1 bB-134) Table 12b

Compounds II, wherein A is 2-chloropyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.12bB-1 to N.12bB-134)

Table 13b

Compounds II, wherein A is 3-chloropyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.13bB-1 to N.13bB-134)

Table 14b

Compounds II, wherein A is 4-chloropyridin-5-yl and B corresponds in each case to one group of one row of Table B (Compounds N.14bB-1 to 11.14bB-134)

Table 15b Compounds II, wherein A is 3-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.15bB-1 to 11.15bB-134)

Table 16b

Compounds II, wherein A is 4-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.16bB-1 to 11.16bB-134) Table 17b

Compounds II in which A is 5-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.17bB-1 to N.17bB-134) Table 18b

Compounds II in which A is 6-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.18bB-1 to 11.18bB-134)

Table 19b Compounds II, wherein A is 2-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.19bB-1 to 11.19bB-134)

Table 20b

Compounds II, wherein A is 4-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.20bB-1 to M.20bB-134). Table 21b

Compounds II in which A is 5-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.21 bB-1 to 11.21 bB-134)

Table 22b

Compounds II, wherein A is 6-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.22bB-1 to N.22bB-134)

Table 23b

Compounds II, wherein A is 2-fluoropyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.23bB-1 to N.23bB-134)

Table 24b Compounds II, wherein A is 3-fluoropyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.24bB-1 to N.24bB-134)

Table 25b

Compounds II, wherein A is 3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.25bB-1 to M.25bB-134) Table 26b

Compounds II in which A is 4-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.26bB-1 to N.26bB-134)

Table 27b

Compounds II, wherein A is 5-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.27bB-1 to N.27bB-134)

Table 28b

Compounds II in which A is 6-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.28bB-1 to N.28bB-134)

Table 29b Compounds II, wherein A is 2-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table B (compounds N.29bB-1 to N.29bB-134)

Table 30b

Compounds II, wherein A is 4-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.30bB-1 to N.30bB-134). Table 31 b

Compounds II in which A is 5-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.31 bB-1 to 11.31 bB-134) Table 32b

Compounds II, wherein A is 6-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.32bB-1 to N.32bB-134)

Table 33b Compounds II, in which A is 2-methylpyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.33bB-1 to N.33bB-134)

Table 34b

Compounds II, wherein A is 3-methylpyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.34bB-1 to N.34bB-134) Table 35b

Compounds II, wherein A is 4-methylpyridin-5-yl and B corresponds in each case to one group of one row of Table B (Compounds N.35bB-1 to N.35bB-134)

Table 36b

Compounds II in which A is 3-methoxypyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.36bB-1 to N.36bB-134)

Table 37b

Compounds II in which A is 4-methoxypyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.37bB-1 to M.37bB-134)

Table 38b Compounds II in which A is 5-methoxypyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.38bB-1 to N.38bB-134)

Table 39b

Compounds II, wherein A is 6-methoxypyridin-2-yl and B corresponds in each case to one group of one row of Table B (compounds N.39bB-1 to N.39bB-134) Table 40b

Compounds II in which A is 2-methoxypyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.40bB-1 to N.40bB-134)

Table 41 b

Compounds II in which A is 4-methoxypyridin-3-yl and B corresponds in each case to one group of one row of Table B (compounds 11.41 bB-1 to 11.41 bB-134)

Table 42b

Compounds II in which A is 5-methoxypyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.42bB-1 to N.42bB-134)

Table 43b Compounds II, wherein A is 6-methoxypyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.43bB-1 to M.43bB-134)

Table 44b

Compounds II, wherein A is 2-methoxypyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.44bB-1 to M.44bB-134) Table 45b

Compounds II in which A is 3-methoxypyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.45bB-1 to N.45bB-134) Table 46b

Compounds II in which A is 3,5-dichloropyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.46bB-1 to M.46bB-134)

Table 47b Compounds II, wherein A is 2,4-dichloropyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.47bB-1 to M.47bB-134)

Table 48b

Compounds II, wherein A is 2,5-dichloropyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.48bB-1 to N.48bB-134) Table 49b

Compounds II in which A is 2,6-dichloropyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.49bB-1 to N.49bB-134)

Table 50b

Compounds II in which A is 2,6-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.50bB-1 to N.50bB-134)

Table 51 b

Compounds II, wherein A is 3,5-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.51 bB-1 to 11.51 bB-134)

Table 52b Compounds II, wherein A is 3,6-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table B (compounds N.52bB-1 to M.52bB-134)

Table 53b

Compounds II, wherein A is 2,5-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.53bB-1 to M.53bB-134) Table 54b

Compounds II, wherein A is 2,3-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.54bB-1 to N.54bB-134)

Table 55b

Compounds II in which A is 2,4-dichloropyridin-5-yl and B corresponds in each case to one group of one row of Table B (Compounds N.55bB-1 to N.55bB-134)

Table 56b

Compounds II in which A is 3,5-difluoropyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.56bB-1 to M.56bB-134)

Table 57b Compounds II, wherein A is 3,5-difluoropyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.57bB-1 to M.57bB-134)

Table 58b

Compounds II, wherein A is 2,3-difluoropyridin-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.58bB-1 to M.58bB-134) Table 59b

Compounds II wherein A is 3,5-dimethylpyridin-2-yl and B are each one Group of a row of Table B corresponds (compounds N.59bB-1 to M.59bB-

134) Table 60b

Compounds II, in which A is 3,4-dimethylpyridin-2-yl and B corresponds in each case to one group of one row of Table B (compounds N.60bB-1 to 11.6ObB-

134) Table 61 b

Compounds II wherein A is 4,6-dimethylpyridin-3-yl and B are each one

Group of a row corresponds to Table B (compounds 11.61 bB-1 to 11.61 bB-134)

Table 62b

Compounds II, wherein A is 2,4-dimethylpyridin-3-yl and B are each one

Group of a row of Table B corresponds (compounds N.62bB-1 to N.62bB-

134) Table 63b

Compounds II wherein A is 3,5-dimethylpyridin-4-yl and B are each one

Group of a row corresponds to Table B (compounds N.63bB-1 to N.63bB-

134)

Table 64b Compounds II wherein A is 2-chloro-3-fluoropyridin-4-yl and B are each one

Group of a row corresponds to Table B (compounds N.64bB-1 to N.64bB-

134) Table 65b

Compounds II, wherein A is 4-chloro-3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table B (compounds N.65bB-1 to N.65bB-

134) Table 66b

Compounds II wherein A is 5-chloro-3-methylpyridin-2-yl and B is one each

Group of a row corresponds to Table B (compounds N.66bB-1 to N.66bB-134)

Table 67b

Compounds II wherein A is 5-fluoro-3-methylpyridin-2-yl and B are each one

Group of a row corresponds to Table B (compounds N.67bB-1 to M.67bB-

134) Table 68b

Compounds II, wherein A is 3-chloro-5-trifluoromethylpyridin-2-yl and B corresponds in each case to one group of one row of Table B (compounds N.68bB-1 to

N.68bB-134). Table 69b Compounds II, wherein A is 2-chloro-6-trifluoromethylpyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.69bB-1 to

N.69bB-134) Table 70b

Compounds II, wherein A is 2,4-dichloro-6-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.70bB-1 to M.70bB-134) Table 71b

Compounds II in which A is 3,4,5-trichloropyridin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.71 bB-1 to 11.71 bB-134)

Table 72b Compounds II, wherein A is 2,4,6-trichloropyridin-3-yl and B are each one

Group of a row corresponds to Table B (compounds N.72bB-1 to N.72bB-134)

Table 73b

Compounds II in which A is pyrimidin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.73bB-1 to N.73bB-134)

Table 74b

Compounds II in which A is pyrimidin-5-yl and B corresponds in each case to one group of one row of Table B (Compounds N.74bB-1 to N.74bB-134)

Table 75b Compounds II, wherein A is 6-chloropyrimidin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.75bB-1 to M.75bB-134)

Table 76b

Compounds II, wherein A is 6-methylpyrimidin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.76bB-1 to M.76bB-134) Table 77b

Compounds II in which A is 6-methoxypyrimidin-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.77bB-1 to N.77bB-134)

Table 78b Compounds II, wherein A is 2,4-dichloropyrimidin-3-yl and B are each one

Group of one row corresponds to Table B (compounds N.78bB-1 to N.78bB-134)

Table 79b

Compounds II, in which A is 2,6-dichloropyrimidin-3-yl and B corresponds in each case to one group of one row of Table B (compounds N.79bB-1 to N.79bB-

134)

Table 80b

Compounds II in which A is 2,4-difluoropyrimidin-3-yl and B corresponds in each case to one group of one row of Table B (compounds N80bB-1 to 11.8ObB-134)

Table 81 b

Compounds II wherein A is 2,6-difluoropyrimidin-3-yl and B are each one Group of a row corresponds to Table B (compounds 11.81 bB-1 to 11.81 bB-134)

Table 82b

Compounds II in which A is 1, 3,5-triazin-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.82bB-1 to N.82bB-134)

Table 83b

Compounds II, wherein A is thien-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.83bB-1 to N.83bB-134)

Table 84b Compounds II, wherein A is thien-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.84bB-1 to N.84bB-134)

Table 85b

Compounds II, wherein A is 5-chlorothien-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.85bB-1 to N.85bB-134) Table 86b

Compounds II, wherein A is 2-chlorothien-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.86bB-1 to N.86bB-134)

Table 87b

Compounds II in which A is 4-chlorothien-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.87bB-1 to N87bB-134)

Table 88b

Compounds II, wherein A is 5-chlorothien-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.88bB-1 to N.88bB-134)

Table 89b Compounds II, wherein A is 2-bromothien-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.89bB-1 to N.89bB-134)

Table 90b

Compounds II, wherein A is 4-bromothien-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.90bB-1 to N.90bB-134). Table 91b

Compounds II, wherein A is 5-bromothien-3-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.91 bB-1 to 11.91 bB-134)

Table 92b

Compounds II in which A is 5-methylthien-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.92bB-1 to N92bB-134)

Table 93b

Compounds II in which A is 2-methylthien-4-yl and B corresponds in each case to one group of one row of Table B (compounds N93bB-1 to N93bB-134)

Table 94b Compounds II, wherein A is 4,5-dichlorothien-2-yl and B corresponds in each case to one group of one row of Table B (compounds N94bB-1 to N94bB-134) Table 95b

Compounds II in which A is 2,5-dichlorothien-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.95bB-1 to M.95bB-134)

Table 96b Compounds II in which A is 2,3-dichlorothien-4-yl and B corresponds in each case to one group of one row of Table B (compounds N96bB-1 to N96bB-134)

Table 97b

Compounds II in which A is 2,5-dibromothien-3-yl and B corresponds in each case to one group of one row of Table B (compounds N97bB-1 to M.97bB-134) Table 98b

Compounds II in which A is 4,5-dimethylthien-2-yl and B corresponds in each case to one group of one row of Table B (compounds N98bB-1 to N98bB-134)

Table 99b

Compounds II in which A is 2,5-dimethylthien-3-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.99bB-1 to 11.99bB-134)

Table 10b

Compounds II in which A is 2,3-dimethylthien-4-yl and B corresponds in each case to one group of one row of Table B (Compounds II.100bB-1 to II.100bB-134)

Table 101b Compounds II, wherein A is 3,4,5-trichlorothien-2-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.101 bB-1 to N.101 bB-134)

Table 102b

Compounds II wherein A is 2,4,5-trichlorothien-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.102bB-1 to 11.102bB-134) Table 103b

Compounds II in which A is 2,4,5-tribromothien-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.103bB-1 to 11.103bB-134)

Table 104b

Compounds II in which A is 3,4,5-trimethylthien-2-yl and B corresponds in each case to one group of one row of Table B (compounds N104bB-1 to M.104bB-

134)

Table 105b

Compounds II, wherein A is 4-chlorofur-2-yl and B corresponds in each case to one group of one row of Table B (Compounds M.105bB-1 to 11.105bB-134). Table 106b

Compounds II in which A is 5-chlorofur-2-yl and B corresponds in each case to one group of one row of Table B (Compounds M.106bB-1 to 11.106bB-134)

Table 107b

Compounds II, wherein A is 3-bromo-fur-2-yl and B corresponds in each case to one group of one row of Table B (Compounds M.107bB-1 to 11.107bB-134) Table 108b

Compounds II, wherein A is 4-bromo-fur-2-yl and B corresponds in each case to one group of one row of Table B (Compounds M.108bB-1 to 11.108bB-134)

Table 109b compounds II wherein A is 5-bromo-fur-2-yl and B each represents a group of one

Line of Table B corresponds (compounds M.109bB-1 to 11.109bB-134)

Table 1 1Ob

Compounds II in which A is 3,4-dichloropur-2-yl and B in each case corresponds to one group of one row of Table B (Compounds 11.1 10bB-1 to II.1 10bB-134)

Compounds II, where A is 4,5-dichloropur-2-yl and B corresponds in each case to one group of one row of Table B (compounds 11.1 11 bB-1 to 11.111 bB-134)

Table 1 12b

Compounds II, wherein A is thiazol-2-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.1 12bB-1 to 11.1 12bB-134)

Table 1 13b

Compounds II, wherein A is thiazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.1 13bB-1 to 11.1 13bB-134)

Table 1 14b Compounds II, wherein A is thiazol-5-yl and B are each a group of one

Line of Table B corresponds (connections 11.1 14bB-1 to 11.1 14bB-134)

Table 1 15b

Compounds II, wherein A is isothiazol-3-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.115bB-1 to 11.1 15bB-134). Table 1 16b

Compounds II in which A is isothiazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.116bB-1 to 11.1 16bB-134)

Table 1 17b

Compounds II in which A is isothiazol-5-yl and B in each case corresponds to one group of one row of Table B (Compounds N.1 17bB-1 to 11.1 17bB-134)

Table 1 18b

Compounds II, wherein A is 2-chlorothiazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.118bB-1 to 11.1 18bB-134)

Table 1 19b Compounds II in which A is 2-chlorothiazol-5-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.119bB-1 to 11.1 19bB-134)

Table 120b

Compounds II, wherein A is 4-chlorothiazol-5-yl and B corresponds in each case to one group of one row of Table B (Compounds II.12ObB-1 to M.120bB-134). Table 121 b

Compounds II in which A is 2-bromothiazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.121 bB-1 to 11.121 bB-134) Table 122b

Compounds II in which A is 2-bromothiazol-5-yl and B corresponds in each case to one group of one row of Table B (Compounds N.122bB-1 to N.122bB-134)

Table 123b Compounds II in which A is 2,4-dichlorothiazol-5-yl and B corresponds in each case to one group of one row of Table B (Compounds N.123bB-1 to N.123bB-134)

Table 124b

Compounds II in which A is 3-chloroisothiazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.124bB-1 to N.124bB-134) Table 125b

Compounds II in which A is 5-methylisothiazol-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.125bB-1 to N.125bB-134)

Table 126b

Compounds II in which A is 3-methylisothiazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.126bB-1 to N.126bB-134)

Table 127b

Compounds II in which A is 3-methylisothiazol-5-yl and B corresponds in each case to one group of one row of Table B (Compounds N.127bB-1 to N.127bB-134)

Table 128b Compounds II, wherein A is 4,5-dichloroisothiazol-3-yl and B are each one

Group of a row corresponds to Table B (compounds N.128bB-1 to 11.128bB-134)

Table 129b

Compounds II, wherein A is 4,5-dimethylisothiazol-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.129bB-1 to N.129bB-

134)

Table 130b

Compounds II in which A is 3,5-dimethylisothiazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.130bB-1 to II.13ObB-134)

Table 131 b

Compounds II, wherein A is 3,4-dichloroisothiazol-5-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.131 bB-1 to 11.131 bB-134) Table 132b

Compounds II in which A is oxazol-2-yl and B corresponds in each case to one group of one row of Table B (Compounds N.132bB-1 to 11.132bB-134)

Table 133b

Compounds II, wherein A is oxazol-4-yl and B corresponds in each case to a group of a row of Table B (Compounds N.133bB-1 to 11.133bB-134) Table 134b

Compounds II, wherein A is oxazol-5-yl and B corresponds in each case to one group of one row of Table B (Compounds N.134bB-1 to N.134bB-134)

Table 135b Compounds II wherein A is isoxazol-3-yl and B is each a group of one

Line of Table B corresponds (connections N.135bB-1 to 11.135bB-134)

Table 136b

Compounds II, wherein A is isoxazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.136bB-1 to 11.136bB-134) Table 137b

Compounds II in which A is isoxazol-5-yl and B corresponds in each case to one group of one row of Table B (Compounds N.137bB-1 to 11.137bB-134)

Table 138b

Compounds II in which A is 3-chloroisoxazol-5-yl and B corresponds in each case to one group of one row of Table B (Compounds N.138bB-1 to 11.138bB-134)

Table 139b

Compounds II in which A is 5-methylisoxazol-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.139bB-1 to 11.139bB-134)

Table 140b Compounds II, wherein A is 5-methylisoxazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.140bB-1 to M.140bB-134)

Table 141 b

Compounds II, wherein A is 3-methylisoxazol-5-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.141 bB-1 to 11.141 bB-134) Table 142b

Compounds II in which A is 3,5-dimethylisoxazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.142bB-1 to N.142bB-134)

Table 143b Compounds II wherein A is 3-chloro-5-methylisoxazol-4-yl and B are each one

Group of a row corresponds to Table B (compounds N.143bB-1 to N.143bB-134)

Table 144b

Compounds II, wherein A is 3-methyl-4-chloroisoxazol-5-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.144bB-1 to 11.144bB-

134)

Table 145b

Compounds II, wherein A is 1-methylpyrazol-3-yl and B corresponds in each case to one group of one row of Table B (Compounds N.145bB-1 to 11.145bB-134) Table 146b

Compounds II in which A is 1-methylpyrazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.146bB-1 to N.146bB-134) Table 147b

Compounds II, wherein A is 1-methylpyrazol-5-yl and B corresponds in each case to one group of one row of Table B (Compounds N.147bB-1 to 11.147bB-134)

Table 148b Compounds II wherein A is 1, 3-dimethylpyrazol-4-yl and B are each one

Group of a row corresponds to Table B (compounds II.148bB-1 to 11.148bB-134)

Table 149b

Compounds II in which A is 1,5-dimethylpyrazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.149bB-1 to M.149bB-

134)

Table 150b

Compounds II in which A is 1, 3,5-trimethylpyrazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds N.150bB-1 to II.15ObB-134)

Table 151 b

Compounds II in which A is 1-methylimidazol-4-yl and B corresponds in each case to one group of one row of Table B (Compounds 11.151 bB-1 to 11.151 bB-134)

Table 152b compounds II, wherein A is 1, 5-dimethylimidazol-4-yl and B are each one

Group of a row corresponds to Table B (compounds N.152bB-1 to 11.152bB-134)

Table 153b

Compounds II in which A is 1,2-dimethylimidazol-5-yl and B corresponds in each case to one group of one row of Table B (compounds 11.153bB-1 to 11.153bB-

134)

Table 154b

Compounds II in which A is 1,4-dimethylimidazol-5-yl and B corresponds in each case to one group of one row of Table B (compounds N.154bB-1 to 11.154bB-134)

Table 155b

Compounds II, wherein B is pyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.155bB-1 to 11.155bB-134)

Table 156b Compounds II, wherein B is pyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.156bB-1 to 11.156bB-134)

Table 157b

Compounds II, wherein B is pyridin-4-yl and A corresponds in each case to one group of a row of Table B (Compounds N.157bB-1 to 11.157bB-134) Table 158b

Compounds II, wherein B is 3-chloropyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.158bB-1 to 11.158bB-134) Table 159b

Compounds II in which B is 4-chloropyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.159bB-1 to 11.159bB-134)

Table 160b Compounds II in which B is 5-chloropyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.160bB-1 to 11.160bB-134)

Table 161 b

Compounds II, wherein B is 6-chloropyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds 11.161 bB-1 to 11.161 bB-134) Table 162b

Compounds II, wherein B is 2-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.162bB-1 to 11.162bB-134)

Table 163b

Compounds II, wherein B is 4-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.163bB-1 to 11.163bB-134)

Table 164b

Compounds II in which B is 5-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.164bB-1 to 11.164bB-134)

Table 165b Compounds II, wherein B is 6-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.165bB-1 to 11.165bB-134)

Table 166b

Compounds II, wherein B is 2-chloropyridin-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.166bB-1 to 11.166bB-134) Table 167b

Compounds II in which B is 3-chloropyridin-4-yl and A corresponds in each case to one group of one row of Table B (Compounds M.167bB-1 to 11.167bB-134)

Table 168b

Compounds II, wherein B is 4-chloropyridin-5-yl and A corresponds in each case to one group of one row of Table B (Compounds N.168bB-1 to 11.168bB-134)

Table 169b

Compounds II in which B is 3-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.169bB-1 to 11.169bB-134)

Table 170b Compounds II, wherein B is 4-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.170bB-1 to 11.170bB-134)

Table 171 b

Compounds II, wherein B is 5-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds 11.171 bB-1 to 11.171 bB-134) Table 172b

Compounds II, wherein B is 6-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.172bB-1 to 11.172bB-134) Table 173b

Compounds II in which B is 2-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.173bB-1 to 11.173bB-134)

Table 174b Compounds II, wherein B is 4-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.174bB-1 to 11.174bB-134)

Table 175b

Compounds II, wherein B is 5-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.175bB-1 to 11.175bB-134) Table 176b

Compounds II, wherein B is 6-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.176bB-1 to 11.176bB-134)

Table 177b

Compounds II in which B is 2-fluoropyridin-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.177bB-1 to 11.177bB-134)

Table 178b

Compounds II, wherein B is 3-fluoropyridin-4-yl and A corresponds in each case to one group of one row of Table B (Compounds 11.178bB-1 to 11.178bB-134)

Table 179b Compounds II in which B is 3-methylpyridin-2-yl and A in each case corresponds to one group of one row of Table B (Compounds N.179bB-1 to 11.179bB-134)

Table 180b

Compounds II, wherein B is 4-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.180bB-1 to 11.180bB-134). Table 181 b

Compounds II, wherein B is 5-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.181 bB-1 to 11.181 bB-134)

Table 182b

Compounds II in which B is 6-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.182bB-1 to 11.182bB-134)

Table 183b

Compounds II in which B is 2-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.183bB-1 to 11.183bB-134)

Table 184b Compounds II in which B is 4-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.184bB-1 to 11.184bB-134)

Table 185b

Compounds II, wherein B is 5-methylpyridin-3-yl and A corresponds in each case to one group of a row of Table B (Compounds N.185bB-1 to 11.185bB-134) Table 186b

Compounds II in which B is 6-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.186bB-1 to 11.186bB-134) Table 187b

Compounds II in which B is 2-methylpyridin-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.187bB-1 to 11.187bB-134)

Table 188b Compounds II, wherein B is 3-methylpyridin-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.188bB-1 to 11.188bB-134)

Table 189b

Compounds II, wherein B is 4-methylpyridin-5-yl and A corresponds in each case to one group of one row of Table B (Compounds N.189bB-1 to 11.189bB-134) Table 190b

Compounds II, wherein B is 3-methoxypyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.190bB-1 to 11.190bB-134)

Table 191 b

Compounds II in which B is 4-methoxypyridin-2-yl and A in each case corresponds to one group of one row of Table B (Compounds 11.191 bB-1 to 11.191 bB-134)

Table 192b

Compounds II, wherein B is 5-methoxypyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.192bB-1 to 11.192bB-134)

Table 193b Compounds II in which B is 6-methoxypyridin-2-yl and A in each case corresponds to one group of one row of Table B (Compounds N.193bB-1 to 11.193bB-134)

Table 194b

Compounds II, wherein B is 2-methoxypyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.194bB-1 to 11.194bB-134) Table 195b

Compounds II in which B is 4-methoxypyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.195bB-1 to 11.195bB-134)

Table 196b

Compounds II in which B is 5-methoxypyridin-3-yl and A in each case corresponds to one group of one row of Table B (Compounds N.196bB-1 to 11.196bB-134)

Table 197b

Compounds II, wherein B is 6-methoxypyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.197bB-1 to 11.197bB-134)

Table 198b Compounds II in which B is 2-methoxypyridin-4-yl and A in each case corresponds to one group of one row of Table B (Compounds N.198bB-1 to 11.198bB-134)

Table 199b

Compounds II, wherein B is 3-methoxypyridin-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.199bB-1 to 11.199bB-134) Table 200b

Compounds II in which B is 3,5-dichloropyridin-2-yl and A in each case corresponds to one group of one row of Table B (Compounds N.200bB-1 to M.200bB-134) Table 201 b

Compounds II, wherein B is 2,4-dichloropyridin-3-yl and A in each case corresponds to one group of one row of Table B (Compounds 11.201 bB-1 to 11.201 bB-134)

Table 202b Compounds II in which B is 2,5-dichloropyridin-3-yl and A in each case corresponds to one group of one row of Table B (Compounds N.202bB-1 to M.202bB-134)

Table 203b

Compounds II, wherein B is 2,6-dichloropyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.203bB-1 to M.203bB-134) Table 204b

Compounds II in which B is 2,6-dichloropyridin-4-yl and A in each case corresponds to one group of one row of Table B (Compounds N.204bB-1 to M.204bB-134)

Table 205b

Compounds II, where B is 3,5-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table B (compounds N.205bB-1 to M.205bB-134)

Table 206b

Compounds II in which B is 3,6-dichloropyridin-4-yl and A in each case corresponds to one group of one row of Table B (Compounds N.206bB-1 to M.206bB-134)

Table 207b Compounds II in which B is 2,5-dichloropyridin-4-yl and A in each case corresponds to one group of one row of Table B (Compounds N.207bB-1 to M.207bB-134)

Table 208b

Compounds II, wherein B is 2,3-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.208bB-1 to M.208bB-134) Table 209b

Compounds II in which B is 2,4-dichloropyridin-5-yl and A in each case corresponds to one group of one row of Table B (Compounds M.209bB-1 to M.209bB-134)

Table 210b

Compounds II in which B is 3,5-difluoropyridin-2-yl and A in each case corresponds to one group of one row of Table B (Compounds 11.21 ObB-1 to M.210bB-134)

Table 211 b

Compounds II in which B is 3,5-difluoropyridin-4-yl and A in each case corresponds to one group of one row of Table B (Compounds 11.21 1 bB-1 to 11,211 bB-134)

Table 212b Compounds II in which B is 2,3-difluoropyridin-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.212bB-1 to N.212bB-134)

Table 213b

Compounds II in which B is 3,5-dimethylpyridin-2-yl and A in each case corresponds to one group of one row of Table B (Compounds 11.213bB-1 to 11.213bB-134)

Table 214b

Compounds II wherein B is 3,4-dimethylpyridin-2-yl and A is each one Group of a row corresponds to Table B (compounds 11.214bB-1 to M.214bB-

134) Table 215b

Compounds II, wherein B is 4,6-dimethylpyridin-3-yl and A corresponds in each case to one group of one row of Table B (compounds 11.215bB-1 to 11.215bB-

134) Table 216b

Compounds II wherein B is 2,4-dimethylpyridin-3-yl and A is one each

Group of a row corresponds to Table B (compounds 11.216bB-1 to N.216bB-134)

Table 217b

Compounds II wherein B is 3,5-dimethylpyridin-4-yl and A is each one

Group of a row corresponds to Table B (compounds 11.217bB-1 to M.217bB-

134) Table 218b

Compounds II wherein B is 2-chloro-3-fluoropyridin-4-yl and A is each one

Group of a row of Table B corresponds (compounds 11.218bB-1 to 11.218bB-

134)

Table 219b Compounds II wherein B is 4-chloro-3-methylpyridin-2-yl and A is each one

Group corresponds to one row of Table B (compounds 11.219bB-1 to 11.219bB-

134) Table 220b

Compounds II in which B is 5-chloro-3-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.220bB-1 to M.220bB-

134) Table 221 b

Compounds II wherein B is 5-fluoro-3-methylpyridin-2-yl and A is one each

Group of a row corresponds to Table B (connections 11.221 bB-1 to 11.221 bB-134)

Table 222b

Compounds II, wherein B is 3-chloro-5-trifluoromethylpyridin-2-yl and A corresponds in each case to one group of a row of Table B (Compounds N.222bB-1 to

N.222bB-134) Table 223b

Compounds II, wherein B is 2-chloro-6-trifluoromethylpyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.223bB-1 to

N.223bB-134) Table 224b Compounds II, wherein B is 2,4-dichloro-6-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.224bB-1 to

N.224bB-134) Table 225b

Compounds II wherein B is 3,4,5-trichloropyridin-2-yl and A is one each

Group of one row of Table B corresponds (connections N.225bB-1 to N.225bB-

134) Table 226b

Compounds II wherein B is 2,4,6-trichloropyridin-3-yl and A is one each

Group of one row of Table B corresponds (compounds N.226bB-1 to N.226bB-

134)

Table 227b Compounds II wherein B is pyrimidin-2-yl and A is each a group of one

Row of Table B corresponds (Compounds N.227bB-1 to N.227bB-134) Table 228b

Compounds II wherein B is pyrimidin-5-yl and A is each a group of one

Row of Table B corresponds (Compounds N.228bB-1 to N.228bB-134) Table 229b

Compounds II in which B is 6-chloropyrimidin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.229bB-1 to M.229bB-134) Table 230b

Compounds II in which B is 6-methylpyrimidin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.230bB-1 to N.230bB-134)

Table 231 b

Compounds II wherein B is 6-methoxypyrimidin-3-yl and A is each one

Group of a row corresponds to Table B (connections 11.231 bB-1 to 11.231 bB-

134) Table 232b

Compounds II wherein B is 2,4-dichloropyrimidin-3-yl and A is each one

Group of a row corresponds to Table B (compounds N.232bB-1 to N.232bB-

134)

Table 233b Compounds II wherein B is 2,6-dichloropyrimidin-3-yl and A is each one

Group of one row of Table B corresponds (compounds N.233bB-1 to N.233bB-

134) Table 234b

Compounds II in which B is 2,4-difluoropyrimidin-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.234bB-1 to N.234bB-

134) Table 235b

Compounds II wherein B is 2,6-difluoropyrimidin-3-yl and A is each one

Group of a row corresponds to Table B (compounds N.235bB-1 to N.235bB-134) Table 236b

Compounds II in which B is 1, 3,5-triazin-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.236bB-1 to N.236bB-134)

Table 237b Compounds II in which B is thien-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.237bB-1 to M.237bB-134)

Table 238b

Compounds II, wherein B is thien-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.238bB-1 to N.238bB-134) Table 239b

Compounds II, wherein B is 5-chlorothien-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.239bB-1 to M.239bB-134)

Table 240b

Compounds II, where B is 2-chlorothien-3-yl and A corresponds in each case to one group of one row of Table B (Compounds M.240bB-1 to M.240bB-134)

Table 241 b

Compounds II, wherein B is 4-chlorothien-3-yl and A corresponds in each case to one group of one row of Table B (Compounds 11.241 bB-1 to 11.241 bB-134)

Table 242b Compounds II in which B is 5-chlorothien-3-yl and A in each case corresponds to one group of one row of Table B (Compounds N.242bB-1 to N.242bB-134)

Table 243b

Compounds II, wherein B is 2-bromothien-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.243bB-1 to N.243bB-134) Table 244b

Compounds II in which B is 4-bromothien-3-yl and A in each case corresponds to one group of one row of Table B (Compounds N.244bB-1 to N.244bB-134)

Table 245b

Compounds II, where B is 5-bromothien-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.245bB-1 to N.245bB-134)

Table 246b

Compounds II, wherein B is 5-methylthien-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.246bB-1 to N.246bB-134)

Table 247b Compounds II in which B is 2-methylthien-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.247bB-1 to N.247bB-134)

Table 248b

Compounds 11, wherein B is 4,5-dichlorothien-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.248bB-1 to N.248bB-134) Table 249b

Compounds 11, wherein B is 2,5-dichlorothien-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.249bB-1 to M.249bB-134) Table 250b

Compounds 11, wherein B is 2,3-dichlorothien-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.250bB-1 to N.250bB-134)

Table 251b Compounds 11, wherein B is 2,5-dibromothien-3-yl and A corresponds in each case to one group of one row of Table B (Compounds 11.251 bB-1 to 11.251 bB-134)

Table 252b

Compounds II, wherein B is 4,5-dimethylthien-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.252bB-1 to M.252bB-134) Table 253b

Compounds II in which B is 2,5-dimethylthien-3-yl and A in each case corresponds to one group of one row of Table B (Compounds N.253bB-1 to N.253bB-134)

Table 254b

Compounds 11, wherein B is 2,3-dimethylthien-4-yl and A corresponds in each case to one group of one row of Table B (compounds N.254bB-1 to N.254bB-134)

Table 255b

Compounds II in which B is 3,4,5-trichlorothien-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.255bB-1 to N.255bB-134)

Table 256b Compounds II in which B is 2,4,5-trichlorothien-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.256bB-1 to N.256bB-134)

Table 257b

Compounds II, wherein B is 2,4,5-tribromothien-3-yl and A corresponds in each case to one group of a row of Table B (Compounds N.257bB-1 to M.257bB-134) Table 258b

Compounds II in which B is 3,4,5-trimethylthien-2-yl and A in each case corresponds to one group of one row of Table B (Compounds N.258bB-1 to N.258bB-134)

Table 259b Compounds II wherein B is 4-chlorofur-2-yl and A is each a group of one

Line of Table B corresponds (compounds N.259bB-1 to M.259bB-134)

Table 260b

Compounds II, wherein B is 5-chlorofur-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.260bB-1 to M.260bB-134). Table 261 b

Compounds II, wherein B is 3-bromo-fur-2-yl and A corresponds in each case to one group of one row of Table B (Compounds 11.261 bB-1 to 11.261 bB-134)

Table 262b

Compounds II in which B is 4-bromo-fur-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.262bB-1 to N.262bB-134) Table 263b

Compounds II, wherein B is 5-bromo-fur-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.263bB-1 to N.263bB-134)

Table 264b Compounds II in which B is 3,4-dichloropur-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.264bB-1 to N.264bB-134)

Table 265b

Compounds II, wherein B is 4,5-dichloropur-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.265bB-1 to N.265bB-134) Table 266b

Compounds II in which B is thiazol-2-yl and A in each case corresponds to one group of one row of Table B (Compounds N.266bB-1 to N.266bB-134)

Table 267b

Compounds II in which B is thiazol-4-yl and A in each case corresponds to one group of one row of Table B (Compounds M.267bB-1 to M.267bB-134)

Table 268b

Compounds II, wherein B is thiazol-5-yl and A corresponds in each case to one group of one row of Table B (Compounds N.268bB-1 to N.268bB-134)

Table 269b Compounds II wherein B is isothiazol-3-yl and A is each a group of one

Line of Table B corresponds (compounds N.269bB-1 to N.269bB-134)

Table 270b

Compounds II, wherein B is isothiazol-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.270bB-1 to M.270bB-134). Table 271 b

Compounds II in which B is isothiazol-5-yl and A in each case corresponds to one group of one row of Table B (Compounds 11.271 bB-1 to 11.271 bB-134)

Table 272b

Compounds II in which B is 2-chlorothiazol-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.272bB-1 to N.272bB-134)

Table 273b

Compounds II, wherein B is 2-chlorothiazol-5-yl and A corresponds in each case to one group of one row of Table B (Compounds N.273bB-1 to N.273bB-134)

Table 274b Compounds II in which B is 4-chlorothiazol-5-yl and A corresponds in each case to one group of one row of Table B (Compounds N.274bB-1 to N.274bB-134)

Table 275b

Compounds II, wherein B is 2-bromothiazol-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.275bB-1 to N.275bB-134) Table 276b

Compounds II in which B is 2-bromothiazol-5-yl and A in each case corresponds to one group of one row of Table B (Compounds N.276bB-1 to N.276bB-134) Table 277b

Compounds II in which B is 2,4-dichlorothiazol-5-yl and A in each case corresponds to one group of one row of Table B (Compounds N.277bB-1 to N.277bB-134)

Table 278b Compounds II in which B is 3-chloroisothiazol-4-yl and A in each case corresponds to one group of one row of Table B (Compounds N.278bB-1 to N.278bB-134)

Table 279b

Compounds II, wherein B is 5-methylisothiazol-3-yl and A in each case corresponds to one group of one row of Table B (Compounds N.279bB-1 to M.279bB-134) Table 280b

Compounds II in which B is 3-methylisothiazol-4-yl and A in each case corresponds to one group of one row of Table B (Compounds N.280bB-1 to M.280bB-134)

Table 281 b

Compounds II in which B is 3-methylisothiazol-5-yl and A in each case corresponds to one group of one row of Table B (Compounds 11.281 bB-1 to 11.281 bB-134)

Table 282b

Compounds II, wherein B is 4,5-dichloroisothiazol-3-yl and A corresponds in each case to one group of one row of Table B (Compounds N.282bB-1 to N.282bB-134) Table 283b

Compounds II in which B is 4,5-dimethylisothiazol-3-yl and A in each case corresponds to one group of one row of Table B (Compounds N.283bB-1 to N.283bB-134)

Table 284b Compounds II wherein B is 3,5-dimethylisothiazol-4-yl and A is each one

Group of a row corresponds to Table B (compounds N.284bB-1 to M.284bB-134)

Table 285b

Compounds II in which B is 3,4-dichloroisothiazol-5-yl and A corresponds in each case to one group of one row of Table B (Compounds N.285bB-1 to M.285bB-

134)

Table 286b

Compounds II, wherein B is oxazol-2-yl and A corresponds in each case to one group of one row of Table B (Compounds N.286bB-1 to N.286bB-134) Table 287b

Compounds II, wherein B is oxazol-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.287bB-1 to N.287bB-134)

Table 288b

Compounds II in which B is oxazol-5-yl and A in each case corresponds to a group in a row of Table B (Compounds N.288bB-1 to N.288bB-134) Table 289b

Compounds II in which B is isoxazol-3-yl and A in each case corresponds to one group of one row of Table B (Compounds N.289bB-1 to M.289bB-134)

Table 290b Compounds II wherein B is isoxazol-4-yl and A is each a group of one

Line of Table B corresponds (compounds N.290bB-1 to M.290bB-134)

Table 291 b

Compounds II, wherein B is isoxazol-5-yl and A corresponds in each case to one group of one row of Table B (Compounds 11.291 bB-1 to 11.291 bB-134) Table 292b

Compounds II in which B is 3-chloroisoxazol-5-yl and A in each case corresponds to one group of one row of Table B (Compounds N.292bB-1 to M.292bB-134)

Table 293b

Compounds II in which B is 5-methylisoxazol-3-yl and A in each case corresponds to one group of one row of Table B (Compounds N.293bB-1 to M.293bB-134)

Table 294b

Compounds II in which B is 5-methylisoxazol-4-yl and A in each case corresponds to one group of one row of Table B (Compounds N.294bB-1 to M.294bB-134)

Table 295b Compounds II in which B is 3-methylisoxazol-5-yl and A corresponds in each case to one group of one row of Table B (Compounds N.295bB-1 to N.295bB-134)

Table 296b

Compounds II in which B is 3,5-dimethylisoxazol-4-yl and A in each case corresponds to one group of one row of Table B (Compounds N.296bB-1 to N.296bB-134)

Table 297b

Compounds II, wherein B is 3-chloro-5-methylisoxazol-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.297bB-1 to N.297bB-134) Table 298b

Compounds II in which B is 3-methyl-4-chloroisoxazol-5-yl and A in each case corresponds to one group of one row of Table B (Compounds N.298bB-1 to M.298bB-134)

Table 299b Compounds II in which B is 1-methylpyrazol-3-yl and A in each case corresponds to one group of one row of Table B (Compounds N.299bB-1 to N.299bB-134)

Table 300b

Compounds II, wherein B is 1-methylpyrazol-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.300bB-1 to N.300bB-134) Table 301b

Compounds II in which B is 1-methylpyrazol-5-yl and A in each case corresponds to one group of one row of Table B (Compounds 11.301 bB-1 to 11.301 bB-134) Table 302b

Compounds II, wherein B is 1, 3-dimethylpyrazol-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.302bB-1 to M.302bB-134) Table 303b

Compounds II in which B is 1,5-dimethylpyrazol-4-yl and A in each case corresponds to one group of one row of Table B (Compounds N.303bB-1 to M.303bB-134)

Table 304b Compounds II wherein B is 1, 3,5-trimethylpyrazol-4-yl and A is each one

Group of a row corresponds to Table B (compounds N.304bB-1 to M.304bB-134)

Table 305b

Compounds II in which B is 1-methylimidazol-4-yl and A in each case corresponds to one group of one row of Table B (Compounds N.305bB-1 to M.305bB-134)

Table 306b

Compounds II, wherein B is 1, 5-dimethylimidazol-4-yl and A corresponds in each case to one group of one row of Table B (Compounds N.306bB-1 to M.306bB-134) Table 307b

Compounds II, where B is 1, 2-dimethylimidazol-5-yl and A in each case corresponds to one group of one row of Table B (Compounds M.307bB-1 to M.307bB-134)

Table 308b Compounds II wherein B is 1,4-dimethylimidazol-5-yl and A is each one

Group of one row corresponds to Table B (compounds N.308bB-1 to M.308bB-134)

Table 309b

Compounds II in which B is 2-furyl and A in each case corresponds to one group of one row of Table B (Compounds M.309bB-1 to M.309bB-134)

Table 310b

Compounds II in which B is cyclopropyl and A in each case corresponds to one group of one row of Table B (Compounds N.310bB-1 to M.310bB-134)

Table 311b Compounds II wherein B is cyclopentyl and A is each a group of one

Line of Table B corresponds (connections 11.311 bB-1 to 11.311 bB-134)

Table 312b

Compounds II, wherein B is cyclohexyl and A in each case corresponds to one group of one row of Table B (Compounds N.312bB-1 to N.312bB-134) Table 313b

Compounds II, wherein B is 1-methylcycloprop-1-yy and A in each case corresponds to one group of one row of Table B (Compounds N.313bB-1 to N.313bB-134) Table 314b

Compounds II in which B is 1-methylcyclopent-1-yl and A in each case corresponds to one group of one row of Table B (Compounds 11.314bB-1 to N.314bB-134)

Table 315b Compounds II in which B is 1-methylcyclohex-1-yl and A in each case corresponds to one group of one row of Table B (Compounds 11.315bB-1 to 11.315bB-134)

Table 316b

Compounds II, wherein B is 1-chlorocycloprop-1-yl and A corresponds in each case to one group of one row of Table B (Compounds N.316bB-1 to N.316bB-134) Table 317b

Compounds II, wherein B is methyl and A in each case corresponds to one group of a row of Table B (Compounds M.317bB-1 to M.317bB-134)

Table 318b

Compounds II, wherein B is ethyl and A corresponds in each case to one group of one row of Table B (Compounds M.318bB-1 to N.318bB-134)

Table 319b

Compounds II in which B is n-propyl and A in each case corresponds to one group of one row of Table B (Compounds N.319bB-1 to N.319bB-134)

Table 320b Compounds II, wherein B is i-propyl and A in each case corresponds to one group of one row of Table B (Compounds N.320bB-1 to M.320bB-134)

Table 321 b

Compounds II, wherein B is n-butyl and A corresponds in each case to one group of one row of Table B (Compounds 11.321 bB-1 to 11.321 bB-134) Table 322b

Compounds II, where B is sec-butyl and A in each case corresponds to one group of one row of Table B (Compounds N.322bB-1 to M.322bB-134)

Table 323b

Compounds II in which B is tert-butyl and A in each case corresponds to one group of one row of Table B (Compounds N.323bB-1 to M.323bB-134)

Table 324b

Compounds II, wherein B is iso-butyl and A in each case corresponds to one group of a row of Table B (Compounds N.324bB-1 to M.324bB-134)

Table B

1.1-1 1.1-2 1.1-3

1.1-4 I.2

In particular, with regard to their use, the compounds III according to the invention which are compiled in the following Tables 1c to 308c (compounds III.1-1, III.1-2, III.1-3, III.1-4, III.2) are preferred , The groups mentioned in the tables for a substituent also individually, independently of the combination in which they are mentioned, represent a particularly preferred embodiment of the relevant substituent.

Table 1 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is pyridin-2-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1- 1.1 cC-1 to 111.1-1.1 cC-389; IM.1 -2.1 cC-1 to 111.1-2.1 cC-389; 111.1-3.1 cC-1 to III.1- 3.1 cC-389; 111.1 -4.1 cC-1 to 111.1-4.1 cC-389; IN.2.1cC-1 to IN.2.1cC-389)

Table 2c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is pyridin-3-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1-1.2cC-1 to III.1-1.2cC-389; IN.1-2.2cC-1 to IN.1-2.2cC-389; 111.1 -3.2cC-1 to III.1-3.2cC -389; 111.1 -4.2cC-1 to IN.1-4.2cC-389; IN.2.2cC-1 to IN.2.2cC-389)

Table 3c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is pyridin-4-yl and B corresponds in each case to one group of one line of Table C ( Compounds III.1- 1.3cC-1 to III.1-1.3cC-389; 111.1 -2.3cC-1 to lll.1-2.3cC-389; 111.1-3.3cC-1 to III.1- 3.3cC-389; 111.1 -4.3cC-1 to IN.1-4.3cC-389; IN.2.3cC-1 to IN.2.3cC-389)

Table 4c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-chloropyridin-2-yl and B are each a group of one row of Table C. corresponds (compounds 111.1 -1 .4cC-1 to 111.1 -1 .4cC-389; 111.1 -2.4cC-1 to IN.1 -2.4cC-389; 111.1 -3.4cC-1 to III.1-3.4cC-389) ; 111.1 -4.4cC-1 to IN.1-4.4cC-389; IN.2.4cC-1 to IN.2.4cC-389)

Table 5c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-chloropyridin-2-yl and B is in each case one group of one row of Table C. corresponds to ((compounds III.1-1.5cC-1 to 111.1-1.5cC-389; IN.1-2.5cC-1 to IN.1-2.5cC-389; 111.1 -3.5cC-1 to III.1-3.5 cC-389; 111.1 -4.5cC-1 to IN.1-4.5cC-389; IN.2.5cC-1 to IN.2.5cC-389)

Table 6c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-chloropyridin-2-yl and B are each a group of one row of Table C. corresponds (Compounds lll.1-1.6cC-1 to 111.1-1.6cC-389; 111.1 -2.6cC-1 to IN.1-2.6cC-389; 111.1 -3.6cC-1 to lll.1-3.6cC-389 111.1 -4.6cC-1 to IN.1-4.6cC-389; IN.2.6cC-1 to IN.2.6cC-389)

Table 7c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 6-chloropyridin-2-yl and B are each a group of one line of Table C. (Compounds III.1-1.7cC-1 to III.1-1.7cC-389; IN.1-2.7cC-1 to IN.1-2.7cC-389; IN.1-3.7cC-1 to III. 1-3.7cC-389; IN.1-4.7cC-1 to IN.1-4.7cC-389; IN.2.7cC-1 to IN.2.7cC-389)

Table 8c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-chloropyridin-3-yl and B are each a group of one row of Table C. corresponds (compounds III.1-1.8cC-1 to 111.1-1.8cC-389; 111.1 -2.8cC-1 to IN.1-2.8cC-389; 111.1 -3.8cC-1 to III.1-3.8cC-389) 111.1 -4.8cC-1 to IN.1-4.8cC-389; IN.2.8cC-1 to IN.2.8cC-389)

Table 9c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-chloropyridin-3-yl and B are each a group of one row of Table C. corresponds (Compounds 111.1-1.9cC-1 to 111.1-1.9cC-389; 111.1 -2.9cC-1 to IN.1-2.9cC-389; 111.1 -3.9cC-1 to lll.1-3.9cC-389; 111.1 -4.9cC-1 to IN.1-4.9cC-389; IN.2.9cC-1 to IN.2.9cC-389)

Table 10c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-chloropyridin-3-yl and B are each a group of one row of Table C. corresponds (compounds 111.1-1.1OcC-I to 111.1-1.10cC-389; 111.1 -2.1 OcC-1 to IN.1-2.10cC-389; III.1-3.10cC-1 to III.1-3.10cC-389) 111.1 -4.1 OcC-1 to 111.1-4.1 OcC-389; IN.2.10cC-1 to III.2.10CC-389)

Table 11c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2 wherein A is 6-chloropyridin-3-yl and B is each a group of one line Table C corresponds to (Compounds 111.1-1.11 cC-1 to 111.1-1.11 cC-389; III.1-2.1 1cC-1 to 111.1-2.11 cC-389; III.1- 3.11 cC-1 to IM.1-3.11 cC-389; 111.1 -4.11 cC-1 to III.1-4.1 1cC-389; 111.2.11 cC-1 to

III.2.11 CC-389) Table 12c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-chloropyridin-4-yl and B are each a group of one line of Table C. corresponds (compounds III.1-1.12cC-1 to IN.1-1.12cC-389; 111.1 -2.12cC-1 to IN.1-2.12cC-389; III.1-3.12cC-1 to IM.1- 3.12cC-389; 111.1 -4.12cC-1 to IN.1-4.12cC-389; IN.2.12cC-1 to lll.2.12cC-389) Table 13c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-chloropyridin-4-yl and B corresponds in each case to one group of one row of Table C (Compounds 111.1-1.13cC-1 to 111.1 -1.13 cC-389; 111.1 -2.13cC-1 to IN.1-2.13cC-389; III.1- 3.13cC-1 to IN.1-3.13cC-389; 111.1 -4.13cC-1 to 111.1-4.13cC- 389, IN.2.13cC-1 to III.2.13cC-389) Table 14c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-chloropyridin-5-yl and B is in each case one group of one row of Table C. (Compounds 111.1-1.14cC-1 to 111.1-1.14cC-389; 111.1 -2.14cC-1 to IN.1-2.14cC-389; III.1- 3.14cC-1 to IM.1-3.14cC-389 IN.1-4.14cC-1 to IN.1-4.14cC-389; IN.2.14cC-1 to III.2.14cC-389)

Table 15c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-fluoropyridin-2-yl and B are each a group of one line of Table C. (Compounds III.1-1.15cC-1 to IN.1-1.15cC-389; 111.1 -2.15cC-1 to IN.1-2.15cC-389; III.1- 3.15cC-1 to IN.1). 3.15cC-389; 111.1 -4.15cC-1 to 111.1 -4.15cC-389; IN.2.15cC-1 to

III.2.15CC-389) Table 16c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-fluoropyridin-2-yl and B are each a group of one line of Table C. corresponds (compounds 111.1-1.16cC-1 to 111.1-1.16cC-389; 111.1 -2.16cC-1 to IN.1-2.16cC-389; III.1-

3.16cC-1 to III.1 -3.16cC-389; 111.1 -4.16cC-1 to 111.1 -4.16cC-389; IN.2.16cC-1 to III.2.16cC-389) Table 17c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-fluoropyridin-2-yl and B are each a group of one line of Table C. (Compounds III.1-1.17CC-1 to III.1-1.17CC-389; 111.1 -2.17CC-1 to III.1-2.17CC-389; III.1- 3.17CC-1 to III.1- 3.17cC-389; 111.1 -4.17cC-1 to 111.1-4.17cC-389; lll.2.17cC-1 to III.2.17CC-389). Table 18c Compounds III.1-1, III.1-2, III. 1-3, III.1-4 and III.2, in which A is 6-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.18cC-1 to 111.1-1.18cC- 389; 111.1 -2.18cC-1 to IN.1-2.18cC-389; III.1- 3.18cC-1 to MI.1 -3.18cC-389; 111.1 -4.18cC-1 to 111.1 -4.18cC-389; MI.2.18cC-1 to III.2.18CC-389) Table 19c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-fluoropyridin-3-yl and B each represents a group of one row of Table C. (Compounds Ill.1-1.19cC-1 to 111.1 -1.19cC-389; 111.1 -2.19cC-1 to IN.1-2.19cC-389; III.1- 3.19cC-1 to IN.1-3.19cC -389; 111.1 -4.19cC-1 to 111.1-4.19cC-389; IN.2.19cC-1 to III.2.19CC-389) Table 20c Compounds III.1-1, III.1-2, III.1- 3, III.1-4 and III.2, where A is 4-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.2OcC-I to III.1-1.20cC- 389; IM.1-2.20cC-1 to IM.1-2.20cC-389; III.1- 3.20cC-1 to IN.1-3.20cC-389; IN.1-4.20cC-1 to IN.1 -4.20cC-389; IN.2.20cC-1 to lll.2.20cC-389) Table 21c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-fluoropyridin-3-yl and B each represents a group of one row of Table C. (Compounds 111.1 -1 .21 cC-1 to 111.1 -1 .21 cC-389; 111.1 -2.21 cC-1 to 111.1 -2.21 cC-389; III.1 to 3.21 cC-1 to 111.1-3.21 cC-389 111.1 -4.21 cC-1 to IN.1-4.21cC-389, IN.2.21 cC-1 to III.2.21 cC-389)

Table 22c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 6-fluoropyridin-3-yl and B each represents a group of one row of Table C. corresponds (compounds III.1-1.22cC-1 to 111.1-1.22cC-389; IN.1-2.22cC-1 to IN.1-2.22cC-389; III.1- 3.22cC-1 to IN.1- 3.22cC-389; 111.1 -4.22cC-1 to IN.1-4.22cC-389; IN.2.22cC-1 to lll.2.22cC-389) Table 23c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-fluoropyridin-4-yl and B are each a group of one row of Table C. corresponds (compounds 111.1-1.23cC-1 to 111.1-1.23cC-389; IN.1-2.23cC-1 to IN.1-2.23cC-389; III.1-

3.23cC-1 to IN.1-3.23cC-389; 111.1 -4.23cC-1 to IN.1-4.23cC-389; IN.2.23cC-1 to III.2.23cC-389) Table 24c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-fluoropyridin-4-yl and B are each a group of one line of Table C. corresponds (compounds III.1-1.24cC-1 to 111.1-1.24cC-389; IN.1-2.24cC-1 to IN.1-2.24cC-389; III.1- 3.24cC-1 to IN.1- 3.24cC-389; 111.1 -4.24cC-1 to IN.1-4.24cC-389; IN.2.24cC-1 to III.2.24CC-389) Table 25c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.25cC-1 to 111.1 -1.25cC-389; 111.1 -2.25cC-1 to IN.1-2.25cC-389; III.1- 3.25cC-1 to IM.1-3.25cC-389; 111.1 -4.25cC-1 to lll.1-4.25cC-389; MI.2.25cC-1 to III.2.25CC-389) Table 26c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-methylpyridin-2-yl and B are each a group of one line of Table C. corresponds (compounds III.1-1.26cC-1 to 111.1-1.26cC-389; 111.1 -2.26cC-1 to IM.1-2.26cC-389; III.1- 3.26cC-1 to IM.1-3.26cC -389; IN.1-4.26cC-1 to IN.1-4.26cC-389; MI.2.26cC-1 to III.2.26CC-389) Table 27c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.27cC-1 to III .1-1.27CC-389; 111.1 -2.27cC-1 to IM.1-2.27cC-389; III.1-3.27cC-1 to III.1-3.27CC-389; 111.1 -4.27cC-1 to IN .1-4.27cC-389; MI.2.27cC-1 to III.2.27CC-389) Table 28c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 6-methylpyridin-2-yl and B are each a group of one line of Table C. corresponds (compounds 111.1-1.28cC-1 to 111.1-1.28cC-389; 111.1 -2.28cC-1 to IM.1-2.28cC-389; III.1-3.28cC-1 to IM.1-3.28cC-389) IN.1-4.28cC-1 to IN.1-4.28cC-389; IM.2.28cC-1 to III.2.28CC-389)

Table 29c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-methylpyridin-3-yl and B are each a group of one line of Table C. (Compounds III.1-1.29cC-1 to 111.1-1.29cC-389; IM.1-2.29cC-1 to IM.1-2.29cC-389; III.1- 3.29cC-1 to IM.1- 3.29cC-389; 111.1 -4.29cC-1 to IN.1-4.29cC-389; MI.2.29cC-1 to lll.2.29cC-389) Table 30c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-methylpyridin-3-yl and B are each a group of one line of Table C. corresponds (Compounds III.1-1.3OcC-I to 111.1-1.30cC-389; 111.1 -2.30cC-1 to IM.1-2.30cC-389; III.1-

3.30cC-1 to IM.1-3.30cC-389; IN.1-4.30cC-1 to IN.1-4.30cC-389; MI.2.30cC-1 to lll.2.30cC-389) Table 31 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-methylpyridin-3-yl and B are each a group of one line of Table C. (Compounds III.1-1.31 cC-1 to 111.1 -1.31 cC-389; 111.1 -2.31 cC-1 to 111.1-2.31 cC-389; III.1- 3.31 cC-1 to 111.1-3.31 cC-389; 111.1 -4.31 cC-1 to IN.1-4.31cC-389; MI.2.31 cC-1 to III.2.31 CC-389) Table 32c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 6-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table C (Compounds 111.1-1.32cC-1 to 111.1-1.32cC-389, IM. 1-2.32cC-1 to IM.1-2.32cC-389; III.1- 3.32cC-1 to IM.1-3.32cC-389; 111.1 -4.32cC-1 to III.1-4.32cC-389; MI.2.32cC-1 to III.2.32CC-389) Table 33c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-methylpyridin-4-yl and B are each a group of one line of Table C. corresponds (Compounds lll.1-1.33cC-1 to 111.1-1.33cC-389) Table 34c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-methylpyridin-4-yl and B are each a group of one line of Table C. corresponds (Compounds 111.1-1.34cC-1 to 111.1-1.34cC-389; IM.1-2.34cC-1 to IM.1-2.34cC-389; III.1-

3.34cC-1 to IM.1-3.34cC-389; 111.1 -4.34cC-1 to IN.1-4.34cC-389; MI.2.34cC-1 to III.2.34cC-389) Table 35c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-methylpyridin-5-yl and B are each a group of one line of Table C. corresponds (compounds III.1-1.35cC-1 to 111.1-1.35cC-389; IM.1-2.35cC-1 to IM.1-2.35cC-389; III.1- 3.35cC-1 to MI.1- 3.35cC-389; 111.1 -4.35cC-1 to IN.1-4.35cC-389; MI.2.35cC-1 to III.2.35CC-389) Table 36c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-methoxypyridin-2-yl and B corresponds in each case to one group of one row of Table C (compounds III.1.1.36cC-1 to 111.1 -1.36cC-389; 111.1 -2.36cC-1 to IN.1-2.36cC-389; III.1-3.36cC-1 to IM.1-3.36cC-389; IN.1-4.36cC-1 to IN .1-4.36cC-389; MI.2.36cC-1 to III.2.36CC-389) Table 37c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-methoxypyridin-2-yl and B are each a group of one row of Table C. (Compounds III.1-1.37cC-1 to III.1-1.37cC-389; 111.1 -2.37cC-1 to 111.1 -2.37cC-389; III.1- 3.37cC-1 to III.1-3.37CC -389; 111.1 -4.37cC-1 to IN.1-4.37cC-389; MI.2.37cC-1 to III.2.37CC-389)

Table 38c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-methoxypyridin-2-yl and B are each a group of one line of Table C. (Compounds III.1-1.38cC-1 to 111.1-1.38cC-389; 111.1 -2.38cC-1 to IN.1-2.38cC-389; III.1- 3.38cC-1 to IM.1-3.38cC -389; 111.1 -4.38cC-1 to IN.1-4.38cC-389; MI.2.38cC-1 to

III.2.38CC-389) Table 39c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 6-methoxypyridin-2-yl and B are each a group of one line of Table C. corresponds (compound 111.1-1.39cC-1 to 111.1-1.39cC-389; IM.1-2.39cC-1 to IN.1-2.39cC-389; III.1-

3.39cC-1 to IM.1-3.39cC-389; 111.1 -4.39cC-1 to IN.1-4.39cC-389; MI.2.39cC-1 to III.2.39cC-389) Table 40c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-methoxypyridin-3-yl and B each represents a group of one line of Table C. corresponds (compounds III.1-1.40cC-1 to 111.1-1.40cC-389; IM.1-2.40cC-1 to IM.1-2.40cC-389; III.1-3.40cC-1 to IM.1- 3.40cC-389; IN.1-4.40cC-1 to IN.1-4.40cC-389; MI.2.40cC-1 to

III.2.40CC-389) Table 41 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-methoxypyridin-3-yl and B are each a group of one row of Table C. corresponds (compound fertilize IM.1-1.41cC-1 to 111.1 -1.41 cC-389; 111.1 -2.41 cC-1 to 111.1-2.41 cC-389; III.1-

3.41 cC-1 to 111.1-3.41 cC-389; 111.1 -4.41 cC-1 to IN.1-4.41cC-389; IN.2.41 cC-1 to III.2.41 cC-389) Table 42c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-methoxypyridin-3-yl and B each represents a group of one row of Table C. (Compounds III.1-1.42cC-1 to 111.1-1.42cC-389; IN.1-2.42cC-1 to IN.1-2.42cC-389; III.1- 3.42cC-1 to IN.1- 3.42cC-389; 111.1 -4.42cC-1 to IN.1-4.42cC-389; IN.2.42cC-1 to III.2.42CC-389) Table 43c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 6-methoxypyridin-3-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.43cC-1 to 111.1 -1.43cC-389; 111.1 -2.43cC-1 to IN.1-2.43cC-389; III.1- 3.43cC-1 to IN.1-3.43cC-389; 111.1 -4.43cC-1 to IN.1 -4.43cC-389; IN.2.43cC-1 to III.2.43CC-389) Table 44c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-methoxypyridin-4-yl and B are each a group of one row of Table C. corresponds (compounds III.1-1.44cC-1 to 111.1-1.44cC-389; IN.1-2.44cC-1 to IN.1-2.44cC-389; III.1- 3.44cC-1 to IN.1- 3.44cC-389; IN.1-4.44cC-1 to IN.1-4.44cC-389; IN.2.44cC-1 to lll.2.44cC-389)

Table 45c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-methoxypyridin-4-yl and B are each a group of one line of Table C. (Compounds III.1-1.45cC-1 to 111.1-1.45cC-389; IN.1-2.45cC-1 to IN.1-2.45cC-389; III.1- 3.45cC-1 to IN.1- 3.45cC-389; IN.1-4.45cC-1 to IN.1-4.45cC-389; IN.2.45cC-1 to

III.2.45CC-389) Table 46c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3,5-dichloropyridin-2-yl and B is in each case a group of one line of Table C corresponds to (compound 111.1 -1.46cC-1 to 111.1-1.46cC-389; 111.1 -2.46cC-1 to IN.1-2.46cC-389; III.1-

3.46cC-1 to IN.1-3.46cC-389; IN.1-4.46cC-1 to IN.1-4.46cC-389; IN.2.46cC-1 to III.2.46cC-389) Table 47c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,4-dichloropyridin-3-yl and B is in each case a group of one line of Table C corresponds to (compounds III.1-1.47cC-1 to III.1-1.47cC-389; III.1 -2.47cC-1 to IN.1-2.47cC-389; III.1- 3.47cC-1 to IN. 1-3.47cC-389; IN.1-4.47cC-1 to IN.1-4.47cC-389; IN.2.47cC-1 to

III.2.47CC-389) Table 48c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,5-dichloropyridin-3-yl and B is in each case a group of a line of Table C corresponds to (Compound 111.1-1.48cC-1 to 111.1-1.48cC-389; 111.1 -2.48cC-1 to IN.1-2.48cC-389; III.1-

3.48cC-1 to IM.1-3.48cC-389; IN.1-4.48cC-1 to IN.1-4.48cC-389; MI.2.48cC-1 to lll.2.48cC-389) Table 49c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,6-dichloropyridin-3-yl and B each represents a group of a line of Table C corresponds to (Compounds III.1-1.49cC-1 to 111.1-1.49cC-389; IM.1-2.49cC-1 to IN.1-2.49cC-389; III.1-3.49cC-1 to IM. 1-3.49cC-389; 111.1 -4.49cC-1 to IN.1-4.49cC-389; MI.2.49cC-1 to III.2.49CC-389) Table 50c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, wherein A is 2,6-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.5OcC-I to III.1- 3.50cC-1 to IM.1-3.50cC-389; IN.1-4.50cC -1 to IN.1-4.50cC-389; MI.2.50cC-1 to III.2.50CC-389) Table 51c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3,5-dichloropyridin-4-yl and B is in each case a group of one line of Table C corresponds to (Compounds 111.1 -1.51 cC-1 to 111.1 -1 .51 cC-389; 111.1 to -2.51 cC-1 to 111.1 to -2.51 cC-389; III.1 to 3.51 cC-1 to 111.1 to 3.51 cC-389 111.1 -4.51 cC-1 to IN.1-4.51cC-389; MI.2.51 cC-1 to III.2.51 cC-389)

Table 52c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3,6-dichloropyridin-4-yl and B is in each case a group of one line of Table C corresponds (Compounds III.1-1.52cC-1 to 111.1-1.52cC-389; IM.1-2.52cC-1 to IN.1-2.52cC-389; III.1- 3.52cC-1 to IM. 1-3.52cC-389; 111.1 -4.52cC-1 to IN.1-4.52cC-389; MI.2.52cC-1 to

III.2.52CC-389) Table 53c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,5-dichloropyridin-4-yl and B is in each case a group of a line of Table C corresponds to (compound IM.1-1.53cC-1 to 111.1-1.53cC-389; IM.1-2.53cC-1 to IN.1-2.53cC-389; III.1-

3.53cC-1 to IM.1-3.53cC-389; 111.1 -4.53cC-1 to IN.1-4.53cC-389; MI.2.53cC-1 to III.2.53cC-389) Table 54c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,3-dichloropyridin-4-yl and B each represents a group of a line of Table C corresponds (Compounds III.1-1.54cC-1 to 111.1-1.54cC-389; IM.1-2.54cC-1 to IN.1-2.54cC-389; III.1- 3.54cC-1 to IM. 1-3.54cC-389; 111.1 -4.54cC-1 to IN.1-4.54cC-389; MI.2.54cC-1 to

III.2.54CC-389) Table 55c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,4-dichloropyridin-5-yl and B is in each case a group of one line of Table C corresponds to (compound IM.1-1.55cC-1 to 111.1-1.55cC-389; IM.1-2.55cC-1 to IN.1-2.55cC-389; III.1-

3.55cC-1 to IN.1-3.55cC-389; IN.1-4.55cC-1 to IN.1-4.55cC-389; IN.2.55cC-1 to III.2.55CC-389) Table 56c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3,5-difluoropyridin-2-yl and B each represents a group of a line of Table C corresponds (Compounds III.1-1.56cC-1 to 111.1-1.56cC-389; 111.1 -2.56cC-1 to IN.1-2.56cC-389; III.1- 3.56cC-1 to IN.1- 3.56cC-389; IN.1-4.56cC-1 to IN.1-4.56cC-389; IN.2.56cC-1 to III.2.56CC-389) Table 57c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, wherein A is 3,5-difluoropyridin-4-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.57cC -1 to III.1-1.57cC-389; 111.1 -2.57cC-1 to IN.1-2.57cC-389; III.1- 3.57cC-1 to III.1-3.57cC-389; 111.1 -4.57cC -1 to IN.1-4.57cC-389; IN.2.57cC-1 to III.2.57CC-389) Table 58c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,3-difluoropyridin-4-yl and B each represents a group of a line of Table C corresponds (compounds III.1-1.58cC-1 to 111.1-1.58cC-389; 111.1 -2.58cC-1 to IN.1-2.58cC-389; III.1- 3.58cC-1 to IN.1- 3.58cC-389, IN.1-4.58cC-1 to IN.1-4.58cC-389, IN.2.58cC-1 to III.2.58cC-389)

Table 59c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3,5-dimethylpyridin-2-yl and B each represents a group of a line of Table C corresponds (Compounds III.1-1.59cC-1 to 111.1-1.59cC-389; 111.1 -2.59cC-1 to IN.1-2.59cC-389; III.1- 3.59cC-1 to IN.1- 3.59cC-389; IN.1-4.59cC-1 to IN.1-4.59cC-389; IN.2.59cC-1 to

III.2.59CC-389) Table 60c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3,4-dimethylpyridin-2-yl and B each represents a group of a line of Table C corresponds (Compound 111.1-1.6 OcC-I to 111.1-1.60cC-389; 111.1 -2.60cC-1 to IM.1-2.60cC-389; III.1-

3.60cC-1 to IM.1-3.60cC-389; 111.1 -4.60cC-1 to IN.1-4.60cC-389; MI.2.60cC-1 to lll.2.60cC-389) Table 61 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4,6-dimethylpyridin-3-yl and B is in each case a group of one line of Table C corresponds (Compounds Ill.1-1.61cC-1 to 111.1-1.61 cC-389; 111.1 -2.61 cC-1 to 111.1-2.61 cC-389; III.1-3.61 cC-1 to 111.1-3.61 cC-389 111.1 -4.61 cC-1 to IN.1-4.61cC-389; IN.2.61 cC-1 to

III.2.61 CC-389) Table 62c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,4-dimethylpyridin-3-yl and B each represents a group of a line of Table C corresponds to (compound IN.1-1.62cC-1 to 111.1-1.62cC-389; 111.1 -2.62cC-1 to IN.1-2.62cC-389; III.1-

3.62cC-1 to IN.1-3.62cC-389; IN.1-4.62cC-1 to IN.1-4.62cC-389; IN.2.62cC-1 to III.2.62cC-389) Table 63c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3,5-dimethylpyridin-4-yl and B each represents a group of a line of Table C corresponds to (Compounds III.1-1.63cC-1 to 111.1-1.63cC-389; 111.1 -2.63cC-1 to IN.1-2.63cC-389; III.1- 3.63cC-1 to IN.1- 3.63cC-389; IN.1-4.63cC-1 to IN.1-4.63cC-389; IN.2.63cC-1 to III.2.63CC-389) Table 64c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, wherein A is 2-chloro-3-fluoropyridin-4-yl and B corresponds in each case to one group of one row of Table C (Compounds 111.1-1.64cC -1 to 111.1-1.64cC-389; 111.1 -2.64cC-1 to III.1- 2.64cC-389; 111.1 -3.64cC-1 to IN.1-3.64cC-389; IN.1-4.64cC-1 to IN.1-4.64cC-389; III.2.64cC-1 to IN.2.64cC-389) Table 65c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-chloro-3-methylpyridin-2-yl and B is each a group of one Row of Table C corresponds (Compounds 111.1-1.65cC-1 to 111.1-1.65cC-389; 111.1 -2.65cC-1 to III.1- 2.65cC-389; 111.1 -3.65cC-1 to IN.1-3.65cC -389; IN.1-4.65cC-1 to IN.1-4.65cC-389; III.2.65CC-1 to IN.2.65cC-389)

Table 66c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-chloro-3-methylpyridin-2-yl and B is each a group of one Row of Table C corresponds (Compounds 111.1-1.66cC-1 to 111.1-1.66cC-389; 111.1 -2.66cC-1 to III.1-2.6cC-389; 111.1 -3.66cC-1 to IN.1-3.66cC -389; 111.1 -4.66cC-1 to IN.1-4.66cC-389; III.2.66cC-1 to IN.2.66cC-389) Table 67c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-fluoro-3-methylpyridin-2-yl and B is each a group of one Corresponds to the row of Table C (compounds IN.1-1.67cC-1 to 111.1-1.67cC-389; IN.1-2.67cC-1 to III.1-

2.67cC-389; IN.1-3.67cC-1 to IN.1-3.67cC-389; 111.1 -4.67cC-1 to IN.1-4.67cC-389; Ill.2.67cC-1 to IN.2.67cC-389) Table 68c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-chloro-5-trifluoromethylpyridin-2-yl and B is each a group of one Row of Table C corresponds (Compounds 111.1-1.68cC-1 to 111.1-1.68cC-389; 111.1 -2.68cC-1 to III.1- 2.68cC-389; 111.1 -3.68cC-1 to IM.1-3.68cC -389; 111.1 -4.68cC-1 to IN.1-4.cC-389;

III.2.68CC-1 to IM.2.68cC-389) Table 69c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-chloro-6-trifluoromethylpyridin-3-yl and B are each a group of one Line of Table C corresponds (compounds 111.1-1.69cC-1 to 111.1-1.69cC-389; 111.1 -2.69cC-1 to III.1-

2.69cC-389; 111.1 -3.69cC-1 to IM.1-3.69cC-389; IN.1-4.69cC-1 to IN.1-4.69cC-389; Ill.2.69cC-1 to IM.2.69cC-389) Table 70c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,4-dichloro-6-methylpyridin-3-yl and B are each one Group of a row of Table C corresponds (Compounds III.1-1.7OcC-I to 111.1-1.70cC-389; IN.1-2.70cC-1 to III.1- 2.70cC-389; 111.1-3.7OcC-I to IM.1-3.70cC-389; 111.1 -4.70cC-1 to IN.1-4.70cC-389; III.2.70CC-1 to IM.2.70cC-389). Table 71c Compounds III.1-1, III .1-2, III.1-3, III.1-4 and III.2, wherein A is 3,4,5-

Trichloropyridin-2-yl and B corresponds in each case to one group of one row of Table C (Compounds 111.1-1.7I cC-I to 111.1 -1.71 cC-389; 111.1 -2.71 cC-1 to III.1- 2.71 cC-389; 111.1-3.71 cC-1 to 111.1-3.71 cC-389; I Il .1 -4.71 cC-1 to 111.1 -4.71 cC-389; ll.2.71 cC-1 to 111.2.71 cC-389) Table 72c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,4,6-trichloropyridin-3-yl and B each represents a group of one Row of Table C corresponds (Compounds 111.1-1.72cC-1 to 111.1-1.72cC-389; 111.1 -2.72cC-1 to III.1-2.72cC-389; 111.1 -3.72cC-1 to IM.1-3.72cC -389; 111.1 -4.72cC-1 to IN.1-4.72cC-389; III.2.72cC-1 to IM.2.72cC-389)

Table 73c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is pyrimidin-2-yl and B in each case corresponds to one group of one row of Table C ( Compounds III.1- 1.73cC-1 to III.1-1.73cC-389; 111.1 -2.73cC-1 to IM.1-2.73cC-389; 111.1 -3.73cC-1 to III.1-3.73cC-389 ; 111.1 -4.73cC-1 to IN.1-4.73cC-389; IM.2.73cC-1 to MI.2.73cC-389)

Table 74c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is pyrimidin-5-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1- 1.74cC-1 to III.1-1.74cC-389; 111.1 -2.74cC-1 to IM.1-2.74cC-389; 111.1 -3.74cC-1 to III.1-3.74cC-389 ; 111.1 -4.74cC-1 to IN.1-4.74cC-389; IM.2.74cC-1 to IM.2.74cC-389)

Table 75c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 6-chloropyrimidine-3 yl and B corresponds in each case to one group of one row of Table C (Compounds III.1-1.75CC-1 to III.1-1.75CC-389; 111.1 -2.75cC-1 to IN.1-2.75cC-389; III 111-4.75cC-1 to IN.1-4.75cC-389, MI.2.75cC-1 to III.2.75CC-389) Table 76c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 6-methylpyrimidin-3-yl and B are each a group of one line of Table C. corresponds (Compounds lll.1-1.76cC-1 to 111.1-1.76cC-389; 111.1 -2.76cC-1 to IN.1-2.76cC-389; III.1- 3.76cC-1 to lll.1-3.76cC -389; 111.1 -4.76cC-1 to IN.1-4.76cC-389; IN.2.76cC-1 to III.2.76cC-389)

Table 77c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 6-methoxypyrimidin-3-yl and B are each a group of one row of Table C. (Compounds III.1-1.77cC-1 to 111.1-1.77cC-389; 111.1 -2.77cC-1 to IN.1-2.77cC-389; III.1- 3.77cC-1 to IN.1-3.77cC -389; 111.1 -4.77cC-1 to IN.1-4.77cC-389; IN.2.77cC-1 to

III.2.77CC-389) Table 78c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and 111.2, wherein A is 2,4-dichloropyrimidin-3-yl and B is in each case one group of one line of Table C. corresponds (compounds 111.1-1.78cC-1 to 111.1-1.78cC-389; IN.1-2.78cC-1 to III.1-

2.78cC-389; IN.1-3.78cC-1 to IN.1-3.78cC-389; 111.1 -4.78cC-1 to IN.1-4.78cC-389; lll.2.78cC-1 to IN.2.78cC-389) Table 79c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and 111.2, wherein A is 2,6-dichloropyrimidin-3-yl and B is in each case one group of one line of Table C. (Compounds 111.1-1.79cC-1 to 111.1-1.79cC-389; 111.1 -2.79cC-1 to III.1-2.79cC-389; 111.1 -3.79cC-1 to 111.1 -3.79cC-389; 111.1 -4.79 cC-1 to IN.1-4.79cC-389; III.2.79cC-1 to IN.2.79cC-389). Table 80c Compounds III.1-1, III.1-2, III.1-3, III. 1-4 and III.2, wherein A is 2,4-difluoropyrimidine

3-yl and B corresponds in each case to one group of one row of Table C (Compounds 111.1-1.8OcC-I to 111.1-1.80cC-389; 111.1 -2.80cC-1 to IN.1-2.80cC-389; III.1 - 3.80cC-1 to IN.1-3.80cC-389; 111.1 -4.80cC-1 to IN.1-4.80cC-389; IN.2.80cC-1 to III.2.80CC-389). Table 81c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,6-difluoropyrimidin-3-yl and B each represents a group of a line of Table C corresponds (Compounds 111.1-1.81cC-1 to 111.1-1.81 cC-389; 111.1 -2.81 cC-1 to 111.1-2.81 cC-389; III.1-3.81 cC-1 to 111.1-3.81 cC-389; 111.1 -4.81 cC-1 to IN.1-4.81cC-389; IN.2.81 cC-1 to III.2.81 CC-389)

Table 82c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 1, 3,5-triazin-2-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.82cC-1 to 111.1-1.82cC-389; 111.1 -2.82cC-1 to IM.1-2.82cC-389; III.1- 3.82cC-1 to IM.1-3.82cC-389; IN.1-4.82cC-1 to IN.1-4.82cC-389; MI.2.82cC-1 to III.2.82CC-389) Table 83c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is thien-2-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1- 1.83cC-1 to 111.1-1.83cC-389; IN.1-2.83cC-1 to IN.1-2.83cC-389; 111.1 -3.83cC-1 to III.1-3.83cC-389 IN.1-4.83cC-1 to IN.1-4.83cC-389; IN.2.83cC-1 to IN.2.83cC-389) Table 84c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is thien-3-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1- 1.84cC-1 to 111.1-1.84cC-389; IN.1-2.84cC-1 to IN.1-2.84cC-389; 111.1 -3.84cC-1 to III.1-3.84cC-389 IN.1-4.84cC-1 to IN.1-4.84cC-389; IN.2.84cC-1 to IN.2.84cC-389) Table 85c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-chlorothien-2-yl and B are each a group of one row of Table C. (Compounds III.1-1.85CC-1 to 111.1-1.85cC-389; IN.1-2.85cC-1 to IN.1-2.85cC-389; III.1- 3.85cC-1 to IN.1- 3.85cC-389; IN.1-4.85cC-1 to IN.1-4.85cC-389; IN.2.85cC-1 to III.2.85CC-389)

Table 86c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-chlorothien-3-yl and B are each a group of one row of Table C. corresponds (Compounds lll.1-1.86cC-1 to 111.1-1.86cC-389; 111.1 -2.86cC-1 to IN.1-2.86cC-389; III.1- 3.86cC-1 to IN.1-3.86cC -389; 111.1 -4.86cC-1 to IN.1-4.86cC-389; IN.2.86cC-1 to lll.2.86cC-389) Table 87c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-chlorothien-3-yl and B are each a group of one row of Table C. corresponds (compounds MI.1-1.87cC-1 to 111.1-1.87cC-389; IM.1-2.87cC-1 to IM.1-2.87cC-389; III.1-

3.87cC-1 to III.1-3.87CC-389; IN.1-4.87cC-1 to IN.1-4.87cC-389; IN.2.87cC-1 to III.2.87CC-389) Table 88c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-chlorothien-3-yl and B are each a group of one row of Table C. (Compounds III.1-1.88cC-1 to 111.1-1.88cC-389; 111.1 -2.88cC-1 to IN.1-2.88cC-389; III.1- 3.88cC-1 to IN.1-3.88cC -389; 111.1 -4.88cC-1 to IN.1-4.88cC-389; IN.2.88cC-1 to III.2.88CC-389). Table 89c Compounds III.1-1, III.1-2, III. 1-3, III.1-4 and III.2, in which A is 2-bromothien-3-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.89cC-1 to 111.1-1.89cC- 389; 111.1 -2.89cC-1 to IN.1-2.89cC-389; III.1- 3.89cC-1 to IM.1-3.89cC-389; IN.1-4.89cC-1 to III.1-4.89cC-389; MI.2.89cC-1 to III.2.89CC-389) Table 90c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-bromothien-3-yl and B are each a group of one row of Table C. (Compounds III.1-1.9OcC-I to 111.1-1.90cC-389; IM.1-2.90cC-1 to IM.1-2.90cC-389; III.1- 3.90cC-1 to IN.1- 3.90cC-389; IN.1-4.90cC-1 to IN.1-4.90cC-389; IN.2.90cC-1 to III.2.90CC-389). Table 91c Compounds III.1-1, III.1 -2, III.1-3, III.1-4 and III.2, in which A is 5-bromothien-3-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.91 cC- 1 to 111.1 -1.91 cC-389; 111.1 -2.91 cC-1 to 111.1-2.91 cC-389; III.1- 3.91 cC-1 to 111.1-3.91 cC-389; 111.1 -4.91 cC-1 to IN.1- 4.91cC-389; IN.2.91 cC-1 to III.2.91 cC-389) Table 92c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-methylthien-2-yl and B are each a group of one line of Table C. (Compounds III.1-1.92cC-1 to 111.1-1.92cC-389; IN.1-2.92cC-1 to IN.1-2.92cC-389; III.1- 3.92cC-1 to IN.1- 3.92cC-389; 111.1 -4.92cC-1 to IN.1-4.92cC-389; IN.2.92cC-1 to III.2.92CC-389)

Table 93c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-methylthien-4-yl and B is in each case a group of one line of Table C. (Compounds III.1-1.93cC-1 to 111.1-1.93cC-389; IN.1-2.93cC-1 to IN.1-2.93cC-389; III.1- 3.93cC-1 to IN.1- 3.93cC-389; 111.1 -4.93cC-1 to IN.1-4.93cC-389; IN.2.93cC-1 to III.2.93cC-389) Table 94c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4,5-dichlorothien-2-yl and B is in each case a group of a line of Table C corresponds (Compounds 111.1-1.94cC-1 to 111.1-1.94cC-389; IN.1-2.94cC-1 to IN.1-2.94cC-389; III.1-

3.94cC-1 to IN.1-3.94cC-389; 111.1 -4.94cC-1 to IN.1-4.94cC-389; IN.2.94cC-1 to III.2.94cC-389) Table 95c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,5-dichlorothien-3-yl and B is in each case a group of a line of Table C corresponds to (Compounds III.1-1.95CC-1 to 111.1-1.95cC-389; IN.1-2.95cC-1 to IN.1-2.95cC-389; III.1-3.95cC-1 to IN. 1-3.95cC-389; 111.1 -4.95cC-1 to IN.1-4.95cC-389; IN.2.95cC-1 to III.2.95CC-389). Table 96c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, wherein A is 2,3-dichlorothien-4-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.96cC-1 to 111.1-1.96cC-389; 111.1 -2.96cC-1 to IN.1-2.96cC-389; III.1- 3.96cC-1 to IM.1-3.96cC-389; IN.1-4.96cC-1 to III.1-4.96cC-389; IM.2.96cC-1 to III.2.96CC-389) Table 97c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,5-dibromothien-3-yl and B each represents a group of a line of Table C corresponds to (Compounds Ill.1-1.97cC-1 to Ill.1-1.97cC-389; 111.1 -2.97cC-1 to IM.1-2.97cC-389; III.1-3.97cC-1 to III. 1-3.97CC-389; 111.1 -4.97cC-1 to IN.1-4.97cC-389; MI.2.97cC-1 to III.2.97CC-389) Table 98c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, wherein A is 4,5-dimethylthien-2-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.98cC -1 to 111.1-1.98cC-389; 111.1 -2.98cC-1 to IN.1-2.98cC-389; III.1- 3.98cC-1 to IM.1-3.98cC-389; IN.1-4.98cC -1 to IN.1-4.98cC-389; MI.2.98cC-1 to III.2.98cC-389) Table 99c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,5-dimethylthien-3-yl and B each represents a group of a line of Table C corresponds to (Compounds III.1-1.99cC-1 to 111.1-1.99cC-389; IM.1-2.99cC-1 to IN.1-2.99cC-389; III.1-3.99cC-1 to IM. 1-3.99cC-389; 111.1 -4.99cC-1 to IN.1-4.99cC-389; MI.2.99cC-1 to III.2.99CC-389)

Table 10Oc

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,3-dimethylthien-4-yl and B is in each case a group of one line of Table C corresponds (Compounds 111.1-1.10OcC-I to 111.1-1.1 OOcC-389; 111.1-2.100cC-1 to IM.1-2.100cC-389; 111.1-3.10OcC-I to 111.1-3.1 OOcC-389; 111.1 -4.100cC-1 to IN.1-4.100cC-389; lll.2.100cC-1 to 111.2.1 OOcC-389) Table 101c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3,4,5-trichlorothien-2-yl and B each represents a group of one Line of Table C corresponds to (Compound 111.1-1.10I cC-I to 111.1-1.101 cC-389; 111.1-2.101 cC-1 to 111.1-2.101 cC-389; lll.1-3.101 cC-1 to 111.1-3.101 cC-389; 111.1 -4.101 cC-1 to 111.1-4.101 cC-389; lll.2.101 cC-1 to 111.2.101cC-389) Table 102c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,4,5-trichlorothien-3-yl and B each represents a group of one Row of Table C corresponds (Compounds III.1-1.102cC-1 to 111.1-1.102cC-389; 111.1-2.102cC-1 to 111.1-2.102cC-389; III.1-3.102cC-1 to 111.1-3.102cC -389; 111.1 -4.102cC-1 to 111.1-4.102cC-389; lll.2.102cC-1 to IM.2.102cC-389) Table 103c Compounds III.1-1, III.1-2, III.1- 3, III.1-4 and III.2, wherein A is 2,4,5-tribromothienes

3-yl and B corresponds in each case to one group of one row of Table C (Compounds 111.1-1.103cC-1 to 111.1 -1.103cC-389; 111.1-2.103cC-1 to 111.1-2.103cC-389; III.1 -3.103cC-1 to 111.1 -3.103cC-389; 111.1 -4.103cC-1 to 111.1 -4.103cC-389; III.2.103CC-1 to 111.2.103cC-389) Table 104c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3,4,5-trimethylthien-2-yl and B each represents a group of one Line of Table C corresponds (compounds IM.1-1.104cC-1 to 111.1-1.104cC-389; 111.1 -2.104cC-1 to III.1-2.104cC-389; 111.1 -3.104cC-1 to IM.1- 3.104cC-389; 111.1 -4.104cC-1 to III.1- 4.104cC-389; 111.2.104cC-1 to IN.2.104cC-389). Table 105c Compounds III.1-1, III.1-2, III .1-3, III.1-4 and III.2, in which A is 4-chlorofur-2-yl and B corresponds in each case to one group of one row of Table C (compounds III.1- 1.105cC-1 to III.1- III.1- 3.105cC-1 to 111.1-3.105cC-389; 111.1-4.105cC-1 to 111.1-4.105cC-389; IM.105cC-389; 111.1-2.105cC-1 to 111.1-2.105cC-389; III.1-3.105cC-1 to 111.1-3.105cC-389; .2.105cC-1 to III.2.105cC-389) Table 106c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-chlorofur-2-yl and B are each a group of one row of Table C. (Compounds III.1- 1.106cC-1 to 111.1 -1.106cC-389; 111.1-2.106cC-1 to 111.1-2.106cC-389; III.1- 3.106cC-1 to 111.1-3.106cC-389; 111.1 -4.106cC-1 to 111.1-4.106cC-389; IM.2.106cC-1 to lll.2.106cC-389)

Table 107c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-bromo-fur-2-yl and B are each a group of one line of Table C. (Compounds III.1-1.107cC-1 to III.1-1.107CC-389; II 1.1 -2.107cC-1 to 111.1 -2.107cC-389; III.1-3.107cC-1 to IM.1-3.107 cC-389; II 1.1 -4.107cC-1 to 111.1-4.107cC-389; IM.2.107cC-

1 to III.2.107CC-389) Table 108c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-bromo-fur-2-yl and B are each a group of one line of Table C. corresponds (Compounds III.1- 1.108cC-1 to 111.1 -1.108cC-389; 111.1-2.108cC-1 to IN.1-2.108cC-389; III.1-

3.108cC-1 to 111.1-3.108cC-389; 111.1-4.108cC-1 to 111.1-4.108cC-389; IM.2.108cC-1 to lll.2.108cC-38θ) Table 109c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-bromo-fur-2-yl and B are each a group of one line of Table C. corresponds (compounds III.1-

1.109cC-1 to 111.1-1.109cC-389; 111.1 -2.109cC-1 to 111.1-2.109cC-389; III.1-3.109cC-1 to 111.1-3.109cC-389; 111.1 -4.109cC-1 to 111.1-4.109cC-389; IM.2.109cC-1 to lll.2.109cC-38θ) Table 1 1Oc Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3 , 4-dichloropur-2-yl and B corresponds in each case to one group of one row of Table C (Compounds 111.1-1.1 10cC-1 to 111.1-1.1 10cC-389; 111.1-2.1 1OcC-1 to 111.1-2.1 10cC-389; 111.1-3.1 1OcC-I to IM.1-3.1 10cC-389; III.1-4.11 OcC-1 to 111.1-4.1 10cC-389; 111.2.1 10cC-1 to 111.2.1 10cC-389) Table 1 11 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4,5-dichloropur-2-yl and B is in each case a group of one line of Table C corresponds (Compounds 111.1-1.1 11 cC-1 to 111.1-1.1 11 cC-389; 111.1-2.1 11 cC-1 to 111.1-2.1 11 cC-389; 111.1-3.1 11 cC-1 to 111.1-3.1 11 cC -389; 111.1-4.11 1cC-1 to 111.1-4.1 11 cC-389; 111.2.1 11 cC-1 to 111.2.1 1 1cC-389) Table 1 12c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is thiazol-2-yl and B corresponds in each case to one group of one row of Table C (Compounds III.1- 1.112cC-1 to 111.1-1.1 12cC-389; 111.1-2.1 12cC-1 to III.1-2.1 12cC-389; III.1-3.112cC-1 to 111.1-3.1 12cC-389; 111.1-4.1 12cC-1 to III.1-4.1 12cC- 389; 111.2.112cC-1 to lll.2.1 12cC-389) Table 1 13c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is thiazol-4-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1- 1.113cC-1 to 111.1-1.1 13cC-389; 111.1-2.1 13cC-1 to III.1-2.1 13cC-389; III.1- 3.113cC-1 to 111.1-3.1 13cC-389; 111.1 -4.1 13cC-1 to III.1-4.1 13cC-389; 111.2.113cC-1 to III.2.1 13cC-389)

Table 1 14c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is thiazol-5-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1- 1.114cC-1 to 111.1-1.1 14cC-389; 111.1-2.1 14cC-1 to III.1-2.1 14cC-389; III.1-3.114cC-1 to III.1-3.1 14cC-389 III.1-4.1 14cC-1 to III.1-4.1 14cC-389; 111.2.114cC-

1 to III.2.1 14cC-389) Table 1 15c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is isothiazol-3-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1- 1.115cC-1 to III.1-1.1 15cC-389; III.1-2.1 15cC-1 to III.1-2.1 15cC-389; III.1-

3.115cC-1 to 111.1-3.1 15cC-389; 111.1-4.1 15cC-1 to III.1-4.1 15cC-389; 111.2.115cC-1 to III.2.1 15cC-389) Table 1 16c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is isothiazol-4-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1-

1.116cC-1 to 111.1-1.1 16cC-389; 111.1-2.1 16cC-1 to III.1-2.1 16cC-389; III.1-3.16cC-1 to 111.1-3.1 16cC-389; 111.1-4.1 16cC-1 to III.1-4.1 16cC-389; IN.2.116cC-1 to III.2.1 16cC-389) Table 1 17c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is isothiazole -5-yl and B in each case corresponds to one group of one row of Table C (Compounds III.1- 1.117cC-1 to 111.1-1.1 17cC-389; lll.1-2.1 17cC-1 to III.1-2.1 17cC- 389, III.1- 3.117cC-1 to 111.1-3.1 17cC-389; III.1-4.1 17cC-1 to III.1-4.1 17cC-389; III.2.117cC-1 to III.2.1 17CC-389) Table 1 18c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-chlorothiazol-4-yl and B each represents a group of one line of Table C. (Compounds 111.1-1.1 18cC-1 to III.1-1.1 18cC-389; III.1-2.1 18cC-1 to 111.1-2.1 18cC-389; 111.1-3.1 18cC-1 to IM.1-3.1 18cC-389 ; III.1-4.118cC-1 to 111.1-4.1 18cC-389; 111.2.1 18cC-1 to 111.2.1 18cC-389). Table 1 19c Compounds III.1-1, III.1-2, III.1 -3, III.1-4 and III.2, wherein A is 2-chlorothiazol-5-yl and B corresponds in each case to one group of one row of Table C (Compounds 111.1-1.1 19cC-1 to 111.1-1.1 19cC-389 111.1-2.1 19cC-1 to 111.1-2.1 19cC-389; 111.1-3.1 19cC-1 to IM.1-3.1 19cC-389; III.1-4.119cC-1 to 111.1-4.1 19cC-389; 111.2.1 19cC-1 to 111.2.1 19cC-389) Table 120c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 4-chlorothiazol-5-yl and B are each a group of one row of Table C. corresponds (compounds 111.1-1.12OcC-I to 111.1-1.120cC-389; 111.1 -2.120cC-1 to IM.1-2.120cC-389; III.1-3.120cC-1 to IN.1-3.120cC-389) ; 111.1 -4.120cC-1 to IN.1-4.120cC-389; III.2.120cC-1 to IN.2.120cC-389)

Table 121 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-bromothiazol-4-yl and B are each a group of one line of Table C. (Compounds III.1-1.121 cC-1 to 111.1 -1.121 cC-389; 111.1 -2.121 cC-1 to 111.1-2.121 cC-389; III.1-3.121 cC-1 to 111.1-3.121 cC-389; 111.1 -4,121 cC-1 to 111.1-4,121 cC-389; III.2.121 cC-1 to IN.2.121cC-389) Table 122c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2-bromothiazol-5-yl and B are each a group of one row of Table C. corresponds (compounds 111.1-1.122cC-1 to 111.1-1.122cC-389; 111.1-2.122cC-1 to IN.1-2.122cC-389; III.1-3.122cC-1 to IN.1-3.122cC -389; IN.1-4.122cC-1 to IN.1-4.122cC-389; III.2.122cC-1 to IN.2.122cC-389) Table 123c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 2,4-dichlorothiazol-5-yl and B each represents a group of a line of Table C corresponds (Compounds 111.1-1.123cC-1 to 111.1-1.123cC-389; IN.1-2.123cC-1 to IN.1-2.123cC-389; III.1-3.123cC-1 to IN.1- 3.123cC-389; 111.1 -4.123cC-1 to IN.1-4.123cC-389; lll.2.123cC-1 to IN.2.123cC-389) Table 124c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-chloroisothiazol-4-yl and B corresponds in each case to one group of one row of Table C (Compounds III.1-1.124cC-1 to 111.1-1.124 cC-389; IN.1-2.124cC-1 to IN.1-2.124cC-389; III.1-3.124cC-1 to IN.1-3.124cC-389; IN.1-4.124cC-1 to III.1-4.124cC-389; lll.2.124cC-1 to IM.2.124cC-389) Table 125c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-methylisothiazol-3-yl and B is in each case one group of one row of Table C. (Compounds III.1-1.125cC-1 to 111.1-1.125cC-389; IN.1-2.125cC-1 to IN.1-2.125cC-389; III.1-3.125cC-1 to IN.1- 3.125cC-389; IN.1-4.125cC-1 to IN.1-4.125cC-389; III.2.125cC-1 to IN.2.125cC-389) Table 126c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, wherein A is 3-methylisothiazole

4-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.126cC-1 to 111.1-1.126cC-389; IN.1-2.126cC-1 to IN.1-2.126cC-389) lll.1-3.126cC-1 to IN.1-3.126cC-389; IN.1-4.126cC-1 to IN.1-4.126cC-389; lll.2.126cC-1 to IN.2.126cC-389 ) Table 127c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-methylisothiazol-5-yl and B are each a group of one row of Table C. (Compounds III.1-1.127cC-1 to 111.1-1.127cC-389; IN.1-2.127cC-1 to IN.1-2.127cC-389; III.1-3.127cC-1 to IN.1- 3.127cC-389; IN.1-4.127cC-1 to IN.1-4.127cC-389; lll.2.127cC-1 to IN.2.127cC-389)

Table 128c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and 111.2, wherein A is 4,5-dichloroisothiazol-3-yl and B is in each case one group of one row of Table C. corresponds (Compounds III.1-1.128cC-1 to 111.1-1.128cC-389; 111.1 -2.128cC-1 to lll.1 -2.128cC-389; 111.1 -3.128cC-1 to IN.1 -3.128cC-389 111.1 -4.128cC-1 to III.1 -

4.128cC-389; IN.2.128cC-1 to IN.2.128cC-389) Table 129c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and 111.2, wherein A is 4,5-dimethylisothiazol-3-yl and B is in each case a group of one line of Table C. corresponds (compounds IN.1 -1 .129cC-1 to 111.1 -1 .129cC-389; 111.1 -2.129cC-1 to III.1 -2.129cC-389; 111.1 -3.129cC-1 to IN.1 -3.129cC -389; 111.1 -4.129cC-1 to III.1 - 4.129cC-389; IN.2.129cC-1 to IN.2.129cC-389) Table 130c

Compounds III.1 -1, III.1 -2, III.1-3, III.1 -4 and 111.2, wherein A is 3,5-dimethylisothiazol-4-yl and B is in each case one group of one row of Table C. corresponds (compounds 111.1 -1 .13OcC-I to 111.1 -1 .130cC-389; 111.1 -2.130cC-1 to lll.1 -2.130cC-389; 111.1 -3.130cC-1 to IN.1 -3.130cC-389) ; 111.1 -4.130cC-1 to III.1 - 4.130cC-389; 111.2.130cC-1 to 111.2.130cC-389) Table 131c Compounds III.1 -1, III.1 -2, III.1 -3 , III.1 -4 and III.2, where A is 3,4-

Dichloroisothiazol-5-yl and B in each case corresponds to one group of one row of Table C (Compounds III.1 -1 .131 cC-1 to 111.1 -1 .131 cC-389; 111.1 -2,131 cC-1 to lll.1 -2,131 cC-389; 111.1 -3.13I cC-I to 111.1-3.131 cC-389; 111.1 -4,131 cC-1 to III.1 - 4,131 cC-389; 111.2.131 cC-1 to 111.2.131 cC-389) Table 132c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is oxazol-2-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1-

1.132cC-1 to 111.1-1.132cC-389; 111.1 -2.132cC-1 to 111.1-2.132cC-389; III.1-3.322cC-1 to 111.1-3.132cC-389; 111.1 -4.132cC-1 to 111.1-4.132cC-389; IN.2.132cC-1 to III.2.132cC-389) Table 133c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is oxazole 4-yl and B corresponds in each case to one group of one row of Table C (Compounds III.1- 1.133cC-1 to 111.1 -1.133cC-389; 111.1 -2.133cC-1 to 111.1-2.133cC-389; III.1 - 3.133cC-1 to 111.1-3.133cC-389; 111.1 -4.133cC-1 to 111.1-4.133cC-389; IN.2.133cC-1 to IM.2.133cC-389) Table 134c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is oxazol-5-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1- 1.134cC-1 to 111.1-1.134cC-389; 111.1 -2.134cC-1 to 111.1-2.134cC-389; III.1-3.134cC-1 to 111.1-3.134cC-389; 111.1 -4.134 cC-1 to 111.1-4.134cC-389; IN.2.134cC-1 to III.2.134cC-389)

Table 135c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is isoxazol-3-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1- 1.135cC-1 to 111.1-1.135cC-389; 111.1 -2.135cC-1 to 111.1-2.135cC-389; III.1- 3.135cC-1 to 111.1-3.135cC-389; 111.1 -4.135 cC-1 to 111.1-4.135cC-389; IN.2.135cC-

1 to III.2.135cC-389) Table 136c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is isoxazol-4-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1- 1 .136cC-1 to 111.1 -1 .136cC-389; 111.1 -2.136cC-1 to 111.1 -2.136cC-389; III.1 -

3.136cC-1 to 111.1 -3.136cC-389; 111.1 -4.136cC-1 to 111.1 -4.136cC-389; IN.2.136cC-1 to IM.2.136cC-389) Table 137c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which A is isoxazol-5-yl and B corresponds in each case to one group of one row of Table C ( Compounds III.1-

1.137cC-1 to lll.1-1.137cC-389; 111.1 -2.137cC-1 to 111.1 -2.137cC-389; III.1-3.137cC-1 to 111.1-3.137cC-389; 111.1 -4.137cC-1 to 111.1 -4.137cC-389; IN.2.137cC-1 to III.2.137CC-389) Table 138c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is for 3- Chloroisoxazol-5-yl and B corresponds in each case to one group of one row of Table C (Compounds 111.1-1.138cC-1 to 111.1-1.138cC-389; 111.1 -2.138cC-1 to 111.1-2.138cC-389; III.1-3.138cC-1 to 111.1-3.138cC-389; 111.1 -4.138cC-1 to 111.1-4.138cC-389; III.2.138CC-1 to 111.2.138cC-389)

Table 139c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 5-methylisoxazol-3-yl and B is in each case one group of a row of Table C. corresponds (Compounds 111.1-1.139cC-1 to 111.1-1.139cC-389; 111.1-2.139cC-1 to 111.1-2.139cC-389; III.1-3.139cC-1 to 111.1-3.139cC-389; 111.1 -4.139 cC-1 to 111.1-4.139cC-389; III.2.139cC-1 to IM.2.139cC-389) Table 140c Compounds III.1-1, III.1-2, III.1-3, III.1- 4 and III.2, wherein A is 5-methylisoxazol-4-yl and B corresponds in each case to one group of one row of Table C (Compounds 111.1-1.14OcC-I to 111.1-1.140cC-389; IN.1-2.140cC -1 to IN.1-2.140cC-389; III.1-3.140cC-1 to IN.1-3.140cC-389; IN.1-4.140cC-1 to IN.1-4.140cC-389; III. 2.140cC-1 to IN.2.140cC-389) Table 141c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-methylisoxazol-5-yl and B each represents a group of one line of Table C. (Compounds III.1-1.141 cC-1 to 111.1-1.141 cC-389; 111.1-2.141 cC-1 to 111.1-2.141 cC-389; III.1-3.141 cC-1 to 111.1-3.141 cC-389; 111.1 -4,141 cC-1 to IM.1-4,141 cC-389; lll.2.141 cC-1 to IN.2.141cC-389)

Table 142c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and 111.2, wherein A is 3,5-dimethylisoxazol-4-yl and B is in each case one group of one row of Table C. corresponds (Compounds III.1-1.142cC-1 to 111.1-1.142cC-389; 111.1-2.142cC-1 to lll.1-2.142cC-389; 111.1 -3.142cC-1 to IN.1-3.142cC-389) IN.1-4.142cC-1 to III.1-

4.142cC-389; IN.2.142cC-1 to IN.2.142cC-389) Table 143c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-chloro-5-methylisoxazol-4-yl and B is each a group of one Corresponds to the line of Table C (compounds 111.1-1.143cC-1 to 111.1-1.143cC-389; 111.1 -2.143cC-1 to lll.1-2.143cC-389; 111.1 -3.143cC-1 to IN.1- 3.143cC-389; IN.1-4.143cC-1 to III.1-4143cC-389; IN.2.143cC-1 to IN.2.143cC-389) Table 144c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 3-methyl-4-chloroisoxazol-5-yl and B are each a group of one Row of Table C corresponds (Compounds 111.1-1.144cC-1 to IN.1-1.144cC-389; IN.1-2.144cC-1 to lll.1-2.144cC-389; 111.1-3.144cC-1 to IN. 1-3.144cC-389; IN.1-4.144cC-1 to III.1-4144cC-389; IN.2.144cC-1 to IN.2.144cC-389). Table 145c Compounds III.1-1, III. 1-2, III.1-3, III.1-4 and III.2, wherein A is 1-methylpyrazol-3-yl and B corresponds in each case to one group of one row of Table C (compounds III.1-1.145cC-1) to 111.1-1.145cC-389; 111.1-2.145cC-1 to IN.1-2.145cC-389; III.1-3.145CC-1 to IN.1-3.145cC-389; IN.1-4.145cC-1 to III.1-4.145cC-389; III.2.145CC-1 to IM.2.145cC-389) Table 146c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 1-methylpyrazol-4-yl and B are each a group of one line of Table C. corresponds (Compounds lll.1-1.146cC-1 to 111.1-1.146cC-389; 111.1 -2.146cC-1 to IN.1-2.146cC-389; lll.1-3.146cC-1 to IN.1-3.146cC -389; IN.1-4.146cC-1 to IN.1-4.146cC-389; III.2.146cC-1 to IN.2.146cC-389) Table 147c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 1-methylpyrazol-5-yl and B corresponds in each case to one group of one row of Table C (compounds III.1.1.147cC-1 to 111.1 -1.147cC-389; 111.1 -2.147cC-1 to 111.1 -2.147cC-389; lll.1-3.147cC-1 to IN.1-3.147cC-389; IN.1-4.147cC-1 to IN.1 -4.147cC-389; III.2.147cC-1 to IN.2.147cC-389) Table 148c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and 111.2, wherein A is 1, 3-dimethylpyrazol-4-yl and B are each a group of one row of Table C. corresponds (Compounds III.1-1.148cC-1 to 111.1-1.148cC-389; 111.1 -2.148cC-1 to lll.1-2.148cC-389; 111.1 -3.148cC-1 to IN.1-3.148cC-389 IN.1-4.148cC-1 to III.1-4148cC-389; IN.2.148cC-1 to IN.2.148cC-389)

Table 149c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and 111.2, wherein A is 1, 5-dimethylpyrazol-4-yl and B are each a group of one row of Table C. corresponds (Compounds III.1-1.149cC-1 to 111.1-1.149cC-389; 111.1-2.149cC-1 to lll.1-2.149cC-389; IM .1 -3.149cC-1 to IN.1-3.149cC -389; IN.1-4.149cC-1 to III.1-

4.149cC-389; IN.2.149cC-1 to IN.2.149cC-389) Table 150c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 1, 3,5-trimethylpyrazol-4-yl and B are each a group of one Row of Table C corresponds (compounds 111.1-1.15OcC-I to 111.1-1.150cC-389; 111.1 -2.150cC-1 to lll.1-2.150cC-389; 111.1 -3.150cC-1 to IN.1-3.150cC -389; 111.1 -4.150cC-1 to III.1-4,150cC-389; 111.2.150cC-1 to IN.2.150cC-389). Table 151c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein A is 1-methylimidazol-4-yl and B are each a group of one line of Table C. (Compounds III.1-1.151 cC-1 to 111.1-1.151 cC-389; 111.1-2.151 cC-1 to 111.1-2.151 cC-389; III.1-3.151 cC-1 to 111.1-3.151 cC-389; 111.1 -4,151 cC-1 to 111.1-4,151 cC-389; III.2.151 cC-1 to 111.2.151cC-389) Table 152c Compounds III.1-1, III.1-2, III.1-3, III.1 -4 and 111.2, wherein A is 1, 5

Dimethylimidazol-4-yl and B each corresponds to a group of one row of Table C (Compounds III.1-1.152cC-1 to 111.1-1.152cC-389; 111.1-2.152cC-1 to lll.1-2.152cC-389; 111.1-3.152cC-1 to IM.1-3.152cC-389; II 1.1 -4.152cC-1 to III.1-4152cC-389; IM.2.152cC-1 to IM.2.152cC-389) Table 153c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and 111.2, wherein A is 1, 2-dimethylimidazol-5-yl and B is in each case one group of a row of Table C. corresponds (Compounds III.1-1.153cC-1 to 111.1-1.153cC-389; 111.1-2.153cC-1 to lll.1-2.153cC-389; 111.1 -3.153cC-1 to IN.1-3.153cC-389 111.1 -4.153cC-1 to III.1- 4.153cC-389; 111.2.153cC-1 to 111.2.153cC-389) Table 154c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and 111.2, wherein A is 1, 4-

Dimethylimidazol-5-yl and B corresponds in each case to one group of one row of Table C (Compounds III.1-1.154cC-1 to 111.1-1.154cC-389; 111.1-2.154cC-1 to III.1-2.154cC-389 ; 111.1-3.154cC-1 to IN.1-3.154cC-389; IM.1-4.154cC-1 to III.1-4154cC-389; IN.2.154cC-1 to IN.2.154cC-389) 155c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is pyridin-2-yl and A in each case corresponds to one group of one row of Table C ( Compounds III.1-1555cC-1 to 111.1-1.155cC-389; 111.1 -2.155cC-1 to 111.1-2.155cC-389; III.1-3.155cC-1 to 111.1-3.155cC-389; 111.1-4.155 cC-1 to IM.1-4.155cC-389; IN.2.155cC-1 to III.2.155CC-389)

Table 156c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which B is pyridin-3-yl and A corresponds in each case to one group of one row of Table C ( Compounds III.1- 1.156cC-1 to 111.1-1.156cC-389; 111.1-2.156cC-1 to 111.1-2.156cC-389; III.1-3.156cC-1 to 111.1-3.156cC-389; IM.1 -4.156cC-1 to IM.1-4.156cC-389; IN.2.156cC-

1 to MI.2.156cC-389) Table 157c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which B is pyridin-4-yl and A corresponds in each case to one group of one row of Table C ( Compounds III.1-1557cC-1 to MI.1-1.157cC-389; MI.1 -2.157cC-1 to IM.1-2.157cC-389; III.1-

3.157cC-1 to IM.1-3.157cC-389; MI.1 -4.157cC-1 to IM.1-4.157cC-389; IM.2.157cC-1 to IM.2.157CC-389) Table 158c

Compounds MI.1-1, IM.1-2, IM.1-3, IM.1-4 and III.2, wherein B is 3-chloropyridin-2-yl and A is in each case one group of one row of Table C corresponds (compounds MI.1-1.158cC-1 to MI.1-1.158cC-389; 111.1 -2.158cC-1 to IM.1-2.158cC-389; IM.1-3.158cC-1 to IM.1- 3.158cC-389; MI.1 -4.158cC-1 to IM.1-4.158cC-389; IM.2.158CC-1 to IM.2.158cC-389) Table 159c Compounds MI.1-1, IM.1- 2, IM.1-3, IM.1-4 and III.2, wherein B is 4-chloropyridin-2-yl and A corresponds in each case to one group of a row of Table C (compounds MI.1-1.159cC-1 to MI.1-1.159cC-389; IM.1-2.159cC-1 to IM.1-2.159cC-389; III.1 -3.159cC-1 to 111.1 -3.159cC-389; 111.1 -4.159cC-1 to 111.1 -4.159cC-389; III.2.159CC-1 to 111.2.159cC-389) Table 160c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-chloropyridin-2-yl and A is in each case one group of one row of Table C. corresponds (Compounds 111.1-1.16OcC-I to 111.1 -1.160cC-389; 111.1 -2.160cC-1 to 111.1-2.160cC-389; III.1-3.160cC-1 to 111.1-3.160cC-389; 111.1 -4.160 cC-1 to IN.1-4.160cC-389; III.2.160cC-1 to III.2.160cC-389). Table 161c Compounds III.1-1, III.1-2, III.1-3, III. 1-4 and III.2, wherein B is 6-chloropyridin-2-yl and A corresponds in each case to one group of one row of Table C (Compounds 111.1-1.161 cC-1 to 111.1 -1.161 cC-389; 111.1 -2.161 cC -1 to 111.1-2.161 cC-389; III.1-3.161 cC-1 to IN.1-3.161cC-389; 111.1 -4.161 cC-1 to 111.1-4.161 cC-389; III.2.161 cC-1 to 111.2 .161cC-389) Table 162c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-chloropyridin-3-yl and A is in each case one group of one row of Table C. corresponds (Compounds lll.1-1.162cC-1 to 111.1-1.162cC-389; 111.1 -2.162cC-1 to IN.1-2.162cC-389; lll.1-3.162cC-1 to 111.1-3.162cC-389 111.1 -4.162cC-1 to 111.1-4.162cC-389; III.2.162cC-1 to 111.2.162cC-389)

Table 163c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4-chloropyridin-3-yl and A is in each case one group of one row of Table C. corresponds (Compounds 111.1-1.163cC-1 to 111.1-1.163cC-389; 111.1 -2.163cC-1 to 111.1-2.163cC-389; lll.1 -3.163cC-1 to 111.1 -3.163cC-389; 111.1 -4.163 cC-1 to 111.1 -4.163cC-389; III.2.163cC-1 to IN.2.163cC-389) Table 164c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-chloropyridin-3-yl and A is in each case one group of one row of Table C. corresponds (Compounds 111.1 -1 .164cC-1 to 111.1 -1 .164cC-389; 111.1 -2.164cC-1 to IN.1 -2.164cC-389; III.1 -3.164cC-1 to 111.1 -3.164cC -389; 111.1 -4.164cC-1 to 111.1 -4.164cC-389; III.2.164cC-1 to IN.2.164cC-389) Table 165c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 6-chloropyridin-3-yl and A is in each case one group of one row of Table C. corresponds (Compounds lll.1-1.165cC-1 to 111.1-1.165cC-389; 111.1 -2.165cC-1 to IN.1-2.165cC-389; lll.1-3.165cC-1 to 111.1-3.165cC-389 ; 111.1 -4.165cC-1 to 111.1-4.165cC-389; lll.2.165cC-1 to 111.2.165cC-389) Table 166c Compounds III.1-1, III.1-2, III.1-3, III .1-4 and III.2, in which B is 2-chloropyridin-4-yl and A corresponds in each case to one group of one row of Table C (Compounds 111.1-1.166cC-1 to 111.1 -1.166cC-389; 111.1 -2.166 cC-1 to IN.1-2.166cC-389; III.1 -3.166cC-1 to 111.1 -3.166cC-389; 111.1 -4.166cC-1 to III.1 -4.166cC-389; III.2.166CC-1 to 111.2.166cC-389) Table 167c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3-chloropyridin-4-yl and A is in each case one group of one row of Table C. corresponds (compounds III.1-1.167cC-1 to 111.1-1.167cC-389; 111.1 -2.167cC-1 to 111.1-2.167cC-389; III.1-3.167CC-1 to 111.1-3.167cC-389; II 1.1 -467cC-1 to 111.1 -4.167cC-389; III.2.167CC-1 to 111.2.167cC-389) Table 168c Compounds III.1-1, III.1-2, III.1-3, III. 1-4 and III.2, in which B is 4-chloropyridin-5-yl and A corresponds in each case to one group of one row of Table C (compounds III.1-1.168cC-1 to 111.1 -1.168cC-389; 111.1 - 2.168cC-1 to 111.1-2.168cC-389; III.1-3.168cC-1 to 111.1-3.168cC-389; 111.1 -4.168cC-1 to IN.1-4.168cC-389; III.2.168cC-1 to IN.2.168cC-389) Table 169c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3-fluoropyridin-2-yl and A is in each case one group of a row of Table C. (Compounds 111.1-1.169cC-1 to 111.1-1.169cC-389; 111.1 -2.169cC-1 to 111.1-2.169cC-389; lll.1-3.169cC-1 to 111.1-3.169cC-389; 111.1 -4.169 cC-1 to 111.1-4.169cC-389; lll.2.169cC-1 to 111.2.169cC-389)

Table 17Oc

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4-fluoropyridin-2-yl and A is in each case one group of one row of Table C. (Compounds 111.1-1.17OcC-I to 111.1 -1.170cC-389; 111.1 -2.170cC-1 to 111.1-2.170cC-389; lll.1-3.170cC-1 to 111.1-3.170cC-389; IL 1.1 - 4.170cC-1 to 111.1-4.170cC-389; lll.2.170cC-1 to 111.2.170cC-389). Table 171c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-fluoropyridin-2-yl and A is in each case one group of a row of Table C. corresponds (compounds 111.1-1.171 cC-1 to 111.1-1.171 cC-389; 111.1 -2.171 cC-1 to 111.1-2.171 cC-389; lll.1 -3.171 cC-1 to 111.1 -3.171 cC-389; 1.1 -4.171 cC-1 to 111.1 -4.171 cC-389; III.2.171 cC-1 to 111.2.171 cC-389) Table 172c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 6-fluoropyridin-2-yl and A is in each case one group of a row of Table C. corresponds (Compounds 111.1-1.172cC-1 to 111.1-1.172cC-389; 111.1 -2.172cC-1 to 111.1 -2.172cC-389; III.1-3.172cC-1 to 111.1-3.172cC-389; 111.1 -4.172 cC-1 to 111.1-4.172cC-389; III.2.172cC-1 to IN.2.172cC-389) Table 173c Compounds III.1-1, III.1-2, III.1-3, III.1- 4 and III.2, wherein B is 2-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table C (Compounds 111.1-1.173cC-1 to 111.1-1.173cC-389; 111.1 to -2.173cC-1 to 111.1 -2.173cC-389; III.1-3.173cC-1 to 111.1-3.173cC-389; IM.1 -4.173cC-1 to 111.1 -4.173cC-389; lll.2.173cC-1 to IM.2.173cC-389) Table 174c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4-fluoropyridin-3-yl and A is in each case one group of one line of Table C. corresponds (Compounds lll.1-1.174cC-1 to 111.1-1.174cC-389; 111.1 -2.174cC-1 to 111.1 -2.174cC-389; lll.1-3.174cC-1 to 111.1-3.174cC-389; 111.1 -4.174cC-1 to IM.1-4.174cC-389; lll.2.174cC-1 to IN.2.174cC-389) Table 175c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-fluoropyridin-3-yl and A corresponds in each case to one group of a row of Table C (Compounds III.1-1.175CC-1 to 111.1-1.175cC-389; III.1-3.175CC-1 to 111.1-3.175cC-389; 111.1 -4.175cC-1 to IM.1-4.175cC-389; III.2.175CC -1 to IN.2.175cC-389) Table 176c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 6-fluoropyridin-3-yl and A is in each case one group of a row of Table C. (Compounds MI.1-1.176cC-1 to MI.1-1.176cC-389; MI.1 -2.176cC-1 to IM.1-2.176cC-389; III.1-3.176cC-1 to IM. 1-3.176cC-389, M 1.1 -4.176cC-1 to IM.1 -4.176cC-389, III.2.176cC-1 to 111.2.176cC-389)

Table 177c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-fluoropyridin-4-yl and A is in each case one group of a row of Table C. corresponds (compounds MI.1-1.177cC-1 to MI.1 -1.177cC-389; 111.1 -2.177cC-1 to 111.1 -2.177cC-389; IM.1-3.177CC-1 to 111.1-3.177cC-389 111.1 -4.177cC-1 to IM.1-4.177cC-389;

IM.2.177CC-1 to 111.2.177cC-389) Table 178c

Compounds MI.1-1, IM.1-2, IM.1-3, IM.1-4 and III.2, wherein B is 3-fluoropyridin-4-yl and A is in each case one group of one row of Table C. corresponds (compounds MI.1-1.178cC-1 to MI.1-1.178cC-389, IM.1-2.178cC-1 to IM.1-2.178cC-389;

IM.1-3.178cC-1 to IM.1-3.178cC-389; II 1.1 -4.178cC-1 to 111.1 -4.178cC-389; IM.2.178cC-1 to 111.2.178cC-389) Table 179c

Compounds MI.1-1, IM.1-2, IM.1-3, IM.1-4 and III.2, wherein B is 3-methylpyridin-2-yl and A is in each case one group of one row of Table C (Compounds MI.1-1.179cC-1 to MI.1-1.179cC-389; MI.1 -2.179cC-1 to 111.1 -2.179cC-389; IM.1-3.179cC-1 to IM.1- 3.179cC-389; IM.1 -4.179cC-1 to 111.1 -4.179cC-389; IM.2.179cC-1 to IM.2.179cC-389) Table 180c Compounds MI.1-1, IM.1-2, IM.1-3, IM.1-4 and III.2, wherein B is 4-methylpyridin-2-yl and A corresponds in each case to one group of a row of Table C (compounds MI.1-1.18OcC-I to MI .1 -1.180cC-389; MI.1 -2.180cC-1 to IM.1-2.180cC-389; 111.1 -3.18 OCC-I to 111.1 -3.180cC-389; 111.1 -4.180cC-1 to III.1 -4.180cC-389; lll.2.180cC-1 to 111.2.180cC-389) Table 181 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-methylpyridin-2-yl and A is in each case one group of a row of Table C. (Compounds III.1-1.181 cC-1 to 111.1 -1.181 cC-389; 111.1 -2.181 cC-1 to 111.1-2.181 cC-389; III.1-3.181 cC-1 to 111.1-3.181 cC-389; 111.1 -4,181 cC-1 to 111.1-4,181 cC-389; III.2.181 cC-1 to 111.2.181cC-389). Table 182c Compounds III.1-1, III.1-2, III.1-3, III.1 -4 and III.2, wherein B is 6-methylpyridin-2-yl and A corresponds in each case to one group of a row of Table C (compounds III.1-1.182cC-1 to 111.1-1.182cC-389; 111.1 to 2.182 cC-1 to 111.1-2.182cC-389; III.1-3.182cC-1 to 111.1-3.182cC-389; 111.1 -4.182cC-1 to 111.1-4.182cC-389; III.2.182cC-1 to IN. 2.182cC-389) Table 183c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-methylpyridin-3-yl and A is in each case one group of one line of Table C. (Compounds 111.1-1.183cC-1 to 111.1-1.183cC-389; 111.1 -2.183cC-1 to 111.1-2.183cC-389; III.1-3.183cC-1 to 111.1-3.183cC-389; 111.1 -4.183 cC-1 to 111.1-4.183cC-389; lll.2.183cC-1 to 111.2.183cC-389)

Table 184c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4-methylpyridin-3-yl and A is in each case one group of one line of Table C. (Compounds 111.1-1.184cC-1 to 111.1-1.184cC-389; 111.1 -2.184cC-1 to IN.1-2.184cC-389; III.1 -3.184cC-1 to IN.1 -3.184cC-389 ; 111.1 -4.184cC-1 to 111.1 -4.184cC-389; III.2.184cC-1 to IN.2.184cC-389) Table 185c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-methylpyridin-3-yl and A is in each case one group of one row of Table C. corresponds (compounds IN.1-1.185cC-1 to 111.1-1.185cC-389; 111.1 -2.185cC-1 to IN.1-2.185cC-389; III.1-3.185cC-1 to 111.1-3.185cC -389; 111.1 -4.185cC-1 to 111.1-4.185cC-389; III.2.185cC-1 to IN.2.185cC-389) Table 186c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 6-methylpyridin-3-yl and A is in each case one group of one row of Table C. (Compounds III.1-1.186cC-1 to 111.1 -1.186cC-389; 111.1 -2.186cC-1 to 111.1-2.186cC-389; III.1-3.186cC-1 to 111.1-3.186cC-389; 111.1 -4.186cC-1 to IN.1-4.186cC-389; lll.2.186cC-1 to 111.2.186cC-389) Table 187c Compounds III.1-1, III.1-2, III.1-3, III .1-4 and III.2, wherein B is 2-methylpyridin-4-yl and A corresponds in each case to one group of one row of Table C (compounds III.1-1.187cC-1 to 111.1-1.187cC-389; 111.1 -2.187cC-1 to 111.1-2.187cC-389; III.1-3.187CC-1 to 111.1-3.187cC-389; II 1.1 -4.187cC-1 to 111.1 -4.187cC-389; III.2.187CC-1 to 111.2.187cC-389) Table 188c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3-methylpyridin-4-yl and A is in each case one group of one row of Table C. (Compounds III.1-1.188cC-1 to 111.1 -1.188cC-389; 111.1 -2.188cC-1 to 111.1-2.188cC-389; III.1-3.188cC-1 to 111.1-3.188cC-389; 111.1 III.188cC-1 to IN.1-4.188cC-389; III.2.188CC-1 to 111.2.188cC-389). Table 189c Compounds III.1-1, III.1-2, III.1-3, III .1-4 and III.2, wherein B is 4-methylpyridin-5-yl and A corresponds in each case to one group of one row of Table C (compounds III.1-1.189cC-1 to 111.1-1.189cC-389; 111.1 Lll.1-3.189cC-1 to 111.1-3.189cC-389; 111.1 -4.189cC-1 to 111.1-4.189cC-389; lll.2.189cC-1 to IN.2.189cC-389) Table 190c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3-methoxypyridin-2-yl and A is in each case one group of one row of Table C (Compounds 111.1-1.19 OcC-I to 111.1 -1.190cC-389; 111.1-2.190cC-1 to 111.1-2.190cC-389; III.1-3.190cC-1 to 111.1-3.190cC-389; 111.1 -4.190 cC-1 to 111.1-4.190cC-389; III.2.190CC-1 to 111.2.190cC-389)

Table 191 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4-methoxypyridin-2-yl and A is in each case one group of one line of Table C. (Compounds III.1-1.191 cC-1 to 111.1 -1.191 cC-389; 111.1-2.191 cC-1 to 111.1-2.191 cC-389; III.1-3.191 cC-1 to 111.1 -3.191 cC-389; 111.1 -4,191 cC-1 to 111.1-4,191 cC-389; III.2.191 cC-1 to 111.2.191cC-389) Table 192c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-methoxypyridin-2-yl and A is in each case one group of a row of Table C. corresponds (compound IN.1-1.192cC-1 to 111.1-1.192cC-389; 111.1-2.192cC-1 to 111.1-2.192cC-389; III.1-3.192cC-1 to 111.1-3.192cC-389) ; 111.1 -4.192cC-1 to 111.1-4.192cC-389; III.2.192cC-1 to 111.2.192cC-389) Table 193c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 6-methoxypyridin-2-yl and A is in each case one group of a row of Table C. (Compounds 111.1-1.193cC-1 to 111.1-1.193cC-389; 111.1-2.193cC-1 to 111.1-2.193cC-389; III.1-3.193cC-1 to 111.1-3.193cC-389; 111.1 -4.193 cC-1 to 111.1-4.193cC-389; lll.2.193cC-1 to IM.2.193cC-389) Table 194c Compounds III.1-1, III.1-2, III.1-3, III.1- 4 and III.2, wherein B is 2-methoxypyridin-3-yl and A corresponds in each case to one group of one row of Table C (Compounds 111.1-1.194cC-1 to 111.1-1.194cC-389; 111.1-2.194cC-1 to 111.1-2.194cC-389; III.1-3.194cC-1 to 111.1-3.194cC-389; IN.1-4.194cC-1 to 111.1-4.194cC-389; lll.2.194cC-1 to 111.2.194cC-389) Table 195c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4-methoxypyridin-3-yl and A is in each case one group of one row of Table C. corresponds (Compounds lll.1-1.195cC-1 to 111.1-1.195cC-389; 111.1-2.195cC-1 to 111.1-2.195cC-389; lll.1-3.195cC-1 to 111.1-3.195cC-389; 111.1 -4.195cC-1 to 111.1-4.195cC-389; lll.2.195cC-1 to 111.2.195cC-389) Table 196c Compounds III.1-1, III.1-2, III.1-3, III.1 4 and III.2, in which B is 5-methoxypyridin-3-yl and A corresponds in each case to one group of one row of Table C (Compounds III.1-1.196cC-1 to 111.1 -1.196cC-389; 111.1-2.196cC- 1 to 111.1-2.196cC-389; III.1-3.196cC-1 to 111.1-3.196cC-389; 111.1 -4.196cC-1 to 111.1-4.196cC-389; III.2.196cC-1 to IN.2.196cC -389) Table 197c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 6-methoxypyridin-3-yl and A is in each case one group of one row of Table C. corresponds (Compounds lll.1-1.197cC-1 to 111.1-1.197cC-389; 111.1-2.197cC-1 to 111.1 -2.197cC-389; III.1-3.197CC-1 to 111.1-3.197cC-389; IM .1 -4.197cC-1 to 111.1 -4.197cC-389; lll.2.197cC-1 to IN.2.197cC-389)

Table 198c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-methoxypyridin-4-yl and A is in each case one group of a row of Table C. (Compounds 111.1-1.198cC-1 to 111.1 -1.198cC-389; 111.1-2.198cC-1 to 111.1-2.198cC-389; III.1-3.198cC-1 to 111.1-3.198cC-389; 111.1 -4.198 cC-1 to 111.1-4.198cC-389; III.2.198cC-1 to IN.2.198cC-389) Table 199c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3-methoxypyridin-4-yl and A is in each case one group of one row of Table C (Compound 111.1-1.199cC-1 to 111.1-1.199cC-389; 111.1-2.199cC-1 to 111.1-2.199cC-389; lll.1-3.199cC-1 to 111.1-3.199cC-389; 111.1 -4.199cC-1 to 111.1-4.199cC-389; lll.2.199cC-1 to 111.2.199cC-389) Table 200c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3,5-dichloropyridin-2-yl and A is in each case a group of a line of Table C corresponds to (Compounds III.1-1.20OcC-I to 111.1-1.200cC-389; IN.1-2.200cC-1 to IN.1-2.200cC-389; III.1-3.200cC-1 to IN. 1-3.200cC-389; IN.1-4.200cC-1 to IN.1-4.200cC-389; lll.2.200cC-1 to IN.2.200cC-389) Table 201c Compounds III.1-1, III .1-2, III.1-3, III.1-4 and III.2, wherein B is 2,4-dichloropyridin-3-yl and A in each case corresponds to one group of one row of Table C (Compounds III.1 -1.201 CC-1 to 111.1-1.201 cC-389; 111.1-2.201 cC-1 to IN.1-2.201 cC-389; lll.1-3.201 cC-1 to 111.1-3.201 cC-389; 111.1 -4.201 cC-1 to lll.1-4.201 cC-389; lll.2.201 cC-1 to IM.2.201cC-389) Table 202c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,5-dichloropyridin-3-yl and A is in each case a group of a line of Table C corresponds (Compounds III.1-1.202cC-1 to 111.1-1.202cC-389; IN.1-2.202cC-1 to IM.1-2.202cC-389; III.1-3.202cC-1 to IN. 1-3.202cC-389; IN.1-4.202cC-1 to IN.1-4.202cC-389; lll.2.202cC-1 to IN.2.202cC-389) Table 203c Compounds III.1-1, III. 1-2, III.1-3, III.1-4 and III.2, in which B is 2,6-dichloropyridin-3-yl and A corresponds in each case to one group of one row of Table C (compounds III.1- 1.203cC-1 to 111.1-1.203cC-389; IM.1-2.203cC-1 to IN.1-2.203cC-389; lll.1-3.203cC-1 to IN.1-3.203cC-389; IN. 1-4.203cC-1 to IN.1-4.203cC-389; lll.2.203cC-1 to IM.2.203cC-389) Table 204c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,6-dichloropyridin-4-yl and A is in each case a group of a line of Table C corresponds to (Compounds III.1-1.204cC-1 to 111.1-1.204cC-389; IN.1-2.204cC-1 to IN.1-2.204cC-389; III.1-3.204cC-1 to IN. 1-3.204cC-389; IN.1-4.204cC-1 to IN.1-4.204cC-389; lll.2.204cC-1 to IM.2.204cC-389)

Table 205c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3,5-dichloropyridin-4-yl and A is in each case a group of a line of Table C corresponds to (Compounds III.1-1.205cC-1 to 111.1-1.205cC-389; IN.1-2.205cC-1 to IN.1-2.205cC-389; III.1-3.205cC-1 to IN. 1-3.205cC-389; IN.1-4.205cC-1 to IN.1-4.205cC-389; lll.2.205cC-1 to IN.2.205cC-389) Table 206c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3,6-dichloropyridin-4-yl and A is in each case a group of a line of Table C corresponds to (compound IM.1-1.206cC-1 to 111.1-1.206cC-389; IM.1-2.206cC-1 to IN.1-2.206cC-389; III.1-3.206cC-1 to IN.1-3.206cC-389, IN.1-4.206cC-1 to IN.1-4.206cC-389, III.2.206cC-1 to IN.2.206cC-389) Table 207c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,5-dichloropyridin-4-yl and A is in each case a group of a line of Table C corresponds to (Compounds III.1-1.207cC-1 to 111.1-1.207cC-389; IM.1-2.207cC-1 to IN.1-2.207cC-389; III.1-3.207cC-1 to IN. 1-3.207cC-389; 111.1 -4.207cC-1 to IN.1-4.207cC-389; lll.2.207cC-1 to IM.2.207cC-389) Table 208c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, wherein B is 2,3-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table C (compounds III.1-1.208cC -1 to 111.1-1.208cC-389; IN.1-2.208cC-1 to IM.1-2.208cC-389; III.1-3.208cC-1 to IN.1-3.208cC-389; IN.1-4.208cC-1 to III.1-4.208cC-389; III.2.208CC-1 to IM.2.208cC-389) Table 209c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,4-dichloropyridin-5-yl and A is in each case a group of a line of Table C corresponds to (Compounds III.1-1.209cC-1 to 111.1-1.209cC-389; IM.1-2.209cC-1 to IM.1-2.209cC-389; III.1-3.209cC-1 to IN. 1-3.209cC-389; IN.1-4.209cC-1 to IN.1-4.209cC-389; III.2.209CC-1 to IM.2.209cC-389) Table 210c Compounds III.1-1, III. 1-2, III.1-3, III.1-4 and III.2, wherein B is 3,5-difluoropyridin-2-yl and A in each case corresponds to one group of one row of Table C (compounds III.1- 1.21OcC-I to 111.1-1.210cC-389; 111.1-2.21 OcC-1 to IM.1-2.210cC-389; lll.1-3.210cC-1 to IN.1-3.210cC-389; 111.1 -4.21 OcC -1 to IN.1-4.210cC-389; III.2.210cC-1 to IM.2.210cC-389) Table 211c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3,5-difluoropyridin-4-yl and A is in each case a group of a line of Table C corresponds to (Compounds 111.1-1.21 I cC-I to IM.1-1.211 cC-389, III.1-2.21 1 cC-1 to 111.1-2.211 cC-389, III.1-3.211 cC-1 to 111.1- 3.211 cC-389, III.1-4.21 1cC-1 to 111.1-4.211 cC-389, lll.2.211 cC-1 to 111.2.21 1 cC-389)

Table 212c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,3-difluoropyridin-4-yl and A is each a group of a line of Table C corresponds (Compounds 111.1-1.212cC-1 to 111.1-1.212cC-389; 111.1-2.212cC-1 to IM.1-2.212cC-389; III.1-3.212cC-1 to IN.1-3.212cC II-4-212cC-1 to IN.1-4.212cC-389; III.2.212cC-1 to IM.2.212cC-389) Table 213c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3,5-dimethylpyridin-2-yl and A is in each case a group of a line of Table C corresponds to (compound 111.1-1.213cC-1 to 111.1-1.213cC-389; 111.1-2.213cC-1 to IM.1-2.213cC-389; III.1-3.213cC-1 to IN.1- 3.213cC-389; 111.1 -4.213cC-1 to IN.1-4.213cC-389; III.2.213cC-1 to IN.2.213cC-389) Table 214c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3,4-dimethylpyridin-2-yl and A is in each case a group of a line of Table C corresponds (Compounds 111.1-1.214cC-1 to 111.1-1.214cC-389; 111.1-2.214cC-1 to IN.1-2.214cC-389; III.1-3.214cC-1 to IN.1-3.214cC -389; IN.1-4.214cC-1 to IN.1-4.214cC-389; III.2.214cC-1 to IN.2.214cC-389) Table 215c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4,6-dimethylpyridine

3-yl and A corresponds in each case to one group of one row of Table C (Compounds 111.1-1.215cC-1 to 111.1-1.215cC-389; 111.1-2.215cC-1 to IN.1-2.215cC-389; III.1-3.215CC-1 to IN.1-3.215cC-389; 111.1-4.215cC-1 to lll.1-4.215cC-389; III.2.215CC-1 to IM.2.215cC-389) Table 216c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,4-dimethylpyridin-3-yl and A is in each case a group of a line of Table C corresponds to (Compounds III.1-1.216cC-1 to 111.1-1.216cC-389; 111.1-2.216cC-1 to IN.1-2.216cC-389; III.1-3.216cC-1 to IN.1- 3.216cC-389; 111.1 -4.216cC-1 to IN.1-4.216cC-389; III.2.216cC-1 to IN.2.216cC-389) Table 217c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3,5-dimethylpyridine

4-yl and A in each case corresponds to one group of a row of Table C (compounds III.1-1.217cC-1 to 111.1-1.217cC-389; 111.1-2.217cC-1 to IM.1-2.217cC-389; III .1-3.217CC-1 to IN.1-3.217cC-389; 111.1 -4.217cC-1 to IN.1-4.217cC-389; III.2.217cC-1 to IN.2.217cC-389) Table 218c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-chloro-3-fluoropyridin-4-yl and A is each a group of one Row of Table C corresponds (Compounds 111.1-1.218cC-1 to 111.1-1.218cC-389; 111.1 -2.218cC-1 to lll.1-2.218cC-389; 111.1-3.218cC-1 to 111.1-3.218cC-389 111.1 -4.218cC-1 to III.1-4.218cC-389; 111.2.218cC-1 to IN.2.218cC-389)

Table 219c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4-chloro-3-methylpyridin-2-yl and A is each a group of one Row of Table C corresponds (Compounds 111.1-1.219cC-1 to 111.1-1.219cC-389; 111.1 -2.219cC-1 to lll.1-2.219cC-389; IM .1 -3.219cC-1 to 111.1-3.219cC -389; 111.1 -4.219cC-1 to III.1-

4.219cC-389; 111.2.219cC-1 to IN.2.219cC-389) Table 220c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-chloro-3-methylpyridin-2-yl and A is each a group of one Corresponding to the line of Table C (Compounds III.1-1.22OcC-I to 111.1-1.220cC-389; IN.1-2.220cC-1 to lll.1-2.220cC-389; IN.1-3.220cC- 1 to IN.1-3.220cC-389; IN.1-4.220cC-1 to III.1-4.220cC-389; IN.2.220cC-1 to IN.2.220cC-389). Table 221c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-fluoro-3-methylpyridin-2-yl and A is each a group of one Row of Table C corresponds (Compounds 111.1-1.221 cC-1 to 111.1-1.221 cC-389; 111.1-2.221 cC-1 to lll.1-2.221 cC-389; 111.1-3.221 cC-1 to IN.1-3.221cC -389; 111.1-4.221 cC-1 to III.1- 4.221 cC-389; 111.2.221 cC-1 to IN.2.221 cC-389) Table 222c Compounds III.1-1, III.1-2, III. 1-3, III.1-4 and III.2, wherein B is 3-chloro-5-trifluoromethylpyridin-2-yl and A in each case corresponds to one group of one row of Table C (Compounds III.1-1.222cC-1 to 111.1 -1.222cC-389; IN.1-2.222cC-1 to lll.1-2.222cC-389; IM.1-3.222cC-1 to IM.1-3.222cC-389; 111.1 -4.222cC-1 to III.1- 4.222cC-389; IM.2.222cC-1 to IM.2.222cC-389) Table 223c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-chloro-6-trifluoromethylpyridin-3-yl and A is each a group of one Line of Table C corresponds (compounds 111.1-1.223cC-1 to 111.1-1.223cC-389; IN.1-2.223cC-1 to lll.1-2.223cC-389; 111.1 -3.223cC-1 to IN.1- 3.223cC-389; IN.1-4.223cC-1 to III.1- 4.223cC-389; IN.2.223cC-1 to IN.2.223cC-389) Table 224c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, wherein B is 2,4-dichloro-6-methylpyridin-3-yl and A in each case corresponds to one group of one row of Table C (compounds III.1- IN.1-2.224cC-1 to III.1-2.224cC-389; IN.1-3.224cC-1 to IN.1-3.224cC-389; IN. 1-4.224cC-1 to III.1-4,224cC-389; IN.2.224cC-1 to IN.2.224cC-389) Table 225c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3,4,5-trichloropyridin-2-yl and A is each a group of one Row of Table C corresponds (Compounds 111.1-1.225cC-1 to 111.1-1.225cC-389; IN.1-2.225cC-1 to III.1-2.225CC-389; IN.1-3.225cC-1 to IN. 1-3.225cC-389; IN.1-4.225cC-1 to III.1-4.225cC-389; IN.2.225cC-1 to IN.2.225cC-389)

Table 226c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,4,6-trichloropyridin-3-yl and A is each a group of one Line of Table C corresponds (compounds 111.1-1.226cC-1 to 111.1-1.226cC-389; IN.1-2.226cC-1 to lll.1-2.226cC-389; 111.1 -3.226cC-1 to IN.1- 3.226cC-389; 111.1 -4.226cC-1 to III.1-

4.226cC-389; IN.2.226cC-1 to IN.2.226cC-389) Table 227c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is pyrimidin-2-yl and A in each case corresponds to one group of one row of Table C ( Compounds III.1- 1.227cC-1 to 111.1-1.227cC-389; 111.1 -2.227cC-1 to IN.1-2.227cC-389; III.1-

3.227cC-1 to IN.1-3.227cC-389; 111.1 -4.227cC-1 to IN.1-4.227cC-389; IN.2.227cC-1 to III.2.227CC-389) Table 228c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is pyrimidin-5-yl and A in each case corresponds to one group of one line of Table C ( Compounds III.1-

1.228cC-1 to 111.1-1.228cC-389; IN.1-2.228cC-1 to IN.1-2.228cC-389; III.1-3.228cC-1 to IN.1-3.228cC-389; IN.1-4.228cC-1 to IN.1-4.228cC-389; IN.2.228cC-1 to III.2.228CC-389) Table 229c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is for 6- Chloropyrimidin-3-yl and A corresponds in each case to one group of one row of Table C (compounds III.1-1.229cC-1 to 111.1-1.229cC-389; IN.1-2.229cC-1 to IN.1-2.229cC -389; III.1-3.229cC-1 to IN.1-3.229cC-389; IN.1-4.229cC-1 to III.1-4.229cC-389; lll.2.229cC-1 to IM.2.229cC-389) Table 230c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 6-methylpyrimidin-3-yl and A is in each case one group of one row of Table C. (Compounds III.1-1.23OcC-I to 111.1-1.230cC-389; IM.1-2.230cC-1 to IM.1-2.230cC-389; III.1-3.230cC-1 to IN.1- 3.230cC-389; IN.1-4.230cC-1 to IN.1-4.230cC-389; lll.2.230cC-1 to IN.2.230cC-389) Table 231c Compounds III.1-1, III.1 -2, III.1-3, III.1-4 and III.2, wherein B is 6-methoxypyrimidine

3-yl and A in each case corresponds to one group of one row of Table C (compounds III.1-1.231 cC-1 to 111.1-1.231 cC-389; 111.1-2.231 cC-1 to 111.1-2.231 cC-389; -3,231 cC-1 to 111.1-3,231 cC-389; 111.1 -4,231 cC-1 to 111.1-4,231 cC-389; III.2,231 cC-1 to IN.2,231cC-389) Table 232c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,4-dichloropyrimidin-3-yl and A is in each case a group of a line of Table C corresponds (Compounds 111.1-1.232cC-1 to 111.1-1.232cC-389; IN.1-2.232cC-1 to lll.1-2.232cC-389; 111.1 -3.232cC-1 to IN.1-3.232cC -389; IN.1-4.232cC-1 to III.1-4.232cC-389; IN.2.232cC-1 to IN.2.232cC-389)

Table 233c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,6-dichloropyrimidin-3-yl and A is in each case a group of a line of Table C corresponds (Compounds 111.1-1.233cC-1 to 111.1-1.233cC-389; 111.1 -2.233cC-1 to lll.1-2.233cC-389; 111.1-3.233cC-1 to IN.1-3.233cC-389 111.1 -4.233cC-1 to III.1-

4.233cC-389; IN.2.233cC-1 to IN.2.233cC-389) Table 234c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,4-difluoropyrimidin-3-yl and A is in each case a group of a line of Table C corresponds to (Compound 111.1-1.234cC-1 to 111.1-1.234cC-389; IN.1-2.234cC-1 to IN.1-2.234cC-389; III.1-3.234cC-1 to IN. 1-3.234cC-389, IN.1-4.234cC-1 to IN.1-4.234cC-389, III.2.234cC-1 to IN.2.234cC-389) Table 235c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,6-difluoropyrimidin-3-yl and A is in each case a group of a line of Table C corresponds (Compounds III.1-1.235cC-1 to 111.1-1.235cC-389; IN.1-2.235cC-1 to IN.1-2.235cC-389; III.1-3.235cC-1 to IN. 1-3.235cC-389; IN.1-4.235cC-1 to IN.1-4.235cC-389; III.2.235CC-1 to IN.2.235cC-389). Table 236c Compounds III.1-1, III. 1-2, III.1-3, III.1-4 and III.2, wherein B is 1, 3,5-triazin-2-yl and A in each case corresponds to one group of a row of Table C (compounds III. 1-1.236cC-1 to 111.1-1.236cC-389; IN.1-2.236cC-1 to IN.1-2.236cC-389; III.1-3.236cC-1 to IN.1-3.236cC-389; IN.1-4.236cC-1 to III.1-4.236cC-389; III.2.236CC-1 to IM.2.236cC-389) Table 237c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which B is thien-2-yl and A corresponds in each case to one group of one row of Table C ( Compounds III.1-

1.237cC-1 to 111.1 to 1.237cC-389; 111.1 -2.237cC-1 to IN.1-2.237cC-389; III.1-3.237cC-1 to IN.1-3.237cC-389; 111.1 -4.237cC-1 to IN.1-4.237cC-389; IN.2.237cC-1 to III.2.237CC-389) Table 238c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is for thienes 3-yl stands and

A corresponds in each case to one group of one row of Table C (Compounds III.1- 1.238cC-1 to 111.1-1.238cC-389; IM.1-2.238cC-1 to IM.1-2.238cC-389; III.1- 3.238cC-1 to IM.1-3.238cC-389; IN.1-4.238cC-1 to IN.1-4.238cC-389; IM.2.238cC-1 to lll.2.238cC-389) Table 239c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-chlorothien-2-yl and A is in each case one group of a row of Table C. corresponds (Compounds lll.1-1.239cC-1 to 111.1-1.239cC-389; 111.1 -2.239cC-1 to IM.1-2.239cC-389; lll.1-3.239cC-1 to IN.1-3.239cC -389; 111.1 -4.239cC-1 to IN.1-4.239cC-389; III.2.239CC-1 to IM.2.239cC-389)

Table 240c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-chlorothien-3-yl and A is in each case one group of a row of Table C. (Compounds III.1-1.24OcC-I to 111.1-1.240cC-389; IM.1-2.240cC-1 to IM.1-2.240cC-389; lll.1-3.240cC-1 to IN.1- 3.240cC-389; 111.1 -4.240cC-1 to IN.1-4.240cC-389; III.2.240cC-1 to IM.2.240cC-389) Table 241c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4-chlorothien-3-yl and A is in each case one group of a row of Table C. corresponds (compounds MI.1 -1 .241 cC-1 to 111.1 -1 .241 cC-389; 111.1 -2,241 cC-1 to 111.1 -2,241 cC-389; lll.1 -3,241 cC-1 to 111.1) 3,241 cC-389, IM.1 -4,241 cC-1 to 111.1 -4,241 cC-389, III.2.241 cC-1 to IM.2.241 cC-389) Table 242c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-chlorothien-3-yl and A is in each case one group of a row of Table C. corresponds (Compounds lll.1-1.242cC-1 to 111.1-1.242cC-389; 111.1 -2.242C-1 to IM.1-2.242cC-389; III.1-3.242cC-1 to IM.1-3.242cC -389; IN.1-4.242cC-1 to IN.1-4.242cC-389; IM.2.242cC-1 to III.2.242CC-389) Table 243c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-bromothien-3-yl and A in each case corresponds to one group of a row of Table C (compounds III.1-1.243cC-1 to 111.1-1.243 cC-389; IM.1-2.243cC-1 to IM.1-2.243cC-389; III.1-3.243cC-1 to IN.1-3.243cC-389; IN.1-4.243cC-1 to III.1-4.243cC-389; lll.2.243cC-1 to IM.2.243cC-389) Table 244c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4-bromothien-3-yl and A is in each case one group of a row of Table C. (Compounds III.1-1.244cC-1 to 111.1-1.244cC-389; IM.1-2.244cC-1 to IM.1-2.244cC-389; III.1-3.244cC-1 to IN.1- 3.244cC-389; IN.1-4.244cC-1 to IN.1-4.244cC-389; lll.2.244cC-1 to IM.2.244cC-389) Table 245c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, wherein B is 5-bromothien-3-yl and A in each case corresponds to one group of one row of Table C (Compounds III.1-1.245CC-1 to III.1-3.245CC-1 to IN.1-3.245cC-389; IN.1-4.245cC -1 to IN.1-4.245cC-389; III.2.245CC-1 to IM.2.245cC-389) Table 246c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-methylthien-2-yl and A is in each case one group of a row of Table C. (Compounds III.1-1.246cC-1 to 111.1-1.246cC-389; IM.1-2.246cC-1 to IM.1-2.246cC-389; III.1-3.246cC-1 to IN.1- 3.246cC-389; IN.1-4.246cC-1 to IN.1-4.246cC-389; lll.2.246cC-1 to IM.2.246cC-389)

Table 247c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-methylthien-4-yl and A is in each case one group of one row of Table C. corresponds (compounds III.1-1.247cC-1 to 111.1-1.247cC-389; 111.1 -2.247cC-1 to IM.1-2.247cC-389; III.1-3.247CC-1 to IN.1-3.247cC -389; 111.1 -4.247cC-1 to IN.1-4.247cC-389;

III.2.257CC-1 to IM.2.247cC-389) Table 248c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4,5-dichlorothien-2-yl and A is in each case a group of a line of Table C corresponds to (Compounds MI.1-1.248cC-1 to 111.1-1.248cC-389, IM.1-2.248cC-1 to IM.1-2.248cC-389, III.1-3.248cC-1 to IN.1-3.248cC-389; IN.1-4.248cC-1 to IN.1-4.248cC-389; III.2.248cC-1 to IM.2.28cC-389) Table 249c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and I II.2, wherein B is 2,5-dichlorothien-3-yl and A is each a group of one line Table C (Compounds 111.1-1.249cC-1 to 111.1-1.249cC-389, IM.1-2.249cC-1 to IM.1-2.249cC-389, III.1-3.249cC-1 to IN.1 -3.249cC-389; IN.1-4.249cC-1 to IN.1-4.249cC-389; III.2.249cC-1 to IM.2.249cC-389) Table 250c Compounds III.1-1, III.1 -2, III.1-3, III.1-4 and III.2, wherein B is 2,3-dichlorothien-4-yl and A corresponds in each case to one group of one row of Table C (Compounds III.1-1.25 OcC-I to 111.1-1.250cC-389; IM.1-2.250cC-1 to IM.1-2.250cC-389; III.1-3.250cC-1 to IN.1-3.250cC-389; IN.1-4.250cC-1 to III.1-4.250cC-389; III.2.250CC-1 to IM.2.250cC-389) Table 251 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,5-dibromothien-3-yl and A is each a group of a line of Table C corresponds to (compounds III.1-1.251CC-1 to 111.1-1.251CC-389; 111.1-2.251CC-1 to 111.1-2.251CC-389; III.1-3.251CC-1 to 111.1-3.251CC-389 IN.1-4.251cC-1 to 111.1-4.251 cC-389; III.2.251 cC-1 to IN.2.251cC-389) Table 252c Compounds III.1-1, III.1-2, III.1- 3, III.1-4 and III.2, wherein B is 4,5-dimethylthien-2-yl and A in each case corresponds to one group of a row of Table C (compounds III.1-1.252cC-1 to 111.1-1.252 cC-389; IM.1-2.252cC-1 to IM.1-2.252cC-389; III.1-3.252cC-1 to IN.1-3.252cC-389; IN.1-4.252cC-1 to IN .1-4.252cC-389; III.2.252cC-1 to IM.2.252cC-389) Table 253c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,5-dimethylthien-3-yl and A is in each case a group of a line of Table C corresponds (Compounds III.1-1.253cC-1 to 111.1-1.253cC-389; IM.1-2.253cC-1 to IM.1-2.253cC-389; III.1-3.253cC-1 to IN. 1-3.253cC-389; IN.1-4.253cC-1 to IN.1-4.253cC-389; III.2.253CC-1 to IM.2.253cC-389)

Table 254c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,3-dimethylthien-4-yl and A is in each case a group of a line of Table C corresponds to (compounds III.1-1.254cC-1 to 111.1-1.254cC-389; IM.1-2.254cC-1 to IM.1-2.254cC-389; III.1-3.254cC-1 to IN. 1-3.254cC-389; 111.1 -4.254cC-1 to IN.1-4.254cC-389; III.2.254cC-1 to IM.2.254cC-389) Table 255c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3,4,5-trichlorothien-2-yl and A is each a group of one Row of Table C corresponds (compound IM.1-1.255cC-1 to 111.1-1.255cC-389; IM.1-2.255cC-1 to IM.1-2.255cC-389;

III.1-3.255CC-1 to IN.1-3.255cC-389; IN.1-4.255cC-1 to IN.1-4.255cC-389; III.2.255CC-1 to IM.2.255cC-389) Table 256c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,4,5-trichlorothien-3-yl and A is each a group of one Row of Table C corresponds (compounds III.1-1.256cC-1 to 111.1-1.256cC-389; IM.1-2.256cC-1 to IM.1-2.256cC-389; III.1-3.256CC-1 to IN.1-3.256cC-389; IN.1-4.256cC-1 to IN.1-4.256cC-389; III.2.256CC-1 to IM.2.256cC-389) Table 257c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,4,5-tribromothienium

3-yl and A corresponds in each case to one group of one row of Table C (compounds III.1-1.257cC-1 to 111.1-1.257cC-389; IM.1-2.257cC-1 to IM.1-2.257cC-389) ; III.1-3.257CC-1 to IN.1-3.257cC-389; 111.1 -4.257cC-1 to lll.1-4.257cC-389; III.2.257CC-1 to IM.2.257cC-389) Table 258c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3,4,5-trimethylthien-2-yl and A is each a group of one Line of Table C corresponds (compounds 111.1-1.258cC-1 to 111.1-1.258cC-389; IN.1-2.258cC-1 to lll.1-2.258cC-389; 111.1 -3.258cC-1 to IM.1- 3.258cC-389; IN.1-4.258cC-1 to III.1- 4.258cC-389; IM.2.258cC-1 to IM.2.258cC-389) Table 259c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, wherein B is 4-chlorofur-2-yl and A in each case corresponds to one group of one row of Table C (Compounds III.1- 1.259cC-1 to 111.1-1.259cC-389; IN.1-2.259cC-1 to IN.1-2.259cC-389; III.1-3.259cC-1 to IN.1-3.259cC-389; IN.1-4.259cC -1 to IN.1-4.259cC-389; IN.2.259cC-1 to III.2.259cC-389) Table 260c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-chlorofur-2-yl and A is in each case one group of a row of Table C. corresponds (compounds III.1- 1.26OcC-I to 111.1-1.260cC-389; IM.1-2.260cC-1 to IN.1-2.260cC-389; III.1-3.260cC-1 to IN.1- 3.260cC-389; IN.1-4.260cC-1 to IN.1-4.260cC-389; IM.2.260cC-1 to III.2.260CC-389)

Table 261 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3-bromo-fur-2-yl and A is in each case one group of one row of Table C. corresponds (Compounds III.1- 1.261 cC-1 to 111.1-1.261 cC-389; 111.1-2.261 cC-1 to IN.1-2.261 cC-389; III.1-3.261 cC-1 to 111.1-3.261 cC-389 111.1-4.261 cC-1 to 111.1-4.261 cC-389; IN.2.261cC-

1 to IM.2.261 cC-389) Table 262c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4-bromo-fur-2-yl and A is in each case one group of one row of Table C. corresponds (Compounds III.1- 1.262cC-1 to 111.1-1.262cC-389; IN.1-2.262cC-1 to IN.1-2.262cC-389; III.1-

3.262cC-1 to IN.1-3.262cC-389; IN.1-4.262cC-1 to IN.1-4.262cC-389; IN.2.262cC-1 to III.2.262cC-389) Table 263c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-bromo-fur-2-yl and A is in each case one group of one row of Table C. corresponds (compounds III.1-

1.263cC-1 to 111.1-1.263cC-389; IN.1-2.263cC-1 to IN.1-2.263cC-389; III.1- 3.263cC-1 to IN.1-3.263cC-389; IN.1-4.263cC-1 to IN.1-4.263cC-389; IN.2.263cC-1 to III.2.263cC-389) Table 264c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3, 4-dichloropur-2-yl and A in each case corresponds to one group of one row of Table C (compounds III.1-1.264cC-1 to 111.1-1.264cC-389; IN.1-2.264cC-1 to IN.1- 2.264cC-389; III.1-3.264cC-1 to IN.1-3.264cC-389; IN.1-4.264cC-1 to III.1-4.264cC-389; lll.2.264cC-1 to IM.2.264cC-389) Table 265c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4,5-dichloropur-2-yl and A is in each case a group of a line of Table C corresponds (Compounds III.1-1.265CC-1 to 111.1-1.265cC-389; IM.1-2.265cC-1 to IM.1-2.265cC-389; III.1-3.265CC-1 to IN. 1-3.265cC-389; IN.1-4.265cC-1 to IN.1-4.265cC-389; III.2.265CC-1 to IM.2.265cC-389). Table 266c Compounds III.1-1, III. 1-2, III.1-3, III.1-4 and III.2, wherein B is thiazol-2-yl and A in each case corresponds to one group of one row of Table C (Compounds III.1- 1.266cC-1 to III.1-3.266cC-1 to IM.1-3.266cC-389; IN.1-4.266cC -1 to IN.1-4.266cC-389; IM.2.266cC-1 to III.2.266cC-389) Table 267c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which B is thiazol-4-yl and A corresponds in each case to one group of one row of Table C ( Compounds III.1- 1.267cC-1 to 111.1-1.267cC-389; 111.1 -2.267cC-1 to IM.1-2.267cC-389; III.1- 3.267cC-1 to IM.1-3.267cC-389 ; 111.1 -4.267cC-1 to IN.1-4.267cC-389; IM.2.267cC-1 to III.2.267CC-389)

Table 268c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, in which B is thiazol-5-yl and A in each case corresponds to one group of one row of Table C ( Compounds III.1- 1.268cC-1 to 111.1-1.268cC-389; IM.1-2.268cC-1 to IM.1-2.268cC-389; III.1- 3.268cC-1 to IM.1-3.268cC -389; IN.1-4.268cC-1 to IN.1-4.268cC-389; IM.2.268cC-

1 to III.2.268cC-389) Table 269c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is isothiazol-3-yl and A in each case corresponds to one group of one row of Table C ( Compounds III.1- 1.269cC-1 to 111.1-1.269cC-389; IM.1-2.269cC-1 to IM.1-2.269cC-389; III.1-

3.269cC-1 to IM.1-3.269cC-389; IN.1-4.269cC-1 to IN.1-4.269cC-389; IM.2.269cC-1 to III.2.269cC-389) Table 270c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is isothiazol-4-yl and A in each case corresponds to one group of one row of Table C ( Compounds III.1-

1.27OcC-I to lll.1-1.270cC-389; 111.1 -2.270cC-1 to IM.1-2.270cC-389; III.1-3.270cC-1 to IM.1-3.270cC-389; 111.1 -4.270cC-1 to IN.1-4.270cC-389; IM.2.270cC-1 to III.2.270CC-389) Table 271c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is isothiazole -5-yl and A in each case corresponds to one group of one row of Table C (Compounds III.1- 1.271 cC-1 to lll.1-1.271 cC-389; 111.1-2.271 cC-1 to 111.1-2.271 cC-389; III.1- 3,271 cC-1 to 111.1-3,271 cC-389; 111.1 -4,271 cC-1 to 111.1-4,271 cC-389; IM.2.271cC-1 to III.2.271 cC-389) Table 272c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-chlorothiazol-4-yl and A is in each case one group of one row of Table C corresponds (Compounds lll.1-1.272cC-1 to 111.1-1.272cC-389; 111.1 -2.272cC-1 to IN.1-2.272cC-389; lll.1-3.272cC-1 to IN.1-3.272cC -389; 111.1 -4.272cC-1 to IN.1-4.272cC-389; III.2.272cC-1 to IN.2.272cC-389). Table 273c Compounds III.1-1, III.1-2, III. 1-3, III.1-4 and III.2, wherein B is 2-chlorothiazol-5-yl and A in each case corresponds to one group of a row of Table C (compounds III.1-1.273cC-1 to 111.1-1.273 cC-389; 111.1 -2.273cC-1 to IN.1-2.273cC-389; III.1-3.273cC-1 to IN.1-3.273cC-389; 111.1 -4.273cC-1 to IN.1-4.273 cC-389; lll.2273cC-1 to IN.2273cC-389) Table 274c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4-chlorothiazol-5-yl and A is in each case one group of a row of Table C. (Compounds III.1-1.274cC-1 to 111.1-1.274cC-389; 111.1 -2.274cC-1 to IN.1-2.274cC-389; III.1-3.274cC-1 to IN.1-3.274cC -389; 111.1 -4.274cC-1 to IN.1-4.274cC-389; III.2.274cC-1 to IN.2.274cC-389)

Table 275c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-bromothiazol-4-yl and A is in each case one group of one row of Table C (Compounds III.1-1.275CC-1 to 111.1-1.275cC-389; IN.1-2.275cC-1 to IN.1-2.275cC-389; III.1-3.275CC-1 to IN.1- 3.275cC-389; 111.1 -4.275cC-1 to IN.1-4.275cC-389;

III.2.275CC-1 to IN.2.275cC-389) Table 276c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-bromothiazol-5-yl and A is in each case one group of one row of Table C (Compounds 111.1-1.276cC-1 to 111.1-1.276cC-389; IN.1-2.276cC-1 to IN.1-2.276cC-389; lll.1-3.276cC-1 to IN.1- 3.276cC-389; 111.1 -4.276cC-1 to IN.1-4.276cC-389; III.2.276cC-1 to IN.2.276cC-389) Table 277c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2,4-dichlorothiazol-5-yl and A is in each case a group of a line of Table C corresponds to (compounds III.1-1.277cC-1 to 111.1 -1.277cC-389; IN.1-2.277cC-1 to IN.1-2.277cC-389; III.1-3.277cC-1 to IN. 1-3.277cC-389; 111.1 -4.277cC-1 to IN.1-4.277cC-389; III.2.277cC-1 to IN.2.277cC-389) Table 278c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, wherein B is 3-chloroisothiazol-4-yl and A corresponds in each case to one group of one row of Table C (compounds III.1-1.278cC-1 to 111.1-1.278cC-389; IN.1-2.278cC-1 to IN.1-2.278cC-389; III.1-3.278cC-1 to IN.1-3.278cC-389; 111.1 -4.278cC-1 to lll.1-4.278cC-389; lll.2.278cC-1 to IM.2.278cC-389) Table 279c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-methylisothiazol-3-yl and A is in each case one group of one row of Table C. (Compounds 111.1-1.279cC-1 to 111.1-1.279cC-389; IM.1-2.279cC-1 to IM.1-2.279cC-389; III.1-3.279cC-1 to IN.1-3.279cC -389; 111.1 -4.279cC-1 to IN.1-4.279cC-389; III.2.279cC-1 to IM.2.279cC-389) Table 280c Compounds III.1-1, III.1-2, III. 1-3, III.1-4 and III.2, wherein B is 3-methylisothiazole

4-yl and A corresponds in each case to one group of one row of Table C (Compounds III.1-1.28OcC-I to 111.1-1.280cC-389; IM.1-2.280cC-1 to IM.1-2.280cC-389 lll.1-3.280cC-1 to IN.1-3.280cC-389; IN.1-4.280cC-1 to IN.1-4.280cC-389; l.2.280cC-1 to IM.2.280cC-389 ) Table 281 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3-methylisothiazol-5-yl and A is in each case one group of one row of Table C. (Compounds III.1-1.281CC-1 to 111.1-1.281CC-389; 111.1-2.281CC-1 to IM.1-2.281CC-389; III.1-3.281CC-1 to 111.1-3.281CC-389 111.1 -4.281 cC-1 to IN.1-4.281 cC-389; 111.2.281 cC-1 to IM.2.281cC-389)

Table 282c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4,5-dichloroisothiazol-3-yl and A is in each case a group of a line of Table C corresponds (Compounds 111.1-1.282cC-1 to 111.1-1.282cC-389; IM.1-2.282cC-1 to lll.1-2.282cC-389; 111.1 -3.282cC-1 to IM.1-3.282cC -389; 111.1 -4.282cC-1 to III.1-

4.282cC-389; IM.2.282cC-1 to IM.2.282cC-389) Table 283c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 4,5-dimethylisothiazol-3-yl and A is in each case a group of a line of Table C corresponds (Compounds 111.1-1.283cC-1 to 111.1-1.283cC-389; IM.1-2.283cC-1 to lll.1-2.283cC-389; 111.1 -3.283cC-1 to IM.1-3.283cC -389; IN.1-4.283cC-1 to III.1- 4.283cC-389; IM.2.283cC-1 to IM.2.283cC-389) Table 284c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3,5-dimethylisothiazol-4-yl and A is in each case a group of a line of Table C corresponds (Compounds 111.1-1.284cC-1 to 111.1-1.284cC-389; IM.1-2.284cC-1 to lll.1-2.284cC-389; 111.1 -3.284cC-1 to IM.1-3.284cC -389; 111.1 -4.284cC-1 to III.1-4284cC-389; IM.2.284cC-1 to IM.2.284cC-389) Table 285c Compounds III.1-1, III.1-2, III. 1-3, III.1-4 and III.2, where B is 3,4-

Dichloroisothiazol-5-yl and A is in each case one group of one row of Table C (Compounds III.1-1.285cC-1 to 111.1-1.285cC-389; IM.1-2.285cC-1 to III.1-2.285CC-389; 111.1-3.285cC-1 to IM.1-3.285cC-389; IN.1-4.285cC-1 to III.1-4.285cC-389; IM.2.285cC-1 to IM.2.285cC-389) Table 286c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is oxazol-2-yl and A in each case corresponds to one group of one row of Table C ( Compounds III.1-

1.286cC-1 to 111.1-1.286cC-389; IN.1-2.286cC-1 to IN.1-2.286cC-389; III.1-3.286cC-1 to IN.1-3.286cC-389; IN.1-4.286cC-1 to IN.1-4.286cC-389; IN.2.286cC-1 to III.2.286CC-389) Table 287c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is oxazole 4-yl and A in each case corresponds to one group of one row of Table C (Compounds III.1- 1.287cC-1 to 111.1-1.287cC-389; 111.1 -2.287cC-1 to IN.1-2.287cC-389; III .1-3287cC-1 to IN.1-3.287cC-389; 111.1 -4.287cC-1 to IN.1-4.287cC-389; IN.2.287cC-1 to III.2.287CC-389) Table 288c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is oxazol-5-yl and A in each case corresponds to one group of one row of Table C ( Compounds III.1- 1.288cC-1 to 111.1-1.288cC-389; IN.1-2.288cC-1 to IN.1-2.288cC-389; III.1-3.288cC-1 to IN.1-3.288cC -389; IN.1-4.288cC-1 to IN.1-4.288cC-389; IN.2.288cC-1 to III.2.288CC-389)

Table 289c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is isoxazol-3-yl and A in each case corresponds to one group of one line of Table C ( Compounds III.1- 1.289cC-1 to 111.1-1.289cC-389; IN.1-2.289cC-1 to IN.1-2.289cC-389; III.1-3.289cC-1 to IN.1-3.289cC -389; IN.1-4.289cC-1 to IN.1-4.289cC-389; IN.2.289cC-

1 to III.2.289cC-389) Table 290c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is isoxazol-4-yl and A in each case corresponds to one group of one row of Table C ( Compounds III.1- 1.29OcC-I to 111.1-1.290cC-389; IM.1-2.290cC-1 to IN.1-2.290cC-389; III.1-

3.290cC-1 to IN.1-3.290cC-389; IN.1-4.290cC-1 to IN.1-4.290cC-389; IM.2.290cC-1 to III.2.290cC-389) Table 291 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is isoxazol-5-yl and A in each case corresponds to one group of one line of Table C ( Compounds III.1-

1,291 cC-1 to 111.1 to 1,291 cC-389; 111.1-2.291 cC-1 to 111.1-2.291 cC-389; III.1-3,291 cC-1 to 111.1-3.291 cC-389; 111.1 -4,291 cC-1 to 111.1-4,291 cC-389; IN.2.291cC-1 to III.2.291 cC-389) Table 292c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3- Chloroisoxazol-5-yl and A corresponds in each case to one group of one row of Table C (Compounds 111.1-1.292cC-1 to 111.1-1.292cC-389; IN.1-2.292cC-1 to IN.1-2.292cC-389 ; III.1-3.292cC-1 to IN.1-3.292cC-389; IN.1-4.292cC-1 to III.1-4.292cC-389; Ill.2.292cC-1 to IM.2.292cC-389) Table 293c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-methylisoxazol-3-yl and A is in each case one group of a row of Table C. (Compounds III.1-1.293cC-1 to 111.1-1.293cC-389; IM.1-2.293cC-1 to IM.1-2.293cC-389; III.1-3.293cC-1 to IN.1- 3.293cC-389; 111.1 -4.293cC-1 to IN.1-4.293cC-389; III.2.293CC-1 to IM.2.293cC-389) Table 294c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 5-methylisoxazol-4-yl and A in each case corresponds to one group of a row of Table C (compounds III.1-1.294cC-1 to 111.1 -1.294cC-389; IM.1-2.294cC-1 to IM.1-2.294cC-389; lll.1-3.294cC-1 to IN.1-3.294cC-389; IN.1-4.294cC-1 to IN.1-4.294cC-389; III.2.294cC-1 to IM.2.294cC-389) Table 295c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3-methylisoxazol-5-yl and A is in each case one group of one row of Table C. corresponds (compounds III.1-1.295CC-1 to 111.1-1.295cC-389; IM.1-2.295cC-1 to IM.1-2.295cC-389; III.1-3.295CC-1 to IN.1- 3,295cC-389; IN.1-4,295cC-1 to IN.1-4,295cC-389; III.2.295CC-1 to IM.2.295cC-389)

Table 296c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3,5-dimethylisoxazol-4-yl and A is in each case a group of a line of Table C corresponds (Compounds 111.1-1.296cC-1 to 111.1-1.296cC-389; MI.1-2.296cC-1 to lll.1-2.296cC-389; 111.1-3.296cC-1 to IM.1-3.296cC -389; 111.1 -4.296cC-1 to III.1-

4.296cC-389; IM.2.296cC-1 to IM.2.296cC-389) Table 297c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3-chloro-5-methylisoxazol-4-yl and A is each a group of one Corresponds to the line of Table C (Compounds 111.1-1.297cC-1 to 111.1-1.297cC-389; IM.1-2.297cC-1 to

III.1-2.297CC-389; 111.1-3.297cC-1 to IM.1-3.297cC-389; 111.1 -4.297cC-1 to III.1-4,297cC-389; IM.2.297cC-1 to IM.2.297cC-389) Table 298c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 3-methyl-4-chloroisoxazol-5-yl and A is each a group of one Line of Table C corresponds (compounds 111.1-1.298cC-1 to 111.1-1.298cC-389; IM.1-2.298cC-1 to lll.1-2.298cC-389; 111.1 -3.298cC-1 to IM.1- 3.298cC-389; IN.1-4.298cC-1 to III.1- 4.298cC-389; IM.2.298cC-1 to IM.2.298cC-389) Table 299c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, wherein B is 1-methylpyrazol-3-yl and A in each case corresponds to one group of a row of Table C (compounds III.1-1.299cC-1 to 111.1-1.299cC-389; 111.1 -2.299cC-1 to IM.1-2.299cC-389; III.1-3.299cC-1 to IN.1-3.299cC-389; 111.1 -4,299cC-1 to lll.1-4,299cC-389; III.2.299CC-1 to IM.2.299cC-389) Table 300c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 1-methylpyrazol-4-yl and A is in each case one group of one row of Table C corresponds (compounds III.1-1.30OcC-I to 111.1-1.300cC-389; IM.1-2.300cC-1 to IM.1-2.300cC-389; III.1-3.300CC-1 to IN.1- 3.300cC-389, IN.1-4.300cC-1 to IN.1-4.300cC-389, III.2.300CC-1 to IM.2.300cC-389) Table 301c Compounds III.1-1, III.1 -2, III.1-3, III.1-4 and III.2, wherein B is 1-methylpyrazol-5-yl and A corresponds in each case to one group of one row of Table C (Compounds 111.1-1.301 cC-1 to 111.1-1.301 cC-389; 111.1 -2.301 cC-1 to 111.1-2.301 cC-389; lll.1-3.301 cC-1 to 111.1-3.301 cC-389; 111.1 -4.301cC-1 to 111.1-4.301 cC-389 ; lll.2.301 cC-1 to IM.2.301cC-389) Table 302c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 1, 3-dimethylpyrazol-4-yl and A is a group of a line of Table C corresponds (Compounds 111.1-1.302cC-1 to 111.1-1.302cC-389; IN.1-2.302cC-1 to lll.1-2.302cC-389; IN.1-3.302cC-1 to IN.1- 3.302cC-389; IN.1-4.302cC-1 to III.1-4.302cC-389; IN.2.302cC-1 to IM.2.302cC-389)

Table 303c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 1, 5-dimethylpyrazol-4-yl and A is in each case a group of a line of Table C corresponds (Compounds 111.1-1.303cC-1 to 111.1-1.303cC-389; IN.1-2.303cC-1 to lll.1-2.303cC-389; 111.1 -3.303cC-1 to IN.1-3.303cC -389; IN.1-4.303cC-1 to III.1-

4.303cC-389; IM.2.303cC-1 to IN.2.303cC-389) Table 304c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2 wherein B is 1, 3,5-trimethylpyrazol-4-yl and A is each a group of one Row of Table C corresponds (Compounds 111.1-1.304cC-1 to 111.1-1.304cC-389; IN.1-2.304cC-1 to lll.1-2.304cC-389; IN.1-3.304cC-1 to IM. 1-3.304cC-389; IN.1-4.304cC-1 to III.1-4304cC-389; IN.2.304cC-1 to IN.2.304cC-389) Table 305c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 1-methylimidazol-4-yl and A is in each case one group of a row of Table C. corresponds (compounds III.1-1.305CC-1 to 111.1-1.305cC-389; IM.1-2.305cC-1 to IN.1-2.305cC-389; III.1-3.305CC-1 to IN.1- 3.305cC-389; IN.1-4.305cC-1 to IN.1-4.305cC-389; III.2.305CC-1 to IN.2.305cC-389) Table 306c Compounds III.1-1, III.1- 2, III.1-3, III.1-4 and III.2, where B is for 1, 5

Dimethylimidazol-4-yl and A is in each case one group of one row of Table C (Compounds 111.1-1.306cC-1 to 111.1-1.306cC-389; IN.1-2.306cC-1 to III.1-2.306CC-389; IM.1-3.306cC-1 to IM.1-3.306cC-389; IN.1-4.306cC-1 to III.1-4,306cC-389; IM.2.306cC-1 to IM.2.306cC-389) Table 307c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 1, 2-dimethylimidazol-5-yl and A is in each case a group of a line of Table C corresponds (Compounds 111.1-1.307cC-1 to 111.1-1.307cC-389; IM.1-2.307cC-1 to III.1-2.307CC-389; 111.1 -3.307cC-1 to IN.1-3.307cC -389; 111.1 -4.307cC-1 to III.1-4307cC-389; IN.2.307cC-1 to IM.2.307cC-389). Table 308c Compounds III.1-1, III.1-2, III. 1-3, III.1-4 and III.2, where B is 1, 4-

Dimethylimidazol-5-yl and A in each case corresponds to one group of a row of Table C (Compounds 111.1-1.308cC-1 to 111.1-1.308cC-389; IN.1-2.308cC-1 to lll.1-2.308cC-389 IN.1-3.308cC-1 to IN.1-3.308cC-389; IN.1-4.308cC-1 to III.1-4.308cC-389; IN.2.308cC-1 to IM.2.308cC-389 ) Table 309c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 2-furyl and A in each case corresponds to one group of one row of Table C (Compounds III .1- 1.309cC-1 to 111.1-1.309cC-389; IN.1-2.309cC-1 to IN.1-2.309cC-389; III.1-3.309cC-1 to IN.1-3.309cC-389 IN.1-4.309cC-1 to IN.1-4.309cC-389; IM.2.309cC-1 to III.2.309CC-389)

Table 310c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is cyclopropyl and A in each case corresponds to one group of one row of Table C (Compounds III.1 - 1.31 OcC-I to 111.1-1.310cC-389; 111.1 -2.31 OcC-1 to IM.1-2.310cC-389; III.1- 3.310cC-1 to IN.1-3.310cC-389; 111.1-4.31 OcC-1 to IN.1-4.310cC-389; 111.2.31 OcC-

1 to III.2.310cC-38θ) Table 311c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is cyclopentyl and A in each case corresponds to one group of one row of Table C (Compounds III.1 - 1 .31 1 cC-1 to 111.1 -1 .31 1 cC-389; 111.1 -2.31 1 cC-1 to 111.1 -2.31 1 cC-389; III.1 -

3.31 1 cC-1 to 111.1-3.31 1 cC-389; III.1 -4.31 1 cC-1 to 111.1 -4.31 1 cC-389; 111.2.31 1 cC-1 to lll.2.31 1 cC-389) Table 312c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is cyclohexyl and A in each case corresponds to one group of a row of Table C (Compounds III.1 -

1.312cC-1 to 111.1-1.312cC-389; 111.1 -2.312cC-1 to IN.1-2.312cC-389; III.1-3.312cC-1 to IN.1-3.312cC-389; 111.1 -4.312cC-1 to IN.1-4.312cC-389; IN.2.312cC-1 to III.2.312cC-389) Table 313c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is for 1 - Methylcycloprop-

1-yl and A corresponds in each case to one group of one row of Table C (Compounds 111.1-1.313cC-1 to 111.1-1.313cC-389; 111.1-2.313cC-1 to IN.1-2.313cC-389; III.1-3.313cC-1 to IN.1-3.313cC-389; 111.1 -4.313cC-1 to lll.1-4.313cC-389; III.2.313CC-1 to IM.2.313cC-389) Table 314c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 1-methylcyclopent-1-yl and A is in each case one group of one row of Table C. corresponds (Compounds lll.1-1.314cC-1 to 111.1-1.314cC-389; 111.1-2.314cC-1 to IN.1-2.314cC-389; lll.1-3.314cC-1 to IN.1-3.314cC -389; 111.1 -4.314cC-1 to IN.1-4.314cC-389; III.2.314cC-1 to IN.2.314cC-389). Table 315c Compounds III.1-1, III.1-2, III. 1-3, III.1-4 and III.2, wherein B is 1-methylcyclohex-1-yl and A in each case corresponds to one group of a row of Table C (compounds III.1-1.315cC-1 to 111.1-1.315 cC-389; 111.1-2.315cC-1 to IN.1-2.315cC-389; III.1-3.315cC-1 to IN.1-3.315cC-389; 111.1-4.315cC-1 to IN.1-4.315 cC-389; III.2.315cC-1 to IN.2.315cC-389) Table 316c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is 1-chlorocycloprop-i-yl and A is in each case one group of a row of Table C. (Compounds 111.1-1.316cC-1 to 111.1 -1.316cC-389; 111.1-2.316cC-1 to IN.1-2.316cC-389; III.1-3.316cC-1 to IN.1-3.316cC-389) III.1.316CC-1 to 111.2.316cC-389)

Table 317c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is methyl and A in each case corresponds to one group of a row of Table C (Compounds III.1 - 1.317cC-1 to lll.1-1.317cC-389; 111.1 -2.317cC-1 to 111.1 -2.317cC-389; III.1-3.317cC-1 to IN.1-3.317cC-389; 111.1 -4.317 cC-1 to 111.1 -4.317cC-389; IN.2.317cC-

1 to III.2.317cC-389) Table 318c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is ethyl and A in each case corresponds to one group of one row of Table C (Compounds III.1 - 1.318cC-1 to 111.1-1.318cC-389; 111.1 -2.318cC-1 to IN.1-2.318cC-389; III.1-

3.318cC-1 to IN.1-3.318cC-389; 111.1 -4.318cC-1 to IN.1-4.318cC-389; IN.2.318cC-1 to MI.2.318cC-389) Table 319c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is n-propyl and A in each case corresponds to one group of one row of Table C (Compounds III .1-

1.319cC-1 to 111.1 -1.319cC-389; 111.1 -2.319cC-1 to IN.1-2.319cC-389; III.1-3.319cC-1 to IN.1-3.319cC-389; 111.1 -4.319cC-1 to IN.1-4.319cC-389; IN.2.319cC-1 to III.2.319cC-389) Table 320c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is for i Propyl and A corresponds in each case to one group of one row of Table C (Compounds III.1-1320cC-1 to 111.1-1.320cC-389; IN.1-2.320cC-1 to IN.1-2.320cC-389; III .1- 3.320cC-1 to IM.1-3.320cC-389; .1-4.32 OcC-I to IN.1-4.320cC-389; IM.2.320cC-

1 to III.2.320CC-389) Table 321 c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is n-butyl and A in each case corresponds to one group of one row of Table C (Compounds III.1 -

1,321 cC-1 to 111.1 to 1,321 cC-389; 111.1 -2,321 cC -1 to IM.1-2,321 cC-389; III.1-3.221 cC-1 to 111.1-3.321 cC-389; 111.1 -4.321 cC -1 to 111.1-4.321 cC-389; IN.2.321cC-1 to III.2.321 CC-38Θ) Table 322c Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is sec-butyl and

A corresponds in each case to one group of one row of Table C (Compounds III.1- 1.322cC-1 to 111.1-1.322cC-389; IN.1-2.322cC -1 to IM.1-2.322cC-389; III.1- 3.322cC-1 to IN.1-3.322cC-389; IN.1-4.322cC -1 to III.1-4.322cC-389; IN.2.322cC-1 to III.2.322cC-389) Table 323c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and III.2, wherein B is tert-butyl and A in each case corresponds to one group of a row of Table C (compounds III .1- 1.323cC-1 to 111.1-1.323cC-389; 111.1 -2.323cC-1 to IM.1-2.323cC-389; III.1-3.323cC-1 to IN.1-3.323cC-389; IN .1-4.323cC -1 to lll.1-4.323cC-389; IN.2.323cC-1 to III.2.323CC-389)

Table 324c

Compounds III.1-1, III.1-2, III.1-3, III.1-4 and 111.2, wherein B is iso-butyl and A in each case corresponds to one group of one row of Table C (Compounds III.1 IN.1-2.324cC-1 to III.1-2.324cC-389, III.1-3.224cC-1 to IN.1-3.324cC-389, IN .1-4.324cC -1 to lll.1-4.324cC-389; IN.2.324cC-

1 to III.2.324cC-389) Table C

In particular, in view of their use, the compounds V, IVa-1, IVb and VII according to the invention which are compiled in the following Tables 1d to 308d are preferred. The groups mentioned in the tables for a substituent are also considered individually, regardless of the combination in which they are mentioned, a particularly preferred embodiment of the substituent in question.

Table 1 d

Compounds V, IVa-1, IVb and VII, wherein A is pyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.1 dA-1 to V.1dA-425; IVa-1.1dA -1 to IVa-1.1 dA-425; IVb.1dA-1 to IVb.1dA-425; VIMdA-1 to VII.1dA-425) Table 2d

Compounds V, IVa-1, IVb and VII, in which A is pyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.2dA-1 to V.2dA-425; IVa-1.2dA- 1 to IVa-1.2dA-425; IVb.2dA-1 to IVb.2dA-425; VII.2dA-1 to VII.2dA-425) 3d table

Compounds V, IVa-1, IVb and VII, in which A is pyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.3dA-1 to V.3dA-425; IVa-1.3dA- 1 to IVa-1.3dA-425; IVb.3dA-1 to IVb.3dA-425; VII.3dA-1 to VII.3dA-425)

Table 4d

Compounds V, IVa-1, IVb and VII, wherein A is 3-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.4dA-1 to V.4dA-425; IVa-1.4 dA-1 to IVa-1.4dA-425; IVb.4dA-1 to IVb.4dA-425; VII.4dA-1 to VII.4dA-425)

Table 5d

Compounds V, IVa-1, IVb and VII in which A is 4-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.5dA-1 to V.5dA-425; 1.5dA-1 to IVa-1.5dA-425; IVb.5dA-1 to IVb.5dA-425; VII.5dA-1 to VII.5dA-425)

Table 6d

Compounds V, IVa-1, IVb and VII, wherein A is 5-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.6dA-1 to V.6dA-425; IVa-1.6 dA-1 to IVa-1.6dA-425; IVb.6dA-1 to IVb.6dA-425; VII.6dA-1 to VII.6dA-425)

Table 7d

Compounds V, IVa-1, IVb and VII in which A is 6-chloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.7dA-1 to V.7dA-425; IVa-1.7 dA-1 to IVa-1.7dA-425; IVb.7dA-1 to IVb.7dA-425; VII.7dA-1 to VII.7dA-425)

Table 8d

Compounds V, IVa-1, IVb and VII, wherein A is 2-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.8dA-1 to V.8dA-425; IVa-1.8 dA-1 to IVa-1.8dA-425; IVb.8dA-1 to IVb.8dA-425; VII.8dA-1 to VII.8dA-425)

Table 9d

Compounds V, IVa-1, IVb and VII in which A is 4-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.9dA-1 to V.9dA-425; IVa-1.9 dA-1 to IVa-1.9dA-425; IVb.9dA-1 to IVb.9dA-425; VII.9dA-1 to VII.9dA-425)

Table 1 Od

Compounds V, IVa-1, IVb and VII, wherein A is 5-chloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.1 OdA-1 to V.10dA-425; 1.10dA-1 to IVa-1.10dA-425; IVb.10dA-1 to IVb.10dA-425; VII.10dA-1 to VII.10dA-425)

Table 1 1d

Compounds V, IVa-1, IVb and VII, wherein A is 6-chloropyridin-3-yl and B is each because one group corresponds to one row of Table A (compounds V.1 1dA-1 to V.1 1dA-425; IVa-1.1 1dA-1 to IVa-1.1 1dA-425; IVb.11 dA-1 to IVb.1 1dA -425; VII.1 1dA-1 to VII.11 dA-425)

Table 12d Compounds V, IVa-1, IVb and VII, wherein A is 2-chloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds V.12dA-1 to V.12dA-425; IVa -1.12dA-1 to IVa-1.12dA-425; IVb.12dA-1 to IVb.12dA-425; VII.12dA-1 to VII.12dA-425)

Table 13d Compounds V, IVa-1, IVb and VII, wherein A is 3-chloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.13dA-1 to V.13dA-425; IVa -1.13dA-1 to IVa-1.13dA-425; IVb.13dA-1 to IVb.13dA-425; VII.13dA-1 to VII.13dA-425)

Table 14d compounds V, IVa-1, IVb and VII, wherein A is 4-chloropyridin-5-yl and B corresponds in each case to one group of one row of Table A (compounds V.14dA-1 to V.14dA-425; IVa -1.14dA-1 to IVa-1.14dA-425; IVb.14dA-1 to IVb.14dA-425; VII.14dA-1 to VII.14dA-425)

Table 15d compounds V, IVa-1, IVb and VII, wherein A is 3-fluoropyridin-2-yl and B corresponds in each case to one group of a row of Table A (compounds V.15dA-1 to V.15dA-425; IVa -1.15dA-1 to IVa-1.15dA-425; IVb.15dA-1 to IVb.15dA-425; VII.15dA-1 to VII.15dA-425)

Table 16d Compounds V, IVa-1, IVb and VII, wherein A is 4-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.16dA-1 to V.16dA-425; IVa -1.16dA-1 to IVa-1.16dA-425; IVb.16dA-1 to IVb.16dA-425; VII.16dA-1 to VII.16dA-425)

Table 17d Compounds V, IVa-1, IVb and VII, wherein A is 5-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.17dA-1 to V.17dA-425; IVa -1.17dA-1 to IVa-1.17dA-425; IVb.17dA-1 to IVb.17dA-425; VII.17dA-1 to VII.17dA-425)

Table 18d Compounds V, IVa-1, IVb and VII, wherein A is 6-fluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.18dA-1 to V.18dA-425; IVa -1.18dA-1 to IVa-1.18dA-425; IVb.18dA-1 to IVb.18dA-425; VII.18dA-1 to VII.18dA-425)

Table 19d Compounds V, IVa-1, IVb and VII, wherein A is 2-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.19dA-1 to V.19dA-425; IVa-1.19dA-1 to IVa-1.19dA-425; IVb.19dA-1 to IVb.19dA-425;

VII.19dA-1 to VII.19dA-425) Table 2Od

Compounds V, IVa-1, IVb and VII, wherein A is 4-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.20dA-1 to

V.20dA-425; IVa-1.2OdA-I to IVa-1.20dA-425; IVb.20dA-1 to IVb.20dA-425;

VII.20dA-1 to VII.20dA-425) Table 21d

Compounds V, IVa-1, IVb and VII, wherein A is 5-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.21dA-1 to

V.21dA-425; IVa-1.21 dA-1 to IVa-1.21 dA-425; IVb.21 dA-1 to IVb.21dA-425;

VII.21dA-1 to VII.21 dA-425) Table 22d

Compounds V, IVa-1, IVb and VII, wherein A is 6-fluoropyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.22dA-1 to

V.22dA-425; IVa-1.22dA-1 to IVa-1.22dA-425; IVb.22dA-1 to IVb.22dA-425;

VII.22dA-1 to VII.22dA-425) Table 23d

Compounds V, IVa-1, IVb and VII, wherein A is 2-fluoropyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.23dA-1 to

V.23dA-425; IVa-1.23dA-1 to IVa-1.23dA-425; IVb.23dA-1 to IVb.23dA-425;

VII.23dA-1 to VII.23dA-425) Table 24d

Compounds V, IVa-1, IVb and VII, wherein A is 3-fluoropyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.24dA-1 to

V.24dA-425; IVa-1.24dA-1 to IVa-1.24dA-425; IVb.24dA-1 to IVb.24dA-425;

VII.24dA-1 to VII.24dA-425) Table 25d

Compounds V, IVa-1, IVb and VII, wherein A is 3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.25dA-1 to V.25dA-425; IVa-1.25 dA-1 to IVa-1.25dA-425; IVb.25dA-1 to IVb.25dA-425;

VII.25dA-1 to VII.25dA-425) Table 26d

Compounds V, IVa-1, IVb and VII, wherein A is 4-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.26dA-1 to V.26dA-425; IVa-1.26 dA-1 to IVa-1.26dA-425; IVb.26dA-1 to IVb.26dA-425;

VII.26dA-1 to VII.26dA-425) Table 27d

Compounds V, IVa-1, IVb and VII, wherein A is 5-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.27dA-1 to V.27dA-425; IVa-1.27 dA-1 to IVa-1.27dA-425; IVb.27dA-1 to IVb.27dA-425;

VII.27dA-1 to VII.27dA-425) Table 28d

Compounds V, IVa-1, IVb and VII, wherein A is 6-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.28dA-1 to V.28dA-425; IVa-1.28 dA-1 to IVa-1.28dA-425; IVb.28dA-1 to IVb.28dA-425; VII.28dA-1 to VII.28dA-425)

Table 29d

Compounds V, IVa-1, IVb and VII in which A is 2-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.29dA-1 to V.29dA-425; IVa-1.29 dA-1 to IVa-1.29dA-425; IVb.29dA-1 to IVb.29dA-425; VII.29dA-1 to VII.29dA-425)

Table 3Od

Compounds V, IVa-1, IVb and VII, wherein A is 4-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.30dA-1 to V.30dA-425; IVa-1.3 OdA-I to IVa-1.30dA-425; IVb.30dA-1 to IVb.30dA-425; VII.30dA-1 to VII.30dA-425)

Table 31d

Compounds V, IVa-1, IVb and VII, wherein A is 5-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.31dA-1 to V.31dA-425; IVa-1.31 dA-1 to IVa-1.31 dA-425; IVb.31 dA-1 to IVb.31 dA-425; VII.31dA-1 to VII.31 dA-425)

Table 32d

Compounds V, IVa-1, IVb and VII, wherein A is 6-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.32dA-1 to V.32dA-425; IVa-1.32 dA-1 to IVa-1.32dA-425; IVb.32dA-1 to IVb.32dA-425; VII.32dA-1 to VII.32dA-425)

Table 33d

Compounds V, IVa-1, IVb and VII, wherein A is 2-methylpyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.33dA-1 to V.33dA-425; IVa-1.33 dA-1 to IVa-1.33dA-425; IVb.33dA-1 to IVb.33dA-425; VII.33dA-1 to VII.33dA-425)

Table 34d

Compounds V, IVa-1, IVb and VII, wherein A is 3-methylpyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.34dA-1 to V.34dA-425; IVa-1.34 dA-1 to IVa-1.34dA-425; IVb.34dA-1 to IVb.34dA-425; VII.34dA-1 to VII.34dA-425)

Table 35d

Compounds V, IVa-1, IVb and VII, wherein A is 4-methylpyridin-5-yl and B corresponds in each case to one group of a row of Table A (compounds V.35dA-1 to V.35dA-425; IVa-1.35 dA-1 to IVa-1.35dA-425; IVb.35dA-1 to IVb.35dA-425; VII.35dA-1 to VII.35dA-425)

Table 36d

Compounds V, IVa-1, IVb and VII, wherein A is 3-methoxypyridin-2-yl and B each corresponds to one group of one row of Table A (Compounds V.36dA-1 to V.36dA-425; IVa-1.36dA-1 to IVa-1.36dA-425; IVb.36dA-1 to IVb.36dA-425;

VII.36dA-1 to VII.36dA-425) Table 37d Compounds V, IVa-1, IVb and VII, wherein A is 4-methoxypyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds V .37dA-1 to V.37dA-425; IVa-1.37dA-1 to IVa-1.37dA-425; IVb.37dA-1 to IVb.37dA-425;

VII.37dA-1 to VII.37dA-425) Table 38d Compounds V, IVa-1, IVb and VII, wherein A is 5-methoxypyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V .38dA-1 to V.38dA-425; IVa-1.38dA-1 to IVa-1.38dA-425; IVb.38dA-1 to IVb.38dA-425;

VII.38dA-1 to VII.38dA-425) Table 39d Compounds V, IVa-1, IVb and VII, wherein A is 6-methoxypyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds V IVa-1.39dA-1 to IVa-1.39dA-425; IVb.39dA-1 to IVb.39dA-425;

VII.39dA-1 to VII.39dA-425) Table 4Od Compounds V, IVa-1, IVb and VII, wherein A is 2-methoxypyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V .40dA-1 to V.40dA-425; IVa-1.4OdA-I to IVa-1.40dA-425; IVb.40dA-1 to IVb.40dA-425;

VII.40dA-1 to VII.40dA-425) Table 41d Compounds V, IVa-1, IVb and VII, wherein A is 4-methoxypyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds V .41dA-1 to V.41dA-425; IVa-1.41dA-1 to IVa-1.41dA-425; IVb.41 dA-1 to IVb.41 dA-425;

VII.41dA-1 to VII.41 dA-425) Table 42d Compounds V, IVa-1, IVb and VII, wherein A is 5-methoxypyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.42dA-1 to V.42dA-425; IVa-1.42dA-1 to IVa-1.42dA-425; IVb.42dA-1 to IVb.42dA-425;

VII.42dA-1 to VII.42dA-425) Table 43d Compounds V, IVa-1, IVb and VII, wherein A is 6-methoxypyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds V IVa-1.43dA-1 to IVa-1.43dA-425; IVb.43dA-1 to IVb.43dA-425;

VII.43dA-1 to VII.43dA-425) Table 44d Compounds V, IVa-1, IVb and VII, wherein A is 2-methoxypyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds V .44dA-1 to V.44dA-425; IVa-1.44dA-1 to IVa-1.44dA-425; IVb.44dA-1 to IVb.44dA-425;

VII.44dA-1 to VII.44dA-425) Table 45d

Compounds V, IVa-1, IVb and VII, wherein A is 3-methoxypyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds V.45dA-1 to V.45dA-425; IVa-1.45 dA-1 to IVa-1.45dA-425; IVb.45dA-1 to IVb.45dA-425;

VII.45dA-1 to VII.45dA-425) Table 46d

Compounds V, IVa-1, IVb and VII, wherein A is 3,5-dichloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.46dA-1 to V.46dA-425; IVa -1.46dA-1 to IVa-1.46dA-425; IVb.46dA-1 to IVb.46dA-425;

VII.46dA-1 to VII.46dA-425) Table 47d

Compounds V, IVa-1, IVb and VII, wherein A is 2,4-dichloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.47dA-1 to V.47dA-425; IVa -1.47dA-1 to IVa-1.47dA-425; IVb.47dA-1 to IVb.47dA-425;

VII.47dA-1 to VII.47dA-425) Table 48d

Compounds V, IVa-1, IVb and VII, wherein A is 2,5-dichloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.48dA-1 to V.48dA-425; IVa -1.48dA-1 to IVa-1.48dA-425; IVb.48dA-1 to IVb.48dA-425;

VII.48dA-1 to VII.48dA-425) Table 49d

Compounds V, IVa-1, IVb and VII, wherein A is 2,6-dichloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.49dA-1 to V.49dA-425; IVa -1.49dA-1 to IVa-1.49dA-425; IVb.49dA-1 to IVb.49dA-425;

VII.49dA-1 to VII.49dA-425) Table 5Od

Compounds V, IVa-1, IVb and VII in which A is 2,6-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.50dA-1 to V.50dA-425; IVa -1.5 OdA-I to IVa-1.50dA-425; IVb.50dA-1 to IVb.50dA-425;

VII.50dA-1 to VII.50dA-425) Table 51 d

Compounds V, IVa-1, IVb and VII, wherein A is 3,5-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds V.51 dA-1 to V.51dA-425; IVa-1.51 dA-1 to IVa-1.51 dA-425; IVb.51 dA-1 to IVb.51 dA-425;

VII.51dA-1 to VII.51 dA-425) Table 52d

Compounds V, IVa-1, IVb and VII, wherein A is 3,6-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (Compounds V.52dA-1 to V.52dA-425; IVa -1.52dA-1 to IVa-1.52dA-425; IVb.52dA-1 to IVb.52dA-425;

VII.52dA-1 to VII.52dA-425) Table 53d

Compounds V, IVa-1, IVb and VII, wherein A is 2,5-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.53dA-1 to V.53dA-425; IVa -1.53dA-1 to IVa-1.53dA-425; IVb.53dA-1 to IVb.53dA-425; VII.53dA-1 to VII.53dA-425)

Table 54d

Compounds V, IVa-1, IVb and VII, wherein A is 2,3-dichloropyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.54dA-1 to V.54dA-425; IVa -1.54dA-1 to IVa-1.54dA-425; IVb.54dA-1 to IVb.54dA-425; VII.54dA-1 to VII.54dA-425)

Table 55d

Compounds V, IVa-1, IVb and VII, wherein A is 2,4-dichloropyridin-5-yl and B corresponds in each case to one group of one row of Table A (Compounds V.55dA-1 to V.55dA-425; IVa -1.55dA-1 to IVa-1.55dA-425; IVb.55dA-1 to IVb.55dA-425; VII.55dA-1 to VII.55dA-425)

Table 56d

Compounds V, IVa-1, IVb and VII in which A is 3,5-difluoropyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.56dA-1 to V.56dA-425; IVa -1.56dA-1 to IVa-1.56dA-425; IVb.56dA-1 to IVb.56dA-425; VII.56dA-1 to VII.56dA-425)

Table 57d

Compounds V, IVa-1, IVb and VII, wherein A is 3,5-difluoropyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.57dA-1 to V.57dA-425; IVa -1.57dA-1 to IVa-1.57dA-425; IVb.57dA-1 to IVb.57dA-425; VII.57dA-1 to VII.57dA-425)

Table 58d

Compounds V, IVa-1, IVb and VII, wherein A is 2,3-difluoropyridin-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.58dA-1 to V.58dA-425; IVa -1.58dA-1 to IVa-1.58dA-425; IVb.58dA-1 to IVb.58dA-425; VII.58dA-1 to VII.58dA-425)

Table 59d

Compounds V, IVa-1, IVb and VII, wherein A is 3,5-dimethylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.59dA-1 to V.59dA-425; IVa -1.59dA-1 to IVa-1.59dA-425; IVb.59dA-1 to IVb.59dA-425; VII.59dA-1 to VII.59dA-425)

Table 6Od

Compounds V, IVa-1, IVb and VII, wherein A is 3,4-dimethylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.6OdA-1 to V.60dA-425; IVa -1.6 OdA-I to IVa-1.60dA-425; IVb.60dA-1 to IVb.60dA-425; VII.60dA-1 to VII.60dA-425)

Table 61 d

Compounds V, IVa-1, IVb and VII, wherein A is 4,6-dimethylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.61 dA-1 to V.61dA-425, IVa-1.61 dA-1 to IVa-1.61 dA-425, IVb.61 dA-1 to IVb.61 dA -425; VII.61dA-1 to VII.61 dA-425)

Table 62d compounds V, IVa-1, IVb and VII, wherein A is 2,4-dimethylpyridin-3-yl and

B corresponds in each case to one group of one row of Table A (compounds V.62dA-1 to V.62dA-425; IVa-1.62dA-1 to IVa-1.62dA-425; IVb.62dA-1 to IVb.62dA-425; VII.62dA-1 to VII.62dA-425)

Table 63d compounds V, IVa-1, IVb and VII, wherein A is 3,5-dimethylpyridin-4-yl and

B corresponds in each case to one group of one row of Table A (compounds V.63dA-1 to V.63dA-425; IVa-1.63dA-1 to IVa-1.63dA-425; IVb.63dA-1 to IVb.63dA-425; VII.63dA-1 to VII.63dA-425)

Table 64d Compounds V, IVa-1, IVb and VII, wherein A is 2-chloro-3-fluoropyridin-4-yl and

B corresponds in each case to one group of one row of Table A (compounds V.64dA-1 to V.64dA-425; IVa-1.64dA-1 to IVa-1.64dA-425; IVb.64dA-1 to IVb.64dA-425; VII.64dA-1 to VII.64dA-425)

Table 65d Compounds V, IVa-1, IVb and VII, wherein A is 4-chloro-3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.65bB-1 to V.65bB IVa-1.65dA-1 to IVa-1.65dA-425; IVb.65dA-1 to IVb.65dA-425; VII.65dA-1 to VII.65dA-425)

Table 66d Compounds V, IVa-1, IVb and VII, wherein A is 5-chloro-3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds M.66bB-1 to M.66bB IVa-1.66dA-1 to IVa-1.66dA-425; IVb.66dA-1 to IVb.66dA-425; VII.66dA-1 to VII.66dA-425)

Table 67d Compounds V, IVa-1, IVb and VII, wherein A is 5-fluoro-3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.67bB-1 to V.67bB IVa-1.67dA-1 to IVa-1.67dA-425; IVb.67dA-1 to IVb.67dA-425; VII.67dA-1 to VII.67dA-425)

Table 68d compounds V, IVa-1, IVb and VII, wherein A is 3-chloro-5-trifluoromethylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.68bB-1 to V.68bB IVa-1.68dA-1 to IVa-1.68dA-425; IVb.68dA-1 to IVb.68dA-425; VII.68dA-1 to VII.68dA-425)

Table 69d Compounds II, wherein A is 2-chloro-6-trifluoromethylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.69bB-1 to V.69bB-134; IVa-1.69dA-1 to IVa-1.69dA-425; IVb.69dA-1 to IVb.69dA-425;

VII.69dA-1 to VII.69dA-425) Table 7Od

Compounds V, IVa-1, IVb and VII, wherein A is 2,4-dichloro-6-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.70bB-1 to V.70bB IVa-1.7OdA-I to IVa-1.70dA-425; IVb.70dA-1 to

IVb.70dA-425; VII.70dA-1 to VII.70dA-425) Table 71 d

Compounds V, IVa-1, IVb and VII, wherein A is 3,4,5-trichloropyridin-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.71 dA-

1 to V.71dA-425; IVa-1.71 dA-1 to IVa-1.71 dA-425; IVb.71 dA-1 to IVb.71 dA-425;

VII.71 dA-1 to VII.71 dA-425) Table 72d

Compounds V, IVa-1, IVb and VII, wherein A is 2,4,6-trichloropyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.72dA-

1 to V.72dA-425; IVa-1.72dA-1 to IVa-1.72dA-425; IVb.72dA-1 to IVb.72dA-425;

VII.72dA-1 to VII.72dA-425) Table 73d

Compounds V, IVa-1, IVb and VII, wherein A is pyrimidin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.73dA-1 to

V.73dA-425; IVa-1.73dA-1 to IVa-1.73dA-425; IVb.73dA-1 to IVb.73dA-425;

VII.73dA-1 to VII.73dA-425) Table 74d

Compounds V, IVa-1, IVb and VII, wherein A is pyrimidin-5-yl and B corresponds in each case to one group of one row of Table A (compounds V.74dA-1 to

V.74dA-425; IVa-1.74dA-1 to IVa-1.74dA-425; IVb.74dA-1 to IVb.74dA-425;

VII.74dA-1 to VII.74dA-425) Table 75d

Compounds V, IVa-1, IVb and VII, wherein A is 6-chloropyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.75dA-1 to V.75dA-425; IVa-1.75 dA-1 to IVa-1.75dA-425; IVb.75dA-1 to IVb.75dA-425;

VII.75dA-1 to VII.75dA-425) Table 76d

Compounds V, IVa-1, IVb and VII, wherein A is 6-methylpyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.76dA-1 to V.76dA-425; IVa-1.76 dA-1 to IVa-1.76dA-425; IVb.76dA-1 to IVb.76dA-425;

VII.76dA-1 to VII.76dA-425) Table 77d

Compounds V, IVa-1, IVb and VII, wherein A is 6-methoxypyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.77dA-

1 to V.77dA-425; IVa-1.77dA-1 to IVa-1.77dA-425; IVb.77dA-1 to IVb.77dA-425;

VII.77dA-1 to VII.77dA-425) Table 78d

Compounds V, IVa-1, IVb and VII, wherein A is 2,4-dichloropyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.78dA-1 to V.78dA-425; IVa -1.78dA-1 to IVa-1.78dA-425; IVb.78dA-1 to IVb.78dA-425; VII.78dA-1 to VII.78dA-425)

Table 79d

Compounds V, IVa-1, IVb and VII, wherein A is 2,6-dichloropyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.79dA-1 to V.79dA-425; IVa -1.79dA-1 to IVa-1.79dA-425; IVb.79dA-1 to IVb.79dA-425; VII.79dA-1 to VII.79dA-425)

Table 8Od

Compounds V, IVa-1, IVb and VII, wherein A is 2,4-difluoropyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.8OdA-1 to V.80dA-425; IVa -1.8 OdA-I to IVa-1.80dA-425; IVb.80dA-1 to IVb.80dA-425; VII.80dA-1 to VII.80dA-425)

Table 81 d

Compounds V, IVa-1, IVb and VII, wherein A is 2,6-difluoropyrimidin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.81dA-1 to V.81dA-425; IVa -1.81 dA-1 to IVa-1.81 dA-425; IVb.81 dA-1 to IVb.81 dA-425; VII.81dA-1 to VII.81 dA-425)

Table 82d

Compounds V, IVa-1, IVb and VII, wherein A is 1, 3,5-triazin-2-yl and B corresponds in each case to one group of a row of Table A (compounds V.82dA-1 to V.82dA-425 IVa-1.82dA-1 to IVa-1.82dA-425; IVb.82dA-1 to IVb.82dA-425; VII.82dA-1 to VII.82dA-425)

Table 83d

Compounds V, IVa-1, IVb and VII, wherein A is thien-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.83dA-1 to V.83dA-425; IVa-1.83dA- 1 to IVa-1.83dA-425; IVb.83dA-1 to IVb.83dA-425; VII.83dA-1 to VII.83dA-425)

Table 84d

Compounds V, IVa-1, IVb and VII, wherein A is thien-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.84dA-1 to V.84dA-425; IVa-1.84dA- 1 to IVa-1.84dA-425; IVb.84dA-1 to IVb.84dA-425; VII.84dA-1 to VII.84dA-425)

Table 85d

Compounds V, IVa-1, IVb and VII, wherein A is 5-chlorothien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.85dA-1 to V.85dA-425; IVa-1.85 dA-1 to IVa-1.85dA-425; IVb.85dA-1 to IVb.85dA-425; VII.85dA-1 to VII.85dA-425)

Table 86d

Compounds V, IVa-1, IVb and VII, wherein A is 2-chlorothien-3-yl and B is each because one group corresponds to one row of Table A (Compounds V.86dA-1 to V.86dA-425; IVa-1.86dA-1 to IVa-1.86dA-425; IVb.86dA-1 to IVb.86dA-425; VII .86dA-1 to VII.86dA-425)

Table 87d Compounds V, IVa-1, IVb and VII, wherein A is 4-chlorothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.87dA-1 to V.87dA-425; IVa -1.87dA-1 to IVa-1.87dA-425; IVb.87dA-1 to IVb.87dA-425; VII.87dA-1 to VII.87dA-425)

Table 88d Compounds V, IVa-1, IVb and VII, wherein A is 5-chlorothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.88dA-1 to V.88dA-425; IVa -1.88dA-1 to IVa-1.88dA-425; IVb.88dA-1 to IVb.88dA-425; VII.88dA-1 to VII.88dA-425)

Table 89d compounds V, IVa-1, IVb and VI I, wherein A is 2-bromothien-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.89dA-1 to V.89dA-425; IVa-1.89dA-1 to IVa-1.89dA-425; IVb.89dA-1 to IVb.89dA-425; VII.89dA-1 to VII.89dA-425)

Table 9Od Compounds V, IVa-1, IVb and VII, wherein A is 4-bromothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.90dA-1 to V.90dA-425; IVa -1.9 OdA-I to IVa-1.90dA-425; IVb.90dA-1 to IVb.90dA-425; VII.90dA-1 to VII.90dA-425)

Table 91d Compounds V, IVa-1, IVb and VII, wherein A is 5-bromothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.91dA-1 to V.91dA-425; IVa -1.91 dA-1 to IVa-1.91 dA-425; IVb.91 dA-1 to IVb.91dA-425; VII.91dA-1 to VII.91 dA-425)

Table 92d Compounds V, IVa-1, IVb and VII, wherein A is 5-methylthien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.92dA-1 to V.92dA-425; IVa -1.92dA-1 to IVa-1.92dA-425; IVb.92dA-1 to IVb.92dA-425; VII.92dA-1 to VII.92dA-425)

Table 93d Compounds V, IVa-1, IVb and VII, wherein A is 2-methylthien-4-yl and B corresponds in each case to one group of one row of Table A (Compounds V.93dA-1 to V.93dA-425; IVa -1.93dA-1 to IVa-1.93dA-425; IVb.93dA-1 to IVb.93dA-425; VII.93dA-1 to VII.93dA-425)

Table 94d compounds V, IVa-1, IVb and VII, wherein A is 4,5-dichlorothien-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.94dA-1 to V. 94dA-425; IVa-1.94dA-1 to IVa-1.94dA-425; IVb.94dA-1 to IVb.94dA-425;

VII.94dA-1 to VII.94dA-425) Table 95d

Compounds V, IVa-1, IVb and VII, wherein A is 2,5-dichlorothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.95dA-1 to V.95dA-425; IVa -1.95dA-1 to IVa-1.95dA-425; IVb.95dA-1 to IVb.95dA-425;

VII.95dA-1 to VII.95dA-425) Table 96d

Compounds V, IVa-1, IVb and VII, wherein A is 2,3-dichlorothien-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.96dA-1 to V.96dA-425; IVa -1.96dA-1 to IVa-1.96dA-425; IVb.96dA-1 to IVb.96dA-425;

VII.96dA-1 to VII.96dA-425) Table 97d

Compounds V, IVa-1, IVb and VII, wherein A is 2,5-dibromothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.97dA-1 to V.97dA-425; IVa -1.97dA-1 to IVa-1.97dA-425; IVb.97dA-1 to IVb.97dA-425;

VII.97dA-1 to VII.97dA-425) Table 98d

Compounds V, IVa-1, IVb and VII, wherein A is 4,5-dimethylthien-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.98dA-1 to V.98dA-425; IVa -1.98dA-1 to IVa-1.98dA-425; IVb.98dA-1 to IVb.98dA-425;

VII.98dA-1 to VII.98dA-425) Table 99d

Compounds V, IVa-1, IVb and VII, wherein A is 2,5-dimethylthien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.99dA-1 to V.99dA-425; IVa -1.99dA-1 to IVa-1.99dA-425; IVb.99dA-1 to IVb.99dA-425;

VII.99dA-1 to VII.99dA-425) Table 10Od

Compounds V, IVa-1, IVb and VII, wherein A is 2,3-dimethylthien-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.1 OOdA-1 to V.100dA-425; IVa-1.100dA-1 to IVa-1.100dA425; IVb.100dA-1 to IVb.100dA-

425; VII.100dA-1 to VII.100dA-425) Table 101 d

Compounds V, IVa-1, IVb and VII, wherein A is 3,4,5-trichlorothien-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.101 dA-1 to V.101 dA IVa-1.101 dA-1 to IVa-1.101 dA-425; IVb.101 dA-1 to IVb.101 dA-

425; VII.101dA-1 to VII.101 dA-425) Table 102d

Compounds V, IVa-1, IVb and VII, wherein A is 2,4,5-trichlorothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.102dA-1 to V. 102dA-425 IVa-1.102dA-1 to IVa-1.102dA-425; IVb.102dA-1 to IVb.102dA-

425; VII.102dA-1 to VII.102dA-425) Table 103d

Compounds V, IVa-1, IVb and VII, wherein A is 2,4,5-tribromothien-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.103dA-1 to V.103dA-425 IVa-1.103dA-1 to IVa-1.103dA-425; IVb.103dA-1 to IVb.103dA-425; VII.103dA-1 to VII.103dA-425)

Table 104d

Compounds V, IVa-1, IVb and VII, wherein A is 3,4,5-trimethylthien-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.104dA-1 to V.104dA-425 IVa-1.104dA-1 to IVa-1.104dA-425; IVb.104dA-1 to IVb.104dA-425; VII.104dA-1 to VII.104dA-425)

Table 105d

Compounds V, IVa-1, IVb and VII, wherein A is 4-chlorofur-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.105dA-1 to V.105dA-425; IVa-1.105 dA-1 to IVa-1.105dA-425; IVb.105dA-1 to IVb.105dA-425; VII.105dA-1 to VII.105dA-425)

Table 106d

Compounds V, IVa-1, IVb and VII, wherein A is 5-chlorofur-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.106dA-1 to V.106dA-425; IVa-1.106 dA-1 to IVa-1.106dA-425; IVb.106dA-1 to IVb.106dA-425; VII.106dA-1 to VII.106dA-425)

Table 107d

Compounds V, IVa-1, IVb and VII wherein A is 3-bromo-fur-2-yl and B is each a group of one line of Table A (Compounds V.107dA-1 to V.107dA-425; IVa-1.107 dA-1 to IVa-1.107dA-425; IVb.107dA-1 to IVb.107dA-425; VII.107dA-1 to VII.107dA-425)

Table 108d

Compounds V, IVa-1, IVb and VII, wherein A is 4-bromo-fur-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.108dA-1 to V.108dA-425; IVa-1.108 dA-1 to IVa-1.108dA-425; IVb.108dA-1 to IVb.108dA-425; VII.108dA-1 to VII.108dA-425)

Table 109d

Compounds V, IVa-1, IVb and VII wherein A is 5-bromo-fur-2-yl and B is each a group of one line of Table A (Compounds V.109dA-1 to V.109dA-425; IVa-1.109 dA-1 to IVa-1.109dA-425; IVb.109dA-1 to IVb.109dA-425; VII.109dA-1 to VII.109dA-425)

Table 1 1Od

Compounds V, IVa-1, IVb and VII, wherein A is 3,4-dichloropur-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.110dA-1 to V.1 10dA-425; IVa-1.1 10dA-1 to IVa-1.1 1 OdA-425; IVb.110dA-1 to IVb.11 OdA-425; VI 1.110dA-1 to VII.110dA-425)

Table 1 11 d

Compounds V, IVa-1, IVb and VII, wherein A is 4,5-dichloropur-2-yl and B is because one group corresponds to one row of Table A (Compounds V.1 11 dA-1 to V.11 1 dA-425; IVa-1.1 11 dA-1 to IVa-1.1 1 1dA-425; IVb.11 1 dA-1 to IVb.H idA-425, VI 1.11 1dA-1 to VI 1.11 1 dA-425)

Table 1 12d Compounds V, IVa-1, IVb and VII, wherein A is thiazol-2-yl and B corresponds in each case to one group of one row of Table A (Compounds V.112dA-1 to V.112dA-425; 1.1 12dA-1 to IVa-1.1 12dA-425; IVb.1 12dA-1 to IVb.112dA-425; VII.112dA-1 to VII.112dA-425)

Table 1 shows compounds V, IVa-1, IVb and VII in which A is thiazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.113dA-1 to V.113dA-425; 1.1 13dA-1 to IVa-1.1 13dA-425; IVb.1 13dA-1 to IVb.113dA-425; VII.113dA-1 to VII.113dA-425)

Table 1 14d Compounds V, IVa-1, IVb and VII, wherein A is thiazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds V.114dA-1 to V.114dA-425; 1.1 14dA-1 to IVa-1.1 14dA-425; IVb.1 14dA-1 to IVb.114dA-425; VII.114dA-1 to VII.114dA-425)

Table 1 shows compounds V, IVa-1, IVb and VII in which A is isothiazol-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.1 15dA-1 to V.115dA-425; -1.1 15dA-1 to IVa-1.1 15dA-425; IVb.1 15dA-1 to IVb.115dA-425; VII.115dA-1 to VII.115dA-425)

Table 16d Compounds V, IVa-1, IVb and VII, wherein A is isothiazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds V.1 16dA-1 to V.116dA-425; IVa -1.1 16dA-1 to IVa-1.1 16dA-425; IVb.1 16dA-1 to IVb.116dA-425; VII.116dA-1 to VII.116dA-425)

Table 1 shows compounds V, IVa-1, IVb and VII in which A is isothiazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds V.1 17dA-1 to V.117dA-425; -1.1 17dA-1 to IVa-1.1 17dA-425; IVb.1 17dA-1 to IVb.117dA-425; VII.117dA-1 to VII.117dA-425)

Table 1 shows compounds V, IVa-1, IVb and VII in which A is 2-chlorothiazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.118dA-1 to V.118dA-425; IVa-1.1 18dA-1 to IVa-1.1 18dA-425; IVb.118dA-1 to IVb.118dA-425; VII.118dA-1 to VII.118dA-425)

Table 1 19d Compounds V, IVa-1, IVb and VII, wherein A is 2-chlorothiazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds V.119dA-1 to V.119dA-425; IVa-1.1 19dA-1 to IVa-1.1 19dA-425; IVb.119dA-1 to IVb.119dA-

425; VII.119dA-1 to VII.1 19dA-425) Table 12Od

Compounds V, IVa-1, IVb and VII, wherein A is 4-chlorothiazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds V.120dA-1 to V.120dA-425; IVa -1.120dA-1 to IVa-1.120dA-425; IVb.120dA-1 to IVb.120dA-

425; VII.120dA-1 to VII.120dA-425) Table 121 d

Compounds V, IVa-1, IVb and VII, wherein A is 2-bromothiazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.121dA-1 to V.121 dA-425; IVa-1.121 dA-1 to IVa-1.121 dA-425; IVb.121 dA-1 to IVb.121dA-

425; VII.121dA-1 to VI 1.121 dA-425) Table 122d

Compounds V, IVa-1, IVb and VII, wherein A is 2-bromothiazol-5-yl and B in each case corresponds to one group of one row of Table A (Compounds V.122dA-1 to V.122dA-425; IVa -1.122dA-1 to IVa-1.122dA-425; IVb.122dA-1 to IVb.122dA-

425; VII.122dA-1 to VII.122dA-425) Table 123d

Compounds V, IVa-1, IVb and VII in which A is 2,4-dichlorothiazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds V.123dA-1 to V.123dA-425; IVa -1.123dA-1 to IVa-1.123dA425; IVb.123dA-1 to IVb.123dA-

425; VII.123dA-1 to VII.123dA-425) Table 124d

Compounds V, IVa-1, IVb and VII, wherein A is 3-chloroisothiazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds V.124dA-1 to V.124dA-425; IVa-1.124 dA-1 to IVa-1.124dA-425; IVb.124dA-1 to IVb.124dA-

425; VII.124dA-1 to VII.124dA-425) Table 125d

Compounds V, IVa-1, IVb and VII in which A is 5-methylisothiazol-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.125dA-1 to V.125dA-425; IVa-1.125 dA-1 to IVa-1.125dA-425; IVb.125dA-1 to IVb.125dA-

425; VII.125dA-1 to VII.125dA-425) Table 126d

Compounds V, IVa-1, IVb and VII in which A is 3-methylisothiazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds V.126dA-1 to V.126dA-425; IVa-1.126 dA-1 to IVa-1.126dA-425; IVb.126dA-1 to IVb.126dA-

425; VII.126dA-1 to VII.126dA-425) Table 127d

Compounds V, IVa-1, IVb and VII in which A is 3-methylisothiazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds V.127dA-1 to V.127dA-425; IVa-1.127 dA-1 to IVa-1.127dA-425; IVb.127dA-1 to IVb.127dA-

425; VII.127dA-1 to VII.127dA-425) Table 128d

Compounds V, IVa-1, IVb and VII, wherein A is 4,5-dichloroisothiazol-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.128dA-1 to V.128dA-425; IVa -1.128dA-1 to IVa-1.128dA-425; IVb.128dA-1 to IVb.128dA-425; VII.128A-1 to VII.128dA-425)

Table 129d

Compounds V, IVa-1, IVb and VII in which A is 4,5-dimethylisothiazol-3-yl and B corresponds in each case to one group of one row of Table A (Compounds V.129dA-1 to V.129dA-425; IVa -1.129dA-1 to IVa-1.129dA-425; IVb.129dA-1 to IVb.129dA-425; VII.129dA-1 to VII.129dA-425)

Table 13Od

Compounds V, IVa-1, IVb and VII in which A is 3,5-dimethylisothiazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds V.130dA-1 to V.130dA-425; IVa -1.130dA-1 to IVa-1.130dA-425; IVb.130dA-1 to IVb.130dA-425; VII.130dA-1 to VII.130dA-425)

Table 131 d

Compounds V, IVa-1, IVb and VII, wherein A is 3,4-dichloroisothiazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds V.131dA-1 to V.131 dA-425; IVa-1.131 dA-1 to IVa-1.131 dA-425; IVb.131dA-1 to IVb.131 dA-425; VII.131 dA-1 to VI 1.131 dA-425)

Table 132d

Compounds V, IVa-1, IVb and VII in which A is oxazol-2-yl and B corresponds in each case to one group of one row of Table A (compounds V.132dA-1 to V.132dA-425; IVa-1.132dA- 1 to IVa-1.132dA-425; IVb.132dA-1 to IVb.132dA-425; VII.132dA-1 to VII.132dA-425)

Table 133d

Compounds V, IVa-1, IVb and VII, in which A is oxazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.133dA-1 to V.133dA-425; IVa-1.133dA- 1 to IVa-1.133dA-425; IVb.133dA-1 to IVb.133dA-425; VII.133dA-1 to VII.133dA-425)

Table 134d

Compounds V, IVa-1, IVb and VII, wherein A is oxazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds V.134dA-1 to V.134dA-425; IVa-1.134dA- 1 to IVa-1.134dA-425; IVb.134dA-1 to IVb.134dA-425; VII.134dA-1 to VII.134dA-425)

Table 135d

Compounds V, IVa-1, IVb and VII, wherein A is isoxazol-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.135dA-1 to V.135dA-425; IVa-1.135dA- 1 to IVa-1,135dA-425; IVb.135dA-1 to IVb.135dA-425; VII.135dA-1 to VII.135dA-425)

Table 136d

Compounds V, IVa-1, IVb and VII wherein A is isoxazol-4-yl and B are each corresponds to a group of a row of Table A (compounds V.136dA-1 to

V.136dA-425; IVa-1.136dA-1 to IVa-1.136dA-425; IVb.136dA-1 to IVb.136dA-

425; VII.136dA-1 to VII.136dA-425) Table 137d Compounds V, IVa-1, IVb and VII, wherein A is isoxazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds V.137dA -1 to

V.137dA-425; IVa-1.137dA-1 to IVa-1.137dA-425; IVb.137dA-1 to IVb.137dA-

425; VII.137dA-1 to VII.137dA-425) Table 138d Compounds V, IVa-1, IVb and VII, wherein A is 3-chloroisoxazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds V IVA-1.138dA-1 to IVa-1.138dA-425; IVb.138dA-1 to IVb.138dA-

425; VII.138dA-1 to VII.138dA-425) Table 139d Compounds V, IVa-1, IVb and VII, wherein A is 5-methylisoxazol-3-yl and B corresponds in each case to one group of one row of Table A (compounds V IVA-1.139dA-1 to IVa-1.139dA-425; IVb.139dA-1 to IVb.139dA-

425; VII.139dA-1 to VII.139dA-425) Table 14Od Compounds V, IVa-1, IVb and VII, wherein A is 5-methylisoxazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds V IVA-1,140dA-1 to IVa-1,140dA-425; IVb.140dA-1 to IVb.140dA-

425; VII.140dA-1 to VII.140dA-425) Table 141d Compounds V, IVa-1, IVb and VII, wherein A is 3-methylisoxazol-5-yl and B corresponds in each case to one group of one row of Table A (Compounds V.141dA-1 to V.141 dA-425; IVa-1.141 dA-1 to IVa-1.141dA-425; IVb.141 dA-1 to IVb.141 dA-

425; VII.141dA-1 to VII.141 dA-425) Table 142d compounds V, IVa-1, IVb and VII, wherein A is 3,5-dimethylisoxazol-4-yl and

B corresponds in each case to one group of a row of Table A (compounds

V.142dA-1 to V.142dA-425; IVa-1.142dA-1 to IVa-1.142dA-425; IVb.142dA-1 to

IVb.142dA-425; VII.142dA-1 to VII.142dA-425) Table 143d Compounds V, IVa-1, IVb and VII, wherein A is 3-chloro-5-methylisoxazol-4-yl and B is in each case one group of a row of Table A. corresponds (connections

V.143dA-1 to V.143dA-425; IVa-1.143dA-1 to IVa-1.143dA-425; IVb.143dA-1 to

IVb.143dA-425; VII.143dA-1 to VII.143dA-425) Table 144d Compounds V, IVa-1, IVb and VII, wherein A is 3-methyl-4-chloroisoxazol-5-yl and B is in each case one group of a row of Table A. corresponds (connections V.144dA-1 to V.144dA-425; IVa-1.144dA-1 to IVa-1.144dA-425; IVb.144dA-1 to

IVb.144dA-425; VII.144dA-1 to VII.144dA-425) Table 145d

Compounds V, IVa-1, IVb and VII, in which A is 1-methylpyrazol-3-yl and B corresponds in each case to one group of one row of Table A (compounds V.145dA-1 to V.145dA-425; IVa 1.145dA-1 to IVa-1.145dA-425; IVb.145dA-1 to IVb.145dA-

425; VII.145dA-1 to VII.145dA-425) Table 146d

Compounds V, IVa-1, IVb and VII, in which A is 1-methylpyrazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.146dA-1 to V.146dA-425; IVa 1.146dA-1 to IVa-1.146dA-425; IVb.146dA-1 to IVb.146dA-

425; VII.146dA-1 to VII.146dA-425) Table 147d

Compounds V, IVa-1, IVb and VII, in which A is 1-methylpyrazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds V.147dA-1 to V.147dA-425; IVa 1.147dA-1 to IVa-1.147dA-425; IVb.147dA-1 to IVb.147dA-

425; VII.147dA-1 to VII.147dA-425) Table 148d

Compounds V, IVa-1, IVb and VII, wherein A is 1, 3-dimethylpyrazol-4-yl and B in each case corresponds to one group of a row of Table A (compounds

V.148dA-1 to V.148dA-425; IVa-1.148dA-1 to IVa-1.148dA-425; IVb.148dA-1 to

IVb.148dA-425; VII.148dA-1 to VII.148dA-425) Table 149d

Compounds V, IVa-1, IVb and VII, wherein A is 1, 5-dimethylpyrazol-4-yl and B corresponds in each case to one group of one row of Table A (Compounds

V.149dA-1 to V.149dA-425; IVa-1.149dA-1 to IVa-1.149dA-425; IVb.149dA-1 bis

IVb.149dA-425; VII.149dA-1 to VII.149dA-425) Table 15Od

Compounds V, IVa-1, IVb and VII, wherein A is 1, 3,5-trimethylpyrazol-4-yl and B in each case corresponds to one group of a row of Table A (compounds

V.150dA-1 to V.150dA-425; IVa-1,150dA-1 to IVa-1,150dA-425; IVb.150dA-1 to

IVb.150dA-425; VII.150dA-1 to VII.150dA-425) Table 151 d

Compounds V, IVa-1, IVb and VII, wherein A is 1-methylimidazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds V.151dA-1 to V.151 dA-425; 1.151 dA-1 to IVa-1.151 dA-425; IVb.151 dA-1 to IVb.151dA-

425; VII.151dA-1 to VII.151 dA-425) Table 152d

Compounds V, IVa-1, IVb and VII, wherein A is 1, 5-dimethylimidazol-4-yl and B corresponds in each case to one group of one row of Table A (compounds

V.152dA-1 to V.152dA-425; IVa-1.152dA-1 to IVa-1.152dA-425; IVb.152dA-1 bis

IVb.152dA-425; VII.152dA-1 to VII.152dA-425) Table 153d

Compounds V, IVa-1, IVb and VII, wherein A is 1, 2-dimethylimidazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds V.153dA-1 to V.153dA-425; IVa -1.153dA-1 to IVa-1.153dA-425; IVb.153dA-1 to I Vb.153dA-425; VI 1.153dA-1 to VI 1.153dA-425)

Table 154d

Compounds V, IVa-1, IVb and VII, wherein A is 1,4-dimethylimidazol-5-yl and B corresponds in each case to one group of one row of Table A (compounds V.154dA-1 to V.154dA-425; IVa -1.154dA-1 to IVa-1.154dA-425; IVb.154dA-1 to IVb.154dA-425; VII.154dA-1 to VII.154dA-425)

Table 155d

Compounds V, IVa-1, IVb and VII, wherein B is pyridin-2-yl and A corresponds in each case to one group of one row of Table A (compounds V.155dA-1 to V.155dA-425; IVa-1.155dA- 1 to IVa-1.155dA-425; IVb.155dA-1 to IVb.155dA-425; VII.155dA-1 to VII.155dA-425)

Table 156d

Compounds V, IVa-1, IVb and VII, wherein B is pyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.156dA-1 to V.156dA-425; IVa-1.156dA- 1 to IVa-1.156dA-425; IVb.156dA-1 to IVb.156dA-425; VII.156dA-1 to VII.156dA-425)

Table 157d

Compounds V, IVa-1, IVb and VII, wherein B is pyridin-4-yl and A corresponds in each case to one group of one row of Table A (compounds V.157dA-1 to V.157dA-425; IVa-1.157dA- 1 to IVa-1.157dA-425; IVb.157dA-1 to IVb.157dA-425; VII.157dA-1 to VII.157dA-425)

Table 158d

Compounds V, IVa-1, IVb and VII, wherein B is 3-chloropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds V.158dA-1 to V.158dA-425; IVa-1.158 dA-1 to IVa-1.158dA-425; IVb.158dA-1 to IVb.158dA-425; VII.158dA-1 to VII.158dA-425)

Table 159d

Compounds V, IVa-1, IVb and VII in which B is 4-chloropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds V.159dA-1 to V.159dA-425; IVa-1.159 dA-1 to IVa-1.159dA-425; IVb.159dA-1 to IVb.159dA-425; VII.159dA-1 to VII.159dA-425)

Table 16Od

Compounds V, IVa-1, IVb and VII, wherein B is 5-chloropyridin-2-yl and A corresponds in each case to one group of a row of Table A (Compounds V.160dA-1 to V.160dA-425; IVa-1.160 dA-1 to IVa-1.160dA-425; IVb.160dA-1 to IVb.16OdA-425; VII.160dA-1 to VII.160dA-425)

Table 161 d

Compounds V, IVa-1, IVb and VII, wherein B is 6-chloropyridin-2-yl and A is each because one group corresponds to one row of Table A (compounds V.161dA-1 to V.161 dA-425; IVa-1.161 dA-1 to IVa-1.161dA-425; IVb.161 dA-1 to IVb.161dA-425 VII.161dA-1 to VII.161 dA-425)

Table 162d Compounds V, IVa-1, IVb and VII, wherein B is 2-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.162dA-1 to V.162dA-425; IVa -1.162dA-1 to IVa-1.162dA-425; IVb.162dA-1 to IVb.162dA-425; VII.162dA-1 to VII.162dA-425)

Table 163d Compounds V, IVa-1, IVb and VII, wherein B is 4-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.163dA-1 to V.163dA-425; IVa -1.163dA-1 to IVa-1.163dA-425; IVb.163dA-1 to IVb.163dA-425; VII.163dA-1 to VII.163dA-425)

Table 164d Compounds V, IVa-1, IVb and VII, wherein B is 5-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.164dA-1 to V.164dA-425; IVa -1.164dA-1 to IVa-1.164dA-425; IVb.164dA-1 to IVb.164dA-425; VII.164dA-1 to VII.164dA-425)

Table 165d Compounds V, IVa-1, IVb and VII, wherein B is 6-chloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.165dA-1 to V.165dA-425; IVa -1.165dA-1 to IVa-1.165dA-425; IVb.165dA-1 to IVb.165dA-425; VII.165dA-1 to VII.165dA-425)

Table 166d Compounds V, IVa-1, IVb and VII, wherein B is 2-chloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.166dA-1 to V.166dA-425; IVa -1.166dA-1 to IVa-1.166dA-425; IVb.166dA-1 to IVb.166dA-425; VII.166dA-1 to VII.166dA-425)

Table 167d Compounds V, IVa-1, IVb and VII, wherein B is 3-chloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.167dA-1 to V.167dA-425; IVa -1.167dA-1 to IVa-1.167dA-425; IVb.167dA-1 to IVb.167dA-425; VII.167dA-1 to VII.167dA-425)

Table 168d Compounds V, IVa-1, IVb and VII, wherein B is 4-chloropyridin-5-yl and A corresponds in each case to one group of one row of Table A (Compounds V.168dA-1 to V.168dA-425; IVa -1.168dA-1 to IVa-1.168dA-425; IVb.168dA-1 to IVb.168dA-425; VII.168dA-1 to VII.168dA-425)

Table 169d compounds V, IVa-1, IVb and VII, wherein B is 3-fluoropyridin-2-yl and A corresponds in each case to one group of a row of Table A (compounds V.169dA-1 to V.169dA-425; IVa-1.169dA-1 to IVa-1.169dA-425; IVb.169dA-1 to IVb.169dA-

425; VII.169dA-1 to VII.169dA-425) Table 17Od

Compounds V, IVa-1, IVb and VII, wherein B is 4-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table A (compounds V.170dA-1 to V.170dA-425; IVa -1.170dA-1 to IVa-1.170dA-425; IVb.170dA-1 to IVb.17OdA-

425; VII.170dA-1 to VII.170dA-425) Table 171 d

Compounds V, IVa-1, IVb and VII, wherein B is 5-fluoropyridin-2-yl and A in each case corresponds to one group of one row of Table A (compounds V.171 dA-1 to V.171 dA-425 IVa-1.171 dA-1 to IVa-1.171 dA-425; IVb.171 dA-1 to IVb.171dA-

425; VI 1.171 dA-1 to VI 1.171 dA-425) Table 172d

Compounds V, IVa-1, IVb and VII, wherein B is 6-fluoropyridin-2-yl and A corresponds in each case to one group of one row of Table A (compounds V.172dA-1 to V.172dA-425; IVa -1.172dA-1 to IVa-1.172dA-425; IVb.172dA-1 to IVb.172dA-

425; VII.172dA-1 to VII.172dA-425) Table 173d

Compounds V, IVa-1, IVb and VII, wherein B is 2-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.173dA-1 to V.173dA-425; IVa -1.173dA-1 to IVa-1.173dA-425; IVb.173dA-1 to IVb.173dA-

425; VII.173dA-1 to VII.173dA-425) Table 174d

Compounds V, IVa-1, IVb and VII, wherein B is 4-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.174dA-1 to V.174dA-425; IVa -1.174dA-1 to IVa-1.174dA-425; IVb.174dA-1 to IVb.174dA-

425; VII.174dA-1 to VII.174dA-425) Table 175d

Compounds V, IVa-1, IVb and VII, wherein B is 5-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.175dA-1 to V.175dA-425; IVa -1.175dA-1 to IVa-1.175dA-425; IVb.175dA-1 to IVb.175dA-

425; VII.175dA-1 to VII.175dA-425) Table 176d

Compounds V, IVa-1, IVb and VII, wherein B is 6-fluoropyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.176dA-1 to V.176dA-425; IVa -1.176dA-1 to IVa-1.176dA-425; IVb.176dA-1 to IVb.176dA-

425; VII.176dA-1 to VII.176dA-425) Table 177d

Compounds V, IVa-1, IVb and VII, wherein B is 2-fluoropyridin-4-yl and A corresponds in each case to one group of one row of Table A (compounds V.177dA-1 to V.177dA-425; IVa -1.177dA-1 to IVa-1.177dA-425; IVb.177dA-1 to IVb.177dA-

425; VII.177dA-1 to VII.177dA-425) Table 178d

Compounds V, IVa-1, IVb and VII, wherein B is 3-fluoropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.178dA-1 to V.178dA-425; IVa-1.178 dA-1 to IVa-1.178dA-425; IVb.178dA-1 to IVb.178dA-425; VII.178dA-1 to VII.178dA-425)

Table 179d

Compounds V, IVa-1, IVb and VII, wherein B is 3-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds V.179dA-1 to V.179dA-425; IVa-1.179 dA-1 to IVa-1.179dA-425; IVb.179dA-1 to IVb.179dA-425; VII.179dA-1 to VII.179dA-425)

Table 18Od

Compounds V, IVa-1, IVb and VII, wherein B is 4-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds V.180dA-1 to V.180dA-425; IVa-1.180 dA-1 to IVa-1,180dA-425; IVb.180dA-1 to IVb.18OdA-425; VII.180dA-1 to VII.180dA-425)

Table 181 d

Compounds V, IVa-1, IVb and VII, wherein B is 5-methylpyridin-2-yl and A corresponds in each case to one group of one row of Table A (compounds V.181dA-1 to V.181 dA-425; 1.181 dA-1 to IVa-1.181 dA-425; IVb.181 dA-1 to IVb.181dA-425; VII.181dA-1 to VI 1.181 dA-425)

Table 182d

Compounds V, IVa-1, IVb and VII wherein B is 6-methylpyridin-2-yl and A is each a group of one line of Table A (Compounds V.182dA-1 to V.182dA-425; IVa-1.182 dA-1 to IVa-1.182dA-425; IVb.182dA-1 to IVb.182dA-425; VII.182dA-1 to VII.182dA-425)

Table 183d

Compounds V, IVa-1, IVb and VII wherein B is 2-methylpyridin-3-yl and A is each a group of one line of Table A (Compounds V.183dA-1 to V.183dA-425; IVa-1.183 dA-1 to IVa-1.183dA-425; IVb.183dA-1 to IVb.183dA-425; VII.183dA-1 to VII.183dA-425)

Table 184d

Compounds V, IVa-1, IVb and VII wherein B is 4-methylpyridin-3-yl and A is each a group of one line of Table A (Compounds V.184dA-1 to V.184dA-425; IVa-1.184 dA-1 to IVa-1.184dA-425; IVb.184dA-1 to IVb.184dA-425; VII.184dA-1 to VII.184dA-425)

Table 185d

Compounds V, IVa-1, IVb and VII, wherein B is 5-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.185dA-1 to V.185dA-425; IVa-1.185 dA-1 to IVa-1.185dA-425; IVb.185dA-1 to IVb.185dA-425; VII.185dA-1 to VII.185dA-425)

Table 186d

Compounds V, IVa-1, IVb and VII, wherein B is 6-methylpyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.186dA-1 to V.186dA-425, IVa-1.186dA-1 to IVa-1.186dA-425, IVb.186dA-1 to IVb.186dA-

425; VII.186dA-1 to VII.186dA-425). Table 187d Compounds V, IVa-1, IVb and VII, wherein B is 2-methylpyridin-4-yl and A corresponds in each case to one group of one row of Table A (compounds V IVA-1.187dA-1 to IVa-1.187dA-425; IVb.187dA-1 to IVb.187dA-

425; VII.187dA-1 to VII.187dA-425) Table 188d Compounds V, IVa-1, IVb and VII, wherein B is 3-methylpyridin-4-yl and A in each case corresponds to one group of a row of Table A (Compounds V IVa-1.188dA-1 to IVa-1.188dA-425; IVb.188dA-1 to IVb.188dA-

425; VII.188dA-1 to VII.188dA-425) Table 189d Compounds V, IVa-1, IVb and VII, wherein B is 4-methylpyridin-5-yl and A corresponds in each case to one group of one row of Table A (compounds V IVa-1.189dA-1 to IVa-1.189dA-425; IVb.189dA-1 to IVb.189dA-

425; VII.189dA-1 to VII.189dA-425) Table 19Od Compounds V, IVa-1, IVb and VII, wherein B is 3-methoxypyridin-2-yl and A in each case corresponds to one group of a row of Table A (Compounds V IVA-1,190dA-1 to IVa-1,190dA-425; IVb.190dA-1 to IVb.190dA-

425; VII.190dA-1 to VII.190dA-425) Table 191d Compounds V, IVa-1, IVb and VII, wherein B is 4-methoxypyridin-2-yl and A in each case corresponds to one group of one row of Table A (Compounds V.191dA-1 to V.191 dA-425; IVa-1.191 dA-1 to IVa-1.191dA-425; IVb.191dA-1 to IVb.191 dA-

425; VII.191dA-1 to VII.191 dA-425) Table 192d Compounds V, IVa-1, IVb and VII, wherein B is 5-methoxypyridin-2-yl and A in each case corresponds to one group of a row of Table A (Compounds V.192dA-1 to V.192dA-425; IVa-1.192dA-1 to IVa-1.192dA-425; IVb.192dA-1 to IVb.192dA-

425; VII.192dA-1 to VII.192dA-425) Table 193d Compounds V, IVa-1, IVb and VII, wherein B is 6-methoxypyridin-2-yl and A corresponds in each case to one group of one row of Table A (compounds V IVA-1,193dA-1 to IVa-1,193dA-425; IVb.193dA-1 to IVb.193dA-

425; VII.193dA-1 to VII.193dA-425) Table 194d Compounds V, IVa-1, IVb and VII, wherein B is 2-methoxypyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V .194dA-1 to V.194dA-425; IVa-1.194dA-1 to IVa-1.194dA-425; IVb.194dA-1 to IVb.194dA

425; VII.194dA-1 to VII.194dA-425) Table 195d

Compounds V, IVa-1, IVb and VII in which B is 4-methoxypyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.195dA-1 to V.195dA-425; IVa-1.195 dA-1 to IVa-1.195dA-425; IVb.195dA-1 to IVb.195dA-

425; VII.195dA-1 to VII.195dA-425) Table 196d

Compounds V, IVa-1, IVb and VII, wherein B is 5-methoxypyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.196dA-1 to V.196dA-425; IVa-1.196 dA-1 to IVa-1.196dA-425; IVb.196dA-1 to IVb.196dA-

425; VII.196dA-1 to VII.196dA-425) Table 197d

Compounds V, IVa-1, IVb and VII, wherein B is 6-methoxypyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.197dA-1 to V.197dA-425; IVa-1.197 dA-1 to IVa-1.197dA-425; IVb.197dA-1 to IVb.197dA-

425; VII.197dA-1 to VII.197dA-425) Table 198d

Compounds V, IVa-1, IVb and VII, wherein B is 2-methoxypyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.198dA-1 to V.198dA-425; IVa-1.198 dA-1 to IVa-1.198dA-425; IVb.198dA-1 to IVb.198dA-

425; VII.198dA-1 to VII.198dA-425) Table 199d

Compounds V, IVa-1, IVb and VII, wherein B is 3-methoxypyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.199dA-1 to V.199dA-425; IVa-1.199 dA-1 to IVa-1.199dA425; IVb.199dA-1 to IVb.199dA-

425; VII.199dA-1 to VII.199dA-425) Table 20Od

Compounds V, IVa-1, IVb and VII, wherein B is 3,5-dichloropyridin-2-yl and A corresponds in each case to one group of one row of Table A (compounds V.200dA-1 to V.200dA-425; IVa -1.20OdA-I to IVa-1.200dA-425; IVb.200dA-1 to IVb.200dA-

425; VII.200dA-1 to VII.200dA-425) Table 201 d

Compounds V, IVa-1, IVb and VII, wherein B is 2,4-dichloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.201dA-1 to V.201 dA-425; IVa-1.201 dA-1 to IVa-1.201dA-425; IVb.201 dA-1 to IVb.201dA-

425; VII.201dA-1 to VI 1.201 dA-425) Table 202d

Compounds V, IVa-1, IVb and VII, wherein B is 2,5-dichloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.202dA-1 to V.202dA-425; IVa -1.202dA-1 to IVa-1.202dA-425; IVb.202dA-1 to IVb.202dA-

425; VII.202dA-1 to VII.202dA-425) Table 203d

Compounds V, IVa-1, IVb and VII, wherein B is 2,6-dichloropyridin-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.203dA-1 to V.203dA-425; IVa -1.203dA-1 to IVa-1.203dA-425; IVb.203dA-1 to IVb.203dA-425; VII.203dA-1 to VII.203dA-425)

Table 204d

Compounds V, IVa-1, IVb and VII, wherein B is 2,6-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (compounds V.204dA-1 to V.204dA-425; IVa -1.204dA-1 to IVa-1.204dA-425; IVb.204dA-1 to IVb.204dA-425; VII.204dA-1 to VII.204dA-425)

Table 205d

Compounds V, IVa-1, IVb and VII, wherein B is 3,5-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (compounds V.205dA-1 to V.205dA-425; IVa -1205dA-1 to IVa-1.205dA-425; IVb.205dA-1 to IVb.205dA-425; VII.205dA-1 to VII.205dA-425)

Table 206d

Compounds V, IVa-1, IVb and VII, wherein B is 3,6-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.206dA-1 to V.206dA-425; IVa -1.206dA-1 to IVa-1.206dA-425; IVb.206dA-1 to IVb.206dA-425; VII.206dA-1 to VII.206dA-425)

Table 207d

Compounds V, IVa-1, IVb and VII, wherein B is 2,5-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (compounds V.207dA-1 to V.207dA-425; IVa -1.207dA-1 to IVa-1.207dA-425; IVb.207dA-1 to IVb.207dA-425; VII.207dA-1 to VII.207dA-425)

Table 208d

Compounds V, IVa-1, IVb and VII, wherein B is 2,3-dichloropyridin-4-yl and A corresponds in each case to one group of one row of Table A (compounds V.208dA-1 to V.208dA-425; IVa -1.208dA-1 to IVa-1.208dA-425; IVb.208dA-1 to IVb.208dA-425; VII.208dA-1 to VII.208dA-425)

Table 209d

Compounds V, IVa-1, IVb and VII, wherein B is 2,4-dichloropyridin-5-yl and A corresponds in each case to one group of one row of Table A (Compounds V.209dA-1 to V.209dA-425; IVa -1.209dA-1 to IVa-1.209dA-425; IVb.209dA-1 to IVb.209dA-425; VII.209dA-1 to VII.209dA-425)

Table 21d

Compounds V, IVa-1, IVb and VII, wherein B is 3,5-difluoropyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds V.210dA-1 to V.210dA-425; IVa -1.21OdA-I to IVa-1.21 OdA-425; IVb.210dA-1 to IVb.210dA-425; VII.210dA-1 to VII.21 OdA-425)

Table 211 d

Compounds V, IVa-1, IVb and VII, wherein B is 3,5-difluoropyridin-4-yl and A corresponds in each case to one group of one row of Table A (compounds V.211dA-1 to V.21 1 dA-425; IVa-1.211 dA-1 to IVa-1.21 1dA-425; IVb.21 1 dA-1 to IVb.21 1dA-

425; VII.21 1dA-1 to VII.21 1 dA-425) Table 212d Compounds V, IVa-1, IVb and VII, wherein B is 2,3-difluoropyridin-4-yl and A is in each case one group of one row of the table A corresponds to (compounds V.212dA-1 to V.212dA-425; IVa-1.212dA-1 to IVa-1.212dA-425; IVb.212dA-1 to IVb.212dA-

425; VII.212dA-1 to VII.212dA-425) Table 213d Compounds V, IVa-1, IVb and VII, wherein B is 3,5-dimethylpyridin-2-yl and

A corresponds in each case to one group of a row of Table A (compounds

V.213dA-1 to V.213dA-425; IVa-1.213dA-1 to IVa-1.213dA-425; IVb.213dA-1 to

IVb.213dA-425; VII.213dA-1 to VII.213dA-425) Table 214d compounds V, IVa-1, IVb and VII, wherein B is 3,4-dimethylpyridin-2-yl and

A corresponds in each case to one group of a row of Table A (compounds

V.214dA-1 to V.214dA-425; IVa-1.214dA-1 to IVa-1.214dA-425; IVb.214dA-1 to

IVb.214dA-425; VII.214dA-1 to VII.214dA-425) Table 215d Compounds V, IVa-1, IVb and VII, wherein B is 4,6-dimethylpyridin-3-yl and

A corresponds in each case to one group of a row of Table A (compounds

V.215dA-1 to V.215dA-425; IVa-1.215dA-1 to IVa-1.215dA-425; IVb.215dA-1 to

IVb.215dA-425; VII.215dA-1 to VII.215dA-425) Table 216d compounds V, IVa-1, IVb and VII, wherein B is 2,4-dimethylpyridin-3-yl and

A corresponds in each case to one group of a row of Table A (compounds

V.216dA-1 to V.216dA-425; IVa-1.216dA-1 to IVa-1.216dA-425; IVb.216dA-1 to

IVb.216dA-425; VII.216dA-1 to VII.216dA-425) Table 217d Compounds V, IVa-1, IVb and VII, wherein B is 3,5-dimethylpyridin-4-yl and

A corresponds in each case to one group of a row of Table A (compounds

V.217dA-1 to V.217dA-425; IVa-1.217dA-1 to IVa-1.217dA-425; IVb.217dA-1 to

IVb.217dA-425; VII.217dA-1 to VII.217dA-425) Table 218d Compounds V, IVa-1, IVb and VII, wherein B is 2-chloro-3-fluoropyridin-4-yl and

A corresponds in each case to one group of a row of Table A (compounds

V.218dA-1 to V.218dA-425; IVa-1.218dA-1 to IVa-1.218dA-425; IVb.218dA-1 to

IVb.218dA-425; VII.218dA-1 to VII.218dA-425) Table 219d Compounds V, IVa-1, IVb and VII, wherein B is 4-chloro-3-methylpyridin-2-yl and A is in each case one group of a row of Table A. corresponds (connections V.219dA-1 to V.219dA-425; IVa-1.219dA-1 to IVa-1.219dA-425; IVb.219dA-1 to

IVb.219dA-425; VII.219dA-1 to VII.219dA-425) Table 22Od

Compounds V, IVa-1, IVb and VII, wherein B is 5-chloro-3-methylpyridin-2-yl and A in each case corresponds to one group of a row of Table A (Compounds

V.220dA-1 to V.220dA-425; IVa-1.22OdA-I to IVa-1.220dA-425; IVb.220dA-1 to

IVb.220dA-425; VII.220dA-1 to VII.220dA-425) Table 221 d

Compounds V, IVa-1, IVb and VII, wherein B is 5-fluoro-3-methylpyridin-2-yl and A in each case corresponds to one group of a row of Table A (Compounds

V.221dA-1 to V.221 dA-425; IVa-1.221 dA-1 to IVa-1.221 dA-425; IVb.221dA-1 to

IVb.221dA-425; VII.221 dA-1 to VI 1.221 dA-425) Table 222d

Compounds V, IVa-1, IVb and VII, wherein B is 3-chloro-5-trifluoromethylpyridin-2-yl and A corresponds in each case to one group of one row of Table A (Compounds V.222dA-1 to V.222dA-425 IVa-1.222dA-1 to IVa-1.222dA-425; IVb.222dA-1 to IVb.222dA-425; VII.222dA-1 to VII.222dA-425) Table 223d

Compounds V, IVa-1, IVb and VII, wherein B is 2-chloro-6-trifluoromethylpyridin-3-yl and A in each case corresponds to one group of a row of Table A (compounds V.223dA-1 to V.223dA-425 IVa-1.223dA-1 to IVa-1.223dA-425; IVb.223dA-1 to IVb.223dA-425; VII.223dA-1 to VII.223dA-425) Table 224d

Compounds V, IVa-1, IVb and VII, wherein B is 2,4-dichloro-6-methylpyridin-3-yl and A in each case corresponds to one group of a row of Table A (compounds V.224dA-1 to V.224dA IVb-1,224dA-1 to IVa-1,224dA-425; IVb.224dA-1 to IVb.224dA-425; VII.224dA-1 to VII.224dA-425) Table 225d

Compounds V, IVa-1, IVb and VII, wherein B is 3,4,5-trichloropyridin-2-yl and A in each case corresponds to one group of a row of Table A (compounds

V.225dA-1 to V.225dA-425; IVa-1.225dA-1 to IVa-1.225dA-425; IVb.225dA-1 to

IVb.225dA-425; VII.225dA-1 to VII.225dA-425) Table 226d

Compounds V, IVa-1, IVb and VII, wherein B is 2,4,6-trichloropyridin-3-yl and A in each case corresponds to one group of a row of Table A (Compounds

V.226dA-1 to V.226dA-425; IVa-1.226dA-1 to IVa-1.226dA-425; IVb.226dA-1 to

IVb.226dA-425; VII.226dA-1 to VII.226dA-425) Table 227d

Compounds V, IVa-1, IVb and VII, wherein B is pyrimidin-2-yl and A in each case corresponds to one group of a row of Table A (compounds V.227dA-1 to

V.227dA-425; IVa-1.227dA-1 to IVa-1.227dA-425; IVb.227dA-1 to IVb.227dA-

425; VII.227dA-1 to VII.227dA-425) Table 228d

Compounds V, IVa-1, IVb and VII, wherein B is pyrimidin-5-yl and A in each case corresponds to one group of one row of Table A (compounds V.228dA-1 to V.228dA-425; IVa-1.228dA- 1 to IVa-1.228dA-425; IVb.228dA-1 to IVb.228dA-425; VII.228dA-1 to VII.228dA-425)

Table 229d

Compounds V, IVa-1, IVb and VII in which B is 6-chloropyrimidin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.229dA-1 to V.229dA-425; IVa-1.229 dA-1 to IVa-1.229dA-425; IVb.229dA-1 to IVb.229dA-425; VII.229dA-1 to VII.229dA-425)

Table 23Od

Compounds V, IVa-1, IVb and VII, wherein B is 6-methylpyrimidin-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.230dA-1 to V.230dA-425; IVa-1.23 OdA-I to IVa-1.230dA-425; IVb.230dA-1 to IVb.230dA-425; VII.230dA-1 to VII.230dA-425)

Table 231 d

Compounds V, IVa-1, IVb and VII in which B is 6-methoxypyrimidin-3-yl and A in each case corresponds to one group of one row of Table A (compounds V.231dA-1 to V.231 dA-425; 1,231 dA-1 to IVa-1,231 dA-425; IVb.231dA-1 to IVb.231 dA-425; VII.231 dA-1 to VI 1,231 dA-425)

Table 232d

Compounds V, IVa-1, IVb and VII, wherein B is 2,4-dichloropyrimidin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.232dA-1 to V.232dA-425; IVa -1.232dA-1 to IVa-1.232dA-425; IVb.232dA-1 to I Vb.232dA-425; VI 1.232dA-1 to VI 1.232dA-425)

Table 233d

Compounds V, IVa-1, IVb and VII, wherein B is 2,6-dichloropyrimidin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.233dA-1 to V.233dA-425; IVa -1.233dA-1 to IVa-1.233dA-425; IVb.233dA-1 to I Vb.233dA-425; VI 1.233dA-1 to VI 1.233dA-425)

Table 234d

Compounds V, IVa-1, IVb and VII, wherein B is 2,4-difluoropyrimidin-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.234dA-1 to V.234dA-425; IVa -1.234dA-1 to IVa-1.234dA-425; IVb.234dA-1 to I Vb.234dA-425; VI 1.234dA-1 to VI 1.234dA-425)

Table 235d

Compounds V, IVa-1, IVb and VII, wherein B is 2,6-difluoropyrimidin-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.235dA-1 to V.235dA-425; IVa -1.235dA-1 to IVa-1.235dA-425; IVb.235dA-1 to I Vb.235dA-425; VI 1.235dA-1 to VI 1.235dA-425)

Table 236d

Compounds V, IVa-1, IVb and VII, wherein B is 1, 3,5-triazin-2-yl and A is each because one group corresponds to one row of Table A (compounds V.236dA-1 to V.236dA-425; IVa-1.236dA-1 to IVa-1.236dA-425; IVb.236dA-1 to IVb.236dA-425; VII .236dA-1 to VII.236dA-425)

Table 237d Compounds V, IVa-1, IVb and VII, wherein B is thien-2-yl and A are each one

Group of one row of Table A corresponds (Compounds V.237dA-1 to V.237dA-425; IVa-1.237dA-1 to IVa-1.237dA-425; IVb.237dA-1 to IVb.237dA-425; VII.237dA -1 to VII.237dA-425)

Table 238d Compounds V, IVa-1, IVb and VII, wherein B is thien-3-yl and A are each one

Group of one line of Table A corresponds (compounds V.238dA-1 to V.238dA-425; IVa-1.238dA-1 to IVa-1.238dA-425; IVb.238dA-1 to IVb.238dA-425; VII.238dA -1 to VII.238dA-425)

Table 239d Compounds V, IVa-1, IVb and VII, wherein B is 5-chlorothien-2-yl and A corresponds in each case to one group of one row of Table A (Compounds V.239dA-1 to V.239dA-425; IVa -1.239dA-1 to IVa-1.239dA-425; IVb.239dA-1 to IVb.239dA-425; VII.239dA-1 to VII.239dA-425)

Table 24Od compounds V, IVa-1, IVb and VII, wherein B is 2-chlorothien-3-yl and A in each case corresponds to one group of a row of Table A (compounds V.240dA-1 to V.240dA-425; IVa -1.24OdA-I to IVa-1.240dA-425; IVb.240dA-1 to IVb.240dA-425; VII.240dA-1 to VII.240dA-425)

Table 241d Compounds V, IVa-1, IVb and VII, wherein B is 4-chlorothien-3-yl and A in each case corresponds to one group of a row of Table A (compounds V.241dA-1 to V.241 dA-425 IVa-1.241 dA-1 to IVa-1.241dA-425; IVb.241 dA-1 to IVb.241dA-425; VII.241dA-1 to VII.241 dA-425)

Table 242d Compounds V, IVa-1, IVb and VII, wherein B is 5-chlorothien-3-yl and A corresponds in each case to one group of one row of Table A (Compounds V.242dA-1 to V.242dA-425; IVa IV.242dA-1 to IVb.242dA-425; VII.242dA-1 to VII.242dA-425)

Table 243d Compounds V, IVa-1, IVb and VII, wherein B is 2-bromothien-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.243dA-1 to V.243dA-425; IVa -1.243dA-1 to IVa-1.243dA-425; IVb.243dA-1 to IVb.243dA-425; VII.243dA-1 to VII.243dA-425)

Table 244d Compounds V, IVa-1, IVb and VII, wherein B is 4-bromothien-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.244dA-1 to V.244dA-425; IVa-1.244dA-1 to IVa-1.244dA-425; IVb.244dA-1 to IVb.244dA-

425; VII.244dA-1 to VII.244dA-425) Table 245d

Compounds V, IVa-1, IVb and VII in which B is 5-bromothien-3-yl and A in each case corresponds to one group of one row of Table A (compounds V.245dA-1 to V.245dA-425; IVa -1.245dA-1 to IVa-1.245dA-425; IVb.245dA-1 to IVb.245dA-

425; VII.245dA-1 to VII.245dA-425) Table 246d

Compounds V, IVa-1, IVb and VII in which B is 5-methylthien-2-yl and A in each case corresponds to one group of one row of Table A (compounds V.246dA-1 to V.246dA-425; IVa -1.246dA-1 to IVa-1.246dA-425; IVb.246dA-1 to IVb.246dA-

425; VII.246dA-1 to VII.246dA-425) Table 247d

Compounds V, IVa-1, IVb and VII, wherein B is 2-methylthien-4-yl and A in each case corresponds to one group of one row of Table A (compounds V.247dA-1 to V.247dA-425; IVa -1,247dA-1 to IVa-1,247dA-425; IVb.247dA-1 to IVb.247dA-

425; VII.247dA-1 to VII.247dA-425) Table 248d

Compounds V, IVa-1, IVb and VII, wherein B is 4,5-dichlorothien-2-yl and A corresponds in each case to one group of one row of Table A (Compounds V.248dA-1 to V.248dA-425; IVa -1.248dA-1 to IVa-1.248dA-425; IVb.248dA-1 to IVb.248dA-

425; VII.248dA-1 to VII.248dA-425) Table 249d

Compounds V, IVa-1, IVb and VII, wherein B is 2,5-dichlorothien-3-yl and A corresponds in each case to one group of a row of Table A (compounds V.249dA-1 to V.249dA-425; IVa -1.249dA-1 to IVa-1.249dA-425; IVb.249dA-1 to IVb.249dA-

425; VII.249dA-1 to VII.249dA-425) Table 25Od

Compounds V, IVa-1, IVb and VII, wherein B is 2,3-dichlorothien-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.250dA-1 to V.250dA-425; IVa -1.25OdA-I to IVa-1.250dA-425; IVb.250dA-1 to IVb.250dA-

425; VII.250dA-1 to VII.250dA-425) Table 251 d

Compounds V, IVa-1, IVb and VII, wherein B is 2,5-dibromothien-3-yl and A corresponds in each case to one group of a row of Table A (compounds V.251dA-1 to V.251 dA-425; IVa-1.251 dA-1 to IVa-1.251 dA-425; IVb.251 dA-1 to IVb.251dA-

425; VII.251dA-1 to VII.251 dA-425) Table 252d

Compounds V, IVa-1, IVb and VII, wherein B is 4,5-dimethylthien-2-yl and A corresponds in each case to one group of a row of Table A (compounds V.252dA-1 to V.252dA-425; IVa -1.252dA-1 to IVa-1.252dA-425; IVb.252dA-1 to IVb.252dA-

425; VII.252dA-1 to VII.252dA-425) Table 253d

Compounds V, IVa-1, IVb and VII, wherein B is 2,5-dimethylthien-3-yl and A corresponds in each case to one group of a row of Table A (Compounds V.253dA-1 to V.253dA-425; IVa 1.253dA-1 to IVa-1.253dA-425; IVb.253dA-1 to IVb.253dA-425; VI 1.253dA-1 to VI 1.253dA-425)

Table 254d

Compounds V, IVa-1, IVb and VII, wherein B is 2,3-dimethylthien-4-yl and A corresponds in each case to one group of a row of Table A (Compounds V.254dA-1 to V.254dA-425; IVa -1.254dA-1 to IVa-1.254dA-425; IVb.254dA-1 to IVb.254dA-425; VII.254dA-1 to VII.254dA-425)

Table 255d

Compounds V, IVa-1, IVb and VII, wherein B is 3,4,5-trichlorothien-2-yl and A corresponds in each case to one group of a row of Table A (compounds V.255dA-1 to V.255dA-425 IVa-1.255dA-1 to IVa-1.255dA-425; IVb.255dA-1 to IVb.255dA-425; VII.255dA-1 to VII.255dA-425)

Table 256d

Compounds V, IVa-1, IVb and VII, wherein B is 2,4,5-trichlorothien-3-yl and A in each case corresponds to one group of a row of Table A (compounds V.256dA-1 to V.256dA-425 IVa-1.256dA-1 to IVa-1.256dA-425; IVb.256dA-1 to IVb.256dA-425; VII.256dA-1 to VII.256dA-425)

Table 257d

Compounds V, IVa-1, IVb and VII, wherein B is 2,4,5-tribromothien-3-yl and A in each case corresponds to one group of a row of Table A (compounds V.257dA-1 to V.257dA-425 IVa-1.257dA-1 to IVa-1.257dA-425; IVb.257dA-1 to IVb.257dA-425; VII.257dA-1 to VII.257dA-425)

Table 258d

Compounds V, IVa-1, IVb and VII, wherein B is 3,4,5-trimethylthien-2-yl and A corresponds in each case to one group of one row of Table A (compounds V.258dA-1 to V.258dA-425 IVa-1.258dA-1 to IVa-1.258dA-425; IVb.258dA-1 to I Vb.258dA-425; VI 1.258dA-1 to VI 1.258dA-425)

Table 259d

Compounds V, IVa-1, IVb and VII, wherein B is 4-chlorofur-2-yl and A corresponds in each case to one group of one row of Table A (compounds V.259dA-1 to V.259dA-425; IVa-1.259 dA-1 to IVa-1.259dA-425; IVb.259dA-1 to IVb.259 dA-425; VII.259dA-1 to VII.259dA-425)

Table 26Od

Compounds V, IVa-1, IVb and VII, wherein B is 5-chlorofur-2-yl and A corresponds in each case to one group of a row of Table A (Compounds V.260dA-1 to V.260dA-425; IVa-1.26 OdA-I to IVa-1.260dA-425; IVb.260dA-1 to IVb.260dA-425; VII.260dA-1 to VII.260dA-425)

Table 261 d

Compounds V, IVa-1, IVb and VII wherein B is 3-bromo-fur-2-yl and A are each a group corresponding to one row of Table A (compounds V.261 dA-1 to V.261dA-425; IVa-1.261 dA-1 to IVa-1.261 dA-425; IVb.261 dA-1 to IVb.261dA-425; VII.261dA-1 to VII.261 dA-425)

Table 262d Compounds V, IVa-1, IVb and VII, wherein B is 4-bromo-fur-2-yl and A corresponds in each case to one group of one row of Table A (compounds V.262dA-1 to V.262dA-425; IVa -1.262dA-1 to IVa-1.262dA-425; IVb.262dA-1 to IVb.262dA-425; VII.262dA-1 to VII.262dA-425)

Table 263d Compounds V, IVa-1, IVb and VII, wherein B is 5-bromo-fur-2-yl and A corresponds in each case to one group of one row of Table A (Compounds V.263dA-1 to V.263dA-425; IVa -1.263dA-1 to IVa-1.263dA-425; IVb.263dA-1 to IVb.263dA-425; VII.263dA-1 to VII.263dA-425)

Table 264d Compounds V, IVa-1, IVb and VII, wherein B is 3,4-dichloropur-2-yl and A corresponds in each case to one group of one row of Table A (compounds V.264dA-1 to V.264dA-425 IVa-1.264dA-1 to IVa-1.264dA-425; IVb.264dA-1 to IVb.264dA-425; VII.264dA-1 to VII.264dA-425)

Table 265d Compounds V, IVa-1, IVb and VII, wherein B is 4,5-dichloropur-2-yl and A in each case corresponds to one group of one row of Table A (Compounds V.265dA-1 to V.265dA-425 IVa-1.265dA-1 to IVa-1.265dA-425; IVb.265dA-1 to IVb.265dA-425; VII.265dA-1 to VII.265dA-425)

Table 266d Compounds V, IVa-1, IVb and VII, wherein B is thiazol-2-yl and A corresponds in each case to one group of one row of Table A (Compounds V.266dA-1 to V.266dA-425; IVa-1.266 dA-1 to IVa-1.266dA-425; IVb.266dA-1 to IVb.266dA-425; VII.266dA-1 to VII.266dA-425)

Table 267d Compounds V, IVa-1, IVb and VII, wherein B is thiazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.267dA-1 to V.267dA-425; IVa-1.267 dA-1 to IVa-1.267dA-425; IVb.267dA-1 to IVb.267dA-425; VII.267dA-1 to VII.267dA-425)

Table 268d Compounds V, IVa-1, IVb and VII, wherein B is thiazol-5-yl and A corresponds in each case to one group of one row of Table A (compounds V.268dA-1 to V.268dA-425; IVa-1.268 dA-1 to IVa-1.268dA-425; IVb.268dA-1 to IVb.268dA-425; VII.268dA-1 to VII.268dA-425)

Table 269d compounds V, IVa-1, IVb and VII, wherein B is isothiazol-3-yl and A in each case corresponds to one group of a row of Table A (compounds V.269dA-1 to V.269dA-425; IVa-1.269dA-1 to IVa-1.269dA-425; IVb.269dA-1 to IVb.269dA-

425; VII.269dA-1 to VII.269dA-425) Table 27Od

Compounds V, IVa-1, IVb and VII, wherein B is isothiazol-4-yl and A in each case corresponds to one group of a row of Table A (compounds V.270dA-1 to

V.270dA-425; IVa-1.27OdA-I to IVa-1.270dA-425; IVb.270dA-1 to IVb.270dA-

425; VII.270dA-1 to VII.270dA-425) Table 271 d

Compounds V, IVa-1, IVb and VII, wherein B is isothiazol-5-yl and A in each case corresponds to one group of a row of Table A (compounds V.271 dA-1 to

V.271dA-425; IVa-1.271 dA-1 to IVa-1.271 dA-425; IVb.271 dA-1 to IVb.271dA-

425; VI 1.271 dA-1 to VII.271 dA-425) Table 272d

Compounds V, IVa-1, IVb and VII, wherein B is 2-chlorothiazol-4-yl and A in each case corresponds to one group of one row of Table A (compounds V.272dA-1 to V.272dA-425; IVa -1.272dA-1 to IVa-1.272dA-425; IVb.272dA-1 to IVb.272dA-

425; VII.272dA-1 to VII.272dA-425) Table 273d

Compounds V, IVa-1, IVb and VII, wherein B is 2-chlorothiazol-5-yl and A in each case corresponds to one group of one row of Table A (compounds V.273dA-1 to V.273dA-425; IVa -1.273dA-1 to IVa-1.273dA-425; IVb.273dA-1 to IVb.273dA-

425; VII.273dA-1 to VII.273dA-425) Table 274d

Compounds V, IVa-1, IVb and VII, wherein B is 4-chlorothiazol-5-yl and A in each case corresponds to one group of one line of Table A (compounds V.274dA-1 to V.274dA-425; IVa -1,274dA-1 to IVa-1,274dA-425; IVb.274dA-1 to IVb.274dA-

425; VII.274dA-1 to VII.274dA-425) Table 275d

Compounds V, IVa-1, IVb and VII, wherein B is 2-bromothiazol-4-yl and A in each case corresponds to one group of one line of Table A (compounds V.275dA-1 to V.275dA-425; IVa -1.275dA-1 to IVa-1.275dA-425; IVb.275dA-1 to IVb.275dA-

425; VII.275dA-1 to VII.275dA-425) Table 276d

Compounds V, IVa-1, IVb and VII, in which B is 2-bromothiazol-5-yl and A in each case corresponds to one group of one row of Table A (compounds V.276dA-1 to V.276dA-425; IVa -1.276dA-1 to IVa-1.276dA-425; IVb.276dA-1 to IVb.276dA-

425; VII.276dA-1 to VII.276dA-425) Table 277d

Compounds V, IVa-1, IVb and VII, wherein B is 2,4-dichlorothiazol-5-yl and A corresponds in each case to one group of one row of Table A (Compounds V.277dA-1 to V.277dA-425; IVa -1.277dA-1 to IVa-1.277dA-425; IVb.277dA-1 to IVb.277dA-

425; VII.277dA-1 to VII.277dA-425) Table 278d

Compounds V, IVa-1, IVb and VII, wherein B is 3-chloroisothiazol-4-yl and A corresponds in each case to one group of one row of Table A (compounds V.278dA-1 to V.278dA-425; IVa-1.278 dA-1 to IVa-1.278dA-425; IVb.278dA-1 to IVb.278dA-425; VII.278dA-1 to VII.278dA-425)

Table 279d

Compounds V, IVa-1, IVb and VII, wherein B is 5-methylisothiazol-3-yl and A corresponds in each case to one group of a row of Table A (compounds V.279dA-1 to V.279dA-425; IVa-1.279 dA-1 to IVa-1.279dA-425; IVb.279dA-1 to IVb.279dA-425; VII.279dA-1 to VII.279dA-425)

Table 28Od

Compounds V, IVa-1, IVb and VII, wherein B is 3-methylisothiazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.280dA-1 to V.280dA-425; IVa-1.28 OdA-I to IVa-1.280dA-425; IVb.280dA-1 to IVb.280dA-425; VII.280dA-1 to VII.280dA-425)

Table 281 d

Compounds V, IVa-1, IVb and VII in which B is 3-methylisothiazol-5-yl and A in each case corresponds to one group of one row of Table A (compounds V.281dA-1 to V.281 dA-425; 1.281 dA-1 to IVa-1.281 dA-425; IVb.281 dA-1 to IVb.281dA-425; VI 1.281 dA-1 to VII.281 dA-425)

Table 282d

Compounds V, IVa-1, IVb and VII, wherein B is 4,5-dichloroisothiazol-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.282dA-1 to V.282dA-425; IVa 1.282dA-1 to IVa-1.282dA-425; IVb.282dA-1 to I Vb.282dA-425; VI 1.282dA-1 to VI 1.282dA-425)

Table 283d

Compounds V, IVa-1, IVb and VII, wherein B is 4,5-dimethylisothiazol-3-yl and A corresponds in each case to one group of a row of Table A (compounds V.283dA-1 to V.283dA-425; IVa 1.283dA-1 to IVa-1.283dA-425; IVb.283dA-1 to I Vb.283dA-425; VI 1.283dA-1 to VI 1.283dA-425)

Table 284d

Compounds V, IVa-1, IVb and VII, wherein B is 3,5-dimethylisothiazol-4-yl and A corresponds in each case to one group of a row of Table A (Compounds V.284dA-1 to V.284dA-425; IVa -1.284dA-1 to IVa-1.284dA-425; IVb.284dA-1 to I Vb.284dA-425; VI 1.284dA-1 to VI 1.284dA-425)

Table 285d

Compounds V, IVa-1, IVb and VII, wherein B is 3,4-dichloroisothiazol-5-yl and A corresponds in each case to one group of one row of Table A (compounds V.285dA-1 to V.285dA-425; IVa 1.285dA-1 to IVa-1.285dA-425; IVb.285dA-1 to I Vb.285dA-425; VI 1.285dA-1 to VI 1.285dA-425)

Table 286d

Compounds V, IVa-1, IVb and VII, wherein B is oxazol-2-yl and A is in each case a group corresponds to one row of Table A (compounds V.286dA-1 to V.286dA-425; IVa-1.286dA-1 to IVa-1.286dA-425; IVb.286dA-1 to IVb.286dA-425; VII. 286dA-1 to VII.286dA-425)

Table 287d Compounds V, IVa-1, IVb and VII, wherein B is oxazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.287dA-1 to V.287dA-425; IVa-1.287 dA-1 to IVa-1.287dA-425; IVb.287dA-1 to IVb.287dA-425; VII.287dA-1 to VII.287dA-425)

Table 288d Compounds V, IVa-1, IVb and VII, wherein B is oxazol-5-yl and A corresponds in each case to one group of one row of Table A (compounds V.288dA-1 to V.288dA-425; IVa-1.288 dA-1 to IVa-1.288dA-425; IVb.288dA-1 to IVb.288dA-425; VII.288dA-1 to VII.288dA-425)

Table 289d Compounds V, IVa-1, IVb and VII, wherein B is isoxazol-3-yl and A corresponds in each case to one group of a row of Table A (compounds V.289dA-1 to V.289dA-425; IVa-1.289 dA-1 to IVa-1.289dA-425; IVb.289dA-1 to IVb.289dA-425; VII.289dA-1 to VII.289dA-425)

Table 29Od Compounds V, IVa-1, IVb and VII, wherein B is isoxazol-4-yl and A corresponds in each case to one group of a row of Table A (compounds V.290dA-1 to V.290dA-425; IVa-1.29 OdA-I to IVa-1.290dA-425; IVb.290dA-1 to IVb.290dA-425; VII.290dA-1 to VII.290dA-425)

Table 291d Compounds V, IVa-1, IVb and VII, wherein B is isoxazol-5-yl and A corresponds in each case to one group of one row of Table A (Compounds V.291 dA-1 to V.291dA-425; IVa -1,291 dA-1 to IVa-1,291 dA-425; IVb.291 dA-1 to IVb.291dA-425; VII.291dA-1 to VII.291 dA-425)

Table 292d Compounds V, IVa-1, IVb and VII, wherein B is 3-chloroisoxazol-5-yl and A corresponds in each case to one group of one row of Table A (Compounds V.292dA-1 to V.292dA-425; IVa -1.292dA-1 to IVa-1.292dA-425; IVb.292dA-1 to IVb.292dA-425; VII.292dA-1 to VII.292dA-425)

Table 293d Compounds V, IVa-1, IVb and VII, wherein B is 5-methylisoxazol-3-yl and A corresponds in each case to one group of a row of Table A (compounds V.293dA-1 to V.293dA-425; IVa -1.293dA-1 to IVa-1.293dA-425; IVb.293dA-1 to IVb.293dA-425; VII.293dA-1 to VII.293dA-425)

Table 294d Compounds V, IVa-1, IVb and VII, wherein B is 5-methylisoxazol-4-yl and A corresponds in each case to one group of a row of Table A (compounds V.294dA-1 to V.294dA-425; IVa-1.294dA-1 to IVa-1.294dA-425; IVb.294dA-1 to IVb.294dA-

425; VII.294dA-1 to VII.294dA-425) Table 295d

Compounds V, IVa-1, IVb and VII, wherein B is 3-methylisoxazol-5-yl and A corresponds in each case to one group of one row of Table A (compounds V.295dA-1 to V.295dA-425; IVa-1.295 dA-1 to IVa-1.295dA-425; IVb.295dA-1 to IVb.295dA-

425; VII.295dA-1 to VII.295dA-425) Table 296d

Compounds V, IVa-1, IVb and VII, wherein B is 3,5-dimethylisoxazol-4-yl and A in each case corresponds to one group of a row of Table A (Compounds

V.296dA-1 to V.296dA-425; IVa-1.296dA-1 to IVa-1.296dA-425; IVb.296dA-1 to

IVb.296dA-425; VII.296dA-1 to VII.296dA-425) Table 297d

Compounds V, IVa-1, IVb and VII, wherein B is 3-chloro-5-methylisoxazol-4-yl and A in each case corresponds to one group of a row of Table A (Compounds

V.297dA-1 to V.297dA-425; IVa-1.297dA-1 to IVa-1.297dA-425; IVb.297dA-1 bis

IVb.297dA-425; VII.297dA-1 to VII.297dA-425) Table 298d

Compounds V, IVa-1, IVb and VII, wherein B is 3-methyl-4-chloroisoxazol-5-yl and A in each case corresponds to one group of a row of Table A (Compounds

V.298dA-1 to V.298dA-425; IVa-1.298dA-1 to IVa-1.298dA-425; IVb.298dA-1 bis

IVb.298dA-425; VII.298dA-1 to VII.298dA-425) Table 299d

Compounds V, IVa-1, IVb and VII, wherein B is 1-methylpyrazol-3-yl and A corresponds in each case to one group of one row of Table A (compounds V.299dA-1 to V.299dA-425; IVa-1.299 dA-1 to IVa-1.299dA-425; IVb.299dA-1 to IVb.299dA-

425; VII.299dA-1 to VII.299dA-425) Table 30Od

Compounds V, IVa-1, IVb and VII, in which B is 1-methylpyrazol-4-yl and A in each case corresponds to one group of one row of Table A (compounds V.300dA-1 to V.300dA-425; 1.30OdA-I to IVa-1.300dA-425; IVb.300dA-1 to IVb.300dA-

425; VII.300dA-1 to VII.300dA-425) Table 301 d

Compounds V, IVa-1, IVb and VII, wherein B is 1-methyl-pyrazol-5-yl and A corresponds in each case to one group of one row of Table A (Compounds V.301dA-1 to V.301 dA-425; IVa -1.301 dA-1 to IVa-1.301dA-425; IVb.301 dA-1 to IVb.301dA-

425; VII.301dA-1 to VI 1.301 dA-425) Table 302d

Compounds V, IVa-1, IVb and VII, wherein B is 1, 3-dimethylpyrazol-4-yl and A in each case corresponds to one group of a row of Table A (Compounds

V.302dA-1 to V.302dA-425; IVa-1.302dA-1 to IVa-1.302dA-425; IVb.302dA-1 to

IVb.302dA-425; VII.302dA-1 to VII.302dA-425) Table 303d

Compounds V, IVa-1, IVb and VII, wherein B is 1, 5-dimethylpyrazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.303dA-1 to V.303dA-425; IVa -1.303dA-1 to IVa-1.303dA-425; IVb.303dA-1 to I Vb.303dA-425; VI 1.303dA-1 to VI 1.303dA-425)

Table 304d

Compounds V, IVa-1, IVb and VII, wherein B is 1, 3,5-trimethylpyrazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.304dA-1 to V.304dA-425 IVa-1.304dA-1 to IVa-1.304dA-425; IVb.304dA-1 to I Vb.304dA-425; VI 1.304dA-1 to VI 1.304dA-425)

Table 305d

Compounds V, IVa-1, IVb and VII, wherein B is 1-methylimidazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.305dA-1 to V.305dA-425; IVa-1.305 dA-1 to IVa-1.305dA-425; IVb.305dA-1 to IVb.305dA-425; VII.305dA-1 to VII.305dA-425)

Table 306d

Compounds V, IVa-1, IVb and VII, wherein B is 1, 5-dimethylimidazol-4-yl and A corresponds in each case to one group of one row of Table A (Compounds V.306dA-1 to V.306dA-425; IVa -1.306dA-1 to IVa-1.306dA-425; IVb.306dA-1 to I Vb.306dA-425; VI 1.306dA-1 to VI 1.306dA-425)

Table 307d

Compounds V, IVa-1, IVb and VII, wherein B is 1, 2-dimethylimidazol-5-yl and A corresponds in each case to one group of a row of Table A (Compounds V.307dA-1 to V.307dA-425; IVa -1.307dA-1 to IVa-1.307dA-425; IVb.307dA-1 to I Vb.307dA-425; VI 1.307dA-1 to VI 1.307dA-425)

Table 308d

Compounds V, IVa-1, IVb and VII, wherein B is 1, 4-dimethylimidazol-5-yl and A corresponds in each case to one group of a row of Table A (Compounds V.308dA-1 to V.308dA-425; IVa -1.308dA-1 to IVa-1.308dA-425; IVb.308dA-1 to I Vb.308dA-425; VI 1.308dA-1 to VI 1.308dA-425)

In particular, in view of their use, Compounds IIIa, INb, INc and IIId-1 compiled in the following Tables 309a to 616a are preferred. The groups mentioned in the tables for a substituent Furthermore, independently of the combination in which they are mentioned, they represent a particularly preferred embodiment of the substituent in question.

Table 309a

Compounds IIIa, INb, INc and IIId-1, in which A is pyridin-2-yl and B corresponds in each case to one group in one row of Table A (Compounds Wa.309aA-1 to Nla.309eaA-425, Nlb.309aA- 1 to Nlb.309aA-425, lllc.309aA-l to lllc.309aA-425 and llld-1.309aA-l to llld-1.309aA-425) Table 310a

Compounds IIIa, INb, INc and IIId-1, in which A is pyridin-3-yl and B corresponds in each case to one group in the row of Table A (compounds Nla.310aA-1 to Nla.310eaA-425, Nlb.310aA-1 to Nlb.310aA-425, lllc.310aA-l to lllc.310aA-425 and llld-1.31OaA-l to llld-1.310aA-425). Table 311 a

Compounds IIIa, INb, INc and IIId-1, in which A is pyridin-4-yl and B in each case corresponds to one group in a row of Table A (Compounds Nla.311 aA-1 to Nla.311 eaA-425, Nlb. 311 aA-1 to Nlb.31 1aA-425, Nlc.311 aA-1 to Nlc.311 aA-425 and IMd-1.311aA-1 to llld-1.311 aA-425) Table 312a

Compounds IIIa, INb, INc and IIId-1, where A is 3-chloropyridin-2-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.312aA-1 to Nla.312aA-425, Mlb. 312aA-1 to Nlb.312aA-425, lllc.312aA-l to lllc.312aA-425 and llld-1.312aA-l to llld-1.312aA-425) Table 313a

Compounds IIIa, INb, INc and IIId-1, in which A is 4-chloropyridin-2-yl and B corresponds in each case to one group in one row of Table A (Compounds Nla.313aA-1 to Nla.313aA-425, Nlb. 313aA-1 to Nlb.313aA-425, lllc.313aA-l to lllc.313aA-425 and llld-1.313aA-l to llld-1.313aA-425) Table 314a

Compounds IIIa, INb, INc and IIId-1, in which A is 5-chloropyridin-2-yl and B corresponds in each case to one group in one row of Table A (Compounds Nla.314aA-1 to Nla.314aA-425, Nlb. 314aA-1 to Nlb.314aA-425, lllc.314aA-l to lllc.314aA-425 and llld-1.314aA-l to llld-1.314aA-425) Table 315a

Compounds IIIa, INb, INc and IIId-1, where A is 6-chloropyridin-2-yl and B corresponds in each case to one group in one row of Table A (Compounds Nla.315aA-1 to Nla.315aA-425, Nlb. 315aA-1 to Nlb.315aA-425, lllc.315aA-l to lllc.315aA-425 and llld-1.315aA-l to llld-1.315aA-425) Table 316a

Compounds purple, INb, INc and llld-1, wherein A is 2-chloro-pyridin-3-yl and B in each case corresponds to a group in a row of Table A (Compounds Mla.316aA-1 to Nla.316aA-425, Mlb.316aA-l to lllb.316aA-425, IMc.316aA-l to lllc.316aA-425 and llld-1.316aA-l to llld-1.316aA-425) Table 317a

Compounds purple, INb, INc and llld-1, wherein A is 4-chloropyridin-3-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.317aA-1 to Nla.317aA-425, Mlb.317aA-1 to Nlb.317aA-425, lllc.317aA-l to lllc.317aA-425 and llld-1.317aA-1 to llld-1.317aA-425) Table 318a

Compounds purple, INb, INc and llld-1, wherein A is 5-chloropyridin-3-yl and B corresponds in each case to one group in a row of Table A (Compounds

Mla.318aA-1 to Nla.318aA-425, Mlb.318aA-1 to Nlb.318aA-425, IMc.318aA-1 to lllc.318aA-425 and IIId-1.318aA-1 to IIId-1.318aA-425) Table 319a

Compounds lilac, INb, INc and llld-1, wherein A is 6-chloropyridin-3-yl and B in each case corresponds to a group in a row of Table A (Compounds

Mla.319aA-1 to Nla.319aA-425, Mlb.319aA-1 to Nlb.319aA-425, lllc.319aA-l to lllc.319aA-425 and llld-1.319aA-l to llld-1.319aA-425) Table 320a

Compounds purple, INb, INc and llld-1, wherein A is 2-chloropyridin-4-yl and B in each case corresponds to a group in a row of Table A (Compounds

Mla.320aA-1 to Nla.320aA-425, Mlb.320aA-1 to Nlb.320aA-425, lllc.320aA-l to lllc.320aA-425 and llld-1.32OaA-l to llld-1.320aA-425) Table 321 a

Compounds purple, INb, INc and llld-1, wherein A is 3-chloropyridin-4-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.321aA-1 to Nla.321aA-425, Mlb.321aA-1 to Nb.321 aA-425, lllc.321aA-l to lllc.321 aA-425 and llld-1.321 aA-1 to llld-1.321 aA- 425) Table 322a

Compounds purple, INb, INc and llld-1, wherein A is 4-chloropyridin-5-yl and B corresponds in each case to one group in a row of Table A (Compounds

Mla.322aA-1 to Nla.322aA-425, Mlb.322aA-1 to Nlb.322aA-425, lllc.322aA-l to lllc.322aA-425 and llld-1.322aA-l to llld-1.322aA-425) Table 323a

Compounds purple, INb, INc and llld-1, wherein A is 3-fluoropyridin-2-yl and B each corresponds to a group in a row of Table A (compounds

Nla.323aA-1 to Nla.323aA-425, Nlb.323aA-1 to Nb.323aA-425, lllc.323aA-l to lllc.323aA-425 and llld-1.323aA-l to llld-1.323aA-425) Table 324a

Compounds purple, INb, INc and llld-1, wherein A is 4-fluoropyridin-2-yl and B each corresponds to a group in a row of Table A (compounds

Nla.324aA-1 to Nla.324aA-425, Nlb.324aA-1 to Nb.324aA-425, lllc.324aA-l to lllc.324aA-425 and llld-1.324aA-l to llld-1.324aA-425) Table 325a

Compounds IIIa, INb, INc and IIId-1, where A is 5-fluoropyridin-2-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.325aA-1 to Nla.325aA-425, Mlb. 325aA-1 to Nlb.325aA-425, IMc.325aA-l to lllc.325aA-425 and llld-1.325aA-1 to llld-1.325aA-425)

Table 326a

Compounds IIIa, INb, INc and IIId-1, where A is 6-fluoropyridin-2-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.326aA-1 to Nla.326aA-425, Mlb. 326aA-1 to Nlb.326aA-425, lllc.326aA-l to lllc.326aA-425 and llld-1.326aA-l to llld-1.326aA-425)

Table 327a

Compounds IIIa, INb, INc and IIId-1, where A is 2-fluoropyridin-3-yl and B in each case corresponds to one group in a row of Table A (Compounds Mla.327aA-1 to Nla.327aA-425, Mlb. 327aA-1 to Nlb.327aA-425, lllc.327aA-l to lllc.327aA-425 and llld-1.327aA-l to llld-1.327aA-425)

Table 328a

Compounds IIIa, INb, INc and IIId-1, where A is 4-fluoropyridin-3-yl and B corresponds in each case to one group in a row of Table A (Compounds Mla.328aA-1 to Nla.328aA-425, Mlb. 328aA-1 to Nlb.328aA-425, IMc.328aA-1 to lllc.328aA-425 and llld-1.328aA-1 to llld-1.328aA-425)

Table 329a

Compounds IIIa, INb, INc and IIId-1, where A is 5-fluoropyridin-3-yl and B corresponds in each case to one group in a row of Table A (Compounds Mla.329aA-1 to Nla.329aA-425, Mlb. 329aA-1 to Nlb.329aA-425, lllc.329aA-l to lllc.329aA-425 and llld-1.329aA-l to llld-1.329aA-425)

Table 330a

Compounds IIIa, INb, INc and IIId-1, where A is 6-fluoropyridin-3-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.330aA-1 to Nla.330aA-425, Mlb. 330aA-1 to Nlb.330aA-425, Mlc.330aA-l to lllc.330aA-425 and llld-1.33OaA-l to llld-1.330aA-425)

Table 331 a

Compounds IIIa, INb, INc and IIId-1, where A is 2-fluoropyridin-4-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.331aA-1 to Nla.331aA-425, Mlb. 331aA-1 to Nlb.331 aA-425, lllc.331aA-l to lllc.331 aA-425 and llld-1.331 aA-1 to llld-1.331 aA-425)

Table 332a

Compounds purple, INb, INc and llld-1, wherein A is 3-fluoropyridin-4-yl and B corresponds in each case to one group in a row of Table A (Compounds Mla.332aA-1 to Nla.332aA-425, Mlb. 332aA-1 to Nlb.332aA-425, lllc.332aA-1 to lllc.332aA-425 and llld-1.332aA-1 to llld-1.332aA-425)

Table 333a

Compounds purple, INb, INc and llld-1, wherein A is 3-methylpyridin-2-yl and B each corresponds to a group in a row of Table A (compounds

Mla.333aA-1 to Nla.333aA-425, Mlb.333aA-1 to Nlb.333aA-425, IMc.333aA-1 to lllc.333aA-425 and IMd-1.333aA-1 to Nld-1.333aA-425) Table 334a Compounds IIIa, INb, INc and IIId-1, wherein A is 4-methylpyridin-2-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.334aA-1 to Nla.334aA-425, Mlb.334aA-1 to Nlb.334aA-425, IMc.334aA-1 to lllc.334aA-425 and IIId-1.334aA-1 to IIId-1.334aA-425) Table 335a Compounds IIIa, INb, INc and IIId-1, wherein A is 5-methylpyridin-2-yl and B in each case corresponds to a group in a row of Table A (Compounds

Mla.335aA-1 to Nla.335aA-425, Mlb.335aA-1 to Nlb.335aA-425, IMc.335aA-1 to lllc.335aA-425 and IIId-1.335aA-1 to IIId-1.335aA-425) Table 336a Compounds IIIa, INb, INc and IIId-1, wherein A is 6-methylpyridin-2-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.336aA-1 to Nla.336aA-425, Mlb.336aA-1 to Nlb.336aA-425, IMc.336aA-1 to lllc.336aA-425 and IIId-1.336aA-1 to IIId-1.336aA-425) Table 337a Compounds IIIa, INb, INc and IIId-1, wherein A is 2-methylpyridin-3-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.337aA-1 to Nla.337aA-425, Mlb.337aA-1 to Nlb.337aA-425, lllc.337aA-l to lllc.337aA-425 and llld-1.337aA-1 to llld-1.337aA-425) Table 338a Compounds IIIa, INb, INc and IIId-1, wherein A is 4-methylpyridin-3-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.338aA-1 to Nla.338aA-425, Mlb.338aA-1 to Nlb.338aA-425, IMc.338aA-1 to lllc.338aA-425 and IIId-1.338aA-1 to IIId-1.338aA-425) Table 339a Compounds IIIa, INb, INc and IIId-1, where A is 5-methylpyridin-3-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.339aA-1 to Nla.339aA-425, Mlb.339aA-1 to Nlb.339aA-425, IMc.339aA-1 to lllc.339aA-425 and llld-1.339aA-1 to llld-1.339aA-425) Table 340a Compounds IIIa, INb, INc and IIId-1, wherein A is 6-methylpyridin-3-yl and B corresponds in each case to one group in a row of Table A (Compounds

Mla.340aA-1 to Nla.340aA-425, Mlb.340aA-1 to Nlb.340aA-425, IMc.340aA-l to lllc.340aA-425 and llld-1.34OaA-l to llld-1.340aA-425) Table 341 a Compounds purple, INb, INc and llld-1, wherein A is 2-methylpyridin-4-yl and B each corresponds to a group in a row of Table A (Compounds Mla.341aA-1 to Nla.341aA-425, Mlb.341aA-l to lllb.341 a-425, IMc.341aA-l to lllc.341 aA-425 and llld-1.341 aA-1 to llld-1.341 aA- 425) Table 342a

Compounds purple, INb, INc and llld-1, wherein A is 3-methylpyridin-4-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.342aA-1 to Nla.342aA-425, IIIb.342aA-1 to Nlb.342aA-425, IIIc. 342aA-l to lllc.342aA-425 and llld-1.342aA-l to llld-1.342aA-425) Table 343a

Compounds purple, INb, INc and llld-1, wherein A is 4-methylpyridin-5-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.343aA-1 to Nlb.343aA-425, Mlb.343aA-1 to Nlb.343aA-425, lllc.343aA-l to lllc.343aA-425 and llld-1.343aA-l to llld-1.343aA-425) Table 344a

Compounds purple, INb, INc and llld-1, wherein A is 3-methoxypyridin-2-yl and B each corresponds to a group in a row of Table A (compounds

Mla.344aA-1 to Nla.344aA-425, Mlb.344aA-1 to Nlb.344aA-425, lllc.344aA-l to lllc.344aA-425 and llld-1.344aA-1 to llld-1.344aA-425) Table 345a

Compounds purple, INb, INc and llld-1, wherein A is 4-methoxypyridin-2-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.345aA-1 to Nla.345aA-425, Mlb.345aA-1 to Nlb.345aA-425, lllc.345aA-l to lllc.345aA-425 and llld-1.345aA-1 to llld-1.334aA-425) Table 346a

Compounds purple, INb, INc and llld-1, wherein A is 5-methoxypyridin-2-yl and B in each case corresponds to a group in a row of Table A (Compounds

Mla.346aA-1 to Nla.346aA-425, Mlb.346aA-1 to Nlb.346aA-425, lllc.346aA-l to lllc.346aA-425 and llld-1.346aA-l to llld-1.346aA-425) Table 347a

Compounds purple, INb, INc and llld-1, wherein A is 6-methoxypyridin-2-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.347aA-1 to Nla.347aA-425, Mlb.347aA-1 to Nlb.347aA-425, lllc.347aA-l to lllc.347aA-425 and llld-1.347aA-l to llld-1.347aA-425) Table 348a

Compounds lilac, INb, INc and llld-1, wherein A is 2-methoxypyridin-3-yl and B in each case corresponds to a group in a row of Table A (Compounds

Mla.348aA-1 to Nla.348aA-425, Mlb.348aA-1 to Nlb.348aA-425, IMc.348aA-1 to lllc.348aA-425 and IIId-1.348aA-1 to IIId-1.348aA-425) Table 349a

Compounds purple, INb, INc and llld-1, wherein A is 4-methoxypyridin-3-yl and B corresponds in each case to one group in a row of Table A (Compounds

Mla.349aA-1 to Nla.349aA-425, Mlb.349aA-1 to Nlb.349aA-425, lllc.349aA-l to lllc.349aA-425 and llld-1.349aA-l to llld-1.349aA-425) Table 350a

Compounds IIIa, INb, INc and IIId-1, where A is 5-methoxypyridin-3-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.350aA-1 to Nla.350aA-425, Mlb. 350aA-1 to Nlb.350aA-425, IMc.350aA-l to lllc.350aA-425 and llld-1.35OaA-l to llld-1.350aA-425)

Table 351 a

Compounds IIIa, INb, INc and IIId-1, where A is 6-methoxypyridin-3-yl and B corresponds in each case to one group in a row of Table A (Compounds Mla.351aA-1 to Nla.351aA-425, Mlb. 351aA-1 to Nlb.351 aA-425, lllc.351aA-1 to lllc.351 aA-425 and llld-1.351 aA-1 to llld-1.351 aA-425)

Table 352a

Compounds IIIa, INb, INc and IIId-1, where A is 2-methoxypyridin-4-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.352aA-1 to Nla.352aA-425, Mlb. 352aA-1 to Nlb.352aA-425, lllc.352aA-l to lllc.352aA-425 and llld-1.352aA-l to llld-1.352aA-425)

Table 353a

Compounds IIIa, INb, INc and IIId-1, where A is 3-methoxypyridin-4-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.353aA-1 to Nla.353aA-425, Mlb. 353aA-1 to Nlb.353aA-425, lllc.353aA-l to lllc.353aA-425 and llld-1.353aA-l to llld-1.353aA-425)

Table 354a

Compounds IIIa, INb, INc and IIId-1, where A is 3,5-dichloropyridin-2-yl and B corresponds in each case to one group in one row of Table A (compounds Mla.354aA-1 to Nla.354aA-425, Mlb.354aA-1 to Nlb.354aA-425, lllc.354aA-l to lllc.354aA-425 and llld-1.354aA-l to llld-1.354aA-425)

Table 355a

Compounds IIIa, INb, INc and IIId-1, in which A is 2,4-dichloropyridin-3-yl and B corresponds in each case to one group in one row of Table A (compounds Nla.355aA-1 to Nla.355aA-425, Nlb.355aA-1 to Nlb.355aA-425, lllc.355aA-l to lllc.355aA-425 and llld-1.355aA-l to llld-1.355aA-425)

Table 356a

Compounds IIIa, INb, INc and IIId-1, where A is 2,5-dichloropyridin-3-yl and B corresponds in each case to one group in one row of Table A (compounds Nla.356aA-1 to Nla.356aA-425, Nlb.356aA-1 to Nlb.356aA-425, lllc.356aA-l to lllc.356aA-425 and llld-1.356aA-l to llld-1.356aA-425)

Table 357a

Compounds IIIa, INb, INc and IIId-1, in which A is 2,6-dichloropyridin-3-yl and B corresponds in each case to one group in one row of Table A (compounds Nla.357aA-1 to Nla.357aA-425, Nlb.357aA-1 to Nlb.357aA-425, lllc.357aA-l to lllc.357aA-425 and llld-1.357aA-l to llld-1.357aA-425)

Table 358a

Compounds purple, INb, INc and llld-1, wherein A is 2,6-dichloropyridin-4-yl and B each corresponds to a group in a row of Table A (compounds

Mla.358aA-1 to Nlb.358aA-425, Mlb.358aA-1 to Nlb.358aA-425, IMc.358aA-1 to lllc.358aA-425 and IMd-1.358aA-1 to Nld-1.358aA-425) Table 359a Compounds IIIa, INb, INc and IIId-1, wherein A is 3,5-dichloropyridin-4-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.359aA-1 to Nla.359aA-425, Mlb.359aA-1 to Nlb.359aA-425, IMc.359aA-1 to lllc.359aA-425 and llld-1.359aA-1 to llld-1.359aA-425) Table 360a Compounds IIIa, INb, INc and IIId-1, in which A is 3,6-dichloropyridin-4-yl and B corresponds in each case to one group in one row of Table A (Compounds

Mla.360aA-1 to Nla.360aA-425, Mlb.360aA-1 to Nlb.360aA-425, IMc.360aA-l to lllc.360aA-425 and llld-1.36OaA-l to llld-1.360aA-425) Table 361 a Compounds purple, INb, INc and llld-1, wherein A is 2,5-dichloropyridin-4-yl and B in each case corresponds to a group in a row of Table A (Compounds

Mla.361aA-1 to Nla.361aA-425, Mlb.361aA-1 to Nlb.361 aA-425, lllc.361aA-1 to lllc.361 aA-425 and llld-1.361 aA-1 to llld-1.361 aA- 425). Compounds IIIa, INb, INc and IIId-1, wherein A is 2,3-dichloropyridin-4-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.362aA-1 to Nla.362aA-425, Mlb.362aA-1 to Nlb.362aA-425, lllc.362aA-l to lllc.362aA-425 and llld-1.362aA-l to llld-1.362aA-425) Table 363a Compounds IIIa, INb, INc and IIId-1, wherein A is 2,4-dichloropyridin-5-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.363aA-1 to Nla.363aA-425, Mlb.363aA-1 to Nlb.363aA-425, lllc.363aA-l to lllc.363aA-425 and llld-1.363aA-l to llld-1.363aA-425) Table 364a Compounds IIIa, INb, INc and IIId-1, wherein A is 3,5-difluoropyridin-2-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.364aA-1 to Nla.364aA-425, Mlb.364aA-1 to Nlb.364aA-425, lllc.364aA-l to lllc.364aA-425 and llld-1.364aA-l to llld-1.364aA-425) Table 365a Compounds IIIa, INb, INc and IIId-1, wherein A is 3,5-difluoropyridin-4-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla. 365aA-1 to Nla. 3,665aA-425, Mlb. Table 366a Compounds IIIa, INb, INc and IIId-1, wherein A is 2,3-difluoropyridin-4-yl and B in each case corresponds to one group in a row of Table A (Compounds Mla.366aA-1 to Nla.366aA-425, Mlb.366aA-1 to IIIb.366aA-425, IMc.366aA-1 to lllc.366aA-425 and IIId-1.366aA-1 to IIId-1.366aA-425) Table 367a

Compounds purple, INb, INc and llld-1, wherein A is 3, 5-dimethylpyridin-2-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.367aA-1 to Nla.367aA-425, Mlb.367aA-1 to Nlb.367aA-425, lllc.367aA-l to lllc.367aA-425 and llld-1.367aA-l to llld-1.367aA-425) Table 368a

Compounds purple, INb, INc and llld-1, wherein A is 3,4-dimethylpyridin-2-yl and B in each case corresponds to a group in a row of Table A (Compounds

Mla.368aA-1 to Nla.368aA-425, Mlb.368aA-1 to Nlb.368aA-425, IMc.368aA-1 to lllc.368aA-425 and llld-1.368aA-1 to llld-1.368aA-425) Table 369a

Compounds IIIa, INb, INc and IIId-1, where A is 4,6-dimethylpyridin-3-yl and B corresponds in each case to one group in a row of Table A (Compounds

Mla.369aA-1 to Nla.369aA-425, Mlb.369aA-1 to Nlb.369aA-425, IMc.369aA-l to lllc.369aA-425 and llld-1.369aA-l to llld-1.369aA-425) Table 370a

Compounds purple, INb, INc and llld-1, wherein A is 2,4-dimethylpyridin-3-yl and B in each case corresponds to a group in a row of Table A (Compounds

Mla.370aA-1 to Nla.370aA-425, IIIb.370aA-1 to Nlb.370aA-425, Mlc.370aA-l to lllc.370aA-425 and llld-1.37OaA-l to llld-1.370aA-425) Table 371 a

Compounds purple, INb, INc and llld-1, wherein A is 3,5-dimethylpyridin-4-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.371aA-1 to Nla.371aA-425, Mlb.371aA-1 to Nlb.371 aA-425, lllc.371aA-l to lllc.371 aA-425 and llld-1.371 aA-1 to llld-1.371 aA- 425) Table 372a

Compounds purple, INb, INc and llld-1, wherein A is 2-chloro-3-fluoropyridin-4-yl and B corresponds in each case to one group in a row of Table A (Compounds

Mla.372aA-1 to Nla.372aA-425, Mlb.372aA-1 to Nlb.372aA-425, lllc.372aA-l to lllc.372aA-425 and llld-1.372aA-l to llld-1.372aA-425) Table 373a

Compounds purple, INb, INc and llld-1, wherein A is 4-chloro-3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds

Mla.373aA-1 to Nla.373aA-425, Mlb.373aA-1 to Nlb.373aA-425, lllc.373aA-l to lllc.373aA-425 and llld-1.373aA-l to llld-1.373aA-425) Table 374a

Compounds purple, INb, INc and llld-1, wherein A is 5-chloro-3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds

Mla.374aA-1 to Nla.374aA-425, Mlb.374aA-1 to Nlb.374aA-425, lllc.374aA-l to lllc.374aA-425 and llld-1.374aA-l to llld-1.374aA-425) Table 375a

Compounds purple, INb, INc and llld-1, wherein A is 5-fluoro-3-methylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds Mla.375aA-1 to Nla.375aA-425 , Mlb.375aA-1 to Nlb.375aA-425, IMc.375aA-l to lllc.375aA-425 and llld-1.375aA-1 to llld-1.375aA-425)

Table 376a

Compounds IIIa, INb, INc and IIId-1, wherein A is 3-chloro-5-trifluoromethylpyridin-2-yl and B corresponds in each case to one group of one row of Table A (Compounds Mla.376aA-1 to Nla.376aA-425 , Mlb.376aA-1 to Nlb.376aA-425, lllc.376aA-1 to lllc.376aA-425 and llld-1.376aA-1 to llld-1.376aA-425)

Table 377a

Compounds purple, INb, INc and llld-1, wherein A is 2-chloro-6-trifluoromethylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds Mla.377aA-1 to Nla.377aA-425 , Mlb.377aA-1 to Nlb.377aA-425, lllc.377aA-1 to lllc.377aA-425 and llld-1.377aA-1 to llld-1.377aA-425)

Table 378a

Compounds purple, INb, INc and llld-1, wherein A is 2, 4-dichloro-6-methylpyridin-3-yl and B corresponds in each case to one group of one row of Table A (Compounds Mla.378aA-1 to Nla.378aA -425, Mlb.378aA-1 to Nlb.378aA-425, Mlc.378aA-1 to lllc.378aA-425 and llld-1.378aA-1 to llld-1.378aA-425)

Table 379a

Compounds IIIa, INb, INc and IIId-1, where A is 3,4,5-trichloropyridin-2-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.379aA-1 to Nla.379aA- 425, Mlb.379aA-1 to Nlb.379aA-425, lllc.379aA-l to lllc.379aA-425 and llld-1.379aA-l to llld-1.379aA-425)

Table 380a

Compounds IIIa, INb, INc and IIId-1, in which A is 2,4,6-trichloropyridin-3-yl and B corresponds in each case to one group in one row of Table A (compounds Mla.380aA-1 to Nla.380aA- 425, Mlb.380aA-1 to Nlb.380aA-425, IMc.380aA-l to lllc.380aA-425 and llld-1.38OaA-l to llld-1.380aA-425)

Table 381 a

Compounds IIIa, INb, INc and IIId-1, where A is pyrimidin-2-yl and B in each case corresponds to one group in a row of Table A (compounds III -1 to Nlb.381aA-425, lllc.381aA-l to lllc.381aA-425 and llld-1.381aA-l to llld-1.381 aA-425)

Table 382a

Compounds IIIa, INb, INc and IIId-1, in which A is pyrimidin-5-yl and B corresponds in each case to a group in one row of Table A (compounds Nla.382aA-1 to Nla.382aA-425, IIIb.382aA- 1 to Nlb.382aA-425, lllc.382aA-1 to lllc.382aA-425 and llld-1.382aA-1 to llld-1.382aA-425)

Table 383a

Compounds purple, INb, INc and llld-1, wherein A is 6-chloropyrimidin-3-yl and B each corresponds to a group in a row of Table A (compounds

Mla.383aA-1 to Nla.383aA-425, Mlb.383aA-1 to Nlb.383aA-425, Mlc.383aA-1 to lllc.383aA-425 and IMd-1.383aA-1 to Nld-1.383aA-425) Table 384a Compounds IIIa, INb, INc and IIId-1, wherein A is 6-methylpyrimidin-3-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.384aA-1 to Nla.384aA-425, Mlb.384aA-1 to Nlb.384aA-425, IMc.384aA-l to lllc.384aA-425 and llld-1.384aA-l to llld-1.384aA-425) Table 385a Compounds IIIa, INb, INc and IIId-1 wherein A is 6-methoxypyrimidin-3-yl and

B corresponds in each case to a group in a row of Table A (compounds

Mla.385aA-1 to Nla.385aA-425, Mlb.385aA-1 to Nlb.385aA-425, IMc.385aA-1 to lllc.385aA-425 and llld-1.385aA-1 to llld-1.385aA-425) Table 386a Compounds IIIa, INb, INc and IIId-1, wherein A is 2,4-dichloropyrimidin-3-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.386aA-1 to Nla.386aA-425, IIIb.386aA-1 to Nlb.386aA-425, Mlc.386aA-1 to lllc.386aA-425, and IIId-1.386aA-1 to IIId-1.386aA-425) Table 387a Compounds IIIa, INb, INc and IIId-1, wherein A is 2,6-dichloropyrimidin-3-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.387aA-1 to Nla.387aA-425, Mlb.387aA-1 to Nlb.387aA-425, IMc.387aA-1 to lllc.387aA-425 and llld-1.387aA-1 to llld-1.387aA-425) Table 388a Compounds IIIa, INb, INc and IIId-1, wherein A is 2,4-difluoropyrimidin-3-yl and

B corresponds in each case to a group in a row of Table A (compounds

Mla.388aA-1 to Nla.388aA-425, Mlb.388aA-1 to Nb388aA-425, Mlc.388aA-l to lllc.388aA-425 and llld-1.388aA-1 to llld-1.388aA-425) Table 389a Compounds IIIa, INb, INc and IIId-1, wherein A is 2,6-difluoropyrimidin-3-yl and

B corresponds in each case to a group in a row of Table A (compounds

Mla.389aA-1 to Nla.389aA-425, Mlb.389aA-1 to Nlb.389aA-425, IMc.389aA-1 to lllc.389aA-425 and llld-1.389aA-1 to llld-1.389aA-425) Table 390a Compounds IIIa, INb, INc and IIId-1, wherein A is 1, 3,5-triazin-2-yl and B in each case corresponds to a group in a row of Table A (Compounds

Mla.390aA-1 to Nla.390aA-425, Mlb.390aA-1 to Nlb.390aA-425, IMc.390aA-l to lllc.390aA-425 and llld-1.39OaA-l to llld-1.390aA-425) Table 391 a Compounds IIIa, INb, INc and IIId-1, in which A is thien-2-yl and B in each case corresponds to a group in a row of Table A (Compounds Mla.391aA-1 to Nla.391aA-425, Mlb.391aA-1 to IIIb.391 aA-425, IMc.391aA-1 to IIIc. 391 aA-425 and IIId-1.391 aA-1 to IIId-1.391 aA- 425) Table 392a

Compounds IIIa, INb, INc and IIId-1, in which A is thien-3-yl and B corresponds in each case to one group in one row of Table A (Compounds Nla.392aA-1 to

Nla.392aA-425, Mlb.392aA-1 to Nlb.392aA-425, lllc.392aA-1 to lllc.392aA-425 and llld-1.392aA-1 to llld-1.392aA-425) Table 393a

Compounds purple, INb, INc and llld-1, wherein A is 5-chlorothien-2-yl and B in each case corresponds to a group in a row of Table A (Compounds

Mla.393aA-1 to Nla.393aA-425, Mlb.393aA-1 to Nlb.393aA-425, IMc.393aA-1 to lllc.393aA-425 and llld-1.393aA-1 to llld-1.393aA-425) Table 394a

Compounds purple, INb, INc and llld-1, wherein A is 2-chlorothien-3-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.394aA-1 to Nla.394aA-425, Mlb.394aA-1 to Nlb.394aA-425, lllc.394aA-l to lllc.394aA-425 and llld-1.394aA-l to llld-1.394aA-425) Table 395a

Compounds purple, INb, INc and llld-1, wherein A is 4-chlorothien-3-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.395aA-1 to Nla.395aA-425, Mlb.395aA-1 to Nlb.395aA-425, IMc.395aA-l to lllc.395aA-425 and llld-1.395aA-1 to llld-1.395aA-425) Table 396a

Compounds purple, INb, INc and llld-1, wherein A is 5-chlorothien-3-yl and B each corresponds to a group in a row of Table A (compounds

Mla.396aA-1 to Nla.396aA-425, Mlb.396aA-1 to Nlb.396aA-425, Mlc.396aA-1 to lllc.396aA-425 and llld-1.396aA-1 to llld-1.396aA-425) Table 397a

Compounds purple, INb, INc and llld-1, wherein A is 2-bromothien-3-yl and B in each case corresponds to a group in a row of Table A (Compounds

Mla.397aA-1 to Nla.397aA-425, Mlb.397aA-1 to Nb.397aA-425, lllc.397aA-l to lllc.397aA-425 and llld-1.397aA-l to llld-1.397aA-425) Table 398a

Compounds purple, INb, INc and llld-1, wherein A is 4-bromothien-3-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.398aA-1 to Nla.398aA-425, Mlb.398aA-1 to Nlb.398aA-425, IMc.398aA-1 to lllc.398aA-425 and llld-1.398aA-1 to llld-1.398aA-425) Table 399a

Compounds purple, INb, INc and llld-1, wherein A is 5-bromothien-3-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.399aA-1 to Nla.399aA-425, Mlb.399aA-1 to Nlb.399aA-425, IMc.399aA-1 to lllc.399aA-425 and IIId-1.399aA-1 to IIId-1.399aA-425) Table 400a

Compounds IIIa, INb, INc and IIId-1, where A is 5-methylthien-2-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.400aA-1 to Nla.400aA-425, Mlb. 400aA-1 to Nlb.400aA-425, IMc.400aA-1 to lllc.400aA-425 and llld-1.40OaA-l to llld-1.400aA-425)

Table 401 a

Compounds IIIa, INb, INc and IIId-1, where A is 2-methylthien-4-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.401aA-1 to Nla.4019aA-425, Mlb. 401 aA-1 to Nlb.4019aA-425, IMc.401aA-1 to lllc.401 aA-425 and llld-1.401 aA-1 to llld-1.401 aA-425)

Table 402a

Compounds IIIa, INb, INc and IIId-1, in which A is 4,5-dichlorothien-2-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.402aA-1 to Nla.402aA-425, Mlb.402aA-1 to Nlb.402aA-425, lllc.402aA-l to lllc.402aA-425 and llld-1.402aA-l to llld-1.402aA-425)

Table 403a

Compounds IIIa, INb, INc and IIId-1, in which A is 2,5-dichlorothien-3-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.403aA-1 to Nla.403aA-425, Mlb.403aA-1 to Nlb.403aA-425, IMc.403aA-l to lllc.403aA-425 and llld-1.403aA-l to llld-1.403aA-425)

Table 404a

Compounds IIIa, INb, INc and IIId-1, where A is 2,3-dichlorothien-4-yl and B corresponds in each case to one group in a row of Table A (compounds Mla.404aA-1 to Nla.404aA-425, Mlb.404aA-1 to Nlb.404aA-425, lllc.404aA-l to lllc.404aA-425 and llld-1.404aA-l to llld-1.404aA-425)

Table 405a

Compounds IIIa, INb, INc and IIId-1, in which A is 2,5-dibromothien-3-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.405aA-1 to Nla.405aA-425, Mlb.405aA-1 to Nlb.405aA-425, lllc.405aA-l to lllc.405aA-425 and llld-1.405aA-l to llld-1.405aA-425)

Table 406a

Compounds IIIa, INb, INc and IIId-1, in which A is 4,5-dimethylthien-2-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.406aA-1 to Nla.406aA-425, Mlb.406aA-1 to Nlb.406aA-425, IMc.406aA-l to lllc.406aA-425 and llld-1.406aA-l to llld-1.406aA-425)

Table 407a

Compounds IIIa, INb, INc and IIId-1, in which A is 2,5-dimethylthien-3-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.407aA-1 to Nla.407aA-425, Mlb.407aA-1 to Nlb.407aA-425, lllc.407aA-l to lllc.407aA-425 and llld-1.407aA-l to llld-1.407aA-425)

Table 408a

Compounds IIIa, INb, INc and IIId-1, wherein A is 2,3-dimethylthien-4-yl and B each corresponds to a group in a row of Table A (compounds

Mla.408aA-1 to Nla.408aA-425, Mlb.408aA-1 to Nlb.408aA-425, IMc.408aA-1 to lllc.408aA-425 and IMd-1.408aA-1 to Nld-1.408aA-425) Table 409a Compounds IIIa, INb, INc and IIId-1, wherein A is 3,4,5-trichlorothien-2-yl and

B corresponds in each case to a group in a row of Table A (compounds

Mla.409aA-1 to Nla.409aA-425, Mlb.409aA-1 to Nlb.409aA-425, IMc.409aA-l to lllc.409aA-425 and llld-1.409aA-l to llld-1.409aA-425) Table 410a Compounds IIIa, INb, INc and IIId-1, wherein A is 2,4,5-trichlorothien-3-yl and

B corresponds in each case to a group in a row of Table A (compounds

Mla.410aA-1 to Nla.410aA-425, Mlb.410aA-1 to Nlb.410aA-425, IMc.410aA-l to lllc.410aA-425 and llld-1.41 OaA-l to llld-1.410aA-425) Table 411 a Compounds purple, INb, INc and llld-1, wherein A is 2,4,5-tribromothien-3-yl and

B corresponds in each case to a group in a row of Table A (compounds

Mla.41 1aA-1 to Nla.41 1aA-425, Mlb.41 1aA-1 to Illb.41 1 aA-425, Mlc.41 1aA-1 to

Nlc.411 aA-425 and llld-1.41 1aA-1 to llld-1,411 aA-425). Table 412a Compounds IIIa, INb, INc and IIId-1, wherein A is 3,4,5-trimethylthien-2-yl and B corresponds in each case to a group in a row of Table A (compounds

Mla.412aA-1 to Nla.412aA-425, Mlb.412aA-1 to Nlb.412aA-425, lllc.412aA-l to lllc.412aA-425 and llld-1.412aA-1 to llld-1.412aA-425) Table 413a Compounds IIIa, INb, INc and IIId-1, wherein A is 4-chlorofur-2-yl and B in each case corresponds to one group in a row of Table A (Compounds Nla.413aA-1 to

Nla.413aA-425, Illb.413aA-1 to Illb.413aA-425, Illc.413aA-1 to Illc.413-425 and Illd-1.413aA-1 to Illd-1.413aA-425). Table 414a Compounds IIIa, INb , INc and llld-1, wherein A is 5-chlorofur-2-yl and B each corresponds to a group in a row of Table A (Compounds Nla.414aA-1 to

Mla.414aA-425, Mlb.414aA-1 to Nlb.414aA-425, lllc.414aA-l to lllc.414aA-425 and llld-1.414aA-l to llld-1.414aA-425). Table 415a Compounds IIIa, INb , INc and llld-1, wherein A is 3-bromo-fur-2-yl and B each corresponds to a group in a row of Table A (Compounds Nla.415aA-1 to

Nla.415aA-425, Compounds Illb.415aA-1 to Illb.415aA-425, Illc.415aA-1 to Illc.415aA-425 and Illd-1.415aA-1 to Illd-1.415aA-425). Table 416a Compounds IIIa INb, INc and llld-1, wherein A is 4-bromo-fur-2-yl and B corresponds in each case to one group in a row of Table A (Compounds Nla.416aA-1 to Nla.416aA-425, Compounds Mlb.416aA-1 to Nlb.416aA-425, IMc.416aA-l to lllc.416aA-425 and llld-1.416aA-1 to llld-1.416aA-425) Table 417a

Compounds IIIa, INb, INc and IIId-1, in which A is 5-bromo-fur-2-yl and B corresponds in each case to one group in one row of Table A (Compounds Nla.417aA-1 to

Nla.417aA-425, Mlb.417aA-1 to Nlb.417aA-425, lllc.417aA-l to lllc.417aA-425, and llld-1.417aA-l to llld-1.417aA-425) Table 418a

Compounds purple, INb, INc and llld-1, wherein A is 3,4-dichloropur-2-yl and B each corresponds to a group in a row of Table A (Compounds

Nla.418aA-1 to Nla.418aA-425, Nlb.418aA-1 to Nlb.418aA-425, lllc.418aA-l to lllc.418aA-425, and llld-1.418aA-1 to llld-1.418aA-425) Table 419a

Compounds lilac, INb, INc and llld-1, wherein A is 4,5-dichloropur-2-yl and B in each case corresponds to a group in a row of Table A (compounds

Nla.419aA-1 to Nla.419aA-425, Nlb.419aA-1 to Nlb.419aA-425, lllc.419aA-l to lllc.419aA-425, and llld-1.419aA-1 to llld-1.419aA-425) Table 420a

Compounds purple, INb, INc and llld-1, wherein A is thiazol-2-yl and B each corresponds to a group in a row of Table A (compounds Nla.420aA-1 to

Nla.420aA-425, Nlb.420aA-1 to Nlb.420aA-425, lllc.420aA-l to lllc.420aA-425 and llld-1.42OaA-l to llld-1.420aA-425) Table 421 a

Compounds IIIa, INb, INc and IIId-1, in which A is thiazol-4-yl and B corresponds in each case to one group in one row of Table A (compounds III.421 aA-1 to

Nla.421aA-425, Nlb.421aA-1 to Nlb.421aA-425, lllc.421aA-l to lllc.421aA-425 and llld-1.421aA-l to llld-1.421 aA-425) Table 422a

Compounds IIIa, INb, INc and IIId-1, in which A is thiazol-5-yl and B corresponds in each case to one group in one row of Table A (Compounds Nla.422aA-1 to

Nla.422aA-425, compounds Nlb.422aA-1 to Nlb.422aA-425, lllc.422aA-l to lllc.422aA-425 and llld-1.422aA-l to llld-1.422aA-425) Table 423a

Compounds IIIa, INb, INc and IIId-1, where A is isothiazol-3-yl and B corresponds in each case to one group in one row of Table A (Compounds Nla.423aA-1 to

Nla.423aA-425, Nlb.423aA-1 to Nlb.423aA-425, lllc.423aA-l to lllc.423aA-425, and llld-1.423aA-l to llld-1.423aA-425) Table 424a

Compounds IIIa, INb, INc and IIId-1, where A is isothiazol-4-yl and B in each case corresponds to one group in a row of Table A (Compounds Nla.424aA-1 to

Nla.424aA-425, compounds Nlb.424aA-1 to Nlb.424aA-425, lllc.424aA-l to lllc.424aA-425 and llld-1.424aA-1 to llld-1.424aA-425) Table 425a

Compounds IIIa, INb, INc and IIId-1, where A is isothiazol-5-yl and B in each case corresponds to one group in a row of Table A (Compounds Nla.425aA-1 to Nla.425aA-425, Mlb.425aA- 1 to Nlb.425aA-425, Mlc.425aA-1 to lllc.425aA-425 and llld-1.425aA-1 to llld-1.425aA-425)

Table 426a

Compounds IIIa, INb, INc and IIId-1, in which A is 2-chlorothiazol-4-yl and B in each case corresponds to one group in a row of Table A (Compounds Mla.426aA-1 to Nla.426aA-425, Mlb. 426aA-1 to Nlb.426aA-425, lllc.426aA-l to lllc.426aA-425 and llld-1.426aA-l to llld-1.426aA-425)

Table 427a

Compounds IIIa, INb, INc and IIId-1, where A is 2-chlorothiazol-5-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.427aA-1 to Nla.427aA-425, Mlb. 427aA-1 to Nlb.427aA-425, lllc.427aA-l to lllc.427aA-425 and llld-1.427aA-l to llld-1.427aA-425)

Table 428a

Compounds purple, INb, INc and llld-1, wherein A is 4-chlorothiazol-5-yl and B in each case corresponds to a group in a row of Table A (Compounds Mla.428aA-1 to Nla.428aA-425, Mlb. 428aA-1 to Nlb.428aA-425, IMc.428aA-1 to lllc.428aA-425 and llld-1.428aA-1 to llld-1.428aA-425)

Table 429a

Compounds IIIa, INb, INc and IIId-1, where A is 2-bromothiazol-4-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.429aA-1 to Nla.429aA-425, Mlb. 429aA-1 to Nlb.429aA-425, lllc.429aA-l to lllc.429aA-425 and llld-1.429aA-l to llld-1429aA-425)

Table 430a

Compounds IIIa, INb, INc and IIId-1, where A is 2-bromothiazol-5-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.430aA-1 to Nla.430aA-425, Mlb. 430aA-1 to Nlb.430aA-425, IMc.430aA-l to lllc.430aA-425 and llld-1.43OaA-l to llld-1.430aA-425)

Table 431 a

Compounds IIIa, INb, INc and IIId-1, where A is 2,4-dichlorothiazol-5-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.431aA-1 to Nla.431aA-425, Mlb.431aA-1 to Nlb.431 aA-425, lllc.431aA-1 to lllc.431 aA-425 and llld-1.431 aA-1 to llld-1.431 aA-425)

Table 432a

Compounds purple, INb, INc and llld-1, wherein A is 3-chloroisothiazol-4-yl and B in each case corresponds to a group in a row of Table A (Compounds Mla.432aA-1 to Nla.432aA-425, Mlb. 432aA-1 to Nlb.432aA-425, lllc.432aA-l to lllc.432aA-425 and llld-1.432aA-l to llld-1.432aA-425)

Table 433a

Compounds purple, INb, INc and llld-1, wherein A is 5-methylisothiazol-3-yl and B corresponds in each case to a group in a row of Table A (compounds

Mla.433aA-1 to Nla.433aA-425, Mlb.433aA-1 to Nlb.433aA-425, Mlc.433aA-1 to lllc.433aA-425 and IMd-1.433aA-1 to Nld-1.433aA-425) Table 434a Compounds IIIa, INb, INc and IIId-1, wherein A is 3-methylisothiazol-4-yl and

B corresponds in each case to a group in a row of Table A (compounds

Mla.434aA-1 to Nla.434aA-425, Mlb.434aA-1 to Nlb.434aA-425, IMc.434aA-1 to lllc.434aA-425 and llld-1.434aA-1 to llld-1.434aA-425) Table 435a Compounds IIIa, INb, INc and IIId-1, wherein A is 3-methylisothiazol-5-yl and

B corresponds in each case to a group in a row of Table A (compounds

Mla.435aA-1 to Nla.435aA-425, Mlb.435aA-1 to Nlb.435aA-425, lllc.435aA-1 to lllc.435aA-425 and llld-1.435aA-1 to llld-1.435aA-425) Table 436a Compounds IIIa, INb, INc and IIId-1, wherein A is 4,5-dichloroisothiazol-3-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.436aA-1 to Nla.436aA-425, Mlb.436aA-1 to Nlb.436aA-425, lllc.436aA-1 to lllc.436aA-425 and llld-1.436aA-1 to llld-1.436aA-425) Table 437a Compounds IIIa, INb, INc and IIId-1, wherein A is 4,5-dimethylisothiazol-3-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.437aA-1 to Nla.437aA-425, IIIb.437aA-1 to Nlb.437aA-425, lllc.437aA-l to lllc.437aA-425 and llld-1.437aA-l to llld-1.437aA-425) Table 438a Compounds IIIa, INb, INc and IIId-1, wherein A is 3,5-dimethylisothiazol-4-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.438aA-1 to Nla.438aA-425, Mlb.438aA-1 to Nlb.438aA-425, Mlc.438aA-1 to lllc.438aA-425 and llld-1.438aA-1 to llld-1.438aA-425) Table 439a Compounds IIIa, INb, INc and IIId-1, wherein A is 3,4-dichloroisothiazol-5-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.439aA-1 to Nla.439aA-425, Mlb.439aA-1 to Nlb.439aA-425, lllc.439aA-l to lllc.439aA-425 and llld-1.439aA-l to llld-1.439aA-425) Table 440a Compounds IIIa, INb, INc and IIId-1, in which A is oxazol-2-yl and B in each case corresponds to a group in a row of Table A (Compounds Nla.440aA-1 to

Nla.440aA-425, Mlb.440aA-1 to Nlb.440aA-425, Mlc.440aA-l to lllc.440aA-425 and llld-1.44OaA-l to llld-1.440aA-425) Table 441 a Compounds purple, INb, INc and llld-1, in which A is oxazol-4-yl and B corresponds in each case to one group in one row of Table A (compounds III.441 aA-1 to Hla.441aA-425, Illb.441 aA-1 to Nlb.441aA-425, Illc.441 aA-1 to Ill. 441 aA-425 and Ill. 1.441aA-1 to ||| d-1.441 aA-425) Table 442a

Compounds purple, INb, INc and llld-1, wherein A is oxazol-5-yl and B each corresponds to a group in a row of Table A (compounds Nla.442aA-1 to

Nla.442aA-425, lllb.442aA-1 to Nlb.442aA-425, lllc.442aA-l to lllc.442aA-425, and

Nld-1.442aA-1 to llld-1.442aA-425) Table 443a

Compounds IIIa, INb, INc and IIId-1, where A is isoxazol-3-yl and B corresponds in each case to one group in one row of Table A (Compounds Nla.443aA-1 to

Nla.443aA-425, lllb.443aA-1 to Nlb.443aA-425, lllc.443aA-l to lllc.443aA-425, and

Nld-1.443aA-1 to Nld-1.443aA-425) Table 444a

Compounds IIIa, INb, INc and IIId-1, wherein A is isoxazol-4-yl and B corresponds in each case to one group in one row of Table A (Compounds Nla.444aA-1 to

Mla.444aA-425, Compounds Nlb.444aA-1 to Nlb.444aA-425, lllc.444aA-1 to

IHC 444aA-425 and IIId-1.444aA-1 to IIId-1.444aA-425) Table 445a

Compounds IIIa, INb, INc and IIId-1, where A is isoxazol-5-yl and B corresponds in each case to one group in one row of Table A (Compounds Nla.445aA-1 to

Nla.445aA-425, Compounds Nlb.445aA-1 to Nlb.445aA-425, lllc.445aA-l to lllc.445aA-425 and llld-1.445aA-1 to llld-1.445aA-425) Table 446a

Compounds purple, INb, INc and llld-1, wherein A is 3-chloroisoxazol-5-yl and B in each case corresponds to a group in a row of Table A (Compounds

Nla.446aA-1 to Nla.446aA-425, Nlb.446aA-1 to Nlb.446aA-425, lllc.446aA-l to lllc.446aA-425 and llld-1.446aA-l to llld-1.446aA-425) Table 447a

Compounds purple, INb, INc and llld-1, wherein A is 5-methylisoxazol-3-yl and B each corresponds to a group in a row of Table A (Compounds

Nla.447aA-1 to Nla.447aA-425, Nlb.447aA-1 to Nlb.447aA-425, lllc.447aA-l to lllc.447aA-425 and llld-1.447aA-l to llld-1.447aA-425) Table 448a

Compounds purple, INb, INc and llld-1, wherein A is 5-methylisoxazol-4-yl and B each corresponds to a group in a row of Table A (Compounds

Nla.448aA-1 to Nla.448aA-425, Nlb.448aA-1 to Nlb.448aA-425, lllc.448aA-1 to lllc.448aA-425 and lld-1.448aA-1 to lld-1.448aA-425) Table 449a

Compounds purple, INb, INc and llld-1, wherein A is 3-methylisoxazol-5-yl and B each corresponds to a group in a row of Table A (compounds

Nla.449aA-1 to Nla.449aA-425, Nlb.449aA-1 to Nlb.449aA-425, lllc.449aA-l to lllc.449aA-425 and llld-1.449aA-l to llld-1.449aA-425) Table 450a

Compounds IIIa, INb, INc and IIId-1, in which A is 3,5-dimethylisoxazol-4-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.450aA-1 to Nla.450aA-425, Mlb.450aA-1 to Nlb.450aA-425, IMc.450aA-l to lllc.450aA-425 and llld-1.45OaA-l to llld-1.450aA-425)

Table 451 a

Compounds IIIa, INb, INc and IIId-1, in which A is 3-chloro-5-methylisoxazol-4-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.451 aA-1 to Nla.451 aA-425, Mlb.451aA-1 to Nlb.451 aA-425, lllc.451 aA-1 to lllc.451 aA-425 and llld-1.451 aA-1 to llld-1.451aA-425)

Table 452a

Compounds IIIa, INb, INc and IIId-1, in which A is 3-methyl-4-chloroisoxazol-5-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.452aA-1 to Nla.452aA- 425, Mlb.452aA-1 to Nlb.452aA-425, lllc.452aA-l to lllc.452aA-425 and llld-1.452aA-l to llld-1.452aA-425)

Table 453a

Compounds IIIa, INb, INc and IIId-1, in which A is 1-methylpyrazol-3-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.453aA-1 to Nla.453aA-425, Mlb. 453aA-1 to Nlb.453aA-425, lllc.453aA-l to lllc.453aA-425 and llld-1.453aA-l to llld-1.453aA-425)

Table 454a

Compounds IIIa, INb, INc and IIId-1, wherein A is 1-methylpyrazol-4-yl and B in each case corresponds to one group in a row of Table A (Compounds Mla.454aA-1 to Nla.454aA-425, Mlb. 454aA-1 to Nlb.454aA-425, lllc.454aA-l to lllc.454aA-425 and llld-1.454aA-l to llld-1.454aA-425)

Table 455a

Compounds IIIa, INb, INc and IIId-1, wherein A is 1-methylpyrazol-5-yl and B corresponds in each case to one group in a row of Table A (Compounds Mla.455aA-1 to Nla.455aA-425, Mlb. 455aA-1 to Nlb.455aA-425, lllc.455aA-l to lllc.455aA-425 and llld-1.455aA-l to llld-1.455aA-425)

Table 456a

Compounds IIIa, INb, INc and IIId-1, in which A is 1,3-dimethylpyrazol-4-yl and B corresponds in each case to one group in one row of Table A (Compounds Mla.456aA-1 to Nla.456aA-425, Mlb.456aA-1 to Nlb.456aA-425, lllc.456aA-l to lllc.456aA-425 and llld-1.456aA-l to llld-1.456aA-425)

Table 457a

Compounds IIIa, INb, INc and IIId-1, in which A is 1,5-dimethylpyrazol-4-yl and B corresponds in each case to one group in a row of Table A (compounds Mla.457aA-1 to Nla.457aA-425, Mlb.457aA-1 to Nlb.457aA-425, lllc.457aA-l to lllc.457aA-425 and llld-1.457aA-l to llld-1.457aA-425)

Table 458a

Compounds purple, INb, INc and llld-1, wherein A is 1, 3,5-trimethylpyrazol-4-yl and B corresponds in each case to a group in a row of Table A (compounds

Mla.458aA-1 to Nla.458aA-425, Mlb.458aA-1 to Nlb.458aA-425, IMc.458aA-1 to lllc.458aA-425 and IMd-1.458aA-1 to Nld-1.458aA-425) Table 459a Compounds IIIa, INb, INc and IIId-1, wherein A is 1-methylimidazol-4-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.459aA-1 to Nla.459aA-425, Mlb.459aA-1 to Nlb.459aA-425, IMc.459aA-1 to lllc.459aA-425 and lllld-1.459aA-1 to llld-1.459aA-425) Table 460a Compounds purple, INb, INc and llld-1, wherein A is 1, 5-dimethylimidazol-4-yl and B each corresponds to a group in a row of Table A (Compounds

Mla.460aA-1 to Nla.460aA-425, Mlb.460aA-1 to Nlb.460aA-425, IMc.460aA-1 to lllc.460aA-425 and llld-1.46OaA-l to llld-1.460aA-425) Table 461 a Compounds purple, INb, INc and llld-1, wherein A is 1, 2-dimethylimidazol-5-yl and B in each case corresponds to a group in a row of Table A (Compounds

Mla.461aA-1 to Nla.461aA-425, Mlb.461aA-1 to Nlb.461 aA-425, lllc.461aA-l to lllc.461 aA-425 and llld-1.461 aA-1 to llld-1.461 aA- 425). Table 462a Compounds IIIa, INb, INc and IIId-1, wherein A is 1,4-dimethylimidazol-5-yl and B in each case corresponds to one group in a row of Table A (Compounds

Mla.462aA-1 to Nla.462aA-425, Mlb.462aA-1 to Nlb.462aA-425, lllc.462aA-l to lllc.462aA-425 and llld-1.462aA-l to llld-1.462aA-425) Table 463a Compounds IIIa, INb, INc and IIId-1, wherein B is pyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.463aA-1 to

Nla.463aA-425, Mlb.463aA-1 to Nlb.463aA-425, lllc.463aA-l to lllc.463aA-425 and llld-1.463aA-l to llld-1.463aA-425). Table 464a Compounds IIIa, INb , INc and llld-1, wherein B is pyridin-3-yl and A corresponds in each case to one group in a row of Table A (Compounds Nla.464aA-1 to

Nla.464aA-425, Mlb.464aA-1 to Nlb.464aA-425, lllc.464aA-1 to lllc.464aA-425 and llld-1.464aA-1 to llld-1.464aA-425). Table 465a Compounds IIIa, INb , INc and llld-1, wherein B is pyridin-4-yl and A corresponds in each case to one group in a row of Table A (Compounds Nla.465aA-1 to

Nla.465aA-425, Mlb.465aA-1 to Nlb.465aA-425, lllc.465aA-l to lllc.465aA-425 and llld-1.465aA-l to llld-1.465aA-425). Table 466a Compounds IIIa, INb , INc and llld-1, wherein B is 3-chloropyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.466aA-1 to Nla.466aA-425, Mlb.466aA-l to lllb.466aA-425, IMc.466aA-l to lllc.466aA-425 and llld-1.466aA-l to llld-1.466aA-425) Table 467a

Compounds purple, INb, INc and llld-1, wherein B is 4-chloropyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.467aA-1 to Nla.467aA-425, IIIb.467aA-1 to Nlb.467aA-425, lllc.467aA-l to lllc.467aA-425 and llld-1.467aA-l to llld-1.467aA-425) Table 468a

Compounds IIIa, INb, INc and IIId-1, wherein B is 5-chloropyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.468aA-1 to Nla.468aA-425, Mlb.468aA-1 to Nlb.468aA-425, IMc.468aA-1 to lllc.468aA-425 and llld-1.468aA-1 to llld-1.468aA-425) Table 469a

Compounds IIIa, INb, INc and IIId-1, wherein B is 6-chloropyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.469aA-1 to Nla.469aA-425, Mlb.469aA-1 to Nlb.469aA-425, lllc.469aA-l to lllc.469aA-425 and llld-1.469aA-l to llld-1.469aA-425) Table 470a

Compounds purple, INb, INc and llld-1, wherein B is 2-chloropyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.470aA-1 to Nla.470aA-425, Mlb.470aA-1 to Nlb.470aA-425, IMc.470aA-1 to lllc.470aA-425 and llld-1.47OaA-l to llld-1.470aA-425) Table 471 a

Compounds IIIa, INb, INc and IIId-1, wherein B is 4-chloropyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.471aA-1 to Nla.471aA-425, Mlb.471aA-1 to Nlb.471 aA-425, lllc.471aA-1 to lllc.471 aA-425 and llld-1.471 aA-1 to llld-1.471 aA- 425) Table 472a

Compounds IIIa, INb, INc and IIId-1, wherein B is 5-chloropyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.472aA-1 to Nla.472aA-425, IMb.472aA-1 to Nlb.472aA-425, lllc.472aA-l to lllc.472aA-425 and llld-1.472aA-l to llld-1.472aA-425) Table 473a

Compounds IIIa, INb, INc and IIId-1, wherein B is 6-chloropyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.473aA-1 to Nla.473aA-425, Mlb.473aA-1 to Nlb.473aA-425, lllc.473aA-l to lllc.473aA-425 and llld-1.473aA-l to llld-1.473aA-425) Table 474a

Compounds IIIa, INb, INc and IIId-1, where B is 2-chloropyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.474aA-1 to Nla.474aA-425, Mlb.474aA-1 to Nlb.474aA-425, lllc.474aA-l to lllc.474aA-425 and llld-1.474aA-l to llld-1.474aA-425) Table 475a

Compounds IIIa, INb, INc and IIId-1, where B is 3-chloropyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.475aA-1 to Nla.475aA-425, Mlb. 475aA-1 to Nlb.475aA-425, IMc.475aA-l to lllc.475aA-425 and llld-1.475aA-l to llld-1.475aA-425)

Table 476a

Compounds IIIa, INb, INc and IIId-1, wherein B is 4-chloropyridin-5-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.476aA-1 to Nla.476aA-425, Mlb. 476aA-1 to Nlb.476aA-425, lllc.476aA-l to lllc.476aA-425 and llld-1.476aA-l to llld-1.476aA-425)

Table 477a

Compounds IIIa, INb, INc and IIId-1, where B is 3-fluoropyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.477aA-1 to Nla.477aA-425, Mlb. 477aA-1 to Nlb.477aA-425, lllc.477aA-l to lllc.477aA-425 and llld-1.477aA-l to llld-1.477aA-425)

Table 478a

Compounds IIIa, INb, INc and IIId-1, where B is 4-fluoropyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.478aA-1 to Nla.478aA-425, Mlb. 478aA-1 to Nlb.478aA-425, IMc.478aA-1 to lllc.478aA-425 and llld-1.478aA-1 to llld-1.478aA-425)

Table 479a

Compounds IIIa, INb, INc and IIId-1, where B is 5-fluoropyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.479aA-1 to Nla.479aA-425, Mlb. 479aA-1 to Nlb.479aA-425, lllc.479aA-l to lllc.479aA-425 and llld-1.479aA-l to llld-1.479aA-425)

Table 480a

Compounds IIIa, INb, INc and IIId-1, where B is 6-fluoropyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.480aA-1 to Nla.480aA-425, Mlb. 480aA-1 to Nlb.480aA-425, IMc.480aA-l to lllc.480aA-425 and llld-1.48OaA-l to llld-1.480aA-425)

Table 481 a

Compounds IIIa, INb, INc and IIId-1, wherein B is 2-fluoropyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.481aA-1 to Nla.481aA-425, Mlb. 481aA-1 to Nlb.481 aA-425, IMc.481aA-1 to lllc.481 aA-425 and llld-1.481 aA-1 to llld-1.481 aA-425)

Table 482a

Compounds IIIa, INb, INc and IIId-1, wherein B is 4-fluoropyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.482aA-1 to Nla.482aA-425, Mlb. 482aA-1 to Nlb.482aA-425, lllc.482aA-l to lllc.482aA-425 and llld-1.482aA-l to llld-1.482aA-425)

Table 483a

Compounds purple, INb, INc and llld-1, wherein B is 5-fluoropyridin-3-yl and A each corresponds to a group in a row of Table A (compounds

Mla.483aA-1 to Nla.483aA-425, Mlb.483aA-1 to Nlb.483aA-425, IMc.483aA-1 to lllc.483aA-425 and IMd-1.483aA-1 to Nld-1.483aA-425) Table 484a Compounds IIIa, INb, INc and IIId-1, wherein B is 6-fluoropyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.484aA-1 to Nla.484aA-425, Mlb.484aA-1 to Nlb.484aA-425, IMc.484aA-l to lllc.484aA-425 and llld-1.484aA-1 to llld-1.484aA-425) Table 485a Compounds IIIa, INb, INc and IIId-1, wherein B is 2-fluoropyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.485aA-1 to Nla.485aA-425, Mlb.485aA-1 to Nlb.485aA-425, IMc.485aA-1 to lllc.485aA-425 and llld-1.485aA-1 to llld-1.485aA-425) Table 486a Compounds IIIa, INb, INc and IIId-1, wherein B is 3-fluoropyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.486aA-1 to Nla.486aA-425, Mlb.486aA-1 to Nlb.486aA-425, IMc.486aA-1 to lllc.486aA-425 and llld-1.486aA-1 to llld-1.486aA-425) Table 487a Compounds IIIa, INb, INc and IIId-1, wherein B is 3-methylpyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.487aA-1 to Nla.487aA-425, Mlb.487aA-1 to Nlb.487aA-425, IMc.487aA-1 to lllc.487aA-425 and llld-1.487aA-1 to llld-1.487aA-425) Table 488a Compounds IIIa, INb, INc and IIId-1, wherein B is 4-methylpyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.488aA-1 to Nla.488aA-425, Mlb.488aA-1 to Nlb.488aA-425, IMc.488aA-1 to lllc.488aA-425 and llld-1.488aA-1 to llld-1.488aA-425) Table 489a Compounds IIIa, INb, INc and IIId-1, wherein B is 5-methylpyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.489aA-1 to Nla.489aA-425, Mlb.489aA-1 to Nlb.489aA-425, IMc.489aA-1 to lllc.489aA-425 and llld-1.489aA-1 to llld-1.489aA-425) Table 490a Compounds IIIa, INb, INc and IIId-1, wherein B is 6-methylpyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.490aA-1 to Nla.490aA-425, Mlb.490aA-1 to Nlb.490aA-425, lllc.490aA-l to lllc.490aA-425 and llld-1.49OaA-l to llld-1.490aA-425) Table 491 a Compounds purple, INb, INc and llld-1, wherein B is 2-methylpyridin-3-yl and A in each case corresponds to a group in a row of Table A (Compounds Mla.491aA-1 to Nla.491aA-425, Mlb.491aA-l to lb.491 aA-425, IMc.491aA-l to lllc.491 aA-425 and llld-1.491 aA-1 to llld-1.491 aA- 425) Table 492a

Compounds IIIa, INb, INc and IIId-1, wherein B is 4-methylpyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.492aA-1 to Nla.492aA-425, Mlb.492aA-1 to Nlb.492aA-425, lllc.492aA-l to lllc.492aA-425 and llld-1.492aA-l to llld-1.492aA-425) Table 493a

Compounds IIIa, INb, INc and IIId-1, wherein B is 5-methylpyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.493aA-1 to Nla.493aA-425, Mlb.493aA-1 to Nlb.493aA-425, lllc.493aA-l to lllc.493aA-425 and llld-1.493aA-l to llld-1.493aA-425) Table 494a

Compounds purple, INb, INc and llld-1, wherein B is 6-methylpyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.494aA-1 to Nla.494aA-425, Mlb.494aA-1 to Nlb.494aA-425, lllc.494aA-l to lllc.494aA-425 and llld-1.494aA-l to llld-1.494aA-425) Table 495a

Compounds IIIa, INb, INc and IIId-1, where B is 2-methylpyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.495aA-1 to Nla.495aA-425, Mlb.495aA-1 to Nlb.495aA-425, lllc.495aA-l to lllc.495aA-425 and llld-1.495aA-l to llld-1.495aA-425) Table 496a

Compounds IIIa, INb, INc and IIId-1, wherein B is 3-methylpyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.496aA-1 to Nla.496aA-425, Mlb.496aA-1 to Nlb.496aA-425, lllc.496aA-l to lllc.496aA-425 and llld-1.496aA-l to llld-1.496aA-425) Table 497a

Compounds purple, INb, INc and llld-1, wherein B is 4-methylpyridin-5-yl and A in each case corresponds to a group in a row of Table A (Compounds

Mla.497aA-1 to Nla.497aA-425, Mlb.497aA-1 to Nlb.497aA-425, lllc.497aA-l to lllc.497aA-425 and llld-1.497aA-l to llld-1.497aA-425) Table 498a

Compounds IIIa, INb, INc and IIId-1, where B is 3-methoxypyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.498aA-1 to Nla.498aA-425, Mlb.498aA-1 to Nlb.498aA-425, IMc.498aA-1 to lllc.498aA-425 and llld-1.498aA-1 to llld-1.498aA-425) Table 499a

Compounds IIIa, INb, INc and IIId-1, wherein B is 4-methoxypyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.499aA-1 to Nla.499aA-425, Mlb.499aA-1 to Nlb.499aA-425, lllc.499aA-l to lllc.499aA-425 and llld-1.499aA-l to llld-1.499aA-425) Table 500a

Compounds IIIa, INb, INc and IIId-1, wherein B is 5-methoxypyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.500aA-1 to Nla.500aA-425, Mlb. 500aA-1 to Mlb.500aA-425, IMc.500aA-1 to lllc.500aA-425 and llld-1.50OaA-l to llld-1500aA-425)

Table 501 a

Compounds IIIa, INb, INc and IIId-1, wherein B is 6-methoxypyridin-2-yl and A corresponds in each case to one group in a row of Table A (Compounds Mla.501aA-1 to Nla.501aA-425, Mlb. 501aA-1 to Nlb.501 aA-425, lllc.501aA-1 to lllc.501 aA-425 and llld-1.501 aA-1 to llld-1.501 aA-425)

Table 502a

Compounds IIIa, INb, INc and IIId-1, wherein B is 2-methoxypyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.502aA-1 to Nla.502aA-425, Mlb. 502aA-1 to Nlb.502aA-425, lllc.502aA-1 to lllc.502aA-425 and llld-1.502aA-1 to llld-1.502aA-425)

Table 503a

Compounds IIIa, INb, INc and IIId-1, wherein B is 4-methoxypyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.503aA-1 to Nla.503aA-425, Mlb. 503aA-1 to Nlb.503aA-425, lllc.503aA-l to lllc.503aA-425 and llld-1.503aA-l to llld-1.503aA-425)

Table 504a

Compounds IIIa, INb, INc and IIId-1, wherein B is 5-methoxypyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.504aA-1 to Nla.504aA-425, Mlb. 504aA-1 to Nlb.504aA-425, lllc.504aA-l to lllc.504aA-425 and llld-1.504aA-l to llld-1.504aA-425)

Table 505a

Compounds IIIa, INb, INc and IIId-1, wherein B is 6-methoxypyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.505aA-1 to Nla.505aA-425, Mlb. 505aA-1 to Nlb.505aA-425, lllc.505aA-l to lllc.505aA-425 and llld-1.505aA-l to llld-1.505aA-425)

Table 506a

Compounds IIIa, INb, INc and IIId-1, wherein B is 2-methoxypyridin-4-yl and A corresponds in each case to one group in a row of Table A (Compounds Nla.506aA-1 to Nla.506aA-425, Nlb. 506aA-1 to Nlb.506aA-425, lllc.506aA-l to lllc.506aA-425 and llld-1.506aA-l to llld-1.506aA-425)

Table 507a

Compounds IIIa, INb, INc and IIId-1, wherein B is 3-methoxypyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.507aA-1 to Nla.507aA-425, Nlb. 507aA-1 to Nlb.507aA-425, lllc.507aA-l to lllc.507aA-425 and llld-1.507aA-l to llld-1.507aA-425)

Table 508a

Compounds IIIa, INb, INc and IIId-1, wherein B is 3,5-dichloropyridin-2-yl and A each corresponds to a group in a row of Table A (compounds

Mla.508aA-1 to Nla.508aA-425, Mlb.508aA-1 to Nlb.508aA-425, IMc.508aA-1 to lllc.508aA-425 and IMd-1.508aA-1 to Nld-1.508aA-425) Table 509a Compounds IIIa, INb, INc and IIId-1, wherein B is 2,4-dichloropyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.509aA-1 to Nla.509aA-425, Mlb.509aA-1 to Nlb.509aA-425, IMc.509aA-1 to lllc.509aA-425 and llld-1.509aA-1 to llld-1.509aA-425) Table 510a Compounds IIIa, INb, INc and IIId-1, wherein B is 2,5-dichloropyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.510aA-1 to Nla.510aA-425, Mlb.510aA-1 to Nlb.510aA-425, lllc.510aA-1 to lllc.510aA-425 and llld-1.51 OaA-l to llld-1.510aA-425) Table 511 a Compounds purple, INb, INc and llld-1, wherein B is 2,6-dichloropyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.51 1aA-1 to Nla.51 1aA-425, Mlb.511aA-1 to Illb.51 1 aA-425, Mlc.51 1aA-1 to

Nlc.511 aA-425 and llld-1.51 1aA-1 to llld-1.511 aA-425). Table 512a Compounds IIIa, INb, INc and IIId-1 wherein B is 2,6-dichloropyridin-4-yl and A is each corresponds to a group in a row of Table A (compounds

Mla.512aA-1 to Nla.512aA-425, Mlb.512aA-1 to Nlb.512aA-425, lllc.512aA-1 to lllc.512aA-425 and llld-1.512aA-1 to llld-1.512aA-425) Table 513a Compounds IIIa, INb, INc and IIId-1, wherein B is 3,5-dichloropyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.513aA-1 to Nla.513aA-425, Mlb.513aA-l to lllb.513aA-425, lllc.513aA-l to lllc.513aA-425 and llld-1.513aA-l to llld-1.513aA-425) Table 514a Compounds IIIa, INb, INc and IIId-1, where B is 3,6-dichloropyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.514aA-1 to Nla.514aA-425, Mlb.514aA-1 to Nlb.514aA-425, lllc.514aA-1 to lllc.514aA-425 and llld-1.514aA-1 to llld-1.514aA-425) Table 515a Compounds IIIa, INb, INc and IIId-1, wherein B is 2,5-dichloropyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.515aA-1 to Nla.515aA-425, Mlb.515aA-l to lllb.515aA-425, lllc.515aA-l to lllc.515aA-425 and llld-1.515aA-l to llld-1.515aA-425) Table 516a Compounds IIIa, INb, INc and IIId-1, wherein B is 2,3-dichloropyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.516aA-1 to Nla.516aA-425, IMb.516aA-1 to IIIb.516aA-425, IMc.516aA-1 to IIIc516aA-425, and IIId-1.516aA-1 to IIId-1.516aA-425) Table 517a

Compounds purple, INb, INc and llld-1, wherein B is 2,4-dichloropyridin-5-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.517aA-1 to Nla.517aA-425, Mlb.517aA-1 to Nlb.517aA-425, lllc.517aA-1 to lllc.517aA-425 and llld-1.517aA-1 to llld-1.517aA-425) Table 518a

Compounds IIIa, INb, INc and IIId-1, wherein B is 3,5-difluoropyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.518aA-1 to Nla.518aA-425, Mlb.518aA-1 to Nlb.518aA-425, IMc.518aA-1 to lllc.518aA-425, and IIId-1.518aA-1 to IIId-1.518aA-425) Table 519a

Compounds IIIa, INb, INc and IIId-1, wherein B is 3,5-difluoropyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.519aA-1 to Nla.519aA-425, Mlb.519aA-1 to Nlb.519aA-425, lllc.519aA-1 to lllc.519aA-425 and llld-1.519aA-1 to llld-1.519aA-425) Table 520a

Compounds IIIa, INb, INc and IIId-1, wherein B is 2,3-difluoropyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.520aA-1 to Nla.520aA-425, Mlb.520aA-1 to Nlb.520aA-425, IMc.520aA-1 to lllc.520aA-425, and IIId-1.52OaA-I to IIId-1.520aA-425) Table 521 a

Compounds purple, INb, INc and llld-1, wherein B is 3,5-dimethylpyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.521aA-1 to Nla.521aA-425, Mlb.521aA-1 to Nlb.521 aA-425, lllc.521aA-l to lllc.521 aA-425 and llld-1.521aA-1 to llld-1.521 aA- 425) Table 522a

Compounds purple, INb, INc and llld-1, wherein B is 3,4-dimethylpyridin-2-yl and A in each case corresponds to a group in a row of Table A (Compounds

Mla.522aA-1 to Nla.522aA-425, Mlb.522aA-1 to Nlb.522aA-425, lllc.522aA-1 to lllc.522aA-425 and llld-1.522aA-1 to llld-1.522aA-425) Table 523a

Compounds purple, INb, INc and llld-1, wherein B is 4,6-dimethylpyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.523aA-1 to Nla.523aA-425, Mlb.523aA-1 to Nlb.523aA-425, lllc.523aA-1 to lllc.523aA-425 and llld-1.523aA-1 to llld-1.523aA-425) Table 524a

Compounds purple, INb, INc and llld-1, wherein B is 2,4-dimethylpyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.524aA-1 to Nla.524aA-425, Mlb.524aA-1 to Nlb.524aA-425, lllc.524aA-1 to lllc.524aA-425 and llld-1.524aA-1 to llld-1.524aA-425) Table 525a

Compounds IIIa, INb, INc and IIId-1, in which B is 3,5-dimethylpyridin-4-yl and A in each case corresponds to one group in a row of Table A (compounds Mla.525aA-1 to Nla.525aA-425, Mlb.525aA-1 to Nlb.525aA-425, IMc.525aA-1 to lllc.525aA-425 and llld-1.525aA-1 to llld-1.525aA-425)

Table 526a

Compounds IIIa, INb, INc and IIId-1, where B is 2-chloro-3-fluoropyridin-4-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.526aA-1 to Nla.526aA- 425, Mlb.526aA-1 to Nlb.526aA-425, lllc.526aA-1 to lllc.526aA-425 and llld-1.526aA-1 to llld-1.526aA-425)

Table 527a

Compounds IIIa, INb, INc and IIId-1, where B is 4-chloro-3-methylpyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.527aA-1 to Nla.527aA- 425, Mlb.527aA-1 to Nlb.527aA-425, lllc.527aA-l to lllc.527aA-425 and llld-1.527aA-l to llld-1.527aA-425)

Table 528a

Compounds IIIa, INb, INc and IIId-1, where B is 5-chloro-3-methylpyridin-2-yl and A in each case corresponds to one group in a row of Table A (compounds Mla.528aA-1 to Nla.528aA- 425, Mlb.528aA-1 to Nlb.528aA-425, IMc.528aA-1 to lllc.528aA-425 and llld-1.528aA-1 to llld-1.528aA-425)

Table 529a

Compounds IIIa, INb, INc and IIId-1, where B is 5-fluoro-3-methylpyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.529aA-1 to Nla.529aA- 425, Mlb.529aA-1 to Nlb.529aA-425, lllc.529aA-l to lllc.529aA-425 and llld-1.529aA-l to llld-1.529aA-425)

Table 530a

Compounds IIIa, INb, INc and IIId-1, in which B is 3-chloro-5-trifluoromethylpyridin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.530aA-1 to Nla.530aA- 425, Mlb.530aA-1 to Nlb.530aA-425, Mlc.530aA-l to lllc.530aA-425 and llld-1.53OaA-l to llld-1.530aA-425)

Table 531 a

Compounds IIIa, INb, INc and IIId-1, wherein B is 2-chloro-6-trifluoromethylpyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.531 aA-1 to Nla.531 aA-425, Mlb.531aA-1 to Nlb.531 aA-425, lllc.531 aA-1 to lllc.531 aA-425 and llld-1.531 aA-1 to llld-1.531aA-425)

Table 532a

Compounds IIIa, INb, INc and IIId-1, where B is 2,4-dichloro-6-methylpyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.532aA-1 to Nla. 532aA-425, Mlb.532aA-1 to Nlb.532aA-425, lllc.532aA-1 to lllc.532aA-425 and llld-1.532aA-1 to llld-1.532aA-425)

Table 533a

Compounds purple, INb, INc and llld-1, wherein B is 3,4,5-trichloropyridin-2-yl and A corresponds to a group in a row of Table A (Compounds

Mla.533aA-1 to Nla.533aA-425, Mlb.533aA-1 to Nlb.533aA-425, IMc.533aA-1 to lllc.533aA-425 and IMd-1.533aA-1 to Nld-1.533aA-425) Table 534a Compounds IIIa, INb, INc and IIId-1, wherein B is 2,4,6-trichloropyridin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.534aA-1 to Nla.534aA-425, Mlb.534aA-1 to Nlb.534aA-425, IMc.534aA-1 to lllc.534aA-425, and IIId-1.534aA-1 to IIId-1.534aA-425) Table 535a Compounds IIIa, INb, INc and IIId-1, wherein B is pyrimidin-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.535aA-1 to

Nla.535aA-425, Mlb.535aA-1 to Nlb.535aA-425, Mlc.535aA-1 to lllc.535aA-425 and IIId-1.535aA-1 to IIId-1.535aA-425). Table 536a Compounds IIIa, INb , INc and llld-1, wherein B is pyrimidin-5-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.536aA-1 to

Nla.536aA-425, Mlb.536aA-1 to Nlb.536aA-425, Mlc.536aA-1 to lllc.536aA-425 and llld-1.536aA-1 to llld-1.536aA-425). Table 537a Compounds IIIa, INb , INc and llld-1, wherein B is 6-chloropyrimidin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.537aA-1 to Nla.537aA-425, Mlb.537aA-1 to Nlb.537aA-425, lllc.537aA-1 to lllc.537aA-425 and IIId-1.537aA-1 to IIId-1.537aA-425) Table 538a Compounds IIIa, INb, INc and IIId-1, where B is 6-methylpyrimidin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.538aA-1 to Nla.538aA-425, Mlb.538aA-1 to Nlb.538aA-425, IMc.538aA-1 to lllc.538aA-425, and IIId-1.538aA-1 to IIId-1.538aA-425) Table 539a Compounds IIIa, INb, INc and IIId-1, wherein B is 6-methoxypyrimidin-3-yl and

A corresponds in each case to a group in a row of Table A (compounds

Mla.539aA-1 to Nla.539aA-425, Mlb.539aA-1 to Nlb.539aA-425, IMc.539aA-1 to lllc.539aA-425 and IIId-1.539aA-1 to IIId-1.539aA-425) Table 540a Compounds IIIa, INb, INc and IIId-1, wherein B is 2,4-dichloropyrimidin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.540aA-1 to Nla.540aA-425, Mlb.540aA-1 to Nlb.540aA-425, lllc.540aA-1 to lllc.540aA-425 and llld-1.54OaA-l to llld-1.540aA-425) Table 541a Compounds IIIa, INb, INc and IIId-1, wherein B is 2,6-dichloropyrimidin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.541aA-1 to Nla.541aA-425, Mlb.541aA-1 to Illb.541 aA-425, IMc.541aA-1 to Illc.541 aA-425 and Ill-1.541aA-1 to Ill-1.541 aA- 425) Table 542a

Compounds IIIa, INb, INc and IIId-1, wherein B is 2,4-difluoropyrimidin-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.542aA-1 to Nla.542aA-425, Mlb.542aA-1 to Nlb.542aA-425, IMc.542aA-1 to lllc.542aA-425, and IIId-1.542aA-1 to IIId-1.542aA-425) Table 543a

Compounds purple, INb, INc and llld-1, wherein B is 2,6-difluoropyrimidin-3-yl and A in each case corresponds to a group in a row of Table A (Compounds

Mla.543aA-1 to Nla.543aA-425, Mlb.543aA-1 to Nlb.543aA-425, lllc.543aA-1 to lllc.543aA-425 and llld-1.543aA-1 to llld-1.543aA-425) Table 544a

Compounds purple, INb, INc and llld-1, wherein B is 1, 3,5-triazin-2-yl and A in each case corresponds to a group in a row of Table A (Compounds

Mla.544aA-1 to Nla.544aA-425, Mlb.544aA-1 to Nlb.544aA-425, lllc.544aA-1 to lllc.544aA-425 and llld-1.544aA-1 to llld-1.544aA-425) Table 545a

Compounds IIIa, INb, INc and IIId-1, in which B is thien-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.545aA-1 to

Nla.545aA-425, Mlb.545aA-1 to Nlb.545aA-425, lllc.545aA-l to lllc.545aA-425 and llld-1.545aA-l to llld-1.545aA-425) Table 546a

Compounds IIIa, INb, INc and IIId-1, wherein B is thien-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.546aA-1 to

Nla.546aA-425, Mlb.546aA-1 to Nlb.546aA-425, lllc.546aA-l to lllc.546aA-425, and llld-1.546aA-l to llld-1.546aA-425) Table 547a

Compounds IIIa, INb, INc and IIId-1, where B is 5-chlorothien-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.547aA-1 to Nla.547aA-425, Mlb.547aA-1 to Nlb.547aA-425, lllc.547aA-1 to lllc.547aA-425 and llld-1.547aA-1 to llld-1.547aA-425) Table 548a

Compounds purple, INb, INc and llld-1, wherein B is 2-chlorothien-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.548aA-1 to Nla.548aA-425, Mlb.548aA-1 to Nlb.548aA-425, IMc.548aA-1 to lllc.548aA-425, and IIId-1.548aA-1 to IIId-1.548aA-425) Table 549a

Compounds purple, INb, INc and llld-1, wherein B is 4-chlorothien-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.549aA-1 to Nla.549aA-425, Mlb.549aA-1 to Nlb.549aA-425, Illc.549aA-1 to Illc.549aA-425, and IIId-1.549aA-1 to IIId-1.549aA-425) Table 550a

Compounds IIIa, INb, INc and IIId-1, wherein B is 5-chlorothien-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.550aA-1 to Nla.550aA-425, Mlb. 550aA-1 to Nlb.550aA-425, IMc.550aA-1 to lllc.550aA-425 and llld-1.55OaA-l to llld-1.550aA-425)

Table 551 a

Compounds IIIa, INb, INc and IIId-1, wherein B is 2-bromothien-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.551aA-1 to Nla.551aA-425, Mlb. 551aA-1 to Nlb.551 aA-425, lllc.551aA-1 to lllc.551 aA-425 and llld-1.551aA-1 to llld-1.551 aA-425)

Table 552a

Compounds IIIa, INb, INc and IIId-1, wherein B is 4-bromothien-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.552aA-1 to Nla.552aA-425, Mlb. 552aA-1 to Nlb.552aA-425, lllc.552aA-l to lllc.552aA-425 and llld-1.552aA-l to llld-1.552aA-425)

Table 553a

Compounds IIIa, INb, INc and IIId-1, wherein B is 5-bromothien-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.553aA-1 to Nla.553aA-425, Mlb. 553aA-1 to Nlb.553aA-425, lllc.553aA-l to lllc.553aA-425 and llld-1.553aA-l to llld-1.553aA-425)

Table 554a

Compounds IIIa, INb, INc and IIId-1, wherein B is 5-methylthien-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.554aA-1 to Nla.554aA-425, Mlb. 554aA-1 to Nlb.554aA-425, lllc.554aA-l to lllc.554aA-425 and llld-1.554aA-l to llld-1.554aA-425)

Table 555a

Compounds IIIa, INb, INc and IIId-1, wherein B is 2-methylthien-4-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.555aA-1 to Nla.555aA-425, Mlb. 555aA-1 to Nlb.555aA-425, lllc.555aA-l to lllc.555aA-425 and llld-1.555aA-l to llld-1.555aA-425)

Table 556a

Compounds IIIa, INb, INc and IIId-1, in which B is 4,5-dichlorothien-2-yl and A corresponds in each case to one group in one row of Table A (Compounds Mla.556aA-1 to Nla.556aA-425, Mlb.556aA-1 to Nlb.556aA-425, lllc.556aA-l to lllc.556aA-425 and llld-1.556aA-l to llld-1.556aA-425)

Table 557a

Compounds IIIa, INb, INc and IIId-1, where B is 2,5-dichlorothien-3-yl and A in each case corresponds to one group in a row of Table A (compounds Mla.557aA-1 to Nla.557aA-425, Mlb.557aA-1 to Nlb.557aA-425, lllc.557aA-l to lllc.557aA-425 and llld-1.557aA-l to llld-1.557aA-425)

Table 558a

Compounds IIIa, INb, INc and IIId-1, wherein B is 2,3-dichlorothien-4-yl and A each corresponds to a group in a row of Table A (compounds

Mla.558aA-1 to Nla.558aA-425, Mlb.558aA-1 to Nlb.558aA-425, Mlc.558aA-1 to lllc.558aA-425 and IMd-1.558aA-1 to Nld-1.558aA-425) Table 559a Compounds IIIa, INb, INc and IIId-1, wherein B is 2,5-dibromothien-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.559aA-1 to Nla.559aA-425, Mlb.559aA-1 to Nlb.559aA-425, IMc.559aA-1 to lllc.559aA-425, and IIId-1.559aA-1 to IIId-1.559aA-425) Table 560a Compounds IIIa, INb, INc and IIId-1, wherein B is 4,5-dimethylthien-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.560aA-1 to Nla.560aA-425, Mlb.560aA-1 to Nlb.560aA-425, IMc.560aA-1 to lllc.560aA-425 and IIId-1.56OaA-I to IIId-1.560aA-425) Table 561a Compounds IIIa, INb, INc and IIId-1, wherein B is 2,5-dimethylthien-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.561aA-1 to Nla.561aA-425, Mlb.561aA-1 to Nlb.561 aA-425, lllc.561aA-l to lllc.561 aA-425 and llld-1.561 aA-1 to llld-1.561 aA- 425) Table 562a Compounds IIIa, INb, INc and IIId-1, wherein B is 2,3-dimethylthien-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.562aA-1 to Nla.562aA-425, Mlb.562aA-1 to Nlb.562aA-425, lllc.562aA-1 to lllc.562aA-425 and llld-1.562aA-1 to llld-1.562aA-425) Table 563a Compounds IIIa, INb, INc and IIId-1, wherein B is 3,4,5-trichlorothien-2-yl and

A corresponds in each case to a group in a row of Table A (compounds

Mla.563aA-1 to Nla.563aA-425, Mlb.563aA-1 to Nlb.563aA-425, lllc.563aA-1 to lllc.563aA-425 and llld-1.563aA-1 to llld-1.563aA-425) Table 564a Compounds IIIa, INb, INc and IIId-1 wherein B is 2,4,5-trichlorothien-3-yl and

A corresponds in each case to a group in a row of Table A (compounds

Mla.564aA-1 to Nla.564aA-425, Mlb.564aA-1 to Nlb.564aA-425, lllc.564aA-1 to lllc.564aA-425 and llld-1.564aA-1 to llld-1.564aA-425) Table 565a Compounds IIIa, INb, INc and IIId-1, wherein B is 2,4,5-tribromothien-3-yl and

A corresponds in each case to a group in a row of Table A (compounds

Mla.565aA-1 to Nla.565aA-425, Mlb.565aA-1 to Nlb.565aA-425, lllc.565aA-1 to lllc.565aA-425 and llld-1.565aA-1 to llld-1.565aA-425) Table 566a Compounds IIIa, INb, INc and IIId-1, wherein B is 3,4,5-trimethylthien-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.566aA-1 to Nla.566aA-425, Mlb.566aA-1 to Illb.566aA-425, IMc.566aA-1 to Ill. 566aA-425, and IIId-1.566aA-1 to IIId-1.566aA-425) Table 567a

Compounds IIIa, INb, INc and IIId-1, wherein B is 4-chlorofur-2-yl and A corresponds in each case to one group in a row of Table A (Compounds Nla.567aA-1 to

Nla.567aA-425, Mlb.567aA-1 to Nlb.567aA-425, lllc.567aA-l to lllc.567aA-425 and llld-1.567aA-l to llld-1.567aA-425) Table 568a

Compounds IIIa, INb, INc and IIId-1, wherein B is 5-chlorofur-2-yl and A corresponds in each case to one group in a row of Table A (Compounds Nla.568aA-1 to

Nla.568aA-425, Mlb.568aA-1 to Nlb.568aA-425, Mlc.568aA-1 to lllc.568aA-425 and lld-1.568aA-1 to llld-1.568aA-425) Table 569a

Compounds IIIa, INb, INc and IIId-1, wherein B is 3-bromo-fur-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.569aA-1 to

Nla.569aA-425, Mlb.569aA-1 to Nlb.569aA-425, IMc.569aA-1 to lllc.569aA-425 and IIId-1.569aA-1 to IIId-1.569aA-425) Table 570a

Compounds IIIa, INb, INc and IIId-1, wherein B is 4-bromo-fur-2-yl and A corresponds in each case to one group in a row of Table A (Compounds Nla.570aA-1 to

Nla.570aA-425, Mlb.570aA-1 to Nlb.570aA-425, Mlc.570aA-1 to lllc.570aA-425, and IIId-1.57OaA-I to IIId-1.570aA-425). Table 571a

Compounds IIIa, INb, INc and IIId-1, where B is 5-bromo-fur-2-yl and A in each case corresponds to one group in a row of Table A (compounds III.571 aA-1 to

Nla.571aA-425, Mlb.571aA-1 to Nlb.571aA-425, lllc.571aA-l to lllc.571aA-425, and llld-1.571aA-l to llld-1.571 aA-425) Table 572a

Compounds purple, INb, INc and llld-1, wherein B is 3,4-dichloropur-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.572aA-1 to Nla.572aA-425, Mlb.572aA-1 to Nlb.572aA-425, lllc.572aA-1 to lllc.572aA-425 and llld-1.572aA-1 to llld-1.572aA-425) Table 573a

Compounds purple, INb, INc and llld-1, wherein B is 4,5-dichloropur-2-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.573aA-1 to Nla.573aA-425, Mlb.573aA-1 to Nlb.573aA-425, lllc.573aA-1 to lllc.573aA-425 and llld-1.573aA-1 to llld-1.573aA-425) Table 574a

Compounds IIIa, INb, INc and IIId-1, wherein B is thiazol-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.574aA-1 to

Nla.574aA-425, Mlb.574aA-1 to Nlb.574aA-425, lllc.574aA-1 to lllc.574aA-425 and llld-1.574aA-1 to llld-1.574aA-425) Table 575a

Compounds IIIa, INb, INc and IIId-1, where B is thiazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.575aA-1 to Nla.575aA-425, Mlb.575aA- 1 to Nlb.575aA-425, Mlc.575aA-1 to lllc.575aA-425 and llld-1.575aA-1 to llld-1.575aA-425)

Table 576a

Compounds IIIa, INb, INc and IIId-1, in which B is thiazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.576aA-1 to Nla.576aA-425, Mlb.576aA- 1 to Nlb.576aA-425, lllc.576aA-1 to lllc.576aA-425 and llld-1.576aA-1 to llld-1.576aA-425)

Table 577a

Compounds IIIa, INb, INc and IIId-1, where B is isothiazol-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.577aA-1 to Nla.577aA-425, Mlb.577aA- 1 to Nlb.577aA-425, lllc.577aA-1 to lllc.577aA-425 and llld-1.577aA-1 to llld-1.577aA-425)

Table 578a

Compounds IIIa, INb, INc and IIId-1, where B is isothiazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.578aA-1 to Nla.578aA-425, Nlb.578aA- 1 to Nlb.578aA-425, lllc.578aA-1 to lllc.578aA-425 and llld-1.578aA-1 to llld-1.578aA-425)

Table 579a

Compounds IIIa, INb, INc and IIId-1, where B is isothiazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.579aA-1 to Nla.579aA-425, Nlb.579aA- 1 to Nlb.579aA-425, lllc.579aA-1 to lllc.579aA-425 and llld-1.579aA-1 to llld-1.579aA-425)

Table 580a

Compounds IIIa, INb, INc and IIId-1, wherein B is 2-chlorothiazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.580aA-1 to Nla.580aA-425, Nlb. 580aA-1 to Nlb.580aA-425, lllc.580aA-l to lllc.580aA-425 and llld-1.58OaA-l to llld-1.580aA-425)

Table 581 a

Compounds IIIa, INb, INc and IIId-1, wherein B is 2-chlorothiazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.581aA-1 to Nla.581aA-425, Nlb. 581aA-1 to Nlb.581 aA-425, lllc.581aA-l to lllc.581 aA-425 and llld-1.581 aA-1 to llld-1.581 aA-425)

Table 582a

Compounds IIIa, INb, INc and IIId-1, wherein B is 4-chlorothiazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.582aA-1 to Nla.582aA-425, Nlb. 582aA-1 to Nlb.582aA-425, lllc.582aA-1 to lllc.582aA-425 and llld-1.582aA-1 to llld-1.582aA-425)

Table 583a

Compounds lilac, INb, INc and llld-1, wherein B is 2-bromothiazol-4-yl and A each corresponds to a group in a row of Table A (compounds

Mla.583aA-1 to Nla.583aA-425, Mlb.583aA-1 to Nlb.583aA-425, IMc.583aA-1 to lllc.583aA-425 and IMd-1.583aA-1 to Nld-1.583aA-425) Table 584a Compounds IIIa, INb, INc and IIId-1, wherein B is 2-bromothiazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.584aA-1 to Nla.584aA-425, Mlb.584aA-1 to Nlb.584aA-425, IMc.584aA-1 to lllc.584aA-425, and IIId-1.584aA-1 to IIId-1.584aA-425) Table 585a Compounds IIIa, INb, INc and IIId-1, wherein B is 2,4-dichlorothiazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.585aA-1 to Nla.585aA-425, Mlb.585aA-1 to Nlb.585aA-425, IMc.585aA-1 to lllc.585aA-425 and IIId-1.585aA-1 to IIId-1.585aA-425) Table 586a Compounds IIIa, INb, INc and IIId-1, where B is 3-chloroisothiazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.586aA-1 to Nla.586aA-425, Mlb.586aA-1 to Nlb.586aA-425, IMc.586aA-1 to lllc.586aA-425 and IIId-1.586aA-1 to IIId-1.586aA-425) Table 587a Compounds IIIa, INb, INc and IIId-1, wherein B is 5-methylisothiazol-3-yl and

A corresponds in each case to a group in a row of Table A (compounds

Mla.587aA-1 to Nla.587aA-425, Mlb.587aA-1 to Nlb.587aA-425, IMc.587aA-1 to lllc.587aA-425 and IIId-1.587aA-1 to IIId-1.587aA-425) Table 588a Compounds IIIa, INb, INc and IIId-1, wherein B is 3-methylisothiazol-4-yl and

A corresponds in each case to a group in a row of Table A (compounds

Mla.588aA-1 to Nla.588aA-425, Mlb.588aA-1 to Nlb.588aA-425, IMc.588aA-1 to lllc.588aA-425 and IIId-1.588aA-1 to IIId-1.588aA-425) Table 589a Compounds IIIa, INb, INc and IIId-1, wherein B is 3-methylisothiazol-5-yl and

A corresponds in each case to a group in a row of Table A (compounds

Mla.589aA-1 to Nla.589aA-425, Mlb.589aA-1 to Nlb.589aA-425, IMc.589aA-1 to lllc.589aA-425, and IIId-1.589aA-1 to IIId-1.589aA-425) Table 590a Compounds IIIa, INb, INc and IIId-1, wherein B is 4,5-dichloroisothiazol-3-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.590aA-1 to Nla.590aA-425, Mlb.590aA-1 to Nlb.590aA-425, IMc.590aA-1 to lllc.590aA-425, and IIId-1.59OaA-I to IIId-1.590aA-425) Table 591 a Compounds purple, INb, INc and llld-1, wherein B is 4,5-dimethylisothiazol-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.591aA-1 to Nla.591aA-425, Mlb.591aA-1 to Illb.591 aA-425, IMc.591aA-1 to Ill. 591 aA-425 and Ill d-1.591 aA-1 to Ill d-1.591 aA- 425) Table 592a

Compounds purple, INb, INc and llld-1, wherein B is 3,5-dimethylisothiazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.592aA-1 to Nla.592aA-425, Mlb.592aA-1 to Nlb.592aA-425, lllc.592aA-1 to lllc.592aA-425, and IIId-1.592aA-1 to IIId-1.592aA-425) Table 593a

Compounds purple, INb, INc and llld-1, wherein B is 3,4-dichloroisothiazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.593aA-1 to Nla.593aA-425, Mlb.593aA-1 to Nlb.593aA-425, IMc.593aA-1 to lllc.593aA-425 and IIId-1.593aA-1 to IIId-1.593aA-425) Table 594a

Compounds IIIa, INb, INc and IIId-1, wherein B is oxazol-2-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.594aA-1 to

Nla.594aA-425, compounds Mlb.594aA-1 to Nlb.594aA-425, lllc.594aA-l to lllc.594aA-425 and llld-1.594aA-l to llld-1.594aA-425) Table 595a

Compounds IIIa, INb, INc and IIId-1, wherein B is oxazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.595aA-1 to

Nla.595aA-425, Mlb.595aA-1 to Nlb.595aA-425, Mlc.595aA-l to lllc.595aA-425 and llld-1.595aA-l to llld-1.595aA-425) Table 596a

Compounds IIIa, INb, INc and IIId-1, wherein B is oxazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.596aA-1 to

Nla.596aA-425, compounds Mlb.596aA-1 to Nlb.596aA-425, Mlc.596aA-1 to lllc.596aA-425 and IIId-1.596aA-1 to IIId-1.596aA-425) Table 597a

Compounds IIIa, INb, INc and IIId-1, wherein B is isoxazol-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.597aA-1 to

Nla.597aA-425, Mlb.597aA-1 to Nlb.597aA-425, IIIc. 597aA-1 to lllc.597aA-425, and IIId-1.597aA-1 to IIId-1.597aA-425) Table 598a

Compounds IIIa, INb, INc and IIId-1, wherein B is isoxazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.598aA-1 to

Nla.598aA-425, Mlb.598aA-1 to Nlb.598aA-425, Mlc.598aA-l to lllc.598aA-425 and llld-1.598aA-l to llld-1.598aA-425) Table 599a

Compounds IIIa, INb, INc and IIId-1, wherein B is isoxazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds Nla.599aA-1 to

Nla.599aA-425, Mlb.599aA-1 to Nlb.599aA-425, Mlc.599aA-1 to lllc.599aA-425 and llld-1.599aA-1 to llld-1.599aA-425) Table 600a

Compounds IIIa, INb, INc and IIId-1, wherein B is 3-chloroisoxazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.600aA-1 to Nla.600aA-425, Mlb. 600aA-1 to Mlb.600aA-425, IMc.600aA-1 to lllc.600aA-425 and llld-1.60OaA-l to llld-1.600aA-425)

Table 601 a

Compounds IIIa, INb, INc and IIId-1, wherein B is 5-methylisoxazol-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.601aA-1 to Nla.601aA-425, Mlb. 601aA-1 to Nlb.601 aA-425, lllc.601aA-l to lllc.601 aA-425 and llld-1.601aA-l to llld-1.601 aA-425)

Table 602a

Compounds IIIa, INb, INc and IIId-1, wherein B is 5-methylisoxazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.602aA-1 to Nla.602aA-425, Mlb. 602aA-1 to Nlb.602aA-425, lllc.602aA-1 to lllc.602aA-425 and llld-1.602aA-1 to llld-1.602aA-425)

Table 603a

Compounds IIIa, INb, INc and IIId-1, wherein B is 3-methylisoxazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.603aA-1 to Nla.603aA-425, Mlb. 603aA-1 to Nlb.603aA-425, lllc.603aA-l to lllc.603aA-425 and llld-1.603aA-l to llld-1.603aA-425)

Table 604a

Compounds IIIa, INb, INc and IIId-1, where B is 3,5-dimethylisoxazol-4-yl and A in each case corresponds to one group in a row of Table A (compounds Mla.604aA-1 to Nla.604aA-425, Mlb.604aA-1 to Nlb.604aA-425, IMc.604aA-l to lllc.604aA-425 and llld-1.604aA-l to llld-1.604aA-425)

Table 605a

Compounds IIIa, INb, INc and IIId-1, in which B is 3-chloro-5-methylisoxazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.605aA-1 to Nla.605aA- 425, Mlb.605aA-1 to Nlb.605aA-425, lllc.605aA-l to lllc.605aA-425 and llld-1.605aA-l to llld-1.605aA-425)

Table 606a

Compounds IIIa, INb, INc and IIId-1, in which B is 3-methyl-4-chloroisoxazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.606aA-1 to Nla.606aA- 425, Mlb.606aA-1 to Nlb.606aA-425, Mlc.606aA-1 to lllc.606aA-425 and llld-1.606aA-1 to llld-1.606aA-425)

Table 607a

Compounds IIIa, INb, INc and IIId-1, wherein B is 1-methylpyrazol-3-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.607aA-1 to Nla.607aA-425, Mlb. 607aA-1 to Nlb.607aA-425, IMc.607aA-l to lllc.607aA-425 and llld-1.607aA-l to llld-1.607aA-425)

Table 608a

Compounds purple, INb, INc and llld-1, wherein B is 1-methylpyrazol-4-yl and A each corresponds to a group in a row of Table A (compounds

Mla.608aA-1 to Nla.608aA-425, Mlb.608aA-1 to Nlb.608aA-425, IMc.608aA-1 to lllc.608aA-425 and IMd-1.608aA-1 to Nld-1.608aA-425) Table 609a Compounds IIIa, INb, INc and IIId-1, wherein B is 1-methylpyrazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.609aA-1 to Nla.609aA-425, Mlb.609aA-1 to Nlb.609aA-425, IMc.609aA-1 to lllc.609aA-425 and llld-1.609aA-1 to llld-1.609aA-425) Table 610a Compounds IIIa, INb, INc and IIId-1, wherein B is 1, 3-dimethylpyrazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.610aA-1 to Nla.610aA-425, Mlb.610aA-1 to Nlb.610aA-425, lllc.610aA-l to lllc.610aA-425 and llld-1.61 OaA-l to llld-1.610aA-425) Table 611 a Compounds purple, INb, INc and llld-1, wherein B is 1, 5-dimethylpyrazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.61 1aA-1 to Nla.61 1aA-425, Mlb.611aA-1 to Nlb.61 1 aA-425, Nlc.61 1aA-1 to

Nlc.611 aA-425 and llld-1.61 1aA-1 to llld-1.611 aA-425). Table 612a Compounds IIIa, INb, INc and IIId-1 wherein B is 1, 3,5-trimethylpyrazol-4-yl and A corresponds in each case to a group in a row of Table A (compounds

Mla.612aA-1 to Nla.612aA-425, Mlb.612aA-1 to Nlb.612aA-425, lllc.612aA-1 to lllc.612aA-425 and llld-1.612aA-1 to llld-1.612aA-425) Table 613a Compounds IIIa, INb, INc and IIId-1, where B is 1-methylimidazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.613aA-1 to Nla.613aA-425, Mlb.613aA-1 to Nlb.613aA-425, lllc.613aA-1 to lllc.613aA-425 and llld-1.613aA-1 to llld-1.613aA-425) Table 614a Compounds IIIa, INb, INc and IIId-1, wherein B is 1, 5-dimethylimidazol-4-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.614aA-1 to Nla.614aA-425, Mlb.614aA-1 to Nlb.614aA-425, lllc.614aA-1 to lllc.614aA-425 and llld-1.614aA-1 to llld-1.614aA-425) Table 615a Compounds IIIa, INb, INc and IIId-1, wherein B is 1, 2-dimethylimidazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds

Mla.615aA-1 to Nla.615aA-425, Mlb.615aA-1 to Nlb.615aA-425, lllc.615aA-1 to lllc.615aA-425 and llld-1.615aA-1 to llld-1.615aA-425) Table 616a Compounds IIIa, INb, INc and IIId-1, wherein B is 1,4-dimethylimidazol-5-yl and A in each case corresponds to one group in a row of Table A (Compounds Mla.616aA-1 to Nla.616aA-425, Mlb.616aA-l to lllb.616aA-425, IMc.616aA-l to lllc.616aA-425 and llld-1.616aA-1 to llld-1.616aA-425)

From the preceding tables, the connection names for the individual connections are derived as follows: eg. is the "compound M ^ i aA- ^ K)" (markers added) the compound of the formula M_ according to the invention, in which A is pyridin-2-yl (as indicated in Table 1a) and B is 5-chloropyridine-3 yl (as indicated in line 1_0 of Table A).

The compounds of the invention and their compositions of the invention are useful as fungicides for controlling harmful fungi. They are distinguished by outstanding activity against a broad spectrum of plant-pathogenic, including soil-borne pathogens, which in particular belong to the classes of the Plasmodiophoromycetes, Peronosporomycetes (Syn. Oomyceten), Chytrhdiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes and Deuteromycetes (Syn. Fungi imperfecti) come. They are partially systemically effective and can be used in crop protection as foliar, pickling and soil fungicides. In addition, they are suitable for controlling fungi that attack, among other things, the wood or the roots of plants. In a preferred embodiment, the compounds of the invention are the compounds of formula I.

In a further preferred embodiment, the compounds of the invention are the compounds of the formula II.

Particular importance of the compounds of the invention for the control of a variety of pathogenic fungi on various crops such as cereals, eg. As wheat, rye, barley, triticale, oats or rice, beets, z. Sugar or fodder beets; Kernel, stone and berry fruits, z. Apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries, currants or gooseberries; Legumes, z. Beans, lentils, peas, alfalfa or soybeans; Oil plants, e.g. Rapeseed, mustard, olives, sunflowers, coconut, cocoa, castor beans, oil palm, peanuts or soya; Cucurbits, z. Pumpkins, cucumbers or melons; Fiber plants, z. Cotton, flax, hemp or jute; Citrus fruits, z. Oranges, lemons, grapefruit or mandarins; Vegetables, z. Spinach, lettuce, asparagus, cabbages, carrots, onions, tomatoes, potatoes, squash or paprika; Laurel family, z. Avocados, cinnamon or camphor; Energy and raw material plants, eg. Corn, soy, wheat, rapeseed, sugarcane or oil palm; Corn; Tobacco; Nuts; Coffee; Tea; bananas; Wine (table and grapes); Hop; Grass, z. B. lawn; Rubber plants; Ornamental and forest plants, z. As flowers, shrubs, deciduous and coniferous trees and on the propagation material, for. B. seeds, and the crop of these plants.

The compounds I or the compositions according to the invention are preferably used for combating a multiplicity of fungal pathological conditions. genes in agricultural crops, eg. Potatoes, sugar beets, tobacco, wheat, rye, barley, oats, rice, corn, cotton, soybeans, rape, legumes, sunflowers, coffee or sugarcane; Fruit, vine and ornamental plants and vegetables, eg. As cucumbers, tomatoes, beans and pumpkins and on the propagation material, for. B. seeds, and used the crop of these plants.

The term plant propagating materials includes all generative parts of the plant, e.g. As seeds, and vegetative plant parts, such as cuttings and tubers (eg., Potatoes), which can be used to propagate a plant. These include seeds, roots, fruits, tubers, bulbs, rhizomes, shoots and other plant parts, including seedlings and young plants, which are transplanted after germination or emergence. The young plants can be treated by a partial or complete treatment, eg. B. by immersion or pouring, are protected from harmful fungi.

The treatment of plant propagation materials with the compounds according to the invention or the compositions according to the invention is used for controlling a multiplicity of fungal pathogens in cereal crops, eg. Wheat, rye, barley or oats; Rice, corn, cotton and soy used.

The term "crops" also includes those plants which have been modified by breeding, mutagenesis or genetic engineering, including biotechnological agricultural products currently on the market or under development (see for example http://www.bio.org/speeches/pubs/er/agrLproducts .asp). Genetically engineered plants are plants whose genetic material has been altered in a manner that does not occur under natural conditions by crossing, mutations or natural recombination (i.e., rearrangement of genetic information). As a rule, one or more genes are integrated into the genome of the plant in order to improve the properties of the plant. Such genetic engineering also includes post-translational modifications of proteins, oligo- or polypeptides, e.g. by glycolylation or binding of polymers such as e.g. prenylated, acetylated or farnelysierter residues or PEG residues. By way of example plants are mentioned, which are by breeding and genetic engineering

Measures a tolerance to certain herbicide classes, such as hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors, acetolactate synthase (ALS) -I inhibitors such. Sulfonylureas (EP-A 257 993, US Pat. No. 5,013,659) or imidazolinones (for example US Pat. No. 6,222,100, WO 01/82685, WO 00/26390, WO 97/41218, WO 98/02526, WO 98/02527, WO 04 / 106529, WO 05/20673, WO 03/14357, WO 03/13225,

WO 03/14356, WO 04/16073), Enolpyruvylshikimat-3-phosphate synthase (EPSPS) - inhibitors such. Glyphosate (see, for example, WO 92/00377), glutamine synthetase (GS) inhibitors such as. Glufosinate (see eg EP-A 242 236, EP-A 242 246) or oxynil herbicides (see eg US 5,559,024). By breeding and Mutagene- se was z. B. Clearfield ^® rapeseed (BASF SE, Germany) produced, the tolerance to imidazolinones, z. As imazamox, has. Using genetic engineering methods, crops such as soybeans, cotton, corn, beets and oilseed rape have been produced which are resistant are raised against glyphosate or glufosinate, which (, Germany glufosinate-resistant, Bayer CropScience) are available under the trade names rou- dupReady ^® (glyphosate-resistant, Monsanto, USA) and Liberty Link ^®.

Furthermore, plants are included which, with the aid of genetic engineering measures one or more toxins, eg. B. those from the bacterial strain Bacillus produce. Toxins produced by such genetically engineered plants include e.g. B. insecticidal proteins of Bacillus spp., In particular of B. thuringiensis, such as the endotoxins CrylAb, CrylAc, Cryl F, Cry1 Fa2, Cry2Ab, Cry3A, Cry3Bb1, Cry9c, Cry34Ab1 or Cry35Ab1; or vegetative insecticidal proteins (VIPs), e.g. VIP1, VIP2, VIP3, or VIP3A; insecticidal proteins of nematode-colonizing bacteria, e.g. B. Photorhabdus spp. or Xenorhabdus spp .; Toxins from animal organisms, eg. B. Wepsen, spider or scorpion toxins; fungal toxins, e.g. Eg from Streptomyces; herbal lectins, e.g. From pea or barley; agglutinins; Proteinase inhibitors, e.g. Trypsin inhibitors, serine protease inhibitors, patatin, cystatin or papain inhibitors; Ribosome Inactivating Proteins (RIPs), e.g. Ricin, corn RIP, abrin, luffin, saporin or bryodin; Steroid metabolizing enzymes, e.g. 3-hydroxy steroid oxidase, ecdysteroid IDP glycosyltransferase, cholesterol oxidase, ecdysone inhibitors, or HMG-CoA reductase; ion channel blocker, e.g. B. inhibitors of sodium or calcium channels; Juvenile hormone esterase; Receptors for the diuretic hormone (helicokinin receptors); Stilbene synthase, bibenzyl synthase, chitinases and glucanases. These toxins can also be produced in the plants as proteoxins, hybrid proteins, truncated or otherwise modified proteins. Hybrid proteins are characterized by a novel combination of different protein domains (see, for example, WO 2002/015701). Further examples of such toxins or genetically modified plants which produce these toxins are described in EP-A 374 753, WO 93/07278, WO 95/34656, EP-A 427 529, EP-A 451 878, WO 03 / 18810 and WO 03/52073. The methods for producing these genetically modified plants are known in the art and z. As set forth in the publications mentioned above. Many of the aforementioned toxins confer on the plants that produce them tolerance to pests of all taxonomic arthropod classes, in particular to beetles (Coeleropta), diptera and butterflies (Lepidoptera) and nematodes (Nematoda). Genetically engineered plants that produce one or more genes encoding insecticidal toxins, e.g. As described in the publications mentioned above and partly commercially available, such as. B. YieldGard ^® (corn cultivars producing the toxin CrylAb), YieldGard ^® Plus (corn cultivars producing the toxins CrylAb and Cry3Bb1), StarLink ^® (corn cultivars producing the toxin Cry9c), Herculex ^® RW (corn cultivars toxins which Cry34Ab1, Cry35Ab1 and the enzyme phosphinothricin N-acetyltransferase [PAT] produce); NuCOTN ^® 33B (cotton cultivars producing the toxin CrylAc), Bollgard ^® I (cotton cultivars producing the toxin CrylAc), Bollgard ^® Il (cotton cultivars producing the toxins CrylAc and Cry2Ab2); VIP COT ^® (cotton cultivars producing a VIP-toxin); NewLeaf ^® (potato varieties, the produce the toxin Cry3A); Bt Xtra ^®, NatureGard® ^®, KnockOut ^®, BiteGard ^®, Protec ta ^®, Bt11 (z. B. Agrisure ^® CB) and Bt176 from Syngenta Seeds SAS, France (corn varieties which the toxin CrylAb and the PAT enzyme MIR604 from Syngenta Seeds SAS, France (maize strains producing a modified version of the toxin Cry3A, see WO 03/018810), MON 863 from Monsanto Europe SA, Belgium (maize strains producing the toxin Cry3Bb1), IPC 531 from Monsanto Europe SA, Belgium (cottons producing a modified version of the toxin CrylAc) and 1507 from Pioneer Overseas Corporation, Belgium (maize varieties producing the toxin Cryl F and the PAT enzyme). Furthermore, plants are included, which produce by genetic engineering measures one or more proteins that cause increased resistance or resistance to bacterial, viral or fungal pathogens, such as. B. so-called pathogenesis-related proteins (PR proteins, see EP-A O 392 225), resistance proteins (eg, potato varieties that produce two resistance genes against Phytophthora infestans from the Mexican wild potato Solanum bulbocastanum) or T4 lysozyme (For example, potato varieties that are resistant to bacteria such as Erwinia amylvora through the production of this protein).

Furthermore, plants are included whose productivity has been improved by genetic engineering methods by z. For example, the productivity (eg biomass, grain yield, starch, oil or protein content), the tolerance to drought, salt or other limiting environmental factors or the resistance to pests and fungal, bacterial and viral pathogens is increased.

Furthermore, plants are also included whose ingredients have been modified, in particular to improve the human or animal diet with the aid of genetic engineering methods by z. As oil plants producing health long-chain omega-3 fatty acids or monounsaturated omega-9 fatty acids (eg Nexera ^® - rape, DOW Agro Sciences, Canada.) Produce.

Furthermore, plants are included, which have been modified for the improved production of raw materials by means of genetic engineering methods by z. B. the amylopectin content of potatoes (Amflora ^® potato, BASF SE, Germany) was increased.

The present invention therefore also encompasses the use of compounds according to the invention or their compositions for the treatment of transgenic plants, in particular transgenic soya plants or transgenic maize plants. Transgenic plants are plants as described above, which have been modified by genetic engineering methods, especially plants whose properties have been improved by genetic engineering methods. In particular, the invention encompasses the use of compounds of the invention or their compositions for the treatment of transgenic plants which are resistant to glyphosate, glufosinate or glufosinate-ammonium. In a further embodiment, the invention also encompasses the use of compounds according to the invention or their compositions for the treatment of herbicide-resistant plants. In a In a further embodiment, the invention also encompasses the use of compounds according to the invention or their compositions for the treatment of herbicide-sensitive plants.

In particular, the compounds according to the invention or their compositions according to the invention are suitable for controlling the following plant diseases:

Albugo spp. (White rust) on ornamental plants, vegetable crops (eg A. Candida) and sunflowers (eg BA tragopogonis); Alternaria spp. (Blackness, black spotiness) on vegetables, oilseed rape (for example BA brassicola or A. brassicae), sugar beet (for example BA tenuis), fruit, rice, soybeans and on potatoes (eg A. solani or A. alternata) and tomatoes (eg BA solani or A. alternata) and Alternaria spp. (Earwires) on wheat; Aphanomyces spp. on sugar beets and vegetables; Ascochyta spp. on cereals and vegetables, eg. BA tritici (leaf drought) on wheat and A. hordei on barley; Bipolaris and Drechslera spp. (Teleomorph: Cochliobolus spp.) Z. B. leaf spot diseases (D. maydis and B. zeicola) on maize, e.g. B. brown spot (B. sorokiniana) on cereals and B. B. oryzae on rice and on lawn; Blumeria (formerly: Erysiphe) graminis (powdery mildew) on cereals (eg wheat or barley); Botryosphaeria spp. ('Black Dead Arm Disease') on vines (eg BB obtusa); Botrytis cinerea (Teleomorph: Botryotina fuckeliana: gray mold, gray mold) on berry and pome fruit (including strawberries), vegetables (including lettuce, carrots, celery and cabbage), oilseed rape, flowers, vines, forestry crops and wheat (ear fungus); Bremia lactucae (downy mildew) on salad; Ceratocystis (Syn. Ophiostoma) spp. (Bläuepilz) on deciduous and coniferous trees, z. BC ulmi (elm dying, Dutch elm disease) on elms; Cercospora spp. (Cercospora leaf spot) on maize (eg BC zeae-maydis), rice, sugar beets (eg BC beticola), sugarcane, vegetables, coffee, soybeans (eg BC sojina or C. kikuchii) and rice; Cladosporium spp. on tomato (eg BC fulvum: velvet spot disease) and cereals, eg. BC herbarum (earwax) on wheat; Claviceps purpurea (ergot) on cereals; Cochliobolus (Anamorph: Helminthosporium or Bipolaris) spp. (Leaf spot) on maize (for example BC carbonum), cereals (for example B. sativus, anamorph: B. sorokinia-na: brown spot) and rice (for example BC miyabeanus, anamorph: H. oryzae); Colletotricum (teleomorph: Glomerella) spp. (Burning stains, anthracnose) on cotton (eg BC gossypii), corn (eg BC graminicola: stalk rot and stinging spots), soft fruit, potatoes (eg BC coccodes: wilting), beans (eg BC lindemuthianum) and soybeans (eg. BC truncatum); Corticium spp., Z. BC sasakii (leaf sheath burn) on rice; Corynespora cassiicola (leaf spot) on soybeans and ornamental plants; Cycloconium spp., Z. BC oleaginum on olive; Cylindrocarpon spp. (for example, fruit tree crayfish or vine dying, Teleomorph: Nectria or Neonectria spp.) on fruit trees, grapevines (eg C. liriodendri, Teleomorph: Neonectria liriodendri, 'Black Foot Disease') and many ornamental shrubs; Dematophora (Teleomorph: Rosellinia) necatrix (root / stem rot) on soybeans; Diaporthe spp. z. BD phaseolorum (stalk disease) on soybeans; Drechslera (Syn. Helminthosporium, Teleomorph: Pyrenophora) spp. maize, cereals such as barley (for example BD teres, nettles) and wheat (eg BD triticale) repentis: DTR leaf drought), rice and turf; Esca disease (grapevine dying, apoplexy) on grapevine caused by Formitiporia (Syn. Phellinus) punctata, F. mediterranea, Phaeomoniella chlamydospora (formerly Phaeoacremonium chlamydosporum), Phaeoacremonium aleophilum and / or Botryosphaeria obtusa; Elsinoe spp. on nuclear (E. pyri) and soft fruit (E. veneta: burning spots) and grapevine (E. ampelina: burning spots); Entyloma oryzae (leaf sting) on rice; Epicoccum spp. (Earwires) on wheat; Erysiphe spp. (Powdery mildew) on sugar beet (E. betae), vegetables (eg BE pisi), such as cucumber (for example BE cichoracearum) and cabbage plants, such as rapeseed (for example, B. cruciferarum); Eutypa lata (Eutypa crab or extinction, anamorphic Cytosporina lata, Syn. Libertella blepharis) on fruit trees, vines and many ornamental shrubs; Exserohilum (Syn. Helminthosporium) spp. on maize (eg BE turcicum); Fusarium (Teleomorph: Gibberella) spp. (Wilt, root and stalk rot) on various plants, such. BF graminearum or F. culmorum (root rot and Tauboder whiteness) on cereals (eg wheat or barley), F. oxysporum on tomatoes, F. solani on soybeans and F. verticillioides on maize; Gaeumannomyces graminis (blackleg) on cereals (eg wheat or barley) and maize; Gibberella spp. cereals (eg BG zeae) and rice (eg BG fujikuroi: Bakanae disease); Glomerella cingulata on grapevine, pome fruit and other plants and G. gossypii on cotton; Grainstaining complex of rice; Guignardia bidwellii (black rot) on grapevine; Gymnosporangium spp. on rosaceae and juniper, eg. BG sabinae (pear grid) on pears; Helminthosporium spp. (Syn. Drechslera, Teleomorph: Cochliobolus) on corn, cereals and rice; Hemileia spp., E.g. BH vastatrix (coffee leaf rust) of coffee; Isariopsis clavispora (Syn. Cladosporium vitis) on grapevine; Macrophomina phasolina (Syn. Phaseoli) (root / stem rot) on soybeans and cotton; Microsium (Syn. Fusarium) nivale (snow mold) on cereals (eg wheat or

Barley); Microsphaera diffusa (powdery mildew) on soybeans; Monilinia spp., Z. BM laxa, M. fructicola and M. fructigena (flower and lace drought) on stone fruits and other rosaceae; Mycosphaerella spp. on cereals, bananas, berry fruits and peanuts, such as. BM graminicola (Anamorph: Septoria tritici, Septoria leaf drought) on wheat or M. fijiensis (Black sigatoka disease) on bananas; Peronospora spp. (Downy mildew) on cabbage (for example BP brassicae), oilseed rape (for example P. parasitica), onion plants (for example B. destructor), tobacco (P. tabacina) and soybeans (for example P. manshurica); Phakopsora pachyrhizi and P. meibomiae (soybean rust) on soybeans; Phallophora spp. z. On grapevines (eg BP tracheiphila and P. tetraspora) and soybeans (eg BP gregata: stalk disease); Phoma Hungary (root and stem rot) on oilseed rape and cabbage and P. betae (leaf spots) on sugar beet; Phomopsis spp. on sunflowers, grapevine (eg BP viticola: black spot disease) and soybeans (eg stalk rot: P. phaseoli, teleomorph: Diaporthe phaseolorum); Physoderma maydis (brown spot) on maize; Phytophthora spp. (Wilt, root, leaf, stem and fruit rot) on various plants, such as on paprika and cucurbits (eg BP capsici), soybeans (eg BP megasperma, Syn. P. sojae), potatoes and tomatoes (eg. BP infestans: cabbage and brown rot) and deciduous trees (eg BP ramorum: Plötz- oak dying); Plasmodiophora brassicae (cabbage hernia) on cabbage, oilseed rape, radish and other plants; Plasmopara spp., E.g. BP viticola (vine peronospora, downy mildew) on vines and P. halstedii on sunflowers; Podosphaera spp. (Powdery mildew) of rosaceae, hops, kernels and berries, eg. BP leucotricha to apple; Polymyxa spp., Z. To cereals such as barley and wheat (P. graminis) and sugar beet (P. betae) and the viral diseases conferred thereby; Pseudocercosporella herpotrichoides (straw break, teleomorph: Tapesia yallundae) on cereals, e.g. Wheat or barley; Pseudoperonospora (downy mildew) on various plants, e.g. BP cubensis on cucurbits or P. humili on hops; Pseudo-pezicula tracheiphila (red burner, anamorph: Phialophora) on grapevine; Puccinia spp. (Rust disease) on various plants, eg. BP triticina (wheat brown rust), P. striiformis (yellow rust), P. hordei (dwarf rust), P. graminis (black rust) or P. recondita (rye brown rust) on cereals, such as. Wheat, barley or rye, and asparagus (eg BP asparagi); Pyrenophora (anamorph: Drechslera) tritici-repentis (leaf drought) on wheat or P. teres (netted spots) on barley; Pyricularia spp., E.g. BP oryzae (Teleomorph: Magnaporthe grisea, rice leaf-fire) on rice and P. grisea on lawn and crops; Pythium spp. (Turnip disease) on turf, rice, corn, wheat, cotton, oilseed rape, sunflower, sugar beets, vegetables and other plants (eg BP ultimum or P. aphanidermatum); Ramularia spp., Z. BR collo-cygni (speckled disease / sunburn complex / Physiological leaf spots) on barley and R. beticola on sugar beets; Rhizoctonia spp. on cotton, rice, potatoes, turf, corn, oilseed rape, potatoes, sugar beets, vegetables and various other plants, eg. BR solani (root / stem rot) on soybeans, R. solani (leaf-sheathing) on rice or R. cerealis (pointed eye-spot) on wheat or barley; Rhizopus stolonifer (soft rot) on strawberries, carrots, cabbage, grapevine and tomato; Rhynchosporium secalis (leaf spot) on barley, rye and triticale; Sarocladium oryzae and S. attenuatum (sheath rot) on rice; Sclerotinia spp. (Stem or white rot) in vegetables and crops such as oilseed rape, sunflowers (eg Sclerotinia sclerotium rum) and soybeans (eg BS rolfsii); Septoria spp. on different plants, eg. BS glycines (leaf spot) on soybeans, S. tritici (Septoria leaf drought) on wheat and S. (Syn. Stagonospora) nodorum (leaf and spelled tan) on cereals; Uncinula (Syn. Erysiphe) necator (powdery mildew, anamorphic: Oidium tuckeri) on grapevine; Sexspaeria spp. (Leaf spot) on corn (for example, S. turcicum, Syn. Helminthosporium turcicum) and turf; Sphacelotheca spp. (Dust fires) on maize, (for example BS reiliana: flask brandy), millet and sugarcane; Sphaerotheca fuliginea (powdery mildew) on cucurbits; Spongospora subterranea (powder scab) on potatoes and the viral diseases transmitted thereby; Stagonospora spp. on cereals, z. BS nodorum (leaf and tan, Teleomorph: Leptosphaeria [Syn. Phaeosphaeria] nodorum) on wheat; Synchytrium endobioticum on potatoes (potato cancer); Taphrina spp., Z. BT deformans (curling disease) on peach and T. pruni (pocket disease) on plums; Thielaviopsis spp. (Black root rot) on tobacco, pome fruit, vegetable crops, soybeans and cotton, eg. BT basicola (Syn: Chalara elegans); Tilletia spp. (Stone or Stinkbrand) of cereals, such. BT tritici (Syn. T. caries, Weizensteinbrand) and T. controversa (Zwergsteinbrand) on wheat; Typhula incarnata (snow) on barley or wheat; Urocystis spp., E.g. BU occulta (stalk brandy) on rye; Uromyces spp. (Rust) on vegetables, such as beans (for example, appendiculatus appendix, Syn. U. phaseoli) and sugar beet (for example, Betae); Ustilago spp. (Firefighting) on cereals (for example BU nuda and U. avaenae), maize (for example BU maydis: maize buckthorn brandy) and sugarcane; Venturia spp. (Scab) on apples (eg BV inaequalis) and pears; and Verticillium spp. (Deciduous and cloudy wilt) on various plants, such as fruit and ornamental trees, vines, soft fruit, vegetables and crops, such. BV dahliae on strawberries, rapeseed, potatoes and tomatoes.

The compounds according to the invention are also suitable for controlling harmful fungi in the protection of materials and buildings (eg wood, paper, paint dispersions, fibers or fabrics) and in the protection of stored products. In particular, the following harmful fungi are considered in wood and building protection: Ascomycetes such as Ophiostoma spp., Ceratocystis spp., Aureobasidium pullulans, Sclerophoma spp., Chaetomium spp., Humicola spp., Petriella spp., Trichurus spp .; Basidiomycetes such as Coniophora spp., Coriolus spp., Gloeophyllum spp., Lentinus spp., Pleurotus spp., Poria spp., Serpula spp. and Tyromyces spp., Deuteromycetes such as Aspergillus spp., Cladosporium spp., Penicillium spp., Trichoderma spp., Alternaria spp., Paecilomyces spp. and Zygomycetes such as Mucor spp., moreover, in the protection of the following yeasts: Candida spp. and Saccharomyces cerevisae.

The compounds according to the invention and their compositions according to the invention are suitable for increasing plant health. Moreover, the invention relates to a method of enhancing plant health by treating the plants, the plant propagating material and / or the place where the plants are to grow or grow with an effective amount of the compounds of the invention or their invention. The term "plant health" includes those conditions of a plant and / or its crop which are determined by various indicators individually or in combination with one another, such as yield (eg, increased biomass and / or increased content of utilizable ingredients), plant vitality ( eg increased plant growth and / or greener leaves), quality (eg increased content or composition of certain ingredients) and tolerance to biotic and / or abiotic stress. These plant health status indicators referred to herein may be independent or mutually exclusive.

The invention therefore also relates to the use of compounds according to the invention and / or their agriculturally acceptable salts for controlling phytopathogenic fungi. The invention furthermore relates to a method for controlling phytopathogenic fungi, which comprises treating the fungi or the materials, plants, the soil or seeds to be protected against fungal attack with an effective amount of a compound according to the invention and / or an agriculturally acceptable salt treated by it.

The compounds of the invention are used as such or in the form of a composition by the harmful fungi, their habitat or the plants to be protected against fungal attack, plant propagation materials, eg. As seeds, the soil, surfaces, materials or rooms treated with a fungicidally effective amount of the compounds of the invention. The application may be both before and after the infection of the plants, plant propagation materials, eg. As seeds, the soil, the surfaces, materials or spaces made by the fungi.

Plant propagation materials may be preventively treated with or in advance of sowing, or together with, or even before transplanting, with compounds of the invention or with compositions of the invention thereof. In addition, the invention relates to compositions or agrochemical compositions containing a solvent or solid carrier and at least one compound of the invention, preferably compounds of formula I or preferably compounds of formula II, and the use of these compositions for controlling harmful fungi. The subject of this invention is also an agent or an agrochemical composition comprising at least one compound according to the invention and / or an agriculturally acceptable salt thereof for use in crop protection. Such an agent usually contains at least one liquid or solid carrier.

The invention therefore also encompasses agents or agrochemical compositions which comprise a solid or liquid carrier and a fungicidal compound according to the invention. The term "liquid carrier" is used in this context synonymous with solvents.

An agrochemical composition contains a fungicidally effective amount of a compound of the invention. The term "effective amount" means an amount of the agrochemical composition or compound of the invention which is sufficient to control harmful fungi on crop plants or in material and building protection and does not result in significant damage to the treated crops vary widely and are influenced by numerous factors, such as the harmful fungus to be controlled, the particular crop or material being treated, climatic conditions and compounds. The compounds according to the invention, their N-oxides and their salts can be converted into the types customary for agrochemical compositions, e.g. As solutions, emulsions, suspensions, dusts, powders, pastes and granules. The type of composition depends on the respective purpose; It should in any case ensure a fine and uniform distribution of the compound according to the invention.

The term "agent" in this context is used synonymously with the term "composition", in particular "agrochemical composition", and "formulation". Examples of composition types here are suspensions (SC, OD, FS), pastes, pastilles, wettable powders or dusts (WP, SP, SS, WS, DP, DS) or granules (GR, FG, GG, MG) which are either in Water may be soluble or dispersible, and gels for the treatment of plant propagating materials such as seed (GF). In general, the composition types (eg SC, OD, FS, WG, SG,

WP, SP, SS, WS, GF) diluted. Composition types such as DP, DS, GR, FG, GG and MG are generally used undiluted.

The agrochemical compositions are prepared in a known manner (see, for example, US 3,060,084, EP-A 707,445 (for liquid concentrates), Browning, "Agglomeration", Chemical Engineering, Dec. 4, 1967, 147-48, Perry's Chemical Engineer's Handbook, 4th ed., McGraw-Hill, New York, 1963, 8-57 and et seq., WO 91/13546, US 4,172,714, US 4,144,050, US 3,920,442, US 5,180,587, US 5,232,701, US 5,208,030, GB 2,095,558, US 3,299,566, Klingman: Weed Control as a Science (John Wiley & Sons, New York, 1961), Hance et al .: Weed Control Handbook (8th Ed., Blackwell Scientific Publications, Oxford, 1989) and Mollet, H. and Grubemann, A. : Formulation technology (Wiley VCH Verlag, Weinheim, 2001).

The agrochemical compositions can furthermore also contain auxiliaries customary for crop protection agents, the choice of auxiliaries being based on the specific application form or the active substance.

Examples of suitable auxiliaries are solvents, solid carriers, surface-active substances (such as further solubilizers, protective colloids, wetting agents and adhesives), organic and inorganic thickeners, bactericides, antifreeze agents, defoamers, if appropriate dyes and adhesives (for example for seed treatment). Suitable solvents are water, organic solvents such as mineral oil fractions of medium to high boiling point such as kerosene and diesel oil, coal tar oils and oils of vegetable or animal origin, aliphatic, cyclic and aromatic hydrocarbons, for example paraffins, tetrahydronaphthalene, alkylated naphtha line and derivatives thereof, alkylated benzenes and their derivatives, alcohols such as methanol, ethanol, propanol, butanol and cyclohexanol, gycols, ketones such as cyclohexanone, gamma-butyrolactone, dimethyl fatty acid amides, fatty acids and fatty acid esters and highly polar solvents, for example amines such as N-methylpyrrolidone into consideration. Principle- It is also possible to use solvent mixtures and mixtures of the abovementioned solvents and water.

Solid carriers are mineral earths such as silicic acids, silica gels, silicates, talc, kaolin, limestone, lime, chalk, bolus, loess, clay, dolomite, diatomaceous earth, calcium and magnesium sulfate, magnesium oxide, ground plastics, fertilizers such as ammonium sulfate, ammonium phosphate, Ammonium nitrate, ureas and vegetable products such as cereal flour, tree bark, wood and nutshell flour, cellulose powder or other solid carriers.

Suitable surface-active substances (adjuvants, wetting, adhesion, dispersing or emulsifying agents) are the alkali metal, alkaline earth metal, ammonium salts of aromatic sulfonic acids, eg. B. of lignin (Borresperse ^® grades, Borregaard, Norway), phenol, naphtha lin (Morwet ^® types, Akzo Nobel, USA) and dibutyl (nekal ^® - types, BASF, Germany), and of fatty acids , Alkyl and alkylaryl sulfonates, alkyl, lauryl ether and fatty alcohol sulfates, as well as salts of sulfated hexa-, hepta- and octadecanols and of fatty alcohol glycol ethers, condensation products of sulfonated naphthalene and its derivatives with formaldehyde, condensation products of naphthalene or of naphthalenesulfonic acids with Phenol and formaldehyde, polyoxyethylene octylphenol ethers, ethoxylated isooctyl, octyl or nonylphenol, alkylphenyl, tributylphenyl polyglycol ethers, alkylarylpolyether alcohols, isotridecylalcohol, fatty alcohol ethylene oxide condensates, ethoxylated castor oil, polyoxyethylene or polyoxypropylene alkyl ethers, lauryl alcohol polyglycol ether acetate, sorbitol esters, lignin sulphite liquors and Proteins, denatured proteins, polysaccharides (eg methylc ellulose), hydrophobically modified starches, polyvinyl alcohol (Mowiol ^® types, Clariant, Switzerland), poly-carboxylate (Sokalan ^® types, BASF, Germany), polyalkoxylates, polyvinylamine (Lu pamin ^® types, BASF, Germany), polyethylenimine (Lupasol ^® types, BASF, Germany), polyvinylpyrrolidone and copolymers thereof.

Examples of thickeners (ie, compounds that give the composition a modified flow properties, ie high viscosity at rest and low viscosity in motion) are polysaccharides and organic and inorganic see layered minerals, such as xanthan gum (Kelzan ^®, CP Kelco, U.S.A.), Rhodopol ^® 23 (Rhodia, France) or Veegum ^® (RT Vanderbilt, USA) or attaclay ^® (Engelhard Corp., NJ, USA).

Bactericides may be added to stabilize the composition. Examples of bactericides are those based on dichlorophen and benzyl alcohol hemiformal (Proxel ^®.. Of Messrs. ICI or Acetide ^® RS from Thor Chemie and Kathon ^® MK from Rohm & Haas) and isothiazolinone derivatives such as alkylisothiazolinones and benzisothiazolinones (Acetide ^® MBS Fa. Thor Chemie).

Examples of suitable antifreeze agents are ethylene glycol, propylene glycol, urea and glycerin. Examples of defoamers are silicone emulsions (such as, for example, ^Silikon® SRE, Wacker,

Germany or Rhodorsil ^®, Rhodia, France), long chain alcohols, fatty acids, salts of fatty acids, organofluorine compounds and mixtures thereof. Examples of colorants are both water-insoluble pigments and water-soluble dyes. Examples which may be mentioned are those under the names Rhodamine B, CI Pigment Red 112 and CI Solvent Red 1, Pigment Blue 15: 4, Pigment Blue 15: 3, Pigment Blue 15: 2, Pigment Blue 15: 1, Pigment Blue 80, Pigment yel- low 1, Pigment yellow 13, Pigment red 48: 2, Pigment red 48: 1, Pigment red 57: 1, Pigment red 53: 1, Pigment orange 43, Pigment orange 34, Pigment orange 5, Pigment green 36, Pigment green 7, Pigment white 6, Pigment brown 25, Basic violet 10, Basic violet 49, Acid red 51, Acid red 52, Acid red 14, Acid blue 9, Acid yellow 23, Basic red 10, Basic red 108 well-known dyes and pigments , Examples of adhesives are polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl alcohol and

Cellulose ethers (Tylose ^®, Shin-Etsu, Japan).

For the preparation of directly sprayable solutions, emulsions, pastes or oil dispersions, there are mineral oil fractions of medium to high boiling point, such as kerosene or diesel oil, coal tar oils and oils of vegetable or animal origin, aliphatic, cyclic and aromatic hydrocarbons, e.g. Toluene, xylene, paraffin, tetrahydronaphthalene, alkylated naphthalenes or their derivatives, methanol, ethanol, propanol, butanol, cyclohexanol, cyclohexanone, isophorone, strong polar solvents, e.g. Dimethylsulfoxide, N-methylpyrrolidone or water into consideration.

Powders, dispersants and dusts can be prepared by mixing or grinding together the compounds I and, where present, further active compounds with at least one solid carrier.

Granules, for. As coated, impregnated and homogeneous granules can be prepared by binding the active ingredients to at least one solid carrier. Solid carriers are z. As mineral earths, such as silica gels, silicates, talc, kaolin, Attaclay, limestone, lime, chalk, bolus, loess, clay, dolomite, diatomaceous earth, calcium and magnesium sulfate, magnesium oxide, ground plastics, fertilizers such as ammonium sulfate, ammonium phosphate , Ammonium nitrate, ureas and vegetable products such as cereal flour, bark, wood and nutshell flour, cellulose powders and other solid carriers. Examples of composition types are:

1. Compositions for dilution in water i) Water-soluble concentrates (SL, LS)

10 parts by weight of the active ingredients are dissolved with 90 parts by weight of water or a water-soluble solvent. Alternatively, wetting agents or other adjuvants are added. When diluted in water, the active ingredient dissolves. This gives a composition with 10 wt .-% active ingredient content. ii) Dispersible Concentrates (DC)

20 parts by weight of the active ingredients are dissolved in 70 parts by weight of cyclohexanone with the addition of 10 parts by weight of a dispersant z. B. dissolved polyvinylpyrrolidone. Dilution in water results in a dispersion. The active ingredient content is 20% by weight iii) Emulsifiable Concentrates (EC)

15 parts by weight of the active compounds are dissolved in 75 parts by weight of xylene with the addition of Dodecylbenzenesulfonate and castor oil ethoxylate (each 5 parts by weight) dissolved. Dilution in water results in an emulsion. The composition has 15% by weight active ingredient content. iv) Emulsions (EW, EO, ES) 25 parts by weight of the active compounds are dissolved in 35 parts by weight of xylene with the addition of calcium

Dodecylbenzenesulfonate and castor oil ethoxylate (each 5 parts by weight) dissolved. This mixture is added by means of an emulsifying machine (eg Ultra-Turrax) in 30 parts by weight of water and brought to a homogeneous emulsion. Dilution in water results in an emulsion. The composition has an active ingredient content of 25 wt .-%. v) suspensions (SC, OD, FS)

20 parts by weight of the active ingredients are comminuted with the addition of 10 parts by weight of dispersants and wetting agents and 70 parts by weight of water or an organic solvent in a stirred ball mill to a fine active substance suspension. Dilution in water results in a stable suspension of the active ingredient. The active ingredient content in the composition is 20% by weight. vi) Water-dispersible and water-soluble granules (WG, SG)

50 parts by weight of the active compounds are finely ground with the addition of 50 parts by weight of dispersants and wetting agents and prepared by means of technical equipment (for example extrusion, spray tower, fluidized bed) as water-dispersible or water-soluble granules. Dilution in water results in a stable dispersion or solution of the active ingredient. The composition has an active substance content of 50% by weight. vii) Water-dispersible and water-soluble powders (WP, SP, SS, WS)

75 parts by weight of the active ingredients are ground with the addition of 25 parts by weight of dispersing and wetting agents and silica gel in a rotor-Strator mill. Dilution in water results in a stable dispersion or solution of the active ingredient. The active ingredient content of the composition is 75% by weight. viii) gels (GF)

In a ball mill, 20 parts by weight of the active ingredients, 10 parts by weight of dispersant, 1 part by weight of swelling agent ("gelling agent") and 70 parts by weight of water or an organic solvent are ground to a fine suspension. Dilution with water results in a stable suspension containing 20% by weight of active ingredient 2. Compositions for Direct Application ix) Dusts (DP, DS) 5 parts by weight of the active ingredients are finely ground and finely divided with 95 parts by weight intimately mixed with kaolin, thereby obtaining a dust with 5% by weight of active ingredient x) Granules (GR, FG, GG, MG)

0.5 part by weight of the active ingredients are finely ground and combined with 99.5 parts by weight of carriers. Common processes are extrusion, spray drying or fluidized bed. This gives a granulate for direct application with 0.5 wt .-% active ingredient content. xi) ULV solutions (UL)

10 parts by weight of the active compounds are dissolved in 90 parts by weight of an organic solvent z. B. XyIoI solved. This gives a composition for direct application with 10 wt .-% active ingredient content.

The compositions of the compounds according to the invention generally contain between 0.1 and 95% by weight, preferably between 0.1 and 90% by weight, preferably between 0.5 and 90% by weight of active compound (compound according to the invention). The compounds I and II are used in a purity of 90% to 100%, preferably 95% to 100% (according to NMR spectrum).

For the treatment of plant propagation materials, in particular seed, usually water-soluble concentrates (LS), suspensions (FS), dusts (DS), water-dispersible and water-soluble powders (WS, SS), emulsions (ES), emulsifiable concentrates (EC) and gels ( GF). These compositions can be applied to the propagating materials, in particular seeds, undiluted or, preferably, diluted. In this case, the corresponding composition can be diluted 2 to 10 times, so that 0.01 to 60% by weight, preferably 0.1 to 40% by weight, of active substance is present in the compositions to be used for the stain. The application can be done before or during sowing.

The treatment of plant propagation material, in particular the treatment of seed, are known to the person skilled in the art and are carried out by dusting, coating, pelleting, dipping or impregnating the plant propagation material, wherein the treatment preferably takes place by pelleting, coating and dusting or by furrow treatment, so that z. B. premature germination of the seed is prevented.

For seed treatment, suspensions are preferably used. Typically, such compositions contain 1 to 800 g / l active ingredient, 1 to 200 g / l surfactants, 0 to 200 g / l antifreeze, 0 to 400 g / l binder, 0 to 200 g / l dyes and solvents, preferably water ,

The compounds may be used as such or in the form of their compositions, e.g. B. in the form of directly sprayable solutions, powders, suspensions, dispersions, emulsions, oil dispersions, pastes, dusts, scattering agents or granules by spraying, atomizing, dusting, scattering, coating, dipping or pouring. The composition types depend entirely on the intended use; In any case, they should ensure the finest possible distribution of the active compounds according to the invention.

Aqueous application forms can be prepared from emulsion concentrates, pastes or wettable powders (wettable powders, oil dispersions) by adding water. For the preparation of emulsions, pastes or oil dispersions, the

Substances as such or dissolved in an oil or solvent, are homogenized in water by means of wetting agents, tackifiers, dispersants or emulsifiers. But it can also from effective substance wetting agents, adhesives, dispersants or emulsifiers and possibly solvent or oil concentrates are prepared, which are suitable for dilution with water.

The active compound concentrations in the ready-to-use preparations can be varied within wide ranges. In general, they are between 0.0001 and 10%, preferably between 0.01 and 1%.

The active ingredients can also be successfully used in the ultra-low-volume (ULV) process, whereby it is possible to apply compositions containing more than 95% by weight of active ingredient or even the active ingredient without additives.

The application rates of the compounds of the invention are in the application in crop protection, depending on the nature of the desired effect between 0.001 and 2.0 kg of active ingredient per ha, preferably between 0.005 and 2 kg per ha, preferably between 0.01 and 2.0 kg of active ingredient per ha , more preferably between 0.05 and 0.9 kg per ha, in particular between 0.1 and 0.75 kg per ha.

In the treatment of plant propagation materials, eg. B. State goods, are generally active amounts of from 0.1 to 1000 g / 100 kg of propagating material or seed, preferably 1 to 1000 g / 100 kg, more preferably 1 to 100 g / 100 kg, in particular 5 to 100 g / 100 kg of propagating material or seed used. Another object of the invention is therefore seed containing at least one compound of the invention and / or an agriculturally acceptable salt thereof in an amount of 1 to 1000 g per 100 kg.

When used in material or storage protection, the application rate of active ingredient depends on the type of application and the desired effect. Usual application rates are, for example, 0.001 g to 2 kg, preferably 0.005 g to 1 kg of active ingredient per cubic meter of material treated in the material protection.

Oils of various types, wetting agents, adjuvants, herbicides, bactericides, other fungicides, and / or other pesticides, if appropriate also immediately before use (tank mix), can be added to the compounds (active substances) or the compositions containing them. These agents can be added to the compositions according to the invention in a weight ratio of 1: 100 to 100: 1, preferably 1:10 to 10: 1.

Suitable adjuvants in this sense are in particular: organically modified polysiloxanes, for example Break Thru S ^240® ; Alcohol alkoxylates, eg. As Atplus 245 ^®, Atplus MBA 1303 ^®, Plurafac LF 300 ^® and Lutensol ON 30 ^®; EO-PO block polymers, eg. B. Pluronic RPE 2035 ^® and Genapol B ^®; Alcohol ethoxylates, eg. As Lutensol XP 80 ^®; and sodium dioctylsulfosuccinate, e.g. B. Leophen RA ^®. The compounds according to the invention or their compositions can also be present in the application form as fungicides together with other active compounds, for example with herbicides, insecticides, growth regulators, fungicides or else with fertilizers, as a pre-mix or optionally only immediately before the application (tank mix ). When mixing the compounds according to the invention or the compositions containing them with one or more further active compounds, in particular fungicides, it is possible, for example, in many cases to widen the activity spectrum or to prevent development of resistance. In many cases, synergistic effects are obtained.

Another object of the invention is therefore an agent for crop protection, comprising a compound of the invention, in particular a compound I or a compound II, and at least one further fungicidal, insecticidal and / or herbicidal active ingredient, according to one embodiment, the further active ingredient is a fungicidal active ingredient , in particular one selected from the following list. The active ingredients are preferably present in synergistic amounts.

Another object of the invention relates to a composition comprising a compound of the invention and / or an acid addition or metal salt thereof. This composition also contains as plant protection agent at least one solid or liquid carrier. According to a further embodiment, said compositions may further comprise at least one further fungicidal, insecticidal and / or herbicidal active ingredient.

The fungicides are preferably selected from the following groups:

Strobilurins, carboxylic acid amides such as carboxylic anilides, carboxylic acid morpholides, benzoic acid amides, other carboxamides, azoles such as triazoles, imidazoles, benzimidazoles, others, nitrogen-containing heterocyclyl compounds such as pyridines, pyrimidines, pyrroles, morpholines, dicarboximides, other nitrogen-containing heterocyclyl compounds, thio- and dithiocarbamates , Carbamates, guanidines, antibiotics, nitrophenyl derivatives, organometallic compounds, sulfur-containing heterocyclyl compounds, organophosphorus compounds, organochlorine compounds, inorganic active substances, other fungicides.

The following list of fungicides with which the compounds according to the invention can be used together is intended to illustrate, but not limit, the possible combinations.

A) strobilurins azoxystrobin, dimoxystrobin, enestroburine, fluoxastrobin, kresoxim-methyl, methyminostrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyribencarb, trifloxystrobin, 2- (2- (6- (3-chloro-2-methyl-phenoxy) -5 -fluoro-pyrimidin-4-yloxy) -phenyl) -2-methoxyimino-N- methyl-acetamide, 2- (ortho - ((2,5-dimethylphenyl-oxymethylene) -phenyl) -3-methoxy-acrylic acid methyl ester, 3-methoxy-2- (2- (N- (4-methoxy-phenyl) - cyclopropanecarboximidoylsulfanylmethyl) -phenyl) -acrylic acid methyl ester, 2- (2- (3- (2,6-dichlorophenyl) -1-methyl-allylideneaminooxymethyl) -phenyl) -2-methoxyimino-N-methyl-acetamide;

B) Carboxylic acid amides

- carboxylic acid anilides: benalaxyl, benalaxyl-M, benodanil, bixafen, boscalid, carbo-xin, fenfuram, fenhexamide, flutolanil, furametpyr, isopyrazam, isotianil, kiralaxyl, mepronil, metalaxyl, metalaxyl-M (mefenoxam), ofurace, oxadixyl, oxycarboxin, Penthiopyrad, Sedaxane, Tecloftalam, Thifluzamide, Tiadinil, 2-Amino-4-methylthiazole-5-carboxylic acid anilide, 2-Chloro-N- (1, 1, 3-trimethyl-indan-4-yl) -nicotinamide, N- (3 ', 4'-dichloro-5-fluoro-biphenyl-2-yl) -3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, 5-fluoro-1,3-dimethyl-1H- pyrazole-4-carboxylic acid [2- (1, 3-dimethyl-butyl) -phenyl] -amide, N- (4'-chloro-3 ', 5-difluoro-biphenyl-2-yl) -3-difluoromethyl-1 -methyl-1H-pyrazole-4-carboxylic acid amide, N- (4'-chloro-3 ', 5-difluoro-biphenyl-2-yl) -3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide , N- (3 ', 4'-dichloro-4-fluorobiphenyl-2-yl) -3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (3', 5-difluoro- 4'-methyl-biphenyl-2-yl) -3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (3 ', 5-Difluoro-4'-methyl-biphenyl-2-yl) -3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (2-bicyclopropyl-2-yl-phenyl) -3 -difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (cis-2-bicyclopropyl-2-yl-phenyl) -3-di-fluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide , N- (trans-2-bicyclopropyl-2-ylphenyl) -3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (4'-bromophenyl-2-yl) -4 -difluoromethyl-2-methylthiazole-5-carboxamide, N- (4'-trifluoromethyl-bi-phenyl-2-yl) -4-difluoromethyl-2-methylthiazole-5-carboxylic acid amide, N- (4'-trifluoromethyl) -2-methylthiazole-5-carboxylic acid amide

Chloro-S'-fluorobiphenyl-Y-O-difluoromethyl-methyl-thiazole-δ-carboxamide, 3,4-dichloro-N- (2-cyanophenyl) -isothiazole-5-carboxamide, N- (2 ', 4'-difluorobiphenyl- 2-yl) -1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid amide, N- (2 ', 4'-dichlorophenyl-2-yl) -1-methyl-3-trifluoromethyl-1H pyrazole-4-carboxylic acid amide, N- (2 ', 4'-difluorobiphenyl-2-yl) -3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (2', 4 ' -

Dichlorobiphenyl-2-yl) -3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (2 ', 5'-difluorobiphenyl-2-yl) -1-methyl-3-trifluoromethyl-1H pyrazole-4-carboxylic acid amide, N- (2 ', 5'-dichlorobiphenyl-2-yl) -1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid amide, N- (2', 5 ' -Difluorobiphenyl-2-yl) -3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (2 ', 5'-dichlorobiphenyl-2-yl) -3-difluoromethyl-1-methyl -1 H -pyrazole-4-carboxylic acid amide, N- (3 ', 5'-difluorobiphenyl-2-yl) -1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid amide, N- (3', 5 '-Dichlorobiphenyl-2-yl) -1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid amide, N- (3', 5'-difluorobiphenyl-2-yl) -3-difluoromethyl-1-methyl- 1 H-pyrazole-4-carboxamide, N- (3 ', 5'-dichlorobiphenyl-2-yl) -3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (3'- fluorobiphenyl-2-yl) -1-methyl-3-trifluoro-methyl-

1 H-pyrazole-4-carboxylic acid amide, N- (3'-chlorobiphenyl-2-yl) -1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid amide, N- (3'-fluorobiphenyl-2-yl ) -3-difluoromethyl-1-methyl 1 H-pyrazole-4-carboxylic acid amide, N- (3'-chlorobiphenyl-2-yl) -3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (2'-fluorobiphenyl-2 -yl) -1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid amide, N- (2'-chlorobiphenyl-2-yl) -1-methyl-3-trifluoromethyl-1H-pyrazole 4-carboxamide, N- (2'-fluorobiphenyl-2-yl) -3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (2'-chlorobiphenyl-2-yl) -3- difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (2'-fluoro-4'-chloro-5'-methyl-biphenyl-2-yl) -1-methyl-3-trifluoromethyl-1H pyrazole-4-carboxylic acid amide, N- (3 ', 4', 5'-trifluorobiphenyl-2-yl) -1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid amide, N- (3 ', 4 ', 5'-trifluorophenyl-2-yl) -1-methyl-3-difluoromethyl-1H-pyrazole-4-carboxylic acid amide, N- (2', 4 ', 5'-trifluorobiphenyl-2-yl ) -1-methyl-3-difluoromethyl-1H-pyrazole-4-carboxylic acid amide, N-

(3 ', 4', 5'-Trifluorobiphenyl-2-yl) -3-chlorofluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- [2- (1,1,2,3 , 3,3-hexafluoropropoxy) phenyl] -1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid amide, N- [2- (1,1,3,3,3,3-hexafluoropropoxy) -phenyl] 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- [2- (2-chloro-1,2,3-trifluoroethoxy) phenyl] -1-methyl-3-trifluoromethyl- 1 H-pyrazole-4-carboxylic acid amide, N- [2- (2-chloro)

1, 1, 2-trifluoroethoxy) phenyl] -3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- [2- (1,1,2,2-tetrafluoroethoxy) phenyl] -3 -difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- [2- (1, 1, 2,2-tetrafluoroethoxy) phenyl] -1-methyl-3-trifluoromethyl-1H-pyrazole-4 carboxylic acid amide, N- (4 '- (trifluoromethylthio) biphenyl-2-yl) -3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxamide, N- (4' - (trifluoromethylthio) biphenyl-

2-yl) -1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid amide, 5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxylic acid [2- (1,2-dimethyl -propyl) -phenyl] -amide, N- (2- {4- [3- (4-chlorophenyl) -prop-2-ynyloxy] -3-methoxyphenyl} ethyl) -2-methanesulfonylamino-3-methylbutyramide, N- ( 2- {4- [3- (4-Chloro-phenyl) -prop-2-ynyloxy] -3-methoxyphenyl} -ethyl) -2-ethanesulfonyl-amino-3-methyl-butyramide, N- (3 ', 4'-dichloro) 5-fluoro-biphenyl-2-yl) -3-trifluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid amide, N- (2- (1,3,3-trimethyl-butyl) -phenyl) -1, 3-dimethyl-5-fluoro-1H-pyrazole-4-carboxamide, N- [1,2,3,4-tetrahydro-9- (1-methylethyl) -1, 4-methanonaphthalene-5-yl] -3 - (difluoromethyl) -1-methyl-1H-pyrazole-4-carboxamide, N '- (4- (4-chloro-3-trifluoromethyl-phenoxy) -2,5-dimethyl-phenyl) -N-ethyl-N Methyl formamidine, N '- (4- (4-fluoro-3-trifluoromethyl-phenoxy) -

2,5-dimethylphenyl) -N-ethyl-N-methylformamidine, N '- (2-methyl-5-trifluoromethyl-4- (3-trimethylsilanyl-propoxy) -phenyl) -N-ethyl-N-methyl formamidine and N '- (5-difluoromethyl-2-methyl-4- (3-trimethylsilanyl-propoxy) -phenyl) -N-ethyl-N-methylformamidine; - Carboxylic acid morpholides: dimethomorph, flumorph, pyrimorph;

Benzoic acid amides: flumetover, fluopicolide, fluopyram, zoxamide, N- (3-ethyl-3,5,5-trimethylcyclohexyl) -3-formylamino-2-hydroxybenzamide;

Other carboxamides: carpropamide, diclocymet, mandipropamide, oxytetracycline, silthiofam, N- (6-methoxypyridin-3-yl) cyclopropanecarboxamide; C) Azoles

- Triazoles: azaconazole, bitertanol, bromuconazole, cyproconazole, difenoconazole, diniconazole, diniconazole-M, epoxiconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, metconazole, mycelobutanil, oxpoconazole, paclobutrazole, penconazole, propiconazole, prothioconazo -

Ie, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triticonazole, uniconazole, 1- (4-chlorophenyl) -2 - ([1, 2,4] triazol-1-yl) -cycloheptanol;

- imidazoles: cyazofamide, imazalil, imazalil sulfate, pefurazoate, prochloraz, triflumizo- Ie; Benzimidazoles: benomyl, carbendazim, fuberidazole, thiabendazole;

- Other: Ethaboxam, Etridiazole, Hymexazole, 1- (4-Chloro-phenyl) -1- (propyn-2-yloxy) -3- (4- (3,4-dimethoxyphenyl) -isoxazol-5-yl) -propan-2-one, 2- (4-chloro-phenyl) -N- [4- (3,4-dimethoxyphenyl) -isoxazol-5-yl] -2-prop-2-ynyloxy-acetamide;

D) Nitrogen-containing heterocyclyl compounds

Pyridines: fluazinam, pyrifenox, 3- [5- (4-chloro-phenyl) -2,3-dimethyl-isoxazolidin-3-yl] -pyridine, 3- [5- (4-methyl-phenyl) -2, 3-dimethyl-isoxazolidin-3-yl] -pyridine, 2,3,5,6-tetrachloro-4-methanesulfonyl-pyridine, 3,4,5-trichloropyridine-2,6-dicarbonitrile, N- (1 - (5-bromo-3-chloro-pyridin-2-yl) -ethyl) -2,4-dichloro-nicotinamide, N - ((5-bromo-3-chloro-pyridin-2-yl) -methyl) -2 , 4-dichloro-nicotinamide;

- pyrimidines: bupirimate, cyprodinil, diflumetorim, fenarimol, ferimzone, mepanipyrimine, nitrapyrin, nuarimol, pyrimethanil;

- piperazines: triforins;

- Pyrroles: fludioxonil, fenpiclonil; - Morpholines: aldimorph, dodemorph, dodemorph acetate, fenpropimorph, tride- morph;

- piperidines: fenpropidine;

Dicarboximides: fluorimide, iprodione, procymidone, vinclozolin;

non-aromatic 5-membered heterocycles: famoxadone, fenamidone, flutianil, octhi- non, probenazole, 5-amino-2-isopropyl-3-oxo-4-ortho-tolyl-2,3-dihydropyrazole-1-thiocarboxylic acid allyl ester;

- Other: acibenzolar-S-methyl, amisulbrom, anilazine, blasticidin-S, captafol, captan, quinomethionate, dazomet, debacarb, diclomethine, difenzoquat, difenzoquat-methylsulphate, fenoxanil, folpet, oxolinic acid, piperaline, proquinazid, pyroquilone, quinoxyfen , Triazoxide, tricyclazole, 5-chloro-7- (4-methylpiperidin-1-yl) -6- (2,4,6-trifluorophenyl) - [1, 2,4] triazolo [1, 5- a] pyrimidine, 6- (4-tert-butylphenyl) -5-methyl- [1,2,4] triazolo [1,5-a] pyrimidin-7-ylamine, 5-methyl-6- (3,5, 5-trimethylhexyl) - [1,2,4] triazolo [1,5-a] pyrimidin-7-ylamine, 5-methyl-6-octyl- [1,2,4] triazolo [1,5-a] pyiminimide -7-yl-amine, 6-methyl-5-octyl- [1,2,4] triazolo [1,5-a] pyrimidin-7-yl-amine, 6-ethyl-5-octyl- [1, 2 , 4] triazolo [1,5-a] pyrimidin-7-yl-amine, 5-ethyl-6-octyl-

[1, 2,4] triazolo [1,5-a] pyrimidin-7-ylamine, 5-ethyl-6- (3,5,5-trimethylhexyl) - [1, 2,4] triazolo [1, 5 a] pyrimidin-7-ylamine, 6-octyl-5-propyl- [1,2,4] triazolo [1,5] a] pyimidin-7-yl-amine, 5-methoxymethyl-6-octyl- [1,2,4] triazolo [1,5-a] pyrimidin-7-yl-amine, 6-octyl-5-trifluoromethyl [1 , 2,4] triazolo [1,5-a] pyrimidin-7-yl-amine, 5-trifluoromethyl-6- (3,5,5-trimethylhexyl) - [1, 2,4] triazolo [1,5] a] pyiminimid-7-ylamine, 2-butoxy-6-iodo-3-propyl-chromen-4-one, 5-chloro-1- (4,6-dimethoxy-pyrimidin-2-yl) -2-methyl- 1 H-benzoimidazole, 6- (3,4-dichlorophenyl) -5-methyl- [1,2,4] triazolo [1,5-a] pyimidin-7-ylamine;

E) carbamates and dithiocarbamates

Thio and dithiocarbamates: Ferbam, Mancozeb, Maneb, Metam, Methasulphocarb, Metiram, Propineb, Thiram, Zineb, Ziram;

Carbamates: Diethofencarb, Benthiavalicarb, Iprovalicarb, Propamocarb, Propamocarb hydrochloride, Valiphenal, N- (1- (1- (4-cyanophenyl) ethanesulfonyl) -but-2-yl) carbamic acid (4-fluorophenyl) ester ;

F) Other fungicides

Guanidines: dodine, dodine free base, guazatine, guazatine acetate, iminoctadine, iminoctadine triacetate, iminoctadine tris (albesilat);

Antibiotics: kasugamycin, kasugamycin hydrochloride hydrate, polyoxines, streptomycin, validamycin A;

Nitrophenyl derivatives:

Binapacryl, dicloran, dinobutone, dinocap, nitrothal-isopropyl, tecnazene;

Organometallic compounds: Fentin salts such as, for example, fentin acetate, fentin chloride, fentin hydroxide; Sulfur-containing heterocyclyl compounds: isoprothiolanes, dithianone;

Organophosphorus compounds: edifenphos, fosetyl, fosetyl-aluminum, Iprobenfos, pyrazophos, tolclofos-methyl;

Organochlorine compounds: chlorothalonil, dichlofluanid, dichlorophene, flusulphamide, hexachlorobenzene, pencycuron, pentachlorophenol and its salts, phthalide, quintozene, thiophanate-methyl, tolylfluanid, N- (4-chloro-2-nitro-phenyl) -N-ethyl-4- methyl-benzenesulfonamide;

- Inorganic active substances: Phosphorous acid and its salts, sulfur, Bordeaux broth, copper salts such as copper acetate, copper hydroxide, copper oxychloride, basic copper sulfate; - Other: biphenyl, bronopol, cyflufenamid, cymoxanil, diphenylamine, metrafenone, mildiomycin, oxine-copper, prohexadione-calcium, spiroxamine, tolylfluanid, N- (cyclopropylmethoxyimino- (6-difluoromethoxy-2,3-difluorophenyl) - methyl) -2-phenylacetamide, N '- (4- (4-chloro-3-trifluoromethyl-phenoxy) -2,5-dimethylphenyl) -N-ethyl-N-methylformamidine, N' - 4-fluoro-3-trifluoromethyl-phenoxy) -2,5-dimethyl-phenyl) -N-ethyl-N-methylformamidine, N '- (2-methyl-5-trifluoromethyl-4- (3-trimethylsilanyl-propoxy) ) -phenyl) -N-ethyl-N-methylformamidine, N '- (5-difluoromethyl-2-methyl-4- (3-trimethylsilanyl-propoxy) -phenyl) -N-ethyl-N-methylformamidine, 2- {1- [2- (5-methyl-3- trifluoromethyl-pyrazol-i-y-acyl-piperidine-1-yl-1-thiazole-1-carboxylate-methyl (1,2,3,4-tetrahydronaphthalen-1-yl) -amide, 2- {1 - [2- (5 -Methyl-3-trifluoromethyl-pyrazol-1-yl) -acetyl] -piperidin-4-yl} -thiazole-4-carboxylic acid-methyl- (R) -1, 2,3,4-tetrahydronaphthalen-1-yl amide, acetic acid 6-tert-butyl-8-fluoro-2,3-dimethyl-quinolin-4-yl-ester, methoxy-acetic acid 6-tert-butyl-8-fluoro-2,3-dimethyl quinoline-4-yl-ester;

G) growth regulator

Abscisic acid, amidochlor, ancymidol, 6-benzylaminopurine, brassinolide, butraline, chlormequat (chlorequat chloride), choline chloride, cyclanilide, daminozide, dikegulac, dimethipine, 2,6-dimethylpuridine, ethephon, flumetralin, flurprimidol, fluthiacet, forchlorfenuron, gibberellic acid, inabenfid , indole-3-acetic acid, maleic hydrazide, mefluidide, mepiquat (mepiquat chloride), metconazole, naphthalene acetic acid, N-6-benzyladenine, paclobutrazole, prohexadione (prohexadione-calcium), Prohydrojasmon, thidiazoron, tri-penthenol, tributyl phosphorotrithioate, 2,3 5-tri-iodobenzoic acid, trinexapac-ethyl and uniconazole; H) herbicides

Acetamides: acetochlor, alachlor, butachlor, dimethachlor, dimethenamid, flufenacet, mefenacet, metolachlor, metazachlor, napropamide, naproanilide, pethoxamide, pretilachlor, propachlor, thenylchloro; Amino acid analogues: bilanafos, glyphosate, glufosinate, sulfosate;

Aryloxyphenoxypropionates: Clodinafop, Cyhalofop-butyl, Fenoxaprop, Fluazifop, Haloxyfop, Metamifop, Propaquizafop, Quizalofop, Quizalofop-P-tefuryl;

Bipyridyls: diquat, paraquat;

Carbamates and thiocarbamates: asulam, butylates, carbamides, desmedipham, dimepiperate, eptam (EPTC), esprocarb, molinates, orbencarb, phenmedipham, prosulphocarb, pyributicarb, thiobencarb, triallates;

- cyclohexanediones: butroxydim, clethodim, cycloxydim, profoxydim, sethoxydim, tepraloxydim, tralkoxydim;

- Dinitroanilines: Benfluralin, Ethalfluralin, Oryzalin, Pendimethalin, Prodiamine, Triflura- Nn;

Diphenyl ether: acifluorfen, aclonifen, bifenox, diclofop, ethoxyfen, fomesafen, lactofen, oxyfluorfen;

Hydroxybenzonitriles: bromoxynil, dichlobenil, loxynil;

Imidazolinone: imazamethabenz, imazamox, imazapic, imazapyr, imazaquin, imazethapyr;

Phenoxyacetic acids: clomeprop, 2,4-dichlorophenoxyacetic acid (2,4-D), 2,4-DB, dichlorprop, MCPA, MCPA-thioethyl, MCPB, mecoprop;

- Pyrazines: Chloridazon, Flufenpyr-ethyl, Fluthiacet, Norflurazon, Pyridate;

- pyridines: aminopyralid, clopyralid, diflufenican, dithiopyr, fluridone, fluroxypyr, pilinoram, picolinafen, thiazopyr;

Sulfonylureas: amidosulfuron, azimsulfuron, bensulfuron, chlorimuron-ethyl, chlorosulfuron, cinosulfuron, cyclosulfamuron, ethoxysulfuron, flazasulfuron, fluce- tosulfuron, flupyrsulfuron, foramsulfuron, halosulfuron, imazosulfuron, lodosulfuron, mesosulfuron, metsulfuron-methyl, nicosulfuron, oxasulfuron, primisulfuron, prosulfuron, pyrazosulfuron, rimsulfuron, sulfometuron, sulfosulfuron, thifensulfuron, triasulfuron, tribenuron, trifloxysulfuron, triflusulfuron, tritosulfuron, 1- ((2-chloro-6-propyl-imidazo [1,2-b] pyridazin-3-yl) sulfonyl) -3- (4,6-dimethoxypyrimidin-2-yl) urea;

Triazines: ametryn, atrazine, cyanazine, dimethametryn, ethiozine, hexazinone, metachronon, metribuzin, prometryn, simazine, terbuthylazine, terbutryn, triaziflam;

Ureas: chlorotoluron, da- muron, diuron, fluometuron, isoproturon, linuron, methabenzthiazuron, tebuthiuron;

- other inhibitors of acetolactate synthase: bispyribac sodium, cloransulam methyl, diclosulam, florasulam, flucarbazone, flumetsulam, metosulam, orthosulphamuron, penoxsulam, propoxycarbazone, pyribambenz-propyl, pyribenzoxime, pyriftalid, pyriminobac-methyl, pyrimisulphane, pyrithiobac, pyroxasulphone, pyroxsulam; - Other: Amicarbazone, Aminotriazole, Anilofos, Beflubutamide, Benazoline, Bencarbazone, Benfluresat, Benzofenap, Bentazone, Benzobicyclone, Bromacil, Bromobutide, Bu- tattacil, Butamifos, Cafenstrole, Carfentrazone, Cinidone-Ethlyl, Chlorthal, Cinnamethyl-, Clomazone , Cumyluron, cyprosulfamide, dicamba, difenzoquat, diflufenzopyr, Drechslera monoceras, endothal, ethofumesate, etobenzanide, fentrazamide, flumigorac-pentyl, flumioxazine, flupoxam, fluorochloridone, flurtamone, indanofan, isoxaben, isoxaflutole, lenacil, propanil, propyzamide, Quinclorac, quinmerac, mesotrione, methylarsenoic acid, naptalam, oxadiargyl, oxadiazon, oxaziclomefon, pentoxazone, pinoxaden, pyraclonil, pyraflufen-ethyl, pyrasulfotol, pyrazoxyfen, pyrazolynate, quinoclamin, saflufenacil, sulcotrione, sulfentrazone, terbacil, tefuryltrione, tembotrione, thiencarbazone, Topramezone, 4-hydroxy-3- [2- (2-methoxy-ethoxymethyl) -6-trifluoromethyl-pyridine-3-carbonyl] -bicyclo [3.2.1] oct-3-en-2-one, (3- [ 2-chloro-4-fluoro-5- (3-methyl-2,6-di oxo-4-trifluoromethyl-3,6-dihydro-2H-pyrimidin-1-yl) -phenoxy] -pyridin-2-yloxy) -acetic acid ethyl ester, θ-amino-δ-chloro-cyclopropyl-pyrimidine-4-carboxylic acid methyl ester, 6-Chloro-3- (2-cyclopropyl-6-methyl-phenoxy) -pyridazin-4-ol, 4-amino-3-chloro-6- (4-chloro-phenyl) -5-fluoro-pyridin-2 carboxylic acid,

4-Amino-3-chloro-6- (4-chloro-2-fluoro-3-methoxy-phenyl) -pyridine-2-carboxylic acid methyl ester and 4-amino-3-chloro-6- (4-chloro-3 -dimethylamino-2-fluoro-phenyl) -pyridine-2-carboxylic acid methyl ester; I) Insecticides - Organo (thio) phosphates: Acephate, Azamethiphos, Azinphos-methyl, Chlorpyrifos,

Chlorpyrifos-methyl, chlorfenvinphos, diazinon, dichlorvos, dicrotophos, dimethoate, disulphoton, ethion, fenitrothion, fenthione, isoxathione, malathion, methamidophosphate, methidathion, methyl parathion, mevinphos, monocrotophos, oxydemeton-methyl, paraoxon, parathion, Phenthoate, Phosalone, Phosmet, Phosphamidone, Phorate, Phoxim, Pirimiphos-Methyl, Profenofos, Prothiofos, Sulprophos, Tetrachlorvinphos, Terbufos, Triazophos, Trichlorfon;

Carbamates: alanycarb, aldicarb, bendiocarb, benfuracarb, carbaryl, carbofuran, Carbosulfan, fenoxycarb, furathiocarb, methiocarb, methomyl, oxamyl, pirimicarb, propoxur, thiodicarb, triazamates;

Pyrethroids: allethrin, bifenthrin, cyfluthrin, cyhalothrin, cyphenothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, zeta-cypermethrin, deltamethrin, esfenvalerate, etofenprox, fenpropathrin, fenvalerate, imiprothrin, lambda-cyhalothrin, permethrin, prallethrin, Pyrethrin I and II, resmethrin, silafluofen, tau-fluva- linate, tefluthrin, tetramethrin, tralomethrin, transfluthrin, profluthrin, dimefluthrin, insect growth inhibitors: a) chitin synthesis inhibitors: benzoylureas: chlorofluorazuron, cyramazine, diflubenzuron, flucycloxuron, flufenoxuron Hexaflumuron, Lufenuron, Novaluron, Teflubenzuron, Triflumuron; Buprofezin, diofenolan, hexythiazox, etoxazole, clofentazine; b) ecdysone antagonists: halofenozide, methoxyfenozide, tebufenozide, azadirachtin; c) Juvenoids: Pyriproxyfen, Methoprene, Fenoxycarb; d) lipid biosynthesis inhibitors: spirodiclofen, spiromesifen, spinotetramat; Nicotine receptor agonists / antagonists: clothianidin, dinotefuran, imidacloprid, thiamethoxam, nitenpyram, acetamiprid, thiacloprid, 1- (2-chlorothiazol-5-ylmethyl) -2-nitrimino-3,5-dimethyl- [1, 3,5] triazinane;

GABA antagonists: endosulfan, ethiprole, fipronil, vaniliprole, pyrafluprole, pyriprole, 5-amino-1- (2,6-dichloro-4-methylphenyl) -4-sulfinamoyl-1H-pyrazole-3-thiocarbon acid amide;

Macrocyclic lactones: abamectin, emamectin, milbemectin, lepimectin, spinosad, spinetoram;

Mitochondrial Electron Transport Chain Inhibitor (METI) I Acaricides: Fenazaquin,

Pyridaben, Tebufenpyrad, Tolfenpyrad, Flufenerim; - METI II and III substances: Acequinocyl, Fluacyprim, Hydramethylnon;

- decoupler: chlorfenapyr;

- inhibitors of oxidative phosphorylation: cyhexatin, diafenthiuron, fenbutatin oxide, propargite;

Inhibitors of the sloughing of insects: Cryomazine; Inhibitors of mixed function oxidases: piperonyl butoxide;

Sodium channel blocker: indoxacarb, metaflumizone;

- Other: Benclothiaz, Bifenazate, Cartap, Flonicamid, Pyridalyl, Pymetrozine, Sulfur, Thiocyclam, Flubendiamid, Chlorantraniliprole, Cyazypyr (HGW86); Cynopyphron, Flupyrazofos, Cyflumetofen, Amidoflumet, Imicyafos, Bistrifluron and Pyrifluquinazone.

In particular, the present invention also relates to fungicidal compositions comprising at least one compound of the general formula I and at least one further crop protection active ingredient, eg. B. selected from the active ingredients of the aforementioned groups A) to I), in particular at least one fungicidal active ingredient, in particular selected from the active compounds of the aforementioned groups A) to F), and optionally one or more agriculturally suitable carriers. With regard a reduction in the application rates, these mixtures are of interest, as many with reduced total amount of applied drugs show an improved activity against harmful fungi, especially for certain indications. By simultaneous joint or separate application of compound (s) I with at least one active compound of groups A) to I), the fungicidal activity can be increased to a superadditive extent.

Common application within the meaning of this application means that the at least one compound I and the at least one other active ingredient at the same time at the site of action (ie the attacking plant-damaging fungi and their habitat such as infested plants, plant propagation materials, insebesondere seed, soil, materials or rooms and the before Fungal attack on plants to be protected, plant propagation materials, in particular seeds, soil, materials or spaces) in an amount sufficient for effective control of fungal growth. This can be achieved by simultaneously applying the compounds I and at least one further active ingredient together in a common active ingredient preparation or in at least two separate active ingredient preparations or by applying the active ingredients one after the other at the site of action, whereby the time interval of the individual active substance applications is selected is that the first applied active ingredient at the time of application of / the other drug / substances in sufficient amount is present at the site of action. The time sequence of the application of the active ingredients is of minor importance.

In binary mixtures, d. H. Compositions of the invention comprising a compound I and another active agent, e.g. contain an active compound from groups A) to I), the weight ratio of compound I to the other active ingredient depends on the weight ratio of compound I to 1 further active ingredient on the properties of the respective active ingredients, it is usually in the range of 1: 100 bis 100: 1, often in the range from 1:50 to 50: 1, preferably in the range from 1:20 to 20: 1, particularly preferably in the range from 1:10 to 10: 1, in particular in the range from 1: 3 to 3 :1. The components of the composition according to the invention can be mixed individually or already mixed or packaged as parts according to the kit of parts and reused.

In one embodiment of the invention, the kits (kits) may contain one or more, even all, components which can be used to prepare an agrochemical composition according to the invention. For example, these kits may contain one or more fungicidal component (s) and / or an adjuvant component and / or an insecticidal component and / or a growth regulator component and / or a herbicide. One or more components may be combined or pre-formulated. In embodiments where more than two components are provided in a kit, the components may be combined together and packaged in a single container such as a vessel, bottle, can, bag, sack or canister. In other embodiments, For example, two or more components of a kit may be packaged separately, ie, not pre-formulated or mixed. Kits may contain one or more separate containers such as containers, bottles, cans, bags, sacks or canisters, each container containing a separate component of the agrochemical composition. The components of the composition according to the invention can be mixed individually or already mixed or packaged as parts according to the "kit of parts" and reused. In both forms, one component can be used separately or together with the other components or as part of a kit of parts according to the invention for the preparation of the mixture according to the invention. The user usually uses the composition according to the invention for use in a pre-metering device, in the back splash, in the spray tank or in the spray plane. In this case, the agrochemical composition with water and / or buffer is brought to the desired application concentration, optionally further adjuvants are added, and thus the ready-spray mixture or the agrochemical composition according to the invention is obtained. Usually, 50 to 500 liters of ready-spray mixture per hectare of agricultural land, preferably 100 to 400 liters. In one embodiment, the user may include individual components such as B. mix parts of a kit or a mixture of the composition of the invention itself in the spray tank and optionally add further auxiliaries (tank mix).

In a further embodiment, the user can mix both individual components of the composition according to the invention and partially premixed components, for example components containing compounds I and / or active compounds from groups A) to I), in the spray tank and optionally add further auxiliaries (tank mix). ,

In a further embodiment, the user can use both individual components of the composition according to the invention and partially premixed components, for example components containing compounds I and / or active compounds from groups A) to I), together (for example as a tank mix) or successively. the.

Preference is given to compositions of a compound I (component I) with at least one active ingredient from group A) (component 2) of strobilurins and especially selected from azoxystrobin, dimoxystrobin, fluoxastrobin, kresoxim-methyl, orysastrobin, picoxystrobin, pyraclostrobin and trifloxystrobin. Preference is also given to compositions of a compound I (component I) having at least one active compound selected from group B) (component 2) of the carboxamides and especially selected from bixafen, boscalid, sedaxane, fenhexamide, metaxaxyl, mefenoxam, ofurace, dimethomorph , Flumorph, fluopicolide (picobenzamide), zoxamide, carpropamide and mandipropamide. Also preferred are compositions of a compound I (component I) with at least one active compound selected from the group C) (component 2) of the azoles and especially selected from cyproconazole, difenoconazole, epoxiconazole, fluquincona zol, flusilazole, flutriafol, metconazole, myclobutanil, penconazole, propiconazole, prothio- conazole, triadimefon, triadimenol, tebuconazole, tetraconazole, triticonazole, proclo- raz, cyazofamide, benomyl, carbendazim and ethaboxam.

Also preferred are compositions of a compound I (component I) with at least one active ingredient selected from group D) (component 2) of the nitrogen-containing heterocyclyl compounds and especially selected from fluazinam, cyprinil, fenarimol, mepanipyrim, pyrimethanil, triforin, fludioxonil, Fodemorph, fenpropimorph, tridemorph, fenpropidin, iprodione, vinclozolin, famoxadone, fenamidone, probenazole, proquinazid, acibenzolar-S-methyl, captafol, folpet, fenoxanil and quinoxyfen.

Preference is also given to compositions of a compound I (component I) having at least one active compound selected from the group E) (component 2) of the carbamates and especially selected from mancozeb, metiram, propineb, thiram, iprovalicarb, benthiavalicarb and propamocarb. Preference is also given to compositions of a compound I (component I) having at least one active ingredient selected from the fungicides of group F) (component 2) and especially selected from dithianone, fentin salts such as fentin acetate, fosetyl, fosetyl-aluminum, H3PO3 and salts thereof , Chlorothalonil, dichlofluanid, thiophanate-methyl, copper acetate, copper hydroxide, copper oxychloride, copper sulfate, sulfur, cymoxanil, metrafenone, spiroxamine and 5-chloro-7- (4-methylpiperidin-1-yl) -6- (2,4, 6-trifluorophenyl) - [1, 2,4] -triazolo [1,5-a] pyrimidine.

Accordingly, the present invention further relates to compositions of a compound I (component 1) with a further active ingredient (component 2), the latter selected from the lines D-1 to D-416 in the column "component 2" of Table D. Embodiment of the invention relates to the compositions D-1 to D-416 listed in Table D, wherein in each case one row of Table D corresponds to an agrochemical composition comprising a compound of formula I (component 1), which is preferably one of those described herein as preferred Compounds, and the further active ingredient specified in each row from groups A to I (component 2) According to one embodiment of the invention, component 1 in each row of table D is in each case one of the individualized ones in tables 1a to 308a Compounds of the formula I. The active compounds in the compositions described are each preferably in synergistic wi effective quantities.

Table D: Active ingredient composition comprising an individualized compound I and another active compound from groups A) to I).

The active ingredients mentioned above as component 2, their preparation and their action against harmful fungi are known (see: http: //www.hclrss. Demon.co.uk/index.html; http://www.alanwood.net/pesticides /); they are commercially available. The compounds named after IUPAC, their preparation and their fungicidal action are also known (see Can. J. Plant Sci 48 (6), 587-94, 1968; EP-A 141 317; EP-A 152 031; A 226 917, EP-A 243 970, EP-A 256 503, EP-A 428 941, EP-A 532 022, EP-A 1 028 125, EP-A 1 035 122, EP-A 1 201 648, EP DE 1 922 244, JP 2002316902, DE 19650197, DE 10021412, DE 102005009458, US 3,296,272, US 3,325,503, WO 98/46608, WO 99/14187, WO 99/24413, WO 99/27783, WO 00/29404, WO WO 00/65913, WO 01/54501, WO 01/56358, WO 02/22583, WO 02/40431, WO 03/10149, WO 03/11853, WO 03/14103, WO 03/16286, WO WO 03/63688, WO 03/61388, WO 03/66609, WO 03/74491, WO 04/49804, WO 05/120234, WO 05/123689, WO 05/123690, WO 05/63721, WO 05/87772, WO WO 06/15866, WO 06/87325, WO 06/87343, WO 07/82098, WO 07/90624).

The preparation of the compositions for mixtures of active ingredients in a known manner in the form of compositions containing in addition to the active ingredients, a solvent or solid carrier, for. B. in the manner as indicated for compositions of the compounds I.

With regard to the usual ingredients of such compositions, reference is made to the comments on the compositions containing the compounds I. The compositions for mixtures of active substances are suitable as fungicides for controlling harmful fungi. They are distinguished by outstanding activity against a broad spectrum of phytopathogenic fungi, including soil-borne pathogens, which in particular from the classes of the Plasmodiophore mycetes, Peronosporomycetes (Syn. Oomycetes), Chytridiomycetes, Zygomyces, Ascomycetes, Basidiomycetes and Deuteromycetes (Syn. Fungi imperfecti). Furthermore, reference is made to the comments on the effectiveness of the compounds I and the compositions containing the compounds I.

Another object of the present invention is the use of compounds I and their pharmaceutically acceptable salts for the treatment of diseases, in particular the use of the compounds I as an antimycotic. Thus, one embodiment of the invention relates to a pharmaceutical composition comprising at least one compound of the formula I and / or a pharmaceutically acceptable salt thereof. Another embodiment relates to the use of a compound I and / or a pharmaceutically active salt thereof for the manufacture of an antimycotic.

Yet another object of the present invention is the use of compounds II and their pharmaceutically acceptable salts for the treatment of diseases, in particular the use of the compounds II as an antifungal. Thus, one embodiment of the invention relates to a pharmaceutical composition comprising at least one compound of the formula II and / or a pharmaceutically acceptable salt thereof. A further embodiment relates to the use of a compound II and / or a pharmaceutically active salt thereof for the production of an antimycotic.

Yet another object of the present invention is the use of compounds I and their pharmaceutically acceptable salts for the treatment of tumors in mammals, such as humans. Thus, one embodiment of the invention relates to the use of a compound I and / or a pharmaceutically acceptable salt thereof for the manufacture of an agent which inhibits the growth of tumors and cancer in mammals. By "cancer" is meant in particular a malignant or malignant tumor, e.g. Breast cancer, prostate cancer, lung cancer, CNS cancer, melanocarcinoma, ovarian cancer or kidney cancer, especially in humans.

Yet another object of the present invention is the use of compounds I and their pharmaceutically acceptable salts for the treatment of viral infections, in particular viral infections, which lead to diseases in warm-blooded animals. Thus, one embodiment of the invention relates to the use of a compound I and / or a pharmaceutically active salt thereof for the manufacture of an agent for the treatment of viral infections. The viral diseases to be treated diseases include, for example, HIV and HTLV, influenza virus, rhinovirus diseases, herpes and the like.

Synthesis Examples:

The instructions given in the following synthesis examples were used with appropriate modification of the starting compounds to obtain further compounds of the formula I or the precursors thereof. Melting points were obtained on a Mel-Temp 11 instrument and are uncorrected. 1 H-NMR spectra were measured on a Bruker AC 300 spectrometer at 300 MHz and are based on tetramethylsilane as internal standard (obtained from Aldrich or Cambridge Isotope Laboratories). ESI mass spectra were measured on a Shimadzu LCMS-2010 EV mass spectrometer. APCI mass spectra were measured on a Shimadzu LCMS-2010 EV mass spectrometer.

Example 1 Synthesis of 1 - {[(2SR, 3RS) -3- (2-chloro-3-fluoropyridin-4-yl) -2- (4-fluorophenyl) oxiran-2-yl] methyl} -1 H-1 , 2,4-triazole-5 (4H) -thione (= 1 - {[relative

(2S, 3R) -3- (2-chloro-3-fluoropyridin-4-yl) -2- (4-fluorophenyl) oxiran-2-yl] methyl} -1H-1,2,4-triazole-5 (4H) -thione)

To a solution of 1 - {[(2SR, 3RS) -3- (2-chloro-3-fluoropyridin-4-yl) -2- (4-fluorophenyl) oxiran-2-yl] methyl} -1 H- 1, 2,4-triazole (90 mg, 0:26 mmol) in anhydrous tetrahydro- furan (3 mL) was added at -78 ⁰ C was slowly added n-butyllithium (0.2 mL of a 1.6 M solution in hexanes, 0:32 mmol). The reaction mixture was stirred for 10 min at this temperature and sulfur (16 mg, 0.516 mmol) in tetrahydrofuran (0.5 mL) was added. The reaction solution was stirred for a further three hours at -78 ⁰ C and then methanol (1.0 mL) and ethyl acetate (50 mL) was added. The organic phase was washed with saturated brine (3 x 20 mL) and dried over sodium sulfate. The residue obtained after removal of the solvent was purified by column chromatography (silica gel, ethyl acetate / dichloromethane = 1: 1). 45 mg of an initially contaminated product were obtained which, after repeated recrystallization from dichloromethane / hexane, yielded the target compound (25 mg, 0.07 mmol, 25%). ¹ H-NMR (CD ₃ OD): δ = 8.07 (d, J = 6.0 Hz, 1 H), 7.82 (s, 1 H), 7.37 (dd, J = 6.0, 3.0 Hz, 1 H), 7.32- 7.27 (m, 2H), 7.10 (t, J = 9.0 Hz, 2H), 5.49 (s, 1H), 5.19 (d, J = 12.0 Hz, 1H), 4.80 (d, J = 12.0 Hz, 1 H).

Example 2: Synthesis of 1- [rel- (2S, 3R) -3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) oxiran-2-ylmethyl] -1H-1, 2,4 triazol-5 (4H) -thione To a solution of rel- (2S, 3R) -2-chloro-3- [3- (4-fluorophenyl) -3- [1,2,4] triazol-1-ylmethyl-oxiranyl] -pyridine (1.3 g, 4.0 mmol) (dissolved in anhydrous THF 20 mL) was added at 78 ⁰ C was added dropwise LDA (2.7 mL, 5.5 mmol, 2.0 M in THF) was added. After 30 min. Sulfur (256 mg, 8.0 mmol) was added, the reaction mixture slowly warmed to 20 ⁰ C and then stirred for 18 h. It was then treated with saturated NH 4 Cl solution and the reaction solution extracted with EtOAc (50 ml). The organic phase was washed with saturated brine (3 × 40 ml), dried over Na 2 SO 4 and freed from the solvent. The residue thus obtained was purified by column chromatography (silica gel, hexane / EtOAc) and crystallized twice from hexane / CH 2 Cl. There were isolated (550 mg, 39%) of the target product in the form of a yellow solid.

; ¹ H NMR (300 MHz, CDCl ₃ ) δ 1 1.20 (s, 1 H), 8.43 (dd, 1 H, J = 1.8, 4.8 Hz), 7.94-7.97 (m, 1 H), 7.64 (s, 1 H), 7.51-7.55 (m, 2H), 7.36 (dd, 1 H, J = 4.8, 7.5 Hz), 7.00-7.08 (m, 2H), 4.94 (d, 1 H, J = 14.7 Hz), 4.14 (s, 1 H), 3.88 (d, 1 H, J = 15.0 Hz)

Examples 3 and 4 can be prepared analogously to Example 2 by reacting the relevant triazole compounds with sulfur.

Example 3: Synthesis of 1- [rel- (2S, 3R) -2- (4-fluorophenyl) -3- (pyridin-4-yl) oxiran-2-ylmethyl] -1H-1, 2,4- triazol-5 (4H) -thione

Melting point 143-147 ° C

Example 4: Synthesis of 1- [rel- (2S, 3R) -3- (2-chloro-thiophen-3-yl) -2- (2,4-difluorophenyl) oxiran-2-ylmethyl] -1H-1 , 2,4-triazole-5 (4H) -thione 1H NMR (300 MHz, CDCl ₃ ) δ 7.7 (s, 1H), 7.35-7.15 (m, 3H), 6.92-6.70 (m, 2H), 4.88 (d, 1H), 4.12 (d, 1H), 4.10 (s, 1H)

Example 5: Synthesis of 1- [rel- (2S, 3R) -3- (2-fluorophenyl) -2- (thiophen-2-yl) oxiran-2-ylmethyl] -5- (methylthio) -1H-1 , 2,4-triazole To a solution of 1- [rel- (2S, 3R) -3- (2-fluorophenyl) -2-thiophen-2-yl-oxiranylmethyl] - 1 H- [1, 2,4] triazole (100 mg, 0:33 mmol) in anhydrous THF (4 ml) was added at -78 ⁰ C was added dropwise LDA (0.2 mL, 0.4 mmol, 2.0 M in THF). After 15 min, dimethyl disulfide (38 μL, 0.4 mmol) was added and the solution was stirred for a further 4 h at this temperature. Then, the reaction mixture was treated with saturated NH 4 Cl solution (4 ml) and extracted with EtOAc (20 ml). The organic phase was washed with saturated brine (3 × 20 ml), dried over Na 2 SO 4 and freed from the solvent. The residue thus obtained was purified by column chromatography (silica gel, hexane / EtOAc). After combining the appropriate fractions, 25 mg (22%) of the target product were obtained in the form of a yellow oil. ¹ H NMR (300 MHz, CDCl ₃ ) δ 7.78 (s, 1H), 7.50-7.58 (m, 1H), 7.30-7.40 (m, 1H), 7.20- 7.26 (m, 2H), 7.09- 7.17 (m, 1H), 7.05-7.07 (m, 1H), 6.97-6.95 (m, 1H), 4.53 (d, 1H, J = 15.0 Hz), 4.44 (s, 1H), 4.1 1 (d, 1 H, J = 15.0 Hz), 2.54 (s, 3H)

Example 6: Synthesis of rel- (2S, 3R) -2-chloro-3- [3- (4-fluorophenyl) -3- (5-methylthio) -

1 H-1, 2,4-triazol-1-ylmethyl) oxiran-2-yl] pyridine

To a solution of rel- (2S, 3R) -2-chloro-3- [3- (4-fluorophenyl) -3- [1,2,4] triazol-1-ylmethyl-oxiranyl] -pyridine (200 mg, 0.6 mmol) in anhydrous THF (5 ml) was added LDA (0.4 mL, 0.8 mmol, 2.0 M in THF) at -78 ⁰ C dropwise. After 30 minutes, dimethyl disulfide (75 μL, 0.8 mmol) was added and the solution was stirred for a further 4 h at this temperature. Then, the reaction mixture was treated with saturated NH 4 Cl solution (15 ml) and extracted with EtOAc (20 ml). The organic phase was washed with saturated brine (3 × 20 ml), dried over Na 2 SO 4 and freed from the solvent. The residue thus obtained was purified by column chromatography (silica gel, hexane / EtOAc). After combination of the appropriate fractions gave 95 mg (42%) of the target product in the form of a yellow solid (m.p. 119-120 ⁰ C).

¹ H NMR (300 MHz, CDCl ₃ ) δ 8.44 (dd, 1 H, J = 1.8, 4.8 Hz), 7.92-7.95 (m, 1 H), 7.72 (s, 1 H), 7.36-7.42 (m, 3H), 7.00-7.07 (m, 2H), 4.55 (d, 1 H, J = 14.7 Hz), 4.17 (s, 1 H), 3.92 (d, 1 H, J = 15.0 Hz), 2.49 (s, 3H)

Examples 7, 8 and 9 can be prepared analogously to Example 5 and 6 by reacting the relevant triazole compounds with dimethyl disulfide.

Example 7: Synthesis of 1- [rel- (2S, 3R) -2- (4-fluorophenyl) -3- (pyridin-4-yl) oxiran-2-ylmethyl] -5- (methylthio) -1H- 1, 2,4-triazole 1H NMR (300 MHz, CDCl ₃ ) 58.70 (d, 2H), 7.72 (s, 1H), 7.48 (d, 2H), 7.32-7.29 (m, 2H)

Example 8: Synthesis of 1- [rel- (2S, 3R) -3- (2-chloro-thiophen-3-yl) -2- (2,4-difluorophenyl) oxiran-2-ylmethyl] -5- ( methylthio) -1H-1, 2,4-triazole

Melting point 11 1-1 14 ° C

Example 9: Synthesis of 1- [rel- (2S, 3R) -2- (5-chloro-thiophen-2-yl) -3- (2-chlorophenyl) -oxiran-2-ylmethyl] -5- (methylthio) 1 H-1, 2,4-triazole 1H NMR (300 MHz, CDCl ₃ ) δ 7.80 (s, 1H), 7.59-7.30 (m, 4H), 6.91 (s, 1H), 6.79 (s, 1H), 4.57 (d, 1H), 4.32 (s, 1H), 3.88 (d, 1H), 2.52 (s, 3H)

Example 10: Synthesis of thioacetic acid {2- [rel- (2S, 3R) -3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) oxiranylmethyl] -2H- [1, 2,4 ] triazol-3-yl} ester To a mixture of 1- [rel- (2S, 3R) -3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) oxiran-2-ylmethyl] -1 H-1, 2,4-triazole-5 (4H) -thione (100 mg, 0.3 mmol) and triethylamine (78 μL, 0.6 mmol) in anhydrous THF (3 mL) was added dropwise at 0 ^° C to acetyl chloride (29 μL, 0.4 mmol) was added and stirred for 2 h at this temperature. After distilling off the solvent was taken up with ethyl acetate, extracted with water and the organic phase dried over Na2SO4. Removal of the solvent gave the title compound (15 mg, 100%) as a yellow oil. 1H NMR (300 MHz, CDCl ₃ ) δ 8.43 (dd, 1 H, J = 1.8, 4.8 Hz), 8.27 (s, 1 H), 7.93 (dd, 1 H, J = 1.5, 7.5 Hz), 7.52- 7.56 (m, 2H), 7.35 (dd, 1 H, J = 4.8, 7.5 Hz), 7.02-7.09 (m, 2H),

5.00 (d, 1 H, J = 14.7 Hz), 4.13 (s, 1 H), 3.91 (d, 1 H, J = 14.7 Hz), 2.89 (s, 3H).

Example 11: Synthesis of thiocarbonic acid {2- [rel- (2S, 3R) -3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) oxiranylmethyl] -2H- [1, 2,4 ] triazol-3-yl} -ester methyl ester

To a mixture of 1- [rel- (2S, 3R) -3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) oxiran-2-ylmethyl] -1H-1, 2,4- triazole-5 (4H) -thione (200 mg, 0.6 mmol) and triethylamine (152 μL,

1.1 mmol) in anhydrous THF (10 mL) was added dropwise at 0 ⁰ C methyl chloroformate (64 .mu.L, 0.8 mmol) and then stirred for 3 h at this temperature. EtOAc (20 mL) was then added and washed with saturated brine (3 x 20 mL). The organic phase was dried over Na 2 SO 4 and the solvent was removed by distillation. The residue thus obtained was purified by column chromatography (silica gel, C ^ Cb / EtOAc) and, after combining the appropriate fractions, the target product was obtained in the form of a colorless solid (80 mg, 34%). Melting point 64-66 ⁰ C

¹ H NMR (300 MHz, CDCl ₃ ) δ 8.42-8.44 (m, 1H), 8.08 (s, 1H), 7.91-7.95 (m, 1H), 7.50-7.57 (m, 2H), 7.35 ( dd, 1 H, J = 1.8, 7.8 Hz), 7.01-7.08 (m, 1 H), 5.07 (d, 1 H, J = 15.0 Hz), 4.13 (s, 1 H), 4.02 (s, 3H) , 3.86 (d, 1 H, J = 15.0 Hz)

Example 12: Synthesis of rel (2S, 3R) -2-chloro-3- [3- (4-fluorophenyl) -3- (5-thiocyanato)

[1,2,4] triazole-1-ylmethyl) oxiranyl] pyridine

A mixture of 1- [rel- (2S, 3R) -3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) oxiran-2-ylmethyl] -1H-1,2,4-triazole -5 (4H) -thione (200 mg, 0.6 mmol), triethylamine (152 μL, 1.1 mmol) and BrCN (88 mg, 0.8 mmol) in anhydrous THF (10 mL) was stirred for 2 h at room temperature. Then EtOAc (20 mL) was added and washed with brine (3 x 20 mL). The organic phase was dried over Na 2 SO 4 and the solvent was removed by distillation. The residue thus obtained was purified by column chromatography (silica gel, hexane / EtOAc) and after combination of the appropriate fractions the target product in the form of a farblo- sen solid (150 mg, 70%) melting point 170-172 ⁰ C.

¹ H NMR (300 MHz, CDCl ₃ ) δ 8.47 (dd, 1 H, J = 1.8, 4.8 Hz), 7.86-7.89 (m, 2H), 7.36-7.42 (m, 3H), 7.06-7.12 (m, 2H), 4.78 (d, 1 H, J = 15.0 Hz), 4.22 (d, 1 H, J = 15.0 Hz), 4.21 (s, 1 H)

Example 13 can be prepared analogously to Example 12, starting from the triazole-thione compound obtained in Example 4 .. Example 13: Synthesis of rel- (2S, 3R) -2-chloro-3- [3- (2,4-difluorophenyl) -3- (5-thiocyanato [1,2,4] triazol-1-ylmethyl) -oxiranyl] -thiophene melting point 102-105 ⁰ C.

Example 14: Synthesis of 1,2-bis [rel- (2S, 3R) -3- (2-chlorothien-3-yl) -2- (2,4-difluorophenyl) oxiran-2-ylmethyl) -1 H- 1,2,4-triazol-5-yl] disulfane To a solution of 2- [rel- (2S, 3R) -3- (2-chlorothien-3-yl) -2- (2,4-difluorophenyl) - oxiranylmethyl] -2,4-dihydro- [1,2,4] triazole-3-thione (293 mg, 0.75 mmol) in anhydrous THF (20 mL) was added iodine (192 mg, 0.75 mmol) at room temperature. Subsequently, the reaction mixture was stirred for a further 4 h at this temperature. After removal of the solvent in vacuo, the residue obtained was purified by column chromatography (silica gel, hexane / EtOAc). The target product was obtained in the form of a tough oil (152 mg, 52%). 1H NMR (300 MHz, CDCl ₃ ) δ 7.76 (s, 2H), 7.00-7.16 (m, 6H), 6.71-7.86 (m, 4H), 4.79-4.86 (m, 2H), 4.16-4.25 (m, 2H), 4.08 (s, 2H)

Biological experiments

Glasshouse

drug treatment

The active compounds were prepared separately or together as a stock solution with 25 mg of active ingredient, which with a mixture of acetone and / or DMSO and the

Emulsifier Uniperol® EL (wetting agent with emulsifying and dispersing action based on ethoxylated alkylphenols) in the volume ratio solvent-emulsifier of 99 to 1 ad 10 ml was filled. It was then made up to 100 ml with water. This stock solution was diluted with the described solvent-emulsifier-water mixture to the drug concentration given below. Alternatively, the active ingredients were used as a commercial ready-to-use formulation and diluted with water to the indicated active ingredient concentration.

Use Example 1 - Curative Efficacy Against Soy Rust Caused by Phakopsora pachyrhizi (Phakpa K1)

Leaves of potted soybean seedlings were inoculated with a spore suspension of soybean rust (Phakpsora pachyrhizi). Thereafter, the pots were placed in a high humidity chamber (90-95%) and 23-27 ° C for 24 hours. During this time, the spores germinated and the germ tubes penetrated into the leaf tissue. The infected plants were then sprayed to drip point with the above-described drug solution in the drug concentration below. After the drying of the Spray coating, the test plants were cultivated in the greenhouse at temperatures between 23 and 27 ° C and 60 to 80% relative humidity for 14 days. Then the extent of rust fungus development on the leaves was determined visually in% infestation.

Use Example 2 - Protective Efficiency Against Soybean Rust Caused by Phakopsora pachyrhizi (Phakpa P1)

Leaves of potted soybean seedlings were sprayed to drip point with the above-described active ingredient solution in the concentration of the active ingredients as indicated below. The next day the plants were planted with one

Spore suspension of soybean rust (Phakpsora pachyrhizi) inoculated. Thereafter, the pots were placed in a high humidity chamber (90-95%) and 23-27 ° C for 24 hours. During this time, the spores germinated and the germ tubes penetrated into the leaf tissue. Subsequently, the test plants were cultivated in the greenhouse at temperatures between 23 and 27 ° C and 60 to 80% relative humidity for 14 days. Then the extent of rust fungus development on the leaves was determined visually in% infestation.

Claims

claims 1. azolylmethyloxiranes of the formula I.

wherein the variables have the following meanings: A or B is a saturated or partially unsaturated heterocycle having three, four, five, six, seven, eight, nine, or ten members, or five, six, seven, eight, nine, or ten membered aromatic heterocycle; rocyclus, wherein the heterocycle each contains one, two, three or four heteroatoms from the group O, N and S; and the other variable B or A means one of the above for A or B meanings or Ci-Ce-Al kyl, d-Cs-haloalkyl, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ -haloalkenyl, C ₂ -C ₈ - alkynyl, C C ₂ -C ₈ haloalkynyl, C ₃ -C ₈ cycloalkyl, C ₃ -C ₈ halo genocycloalkyl, phenyl or benzodioxolyl; wherein A and / or B are independently unsubstituted or substituted with one, two, three or four independently selected substituents L; L is halogen, cyano, nitro, cyanato (OCN), C ₈ -alkyl, C ₈ - haloalkyl, phenyl-Ci-C ₆ alkyloxy, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ halo-alkenyl, C ₂ -C ₈ -alkyl kinyl, C ₂ -C ₈ haloalkynyl, C4-Cio-alkadienyl, C ₄ - Cio-Halogenalkadienyl, _{Ci-C8-alkoxy, Ci-C8-haloalkoxy,} Ci _C8 - alkylcarbonyloxy, Ci-C ₈ alkylsulfonyloxy, C ₂ -C ₈ alkenyloxy, C ₂ -C ₈ - haloalkenyloxy, C ₂ -C ₈ alkynyloxy, C ₂ -C ₈ haloalkynyloxy, C ₃ - C ₈ -Cycloalkyl, C ₃ -C ₈ -halocycloalkyl, C ₃ -C ₈ -cycloalkenyl, C ₃ -C ₈ - Halocycloalkenyl, C ₃ -C ₈ cycloalkoxy alkyleneoxy, C ₃ -C 6 -cycloalkenyloxy, hydroxyimino-Ci-C ₈ alkyl, Ci-Cβ alkylene, oxy-C ₂ -C 4 -alkylene, oxy-d- C _3, Ci-C ₈ -Alkoximino-C ₈ alkyl, C ₂ -C ₈ -Alkenyloximino- Ci-C ₈ alkyl, C ₂ -C ₈ -Alkinyloximino-Ci-C ₈ alkyl, S (= O) _n A ¹ , C (OO) A ² , C (SS) A ² , NA ³ A ⁴ , phenyl, phenyloxy or a five- or six-membered saturated, partially unsaturated or aromatic heteroaryl rocyclus containing one, two, three or four heteroatoms from the group O, N and S; where n, A ¹ , A ² , A ³ , A ⁴ mean: n is 0, 1 or 2; A ^{1 is} hydrogen, hydroxy, C 1 -C ₈ -alkyl, C 1 -C -haloalkyl, amino, C 1 -C 6 -alkylamino or C 1 -C ₈ -alkylamino, A ² A ¹ wherein one of said groups, or C2-C8-alkenyl, C ₂ -C ₈ - oxy -AIk- ₈ haloalkenyl, C ₂ -C ₈ -alkyl kinyl, C ₂ -C ₈ haloalkynyl, CrC, Ci- C ₈ haloalkoxy, C 2 -C ₈ alkenyloxy, C ₂ -C ₈ alkenyloxy-halo, _C2-C8 alkynyloxy, _C2-C8 haloalkynyloxy, Cs-C ₈ - cycloalkyl, _C3-C8 halocycloalkyl, _{C3-C8-cycloalkoxy} or _C3-C8 -Halogencycloalkoxy; A ^3, A ⁴ are independently hydrogen, Ci-C ₈ alkyl, Ci-Cs-haloalkyl, C ₂ -C ₈ -alkenyl, C 2 -C ₈ haloalkenyl, C ₂ -C ₈ -alkyl kinyl, C ₂ - C ₈ haloalkynyl, _C3-C8 cycloalkyl, C3-C ₈ -Halogencyclo- alkyl, _C3-C8 cycloalkenyl, or _C3-C8 halocycloalkenyl; where the aliphatic and / or alicyclic and / or aromatic groups of the radical definitions of L can themselves carry one, two, three or four identical or different groups R ^L : R ^{L is} halogen, cyano, nitro, Ci-C ₈ alkyl, _{Ci-C8-haloalkyl,} CrC ₈ - Alkoxy, _{Ci-C8-haloalkoxy, C3-C8} cycloalkyl, C3-C ₈ -Halogencyclo- alkyl, _C3-C8 cycloalkenyl, _C3-C8 cycloalkoxy, C3-C ₈ -Halogencyclo- alkoxy, Ci- C ₈ alkylcarbonyl, _{Ci-C8-alkylcarbonyloxy,} CrC ₈ - alkoxycarbonyl, amino, _{Ci-C8-alkylamino,} di-Ci-C ₈ alkylamino; in which R is hydrogen, Ci-C ₈ alkyl, Ci-C ₈ haloalkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ -haloalkenyl, C ₂ -C ₈ -alkynyl, C ₂ -C ₈ -haloalkynyl, C (= O) R ³ , C (= S) R ³ , SO ₂ R ⁴ or CN; in which R ³ represents hydrogen, Ci-C ₈ alkyl, _{Ci-C8-haloalkyl, Ci-C8-haloalkoxy} or NA ³ A ⁴ represents ₈ alkoxy, Ci-C; and R ⁴ is d-Cs-alkyl, phenyl-Ci-C ₈ -alkyl or phenyl, wherein the Each phenyl group is unsubstituted or substituted by one, two or three groups independently selected from halogen and C 1 -C 4 alkyl; ^■ a group Dl

wherein A and B are as defined above; - a group Dil QNR ¹ #. ^ S> C R- where # is the point of attachment to the triazolyl ring and Q, R ¹ and R ^{2 are} Q O or S; R ^1, R ² independently of one another Ci-C ₈ alkyl, _{Ci-C8-haloalkyl,} d- Cs alkoxy, _{Ci-C8-alkoxy-Ci-C 8} alkoxy, _Ci-C8 haloalkoxy, Ci-C ₈ - alkoxy-Ci-C ₈ alkyl, Ci _-C8-Al alkylthio, C ₂ - C ₈ alkenylthio, C ₂ -C ₈ -alkynylthio, Cs-Cs-cycloalkyl, C ₃ -C ₈ -cycloalkylthio, phenyl, phenyl-C ₁ -C ₄ -alkyl, phenoxy, phenylthio, phenyl-C ₁ -C ₄ alkoxy or NR ⁵ R ⁶ , where R ^{5 is} H or C 1 -C ₈ -alkyl and R ^{6 is} C 1 -C ₈ -alkyl, phenyl-C 1 -C ₄ -alkyl or phenyl or R ⁵ and R ⁶ together are an alkylene chain having four or five carbon atoms or a radical of the formula -CH ₂ -CH ₂ -O-CH ₂ -CH ₂ - or -CH ₂ -CH ₂ -NR ⁷ -CH ₂ -CH ₂ - form in which R ^{7 is} hydrogen or C 1 -C ₄ -alkyl; wherein the aromatic groups in the aforementioned radicals are each independently unsubstituted or substituted by one, two or three groups selected from halogen and C 1 -C ₄ -alkyl; or a group SM, where M means: M is an alkali metal cation, one equivalent of an alkaline earth metal cation, one equivalent of a copper, zinc, iron or nickel cation or an ammonium cation of the formula (E) z ² Z ¹ - NZ ³ (E) in which Z ¹ and Z ^{2 are} independently hydrogen or Ci-Cs-alkyl; Z ³ and Z ^{4 are} independently hydrogen, C ¹ -C 8 alkyl, benzyl or phenyl; wherein the phenyl groups are each unsubstituted or substituted by one, two or three groups independently selected from halogen and C 1 -C 4 alkyl; and their agriculturally acceptable salts. 2. Compounds according to claim 1, wherein a variable of A and B is a five- or six-membered heteroaromatic or phenyl which are unsubstituted or substituted by one, two or three independently selected groups L. 3. Compounds according to claim 2, wherein the other variable of A and B is an optionally substituted 5- or 6-membered heteroaromatic. 4. Compounds according to claim 2, wherein the phenyl group carries one, two or three independently selected groups L. 5. Compounds according to claim 1, wherein A and B mean: A or B represents a tri-, tetra-, penta-, hexa-, si-, e-, n- or ten-membered saturated or partially unsaturated heterocycle or five-, six-, seven-, eight-, nine- or ten-membered aromatic heterocycle, wherein the heterocycle each contains one, two, three or four heteroatoms from the group O, N and S, and wherein the saturated and partially unsaturated heterocycle is unsubstituted or substituted by one, two, three or four independently selected L, and wherein the aromatic heterocycle contains one, two, three or four identical or different independently selected groups L; and the other variable B or A respectively a tri-, four-, five-, six-, seven-, eight-, nine- or ten-membered saturated or partially unsaturated heterocycle, five-, six-, seven-, eight-, nine- or ten-membered aromatic heterocycle, wherein the heterocycle contains one, two, three or four heteroatoms from the group O, N and S, Ci-Cs-alkyl, Ci-Cs-haloalkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ haloalkenyl, C ₂ -C ₈ kinyl -alkyl, halo-C ₂ -C _8, C 3 -C ₈ -cycloalkyl or C 3 -C ₈ halocycloalkyl is alkynyl, wherein said other variable B or A is each unsubstituted or substituted by one, two, three or four independently selected groups L. 6. Compounds according to claim 1, wherein A and B mean: A or B is a five, six, seven, eight, nine or ten membered partially unsaturated heterocycle or a five- or six-membered aromatic heterocycle wherein the heterocycle is one, two, three or four, respectively Heteroatoms from the group O, N and S, and wherein the partially unsaturated heterocycle is unsubstituted or substituted by one, two, three or four L, and wherein the aromatic heterocycle contains one, two, three or four identical or different groups L; and the other variable B or A respectively five-, six-, seven-, eight-, nine- or ten-membered partially unsaturated or aromatic heterocycle, wherein the heterocycle contains one, two, three or four heteroatoms from the group O, N and S, Ci -C ₈ -alkyl, C ₈ haloalkyl, C ₂ -C ₈ alkenyl, C ₂ -C ₈ - haloalkenyl, C ₂ -C ₈ -alkyl kinyl, C ₂ -C ₈ haloalkynyl, C3-C ₈ -cycloalkyl - alkyl, _C3-C8 halocycloalkyl or phenyl; this other variant B or A is in each case unsubstituted or substituted by one, two, three or four independently selected groups L; or A is phenyl substituted with two F; and B is unsubstituted pyridyl, thienyl, thiazolyl, oxazolyl or furyl; or A is phenyl substituted with three F; and B is unsubstituted pyridyl, thienyl, thiazolyl, oxazolyl or furyl; or A is phenyl substituted with one F and another substituent selected from Cl, C 1 -C ₄ alkyl, C 1 -C ₄ haloalkyl and C 1 -C ₄ alkoxy; and B is unsubstituted pyridyl, thienyl, thiazolyl, oxazolyl or furyl; or A or B is phenyl which is substituted by one CN and optionally additionally one, two or three substituents independently selected from halogen, NO ₂ , amino, C 1 -C ₄ -alkyl, C 1 -C ₄ -alkoxy, ci C ₄ - Haloalkyl, _{Ci-C4-haloalkoxy,} Ci-C ₄ alkylamino, -C ₄ - dialkylamino, thio, and Ci -C ₄ -alkyl alkylthio contains; and the other variable B or A is unsubstituted 5-membered or 6-membered heteroaryl containing one, two, three or four heteroatoms from the group O, N and S. 7. Compounds according to any one of claims 2 to 4, wherein the heteroaromatic is in each case independently selected from thiophene, pyrrole, pyrazole, imidazole, isoxazole, isothiazole, oxazole, thiazole, thiadiazole, oxadiazole, triazole and tetrazole, which in each case optionally are substituted. 8. Compounds according to any one of claims 2 to 4, wherein the heteroaromatic is each independently selected from pyridine, pyrimidine and triazine, which are each optionally substituted. 9. Compounds according to any one of the preceding claims, wherein each L is independently selected from halogen, Ci-Ce-Al kyl, Ci-Cs-haloalkyl, C ₂ -Cs alkenyl, Ci-Cs-alkoxy and Ci-Cs-haloalkoxy. 10. A compound according to any one of claims 1 to 9, wherein D is SH or S-Ci-C ₄ - alkyl. 1 1. Compounds according to any one of claims 1 to 9, wherein D is SC (= O) R ³ and R ^{3 is} Ci-C ₄ alkyl. 12. Use of compounds of the formula I according to one of claims 1 to 1 1 and their agriculturally acceptable salts for combating phytopathogenic fungi. 13. A composition comprising a compound of formula I according to any one of claims 1 to 1 1 and / or a salt thereof. 14. The composition of claim 13 further comprising at least one solid or liquid carrier 15. The composition of claim 13 or 14, further comprising at least one further fungicidal, insecticidal and / or herbicidal active ingredient. 16. Seed comprising at least one compound of the formula I according to any one of claims 1 to 1 1 and / or an agriculturally acceptable salt thereof. 17. A method for controlling phytopathogenic fungi, characterized in that the fungi or the fungal infection to be protected materials, plants, the soil or seeds with an effective amount of a compound of formula I according to any one of claims 1 to 1 1 or an agricultural tolerated salt of it. 18. A pharmaceutical composition comprising at least one compound of the formula I according to any one of claims 1 to 1 1 and / or a pharmaceutically acceptable salt thereof. 19. A process for the preparation of an antimycotic comprising the use of at least one compound of formula I according to any one of claims 1 to 11 and / or a pharmaceutically acceptable salt thereof. 20. A process for the preparation of compounds of formula I according to claim 1, wherein D is SR with R = hydrogen, Ci-C ₈ alkyl, Ci-C ₈ haloalkyl, C ₂ - Cs alkenyl, C ₂ -C ₈ haloalkenyl , C2-Cs-alkynyl or C2-C8-haloalkynyl comprising the step (a1) reacting

wherein A and B are as defined for formula I according to any one of claims 1 to 9, with formic acid to compounds 1-1 (D = SH)

to obtain; and, to obtain compounds I wherein D is SR, wherein R is Ci-Cβ-alkyl, d-Cs-haloalkyl, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ - haloalkenyl, C ₂ -C ₈ Alkynyl or C ₂ -C ₈ haloalkynyl means: (b1) Reaction of compounds 1-1 with RX, where X is halogen or trifluoro (C 1 -C ₈ ) alkylsulfonate. 21. A process for the preparation of compounds of formula INb according to claim 20, comprising the step: (a2) Reassemble a purple sleeve

wherein A and B are as defined for formula I according to any one of claims 1 to 9, with a thiocyanate YSCN, wherein Y is an alkali metal or ammonium. 22. A process for the preparation of compounds I according to claim 1, wherein D is SR where R is hydrogen, Ci -C ₈ -alkyl, C ₈ haloalkyl, C ₂ -C ₈ -alkenyl -alkyl, C ₂ -C ₈ -haloalkenyl, C ₂ -C ₈ -alkynyl or C ₂ -C ₈ -haloalkynyl, comprising the step (a3) oxidation of a compound of the formula INc

wherein A and B are as defined for formula I according to any one of claims 1 to 9 to obtain a compound 1-1 according to claim 20; and to obtain compounds I in which D is SR, where R is C 1 -C ₈ -alkyl, Ci-C ₈ haloalkyl, C ₂ -C ₈ -alkenyl -alkyl, C ₂ -C ₈ haloalkenyl, C ₂ -C ₈ alkynyl or C ₂ -C ₈ haloalkynyl: (b3) Reaction of compounds 1-1 with RX, where X is halogen or trifluoro (Ci-C8) alkylsulfonate. 23. A process for the preparation of compounds I according to claim 1, wherein D is SR where R is hydrogen, C -C -alkyl ₈ -alkyl, Ci-C ₈ haloalkyl, C ₂ -C ₈ -alkenyl, C2-C ₈ haloalkenyl, _C2-C8 alkynyl, or _C2-C8 haloalkynyl, comprising the step of: (a4) Converting a V

wherein R ^x1 = Ci-C ₄ alkyl or phenyl, R ^x2 = hydrogen or Ci-C ₄ alkyl, o- of R ^x1 and R ^x2 together form a - (CH ₂ ) S-KeHe and A and B as for Formula I according to any one of claims 1 to 9 are defined, with formic acid, to obtain compounds 1-1 according to claim 19; and, to obtain compounds I wherein D is SR, wherein R is Ci-C ₈ alkyl, Ci-C ₈ -HaIo- genalkyl, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ haloalkenyl, C C ₂ -C ₈ alkynyl or C ₂ -C ₈ haloalkynyl means: (b4) Reaction of compounds 1-1 with RX, where X is halogen or trifluoro (C 1 -C ₈ ) alkylsulfonate. 24. Compounds purple according to claim 21, INb according to claim 20, INc according to claim 22 and INd according to claim 23 and their agriculturally acceptable salts. 25. A process for the preparation of compounds I according to claim 1, wherein D is SR where R is hydrogen, Ci-C ₈ alkyl-Al, C ₈ haloalkyl, C ₂ -C ₈ -alkenyl, C ₂ -C ₈ -haloalkenyl, C ₂ -C ₈ -alkynyl or C ₂ -C ₈ -haloalkynyl, comprising the step (a5) reacting a compound of formula II

wherein A and B are as defined for formula I according to any one of claims 1 to 9, with a strong base and sulfur powder to obtain a compound 1-1 according to claim 20; and, to obtain compounds I, wherein D 5 is SR, wherein R is Ci -C ₈ -alkyl, C ₈ haloalkyl, C ₂ -C ₈ - Alkenyl, _C2-C8 haloalkenyl, _C2-C8 alkynyl, or C2-C means ₈ haloalkynyl, (b5) reacting compounds 1-1 with RX, where X is halogen or trifluoro (C 1 -C ₈ ) alkylsulfonate. 26. A process for the preparation of compounds of the formula II according to claim 25, comprising the step: (a6) Reaction of a compound of the formula III 15 ^A in which Z is a leaving group X (compounds III.1), with 1, 2,4- Triazole and a base. 27. A process for the preparation of compounds of formula III.1 according to claim 20 26, comprising the step: (a7) introducing the leaving group X into a compound of formula III

wherein Z is OH (compounds III.2). 28. Compounds of the formula II according to claim 25, wherein the variables A and B are defined according to claim 5, and their agriculturally and pharmaceutically acceptable salts, excluding compounds of the formula II in which A or B is selected from 2-30-chloropyridin-4-yl, 3-chloropyridin-4-yl, 2,6-dichloropyridin-4-yl, 3,5-dichloropyridin-4-yl, 3,6-dichloropyridin-4-yl, 2-fluoropyridin-4-yl, 3-fluoropyridin-4-yl, 2-chloropyridine 3-yl, 4-chloropyridin-3-yl, 5-chloropyridin-3-yl, 6-chloropyridin-3-yl, 2,4-dichloropyridin-3-yl, 2,5-dichloropyridin-3-yl, 2,6-dichloropyridin-3-yl, 2-fluoropyridin-3-yl, 4-fluoropyridin-3-yl, 5-fluoropyridin-3-yl, 6-fluoropyridin-3-yl, 3-chloropyridin-2-yl, 4-chloropyridin-2-yl, 5-chloropyridin-2-yl, 6-chloropyridin-2-yl, 3-fluoropyridin-2-yl, 4-fluoropyridin-2-yl, 5-fluoropyridin-2-yl, 6- Fluoropyridin-2-yl, 2-methylpyridin-4-yl, 3 Methylpyridin-4-yl, 2-methylpyridin-3-yl, 4-methylpyridin-3-yl, 5-methylpyridyl-3-yl, 6-methylpyridin-3-yl, 3-methylpyridin-2-yl, 4-methylpyridine -2-yl, 5-methylpyridin-2-yl, 6-methylpyridine-2-yl, 2-methoxypyridin-4-yl, 3-methoxypyridin-4-yl, 2-methoxypyridin-3-yl, 4 -Methoxypyridin-3-yl, 5-methoxypyridin-3-yl, 6-methoxypyridin-3-yl, 3-methoxypyridin-2-yl, 4-methoxypyridin-2-yl, 5-methoxypyridin-2-yl, 6-methoxy - pyridin-2-yl, 6-chloropyrimidin-3-yl, 6-methylpyrimidin-3-yl, 6-methoxypyrimidin-3-yl, 2,4-dichloropyrimidin-3-yl, 2,6-dichloropyrimidin-3-yl , 2,4-difluoropyrimidin-3-yl, 2,6-difluoropyrimidin-3-yl, 2-chlorothien-3-yl, 4-chlorothien-3-yl, 5-chlorothien-3-yl, 2,5-dichlorothioiene 3-yl, 2,4,5-trichlorothien-3-yl, 2-bromothien-3-yl, 4-bromothien-3-yl, 5-bromothien-3-yl, 2,5-dibromothien-3-yl , 2,4,5-tribromothien-3-yl, 3-bromo-fur-2-yl, 4-Bromouro-2-yl, 5-bromourfur-2-yl, 4,5-dibromofur-2-yl, 4-chlorofur-2-yl, 5-chlorofur-2-yl, 3,4-dichloropur-2-yl yl, 2-chlorothiazol-5-yl, 4-chlorothiazol-5-yl, 2,4-dichlorothiazol-5-yl, 2-bromothiazol-5-yl, 2-chlorothiazol-4-yl, 2-bromothiazole-4 yl, 1-methylpyrazol-4-yl, 1, 3-dimethylpyrazol-4-yl, 1, 5-dimethylpyrazol-4-yl, 1, 3,5-trimethylpyrazol-4-yl, 1-methylpyrazol-3-yl, 1-methylimidazol-4-yl, 1, 5-dimethylimidazol-4-yl, 1-methyl-pyrazol-5-yl, 1, 2-dimethylimidazol-5-yl and 1, 4-dimethylimidazol-5-yl; and the other variable B or A is unsubstituted 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 4-pyridinyl, 2-thienyl, 3-thienyl, thiazol-4-yl, thiazol-5-yl, oxazol-4-yl , Oxazol-5-yl or 2-furyl. 29 compounds II according to claim 28, wherein A and B are each a five- or six-membered aromatic heterocycle, each independently one, two, three or four heteroatoms from the group O, N and S and one, two, three or four independently selected groups L contains. 30. Compounds of formula III according to claim 26 and 27 A wherein Z is a leaving group X or OH and A and B are as defined in claim 6, and their agriculturally acceptable salts, with the exception of Compounds {(2RS, 3SR) - [3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) oxiran-2-yl] methanol, [(2SR, 3RS) -3- (2.5- Dichlorothiophene-3-yl) -2- (4-fluorophenyl) oxiran-2-yl) -methanol, [(2RS, 3SR) -3- (2-chloropyridin-3-yl) -2- (4-fluorophenyl) oxirane. 2 yl] methyl methanesulfonate and [(2SR, 3RS) -3- (2,5-dichlorothiophen-3-yl) -2- (4-fluorophenyl) oxiran-2-yl] methyl methanesulfonate.